This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use:

This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated.
A copy can be downloaded for personal non-commercial research or study, without prior permission or charge.
This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author.
The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author.
When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given.
Development of *In Vitro* and *In Vivo* Models to Underpin Advances in Human Radiotherapy

Edmund Mark Gray

Presented for Doctor of Philosophy
The University of Edinburgh
2019
Declaration

I declare that this thesis has been composed by me and the work contained within it has been performed by myself, except where otherwise stated. The work presented in this thesis has not been submitted for any other degree or professional qualification.

Edmund Mark Gray
Acknowledgements

I would like to take this opportunity to thank my supervisors Professor David Argyle, Dr Carol Ward, Dr Lisa Pang and Professor Ian Kunkler for their help, support and guidance throughout my PhD. Although not officially my supervisor, Dr Simon Langdon has also been a great support throughout my studies. My thanks go to all members of the Argyle Group in the Roslin Institute, those in the Division of Pathology in the IGMM and those in the IMPACT project for their help and advice.

I consider myself extremely lucky to have been given the opportunity to work in such a fantastic multidisciplinary project as IMPACT. The project has brought together experts in the fields of engineering, chemistry, medicine, veterinary medicine and social science and being part of such a big and friendly team has made my studies and research ever more exciting.

I would like to thank the College of Medicine and Veterinary Medicine for providing the opportunity for me to undertake my PhD at the University of Edinburgh. Similarly, I would like to give my appreciation to the BBSRC and EPSRC for their funding of the IMPACT project. The following people also deserve a specific thank you for their contributions in this study:

- Contributions to bioinformatic data analysis - Dr Arran Turnbull
- Tissue processing and sectioning - Helen Caldwell and Elaine Mclay
- IGMM mass spectrometry – Dr Jimi Wills
- IGMM imaging facility - Matthew Pearson and Dr Laura Murphy
- Veterinary pathology - Dr Linda Morrison
- OPA case identification – Dr Chris Cousens, Dr David Griffiths and Dr Phil Scott
- Dryden farm – James Nixon, Peter Tennant and Adrian Ritchie
- LARIF – Professor Eddie Clutton, Dr Rachael Gregson, Dr Stephen Greenhalgh and Lynne Grant
- University College London – Professor Mervyn Singer and Dr Alex Dyson
- IMPACT engineers – Dr Jamie Marland, Dr Paul Sullivan, Dr Ewen Blair and Dr Andreas Tsiamis

A big thank you goes to my parents Margaret and Malcolm for their support not only during my post graduate studies but my entire life and to my brother Richard who is always willing to proofread my work.

I would also like to thank James for his support and friendship for the last few years since I started my studies and Arran, Carlos and Maria for being great friends.
Abstract (scientific)

Radiotherapy (RT) is commonly used for the local control of many cancer types. Unfortunately, not all patients will achieve a therapeutic benefit, and some will develop loco-regional recurrences and/or metastatic disease. The hypoxic nature of the tumour microenvironment and the development of radioresistant cancer cells can contribute to these treatment failures. Understanding the mechanisms involved in acquired radioresistance and the development of techniques to identify and target hypoxic tumour areas has the potential to improve RT response rates.

The first aim of this project was to investigate the development of acquired radioresistance and identify radiation-induced secreted biomarkers which could be used as indicators of a radiation response or radiosensitivity. Human radioresistant (RR) breast cancer cell lines were developed from parental MCF-7, ZR-751 and MDA-MB-231 cells. Parental and RR cells underwent genotypic, phenotypic and functional characterisation. RR cells exhibited enhanced migration and invasion, with evidence of epithelial-to-mesenchymal transition. MCF-7 RR and ZR-751 RR cell lines exhibited significant phenotypic changes, including loss of ERα and PgR expression and increased EGFR expression, which were associated with the down-regulation of ER signalling genes and up-regulation of genes associated with PI3K, MAPK and WNT pathway activation. A change in subtype classification from luminal A to HER2-overexpressing (MCF-7 RR) and normal-like (ZR-751 RR) subtypes was also observed, consistent with radiation and endocrine therapy resistance and a more aggressive phenotype.

To identify biomarkers secreted in response to radiation, human and canine breast and ovine lung cancer cell lines were radiated. Secretome samples were analysed by liquid chromatography-mass spectrometry. Using results from the MCF-7 cell line, 33 radiation-induced secreted biomarkers were identified which had higher (up to 12-fold) secretion levels compared to untreated controls. Based on secretion profiles and functional analysis 9 candidate biomarkers were selected (YBX3, TK1, SEC24C, EIF3G, EIF4EBP2, NAP1L4, VPS29, GNPNAT1 and DKK1) of which the first 4 underwent in-lab validation. To identify biomarkers related to radiosensitivity transcriptomic analysis identified higher expression of genes encoding 7 of the candidate biomarkers in the MCF-7 cell line compared to its
radioresistant derivative. WB analysis identified increased levels of the 4 biomarkers in the conditioned media of parental cells 24 h post-radiation which was not seen in the RR cell lines. These biomarkers, which had differential gene expression and secretion profiles between parental and RR cell lines, may be useful for both predicting and monitoring a tumour’s response to RT.

A further aim was to investigate the biocompatibility and functionality of an implantable electrochemical sensor, developed within the Engineering and Physical Sciences Research Council funded IMPACT project. This sensor was designed to measure tissue O₂ tension (ptO₂) within a tumour, enabling the identification and monitoring of radioresistant hypoxic tumour areas. This study developed a novel in vivo tumour xenograft model to evaluate the potential of 6 materials (silicon dioxide, silicon nitride, Parylene-C, Nafion, biocompatible EPOTEK epoxy resin and platinum) used in the construction of the sensor, to trigger a foreign body response (FBR) when implanted into a solid tumour. Following implantation none of the materials affected tumour growth and all mice remained healthy. Immunohistochemistry performed on the tumour showed no significant changes in necrosis, hypoxic cell number, proliferation, apoptosis, immune cell infiltration or collagen deposition around the implant site. The absence of a FBR supports their use in the construction of implantable medical devices.

In vivo validation of the O₂ sensor to provide real-time measurements on intra-tumoural ptO₂ was performed using a novel large animal ovine model. To achieve this aim, we developed a novel computed tomography (CT) guided trans-thoracic percutaneous implantation technique for the delivery of sensors into naturally occurring ovine pulmonary adenocarcinoma (OPA) tumours. This model successfully integrated techniques such as ultrasound, general anaesthesia, CT and surgery into the OPA model, all of which are techniques commonly used in the treatment of human lung cancer patients. This methodology resulted in the accurate implantation of sensors into OPA tumours with minimal complications and demonstrated the sensor’s ability to detect changes in intra-tumoural ptO₂ following manipulation of the inspired fractional O₂ concentration (FiO₂).

To investigate other possible clinical applications, sensors were validated for measuring intestinal ptO₂ using a novel rat model. These experiments assessed the
potential of the sensor to monitor intestinal perfusion following an intestinal resection and anastomosis. The sensor was placed onto the serosal surface of the small intestine of anaesthetised rats that were subsequently exposed to ischaemic, hypoxaemic and haemorrhagic insults. Decreases in intestinal \( p_t O_2 \) were observed following superior mesenteric artery occlusion and reductions in \( F_i O_2 \); these changes were reversible after reinstating blood flow or increasing \( F_i O_2 \). These results provided evidence that the sensors could detect changes in intestinal perfusion which could be utilised in a clinical setting to monitor peri-anastomotic intestinal \( p_t O_2 \).

Overall this PhD project has conducted both \textit{in vitro} and \textit{in vivo} work aimed at the investigation of mechanisms of radioresistance, identifying secreted biomarkers of radiosensitivity and validating the ability of an implantable sensor to measure real-time intra-tumoural and visceral surface \( O_2 \) tension. Identification of factors contributing to poor RT responses, such as radioresistance development and hypoxic tumour areas could provide a means by which RT could become personalised. Patients identified as having radioresistant tumours or those not responding to RT based on radiation-induced secreted biomarkers, could be given higher dose of radiation or radiosensitising agents to improve patient outcomes.
Abstract (lay)

Cancer is a disease characterised by the abnormal growth of cells within the body. The disease can cause patients to die either from cancer cells destroying the organ from which they started growing in or from spreading throughout the body. Radiotherapy (RT) is a commonly used cancer treatment that causes cancer cell death through irreparable DNA damage. Unfortunately, this treatment does not always work. Low O₂ levels (hypoxia) within the tumour and the presence of radioresistant (RR) cancer cells can decrease the effectiveness of RT.

Breast cancer is the most commonly diagnosed female cancer in the world, with 2 million cases and 0.7 million deaths occurring per year. Breast tumours can develop resistance to radiation, which leads to the development of aggressive cancer cells and disease recurrence. One of the aims of this project was to model the development of breast cancer radioresistance in the lab so that we can study changes in the cells which could warn doctors of the emergence of treatment resistant cancer cells. To do this, we treated breast cancer cells with high doses of radiation. While many cells died, some survived and were able to grow. These are the RR cells that would kick-start tumour growth after treatment. By developing these cells, in the laboratory setting, we can compare them to the original cells and determine how they are different. The main differences we observed were that the RR cells became more aggressive, with an increased ability to migrate and invade. These cells also showed resistance to endocrine therapy, meaning they had developed resistance to multiple treatment strategies. Differences in the proteins that were released from the original and RR cells in response to radiation were also seen. The main differences we identified were the increased release of EIF3G, SEC24C, YBX3 and TK1 from the original cells, which did not occur in the RR cells. We propose that monitoring the level of these proteins may help doctors monitor a patient’s response to RT and help them to alter the treatment plan accordingly.

Using a sensor that can be implanted into a tumour to measure tissue O₂ concentrations could improve a patient’s treatment through the identification of RR hypoxic tumour areas. Unfortunately, when a foreign material is placed within the body a reaction can occur to isolate it from the surrounding tissues. This foreign body response (FBR) may limit the devices ability to function correctly. The
potential of materials used in the construction of an implantable miniaturised O₂ sensor to trigger this tissue reaction was assessed by implanting them into human tumours grown in mice. None of the materials tested had any effect on tumour growth or mice body weight, with the mice remaining healthy throughout the implantation period. Tumour analysis showed no significant tissue reactions, which supports the use of these materials for devices designed for implantation within tumours. To assess the ability of working sensors to measure O₂ levels within a tumour, we implanted them into sheep lung tumours. In order to improve the model’s clinical usefulness, we used techniques commonly used in the treatment of human lung cancer patients (ultrasound, general anaesthesia, computed tomography and surgery). The method resulted in accurate implantation of sensors into lung tumours with minimal complications and demonstrated the sensor’s ability to detect changes in O₂ levels within the tumour.

The use of these O₂ sensors is not only restricted to cancer patients. One alternative clinical use is for monitoring intestinal O₂ levels as a means of assessing intestinal healing following surgery. To investigate this application sensors were placed onto the surface of the small intestine of anaesthetised rats. These sensors were able to detect lower intestinal O₂ levels following ligation of the blood supply to the intestine and reduction in blood O₂ levels. These results provided evidence that the sensors could detect changes in intestinal oxygenation which could be utilised in clinical settings following surgery.

This PhD project has conducted both in vitro and in vivo work aimed at investigating mechanisms of radioresistance, identifying proteins released from cancer cells in response to radiation and testing the ability of an implantable sensor to measure O₂ levels within a tumour. In the future, these techniques could be used to help personalise RT, whereby patients identified as having RR tumours could be given higher dose of radiation or drugs to improve treatment responses. We have also shown that these sensors could have multiple applications where the measurement of tissue O₂ levels is clinically important.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABE</td>
<td>Arterial base excess</td>
</tr>
<tr>
<td>ACPGBI</td>
<td>Association of Coloproctology of Great Britain and Ireland</td>
</tr>
<tr>
<td>AKT</td>
<td>Protein kinase B</td>
</tr>
<tr>
<td>AL</td>
<td>Anastomotic leak</td>
</tr>
<tr>
<td>ALCAM</td>
<td>Activated leukocyte cell adhesion molecule</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>AP1</td>
<td>Activating protein 1</td>
</tr>
<tr>
<td>ARCON</td>
<td>Accelerated radiotherapy with carbogen with nicotinamide</td>
</tr>
<tr>
<td>ATF</td>
<td>Activating transcription factor</td>
</tr>
<tr>
<td>BAC</td>
<td>Bronchioloalveolar carcinoma</td>
</tr>
<tr>
<td>BCA</td>
<td>Bicinchoninic acid</td>
</tr>
<tr>
<td>BI-P</td>
<td>Binding proteins</td>
</tr>
<tr>
<td>BOLD</td>
<td>Blood oxygen level-dependent</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>BTM</td>
<td>Biologic target volume</td>
</tr>
<tr>
<td>CA</td>
<td>Carbonic anhydrase</td>
</tr>
<tr>
<td>CA 15-3</td>
<td>Carbohydrate antigen 15-3</td>
</tr>
<tr>
<td>CAM</td>
<td>Chorioallantoic membrane</td>
</tr>
<tr>
<td>CDH1</td>
<td>E-cadherin</td>
</tr>
<tr>
<td>CDH2</td>
<td>N-cadherin</td>
</tr>
<tr>
<td>CE</td>
<td>Counter electrode</td>
</tr>
<tr>
<td>CEA</td>
<td>Carcinoembryonic antigen</td>
</tr>
<tr>
<td>CF</td>
<td>Colony formation</td>
</tr>
<tr>
<td>CHOP</td>
<td>C/EBP homologues protein</td>
</tr>
<tr>
<td>CM</td>
<td>Conditioned media</td>
</tr>
<tr>
<td>CMT</td>
<td>Canine mammary tumour</td>
</tr>
<tr>
<td>CO₂</td>
<td>Carbon dioxide</td>
</tr>
<tr>
<td>COPII</td>
<td>Coat protein complex II</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>CTF</td>
<td>Computed tomography combined with fluoroscopy</td>
</tr>
<tr>
<td>Cu</td>
<td>Copper</td>
</tr>
<tr>
<td>Cu-ATSM</td>
<td>Copper-complexed dithiosemicarbazone</td>
</tr>
<tr>
<td>D</td>
<td>Day</td>
</tr>
<tr>
<td>DAB</td>
<td>3,3′-Diaminobenzidine</td>
</tr>
<tr>
<td>DCE-MRI</td>
<td>Dynamic contrast-enhanced magnetic resonance imaging</td>
</tr>
<tr>
<td>dH₂O</td>
<td>Distilled water</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle’s Media</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DPBN</td>
<td>Dose painting by numbers</td>
</tr>
<tr>
<td>DTP</td>
<td>Developmental Therapeutics Program</td>
</tr>
<tr>
<td>DVS</td>
<td>Dose verification system</td>
</tr>
<tr>
<td>enJSRV</td>
<td>Endogenous JSRV</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor 1</td>
</tr>
<tr>
<td>eIF</td>
<td>Eukaryotic initiation factor</td>
</tr>
<tr>
<td>EIF3G</td>
<td>Eukaryotic Translation Initiation Factor 3 Subunit G</td>
</tr>
<tr>
<td>EMT</td>
<td>Epithelial-to-mesenchymal transition</td>
</tr>
<tr>
<td>ER</td>
<td>Oestrogen receptor</td>
</tr>
<tr>
<td>ERE</td>
<td>Oestrogen response elements</td>
</tr>
<tr>
<td>ERS</td>
<td>European Respiratory Society</td>
</tr>
<tr>
<td>ET</td>
<td>Endocrine therapy</td>
</tr>
</tbody>
</table>
**Table of Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>exJSRV</td>
<td>Exogenous JSRV</td>
</tr>
<tr>
<td>FBGC</td>
<td>Foreign body giant cells</td>
</tr>
<tr>
<td>FBR</td>
<td>Foreign body response</td>
</tr>
<tr>
<td>FCS</td>
<td>Foetal calf serum</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and drug administration</td>
</tr>
<tr>
<td>FIJI</td>
<td>Fiji is just ImageJ</td>
</tr>
<tr>
<td>FiO2</td>
<td>Inspired fractional oxygen concentration</td>
</tr>
<tr>
<td>FMISO-PET</td>
<td>18F-fluoromisonidazole–positron emission tomography</td>
</tr>
<tr>
<td>G-CSF</td>
<td>Granulocyte-colony stimulating factor</td>
</tr>
<tr>
<td>GLUT</td>
<td>Glucose transporter</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Granulocyte macrophage colony stimulating factor</td>
</tr>
<tr>
<td>GTV</td>
<td>Gross tumour volume</td>
</tr>
<tr>
<td>Gy</td>
<td>Gray</td>
</tr>
<tr>
<td>H</td>
<td>Hour</td>
</tr>
<tr>
<td>H&amp;E</td>
<td>Haematoxylin and eosin</td>
</tr>
<tr>
<td>Hb</td>
<td>Haemoglobin</td>
</tr>
<tr>
<td>HER2</td>
<td>Human epidermal growth factor receptor tyrosine-protein kinase erbB-2</td>
</tr>
<tr>
<td>hCG-β</td>
<td>β subunit of human chorionic gonadotrophin</td>
</tr>
<tr>
<td>hPTH(1-34)</td>
<td>Human parathyroid hormone fragment (1-34)</td>
</tr>
<tr>
<td>HIF</td>
<td>Hypoxia-inducible factor</td>
</tr>
<tr>
<td>HIF-1</td>
<td>Hypoxia inducible factor-1</td>
</tr>
<tr>
<td>HNSCC</td>
<td>Head and neck squamous cell carcinoma</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>IASLC</td>
<td>International Association for the Study of Lung Cancer</td>
</tr>
<tr>
<td>IC50</td>
<td>Drug/radiation dose required to reduce proliferation by 50%</td>
</tr>
<tr>
<td>ICC</td>
<td>Immunocytochemistry</td>
</tr>
<tr>
<td>IGMM</td>
<td>Institute of Genetics and Molecular Medicine</td>
</tr>
<tr>
<td>IGRT</td>
<td>Image guided radiotherapy</td>
</tr>
<tr>
<td>IF</td>
<td>Immunofluorescence</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>IVL</td>
<td>Intraluminal vesicles</td>
</tr>
<tr>
<td>IMPACT</td>
<td>Implantable Microsystems for Personalised Anti-Cancer Therapy</td>
</tr>
<tr>
<td>IMRT</td>
<td>Intensity-modulated radiotherapy</td>
</tr>
<tr>
<td>IRE1</td>
<td>Inositol-requiring enzyme 1</td>
</tr>
<tr>
<td>ISO</td>
<td>International Standards Agency</td>
</tr>
<tr>
<td>LARIF</td>
<td>Large animal research and imaging facility</td>
</tr>
<tr>
<td>LC-MS</td>
<td>Liquid chromatography–mass spectrometry</td>
</tr>
<tr>
<td>JSRV</td>
<td>Jaagsiekte sheep retrovirus</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma</td>
</tr>
<tr>
<td>MAP</td>
<td>Mean arterial blood pressure</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase</td>
</tr>
<tr>
<td>MEMS</td>
<td>Micro-electro-mechanical system</td>
</tr>
<tr>
<td>Min</td>
<td>Minute</td>
</tr>
<tr>
<td>MISS</td>
<td>Membrane-initiated steroid signalling</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MRSw</td>
<td>Magnetic relaxation switches</td>
</tr>
<tr>
<td>MTOR</td>
<td>Mammalian target of rapamycin</td>
</tr>
<tr>
<td>MTS</td>
<td>Multicellular tumour spheroid</td>
</tr>
<tr>
<td>MVB</td>
<td>Multivesicular body</td>
</tr>
<tr>
<td>n</td>
<td>Number</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Nuclear factor-κB</td>
</tr>
<tr>
<td>NISS</td>
<td>Nuclear-initiated steroid signalling</td>
</tr>
<tr>
<td>NK</td>
<td>Natural killer cells</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>NKT</td>
<td>Natural killer cells T cells</td>
</tr>
<tr>
<td>NOD SCID</td>
<td>Non-obese diabetic severe combined immune deficiency</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Non-small cell lung cancer</td>
</tr>
<tr>
<td>NT</td>
<td>Needle tract</td>
</tr>
<tr>
<td>O₂</td>
<td>Oxygen</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>OE-MRI</td>
<td>Oxygen-enhanced magnetic resonance imaging</td>
</tr>
<tr>
<td>OPA</td>
<td>Ovine pulmonary adenocarcinoma</td>
</tr>
<tr>
<td>P53</td>
<td>Tumour protein 53</td>
</tr>
<tr>
<td>PaO₂</td>
<td>Arterial oxygen partial pressure</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>Arterial carbon dioxide partial pressure</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PBS-T</td>
<td>Phosphate buffered saline-tween20</td>
</tr>
<tr>
<td>PDX</td>
<td>Patient derived xenograft</td>
</tr>
<tr>
<td>PE</td>
<td>Plating efficiency</td>
</tr>
<tr>
<td>PERK</td>
<td>PKR-like endoplasmic reticulum kinase</td>
</tr>
<tr>
<td>PET</td>
<td>Positron emission tomography</td>
</tr>
<tr>
<td>PEU</td>
<td>Polyether polyurethane</td>
</tr>
<tr>
<td>PgR</td>
<td>Progesterone receptor</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphoinositide 3-kinases</td>
</tr>
<tr>
<td>PMN</td>
<td>Polymorphonuclear</td>
</tr>
<tr>
<td>PO₂</td>
<td>Partial pressure of oxygen</td>
</tr>
<tr>
<td>Pt</td>
<td>Platinum</td>
</tr>
<tr>
<td>PTEN</td>
<td>Phosphatase and tensin homolog</td>
</tr>
<tr>
<td>P:\O₂</td>
<td>Tissue oxygen tension</td>
</tr>
<tr>
<td>PTV</td>
<td>Planned target volume</td>
</tr>
<tr>
<td>RBCs</td>
<td>Red blood cells</td>
</tr>
<tr>
<td>RE</td>
<td>Reference electrode</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>Rpm</td>
<td>Revolutions per minute</td>
</tr>
<tr>
<td>RR</td>
<td>Radioresistant</td>
</tr>
<tr>
<td>RR</td>
<td>Respiratory rate</td>
</tr>
<tr>
<td>RT</td>
<td>Radiotherapy</td>
</tr>
<tr>
<td>SaO₂</td>
<td>Haemoglobin oxygen saturation</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium dodecyl sulphate-polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>SCID</td>
<td>Severe combined immune deficiency</td>
</tr>
<tr>
<td>SCLC</td>
<td>Small cell lung cancer</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium dodecyl sulphate</td>
</tr>
<tr>
<td>Sec</td>
<td>Second</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SERD</td>
<td>Selective oestrogen receptor down-regulators or degraders</td>
</tr>
<tr>
<td>SERM</td>
<td>Selective oestrogen receptor modulators</td>
</tr>
<tr>
<td>SF</td>
<td>Survival fraction</td>
</tr>
<tr>
<td>SFM</td>
<td>Serum-free media</td>
</tr>
<tr>
<td>SiO₂</td>
<td>Silicon dioxide</td>
</tr>
<tr>
<td>SIRS</td>
<td>Systemic inflammatory response syndrome</td>
</tr>
<tr>
<td>Si₃N₅</td>
<td>Silicon nitride</td>
</tr>
<tr>
<td>SMA</td>
<td>Superior mesenteric artery</td>
</tr>
<tr>
<td>SRB</td>
<td>Sulforhodamine B</td>
</tr>
<tr>
<td>TAM</td>
<td>Tumour-associated macrophage</td>
</tr>
<tr>
<td>TCA</td>
<td>Trichloroacetic acid</td>
</tr>
<tr>
<td>Ti</td>
<td>Titanium</td>
</tr>
<tr>
<td>TK</td>
<td>Thymidine kinase</td>
</tr>
<tr>
<td>TME</td>
<td>Tumour microenvironment</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumour necrosis factor- α</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>TNBC</td>
<td>Triple negative breast cancer</td>
</tr>
<tr>
<td>TTNB</td>
<td>Trans-thoracic needle biopsy</td>
</tr>
<tr>
<td>UPR</td>
<td>Unfolded protein response</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>VIM</td>
<td>Vimentin</td>
</tr>
<tr>
<td>VHL</td>
<td>von Hippel-Lindau</td>
</tr>
<tr>
<td>WB</td>
<td>Western blot</td>
</tr>
<tr>
<td>WE</td>
<td>Working electrode</td>
</tr>
<tr>
<td>WNT</td>
<td>Wingless/Integrated</td>
</tr>
<tr>
<td>XBP</td>
<td>X-box-binding protein</td>
</tr>
<tr>
<td>YBX</td>
<td>Y-box binding protein</td>
</tr>
</tbody>
</table>
List of Figures

Figure 1.1. Pie charts representing the distribution of cancer cases and deaths for the 10 most common cancer types in the world in 2018. ................................................................. 3
Figure 1.2. PERK, IRE1 and ATF6 pathways of the unfolded protein response ........................................... 13
Figure 1.3. Microscopic and macroscopic images of the IMPACT O₂ sensor ........................................... 21
Figure 1.4. Sequence of inflammatory responses leading to FBGC formation and fibroblast infiltration. .................................................................................................................. 28
Figure 1.5. Human and ovine comparative gross anatomy ............................................................................. 35
Figure 2.1. MTS invasion measurement ........................................................................................................ 53
Figure 3.1. Positive controls used for verifying murine immune antibodies .................................................. 73
Figure 3.2. Representative H&E stained sections from tumours harvested at day 7 .................................. 74
Figure 3.3. Representative H&E stained sections for QuPath analysis of the area of necrosis .............. 74
Figure 3.4. Representative CA9 stained sections from tumours harvested at day 7 ................................. 75
Figure 3.5. Representative CA9 stained sections for QuPath analysis of hypoxia ..................................... 75
Figure 3.6. Representative Ki67 stained sections from tumours harvested at day 7 ............................... 76
Figure 3.7. Representative Ki67 stained sections for QuPath analysis of proliferation ............................ 76
Figure 3.8. Representative caspase 3 stained sections from tumours harvested at day 7 ............................ 77
Figure 3.9. Representative caspase 3 stained sections for QuPath analysis of apoptosis ....................... 77
Figure 3.10. Representative Ly-6G stained sections from tumours harvested at day 7 ............................ 78
Figure 3.11. Representative Ly-6G stained sections for QuPath analysis of neutrophil numbers .......... 78
Figure 3.12. Representative F4/80 stained sections from tumours harvested at day 7 ............................ 79
Figure 3.13. Representative F4/80 stained sections for QuPath analysis of macrophage numbers ...... 79
Figure 3.14. Representative ER-TR7 stained sections from tumours harvested at day 7 ...................... 80
Figure 3.15. Representative ER-TR7 stained sections for QuPath analysis of fibroblast numbers ...... 80
Figure 3.16. Representative Masson’s trichrome stained sections from tumours harvested at day 7 81
Figure 3.17. Representative Masson’s trichrome stained sections for Image J analysis of collagen deposition .................................................................................................................. 81
Figure 3.18. Intra-operative photographs depicting cannulation of the right jugular vein ....................... 83
Figure 3.19. Intra-operative photographs depicting cannulation of the left carotid artery ....................... 84
Figure 3.20. Intra-operative photographs depicting placement of a tracheostomy tube ........................ 84
Figure 3.21. Photographs of an anaesthetised sheep undergoing sensor readings ................................ 87
Figure 3.22. Photographs of imaging and surgical facilities ..................................................................... 88
Figure 4.1. Radioresistant cell lines have increased colony formation ability ............................................ 94
Figure 4.2. Proliferation of the ZR-751 RR cell line is inhibited less than its parental cell line following exposure to radiation .................................................................................................................. 94
Figure 4.3. Proliferation of the MCF-7 RR cell line is inhibited less than its parental cell line following exposure to radiation .................................................................................................................. 95
Figure 4.4. Proliferation of the MDA-MB-231 RR cell line is inhibited less than its parental cell line following exposure to radiation .......................................................................................................................... 96
Figure 4.5. CF and SRB assays comparing MCF-7, MCF-7 RR and MCF-7 rr cell lines .......................... 97
Figure 4.6. Proliferation of the JS7 RR cell line is inhibited less than its parental cell line following exposure to radiation .................................................................................................................. 98
Figure 4.7. Proliferation of the REM-134 RR cell line is inhibited less than its parental cell line following exposure to radiation ................................................................. 98
Figure 4.8. SRB assays comparing REM-134, REM-134 RR and REM-134 rr cell lines ....................... 99
Figure 4.9. Global gene expression analysis identifies significant inherent similarities between RR cell lines derived from ER⁺ cells ........................................................................................................ 100
Figure 4.10. Radioresistant cell lines have modified proliferation rates relative to their parental cells ..................................................................................................................... 102
Figure 4.11. MCF-7 RR and ZR-751 RR MTS show decreased expression of Ki67 ................................. 103
Figure 4.12. Radioresistant cell lines have increased invasion potential ............................................... 105
Figure 4.13. MCF-7 RR cell line has increased migration potential ........................................................ 106
Figure 4.14. ZR-751 RR cell line has increased migration potential ....................................................... 106
Figure 4.15. MDA-MB-231 RR cell line has increased migration potential ............................................. 107
Figure 4.16. MCF-7 RR and ZR-751 RR cells show phenotypic changes consistent with EMT .... 107
Figure 4.17. MCF-7 RR and ZR-751 RR cell lines show increased expression of vimentin, N-cadherin and SNAIL with partial down-regulation of E-cadherin. ....................................................... 109
Figure 4.18. MCF-7 RR and ZR-751 RR cell lines show increased gene expression of vimentin and N-cadherin with the partial down-regulation of E-cadherin. ....................................................... 110
Figure 4.19. WNT signalling is increased in RR cell lines derived from ER+ cells. .................. 111
Figure 4.20. WNT signalling is increased in RR cell lines derived from ER+ cells. .............. 112
Figure 4.21. MCF-7 RR cells show loss of ERα and PgR and gain in EGFR expression. .......... 114
Figure 4.22. ZR-751 RR cells show loss of ERα and PgR and gain in EGFR expression ........ 115
Figure 4.23. MDA-MB-231 parental and RR cells show similar EGFR expression. .............. 116
Figure 4.24. MCF-7 RR and ZR-751 RR cell lines show loss of ERα and PgR expression and gain in EGFR expression. ................................................................. 116
Figure 4.25. Radioresistant cell lines show increased sensitivity to gefitinib. ......................... 117
Figure 4.26. Gefitinib inhibits MCF-7 RR and ZR-751 RR invasion. .................................. 118
Figure 4.27. Western blot results showing activation of MAPK signalling in RR cell lines derived from ER+ cells. ................................................................. 120
Figure 4.28. Western blot results showing activation of PI3K signalling in RR cell lines derived from ER+ cells. ................................................................. 121
Figure 4.29. Gene analysis showing activation of MAPK signalling in RR cell lines derived from ER+ cells. ................................................................. 122
Figure 4.30. Gene analysis showing activation of PI3K signalling in RR cell lines derived from ER+ cells. ................................................................. 122
Figure 4.31. SRB assay showing proliferation of the MCF-7 cell line when exposed to different volumes of transfection reagent. ......................................................... 123
Figure 4.32. Validation of ERα siRNA knockdown in MCF-7 transfected cells. .................... 124
Figure 4.33. ERα siRNA transfection or tamoxifen treatment reduces MCF-7 proliferation. .......... 125
Figure 4.34. Radiation treatment combined with either ERα siRNA transfection or tamoxifen treatment results in an additional reduction in MCF-7 proliferation. ............................ 126
Figure 4.35. EGFR expression increases in MCF-7 cells following ERα siRNA transfection. ...... 126
Figure 4.36. Radioresistant cell lines derived from ER+ cells exhibited a change in oestrogen signalling associated genes and a change in intrinsic breast cancer subtype classification. ..... 128
Figure 4.37. Gene expression and western blot analysis show inherent differences in UPR pathway activation between MCF-7 and MCF-7 RR cell lines. ....................................................... 130
Figure 4.38. Western blot analysis shows inherent differences in UPR pathway activation between ZR-751 and ZR-751 RR cell lines. ....................................................... 130
Figure 5.1. Characterisation of the untreated MCF-7 secretome identified 927 unique proteins up to 24 h post-serum starvation. ......................................................... 145
Figure 5.2. Cell numbers were not affected by a single dose of radiation up to 10 Gy at 24 h post-treatment. ..................................................... .............................. 146
Figure 5.3. Characterisation of the untreated and radiation treated MCF-7 secretome identified 530 common proteins at 24 h. ......................................................... 147
Figure 5.4. Hierarchical clustering identified a cluster of 33 biomarkers with dramatic increase in secretion in response to radiation. ......................................................... 149
Figure 5.5. MCF-7 secretion patterns of the 33 candidate biomarkers remained stable up to 8 hours post-radiation treatment. ......................................................... 150
Figure 5.6. Secretion patterns of the 33 candidate biomarkers in multiple cancer cell types and species identified no common set of candidate biomarkers. ......................................................... 151
Figure 5.7. Protein interaction networks identified protein transport, transcription and translation as enriched clusters within the 33 candidate biomarkers. ......................................................... 152
Figure 5.8. The 9 candidate biomarkers show increased secretion levels at all radiation doses at 24 h post-treatment. ......................................................... 153
Figure 5.9. Similarities in secretion patterns of the 4 biomarkers at 24 h post-radiation treatment were identified between ER- and ER+ cell lines. ......................................................... 155
Figure 5.10. MCF-7 and ZR-751 show higher expression of genes encoding 7 of the 9 candidate biomarkers compared with their RR derivatives. ................................. 157
Figure 5.11. MCF-7 cells grown in 2D monolayers show higher intra-cellular expression of EIF3G, SEC24C, TK1 and YBX3 compared with its RR derivative. ................................. 158
Figure 5.12. MCF-7, ZR-751 and REM-134 MTS show higher intra-cellular expression of SEC24C, TK1 and YBX3 compared with their RR derivatives. ................................. 160
Figure 5.13. MCF-7 secretion levels of SEC24C, EIF3G and TK1 increase in response to radiation.......................................................... 162
Figure 5.14. ZR-751 secretion levels of SEC24C and TK1 increase in response to radiation........... 163
Figure 5.15. MDA-MB-231 RR secretion levels of SEC24C increase in response to radiation............ 164
Figure 5.16. REM-134 secretion levels of SEC24C and EIF3G increase in response to radiation... 165
Figure 5.17. JS7 secretion levels of EIF3G increase in response to radiation.................................................. 166
Figure 5.18. Increased expression of genes encoding EIF3G, SEC24 and YBX3 is seen in patient breast cancer tissue following RT.................................................. 169

Figure 6.1. Photographs of ex-vivo MDA-MB-231 xenograft tumours used in the development of a biomaterial implantation protocol.......................................................... 184
Figure 6.2. Photographs depicting the position of an implanted biomaterial within a xenograft tumour following harvesting and processing for IHC ........................................................................................................ 185
Figure 6.3. Histological appearance of xenograft tumour sections containing the biomaterial implantation site. ........................................................................................................ 185
Figure 6.4. Intra-operative photographs depicting percutaneous biomaterial implantation .............. 187
Figure 6.5. Intra-operative photograph depicting needle tract injury............................................. 187
Figure 6.6. Representative H&E stained sections from untreated tumours harvested at day 7....... 188
Figure 6.7. Representative H&E stained sections from biomaterial implanted tumours harvested at day 7 post-implantation. ........................................................................................................ 188
Figure 6.8. Biomaterials have no effect on mice body weights or xenograft tumour growth up to 7 days post-implantation.......................................................... 190
Figure 6.9. Parylene-C has no effect on mice body weights or xenograft tumour growth up to 14 days post-implantation.......................................................... 191
Figure 6.10. Biomaterials have no effect on the percentage area of tumour necrosis up to 7 days post-implantation ........................................................................................................ 192
Figure 6.11. Parylene-C has no effect on the percentage area of tumour necrosis up to 14 days post-implantation ........................................................................................................ 193
Figure 6.12. Biomaterials have no effect on xenograft cancer cell CA9 staining up to 7 days post-implantation ........................................................................................................ 193
Figure 6.13. Biomaterials have no effect on xenograft cancer cell proliferation up to 7 days post-implantation ........................................................................................................ 195
Figure 6.14. Biomaterials have no effect on xenograft cancer cell apoptosis up to 7 days post-implantation ........................................................................................................ 196
Figure 6.15. Parylene-C has no effect on xenograft cancer cell proliferation and apoptosis up to 14 days post-implantation ........................................................................................................ 197
Figure 6.16. Biomaterials have no effect on neutrophil infiltration within tumour tissue up to 7 days post-implantation ........................................................................................................ 198
Figure 6.17. Biomaterials have no effect on macrophage infiltration within tumour tissue up to 7 days post-implantation ........................................................................................................ 199
Figure 6.18. Parylene-C has no effect on neutrophil and macrophage infiltration within tumour tissue up to 14 days post-implantation .......................................................... 200
Figure 6.19. Macrophage distribution patterns within untreated xenograft tumours ..................... 200
Figure 6.20. Biomaterials have no effect on fibroblast infiltration within xenograft tumour tissue up to 7 days post-implantation ........................................................................................................ 202
Figure 6.21. Biomaterials have no effect on collagen deposition within xenograft tumour tissue up to 7 days post-implantation ........................................................................................................ 203
Figure 6.22. Parylene-C has no effect on fibroblast infiltration and collagen deposition within tumour tissue up to 14 days post-implantation .......................................................... 204
Figure 7.1. Outline of experimental protocols and interventions ..................................................... 221
Figure 7.2. Intra-operative photograph depicting intestinal placement of the sensor .......................... 221
Figure 7.3. Intra-operative photographs depicting SMA isolation, occlusion and release ............. 222
Figure 7.4. Sensor currents and physiological data remain stable in control rats............................... 224
Figure 7.5. Sensor currents rapidly decrease following superior mesenteric artery occlusion ......... 225
Figure 7.6. Sensor currents change in accordance with alterations in FiO2 ..................................... 227
Figure 7.7. Sensor currents remain stable following progressive haemorrhage and autotransfusion 229
Figure 7.8. Intra-operative photographs depicting muscular placement of the IMPACT sensor ...... 230
Figure 7.9. Sensor currents change in accordance with alterations in FiO2 ..................................... 232
Figure 8.1. Photographs depicting development of a percutaneous implantation technique ............. 247
List of Tables

Table 1.1. Methods used for measuring tumour hypoxia ................................................................. 16
Table 2.1. Human, canine and ovine cell lines used in this study .................................................... 46
Table 2.2. Growth media and supplements required for each cell line ............................................ 47
Table 2.3. Summary of culture vessels used ...................................................................................... 48
Table 2.4. Formulas used for cell counting and viability assessment ................................................... 48
Table 2.5. Lysis buffer ......................................................................................................................... 54
Table 2.6. Gels and solutions required for SDS-PAGE and immunoblotting ...................................... 56
Table 2.7. Primary antibodies ........................................................................................................... 57
Table 2.8. siRNA transfection concentrations and volumes required for 96 and 6 well plate formats. 63
Table 3.1. Primary antibodies used in the murine experiments ........................................................... 71
Table 3.2. QuPath parameters for cell detection .................................................................................. 72
Table 3.3. Anaesthesia and analgesia options in sheep diagnosed with OPA ........................................ 87
Table 4.1. IC50 values for each parental and RR cell line up to 144 h post-radiation ...................... 96
Table 4.2. IC50 values for each parental and RR cell line up to 144 h post-radiation ....................... 99
Table 4.3. IC50 values of gefitinib for each parental and RR cell line 72 h post-treatment ............ 117
Table 4.4. ERα percentage knockdown compared to non-targeting transfected cells. ............... 124
Table 5.1. Summary of validation experiments in human breast cancer cell lines ..................... 167
Table 5.2. Summary of validation experiments in canine breast and ovine lung cancer cell lines ... 167
Table 6.1. Previously published studies investigating the in vivo and in vitro biocompatibility testing of IMPACT component biomaterials ......................................................................................... 183
Table 7.1. Risk factors associated with the development of an anastomotic leak ......................... 217
Table 7.2. Current recordings during each SMA occlusion/reperfusion and euthanasia .................. 226
Table 7.3. Current recordings during each FiO2 challenge and euthanasia ....................................... 227
Table 7.4. Current recordings during each haemorrhage procedure and euthanasia ..................... 229
Table 7.5. Current recordings during each FiO2 challenge ............................................................... 232
Table 8.1. OPA cases used for initial refinement of the CT-guided implantation technique ........... 249
Table 8.2. Results from OPA cases used for initial refinement of the implantation technique ....... 251
Table 8.3. OPA cases used following refinement of the CT-guided implantation technique .......... 252
Table 8.4. Results from the OPA cases used in CT-guided implantation procedures .................. 260
Table 8.5. Current recordings generated during each FiO2 challenge ............................................ 265
Table 11.1. Epithelial and mesenchymal gene lists .......................................................................... 341
Table 11.2. WNT signalling and WNT target gene lists ................................................................. 342
Table 11.3. The total 927 secreted proteins identified in the conditioned media of untreated MCF-7 cells up to 24 h post-serum starvation. ................................................................................. 343
Table 11.4. The 239 secreted proteins common to all time points in the conditioned media of untreated MCF-7 cells up to 24 h post-serum starvation.................................................................347
Table 11.5. The 147 secreted proteins which had greater than 2-fold increase in secretion levels in radiation treated MCF-7 cells compared to untreated controls at 24 h post-treatment...........348
Table 11.6. The 33 secreted proteins which had up to 12-fold increase in secretion levels in radiation treated MCF-7 cells compared to untreated controls at 24 h post-treatment.........................348

Table of Contents

1 INTRODUCTION ..................................................................................................................1
  1.1 THE HALLMARKS OF CANCER ......................................................................................1
  1.2 WORLDWIDE CANCER INCIDENCE AND MORTALITY ............................................2
  1.3 UNITED KINGDOM CANCER INCIDENCE AND MORTALITY ..................................2
  1.4 PRECISION MEDICINE ...............................................................................................4
  1.5 BREAST CANCER .........................................................................................................4
     1.5.1 Oestrogen signalling ..............................................................................................5
     1.5.2 Endocrine therapy ...............................................................................................5
  1.6 RADIOThERAPy ............................................................................................................6
     1.6.1 Breast cancer and radiotherapy ............................................................................7
     1.6.2 Using tumour biomarkers for precision radiotherapy ...........................................7
     1.6.3 Secretome analysis for biomarker discovery .......................................................8
  1.7 THE TUMOUR MICROENVIRONMENT .........................................................................9
     1.7.1 Tumour hypoxia .....................................................................................................9
     1.7.2 Hypoxia and its effect on treatment responses .......................................................10
     1.7.3 Cellular response to hypoxia ..............................................................................11
     1.7.4 Endoplasmic reticulum stress and the unfolded protein response .......................12
     1.7.5 Clinical relevance of tumour hypoxia ..................................................................13
     1.7.6 Tumour hypoxia functional imaging ..................................................................14
     1.7.7 Using hypoxic imaging for precision radiotherapy ..............................................16
     1.7.8 Electrochemical oxygen sensors .......................................................................19
     1.7.9 Cancer treatment and implantable technology ...................................................21
     1.7.10 Regulations governing implantable medical devices .......................................24
  1.8 BIOCOMPATIBILITY AND THE FOREIGN BODY RESPONSE ....................................24
     1.8.1 Acute inflammatory response ............................................................................25
     1.8.2 Chronic inflammatory response ..........................................................................26
     1.8.3 Consequences of foreign body giant cell formation .........................................27
     1.8.4 Extracellular matrix remodelling ...................................................................27
  1.9 PRE-ClinICAL IN VITRO MODELS USED IN THE DEVELOPMENT OF CANCER THERAPEUTICS ....28
  1.10 COMPARATIVE ONCOLOGY ......................................................................................31
     1.11.1 Molecular human and canine breast cancer ........................................................31
  1.12 COMPARATIVE HUMAN AND OVINE LUNG ANATOMY AND PHYSIOLOGY ..........34
     1.12.1 Human lung cancer ............................................................................................35
     1.12.2 Models of human lung cancer ..........................................................................36
     1.12.3 Ovine pulmonary adenocarcinoma .................................................................37
     1.12.4 JSRV biology ......................................................................................................37
     1.12.5 Endogenous retrovirus and immune responses ..................................................38
     1.12.6 OPA diagnosis .....................................................................................................39
     1.12.7 OPA histology and comparison with human lung adenocarcinomas ..................39
  1.13 HYPOTHESIS AND AIMS ..........................................................................................40
2 MATERIALS AND METHODS: IN VITRO EXPERIMENTS ........................................45

2.1 INTRODUCTION ........................................................................................................45

2.2 CELL TISSUE CULTURE .......................................................................................45

2.2.1 Cell lines ..............................................................................................................45

2.2.2 Cell culture ..........................................................................................................46

2.2.3 Recovery of cells from liquid nitrogen storage ..................................................47

2.2.4 Cell passage .........................................................................................................47

2.2.5 Cell counting and determination of cell viability ...............................................48

2.2.6 Cryopreservation of cells and storage into liquid nitrogen ..............................48

2.2.7 Irradiation of cells ..............................................................................................49

2.2.8 Development of radioresistant cell lines ..........................................................49

2.2.9 Generation of multicellular tumour spheroids ..................................................50

2.3 CELLULAR ASSAYS ..............................................................................................50

2.3.1 Sulforhodamine B proliferation (SRB) assay ....................................................50

2.3.2 Colony formation assay .......................................................................................51

2.3.3 Scratch (migratory) assays ................................................................................52

2.3.4 MTS invasion assays ...........................................................................................52

2.4 PROTEIN RECOVERY AND DETECTION ..........................................................53

2.4.1 Whole cell protein extraction from adherent cells ............................................53

2.4.2 Protein quantification using the bicinchoninic acid assay ..................................54

2.4.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) ......54

2.4.4 Immunoblotting ...................................................................................................55

2.4.5 Protein quantification using infra-red radiation ................................................56

2.4.6 Membrane Stripping .........................................................................................58

2.4.7 Assessment of the effects of radiation on pathway activation ............................58

2.5 IMMUNOHISTOCHEMISTRY .................................................................................58

2.5.1 Fixation and sectioning of MTS and tissue for immunohistochemistry .............58

2.5.2 Haematoxylin and eosin staining .......................................................................59

2.5.3 Masson’s trichrome staining ..............................................................................59

2.5.4 Vertical immunohistochemistry for paraffin embedded MTS and tissue samples ....60

2.5.5 Horizontal immunocytochemistry and immunofluorescence using chamber slides ....60

2.5.6 Image acquisition ...............................................................................................61

2.6 RNA INTERFERENCE .............................................................................................61

2.6.1 ERa knockdown using siRNA ............................................................................61

2.6.2 Liposome-mediated transfection optimisation ....................................................62

2.7 NUCLEIC ACID ISOLATION AND QUANTIFICATION .......................................63

2.7.1 RNA extraction and assessment of nucleic acid purity .....................................63

2.7.2 Whole-transcriptome gene expression analysis ................................................64

2.8 CANCER CELL SECRETOME ANALYSIS .........................................................65

2.8.1 Assessment of the effects of radiation on secretome profiles of cancer cells ........65

2.8.2 Secretome sample preparation ..........................................................................66

2.8.3 Liquid chromatography-mass spectrometry (LC-MS) and sample analysis ..........66

2.9 IMMUNOHISTOCHEMISTRY AND STATISTICAL ANALYSIS ............................67

3 MATERIALS AND METHODS: IN VIVO EXPERIMENTS ................................68

3.1 INTRODUCTION ......................................................................................................68

3.2 BIOMATERIALS AND METHODS: IN VIVO EXPERIMENTS .........................68

3.2.1 Background .........................................................................................................68

3.2.2 Generation of MDA-MB-231 stock xenograft tumours ......................................68
3.2.3 Generation of MDA-MB-231 xenograft tumours for biomaterial implantation ................................. 69
3.2.4 General anaesthesia for biomaterial implantation procedures ........................................................... 69
3.2.5 Biomaterial fabrication ........................................................................................................................ 69
3.2.6 Biomaterial manufacture ...................................................................................................................... 70
3.2.7 Immunohistochemistry ........................................................................................................................ 70
3.2.8 Immunohistochemical analysis ............................................................................................................ 71
3.3 Validation of functionality of the IMPACT oxygen sensor to measure tissue oxygen tension for clinical applications ......................................................................................................................... 82
3.3.1 Background ........................................................................................................................................ 82
3.3.2 Anaesthesia, arterial and venous cannulation and tracheostomy tube placement ................................. 82
3.4 Development of a pre-clinical ovine pulmonary adenocarcinoma model for human lung cancer and validation of intra-tumoural functionality of the IMPACT oxygen sensor ................................................................. 85
3.4.1 Background ........................................................................................................................................ 85
3.4.2 General anaesthesia for CT imaging and sensor implantations .............................................................. 85
3.4.3 Computed tomography ........................................................................................................................ 88
3.4.4 Oxygen sensor recordings ..................................................................................................................... 88
3.4.5 Statistical Analysis ............................................................................................................................... 89

4 DEVELOPMENT AND CHARACTERISATION OF ACQUIRED RADIORESISTANT BREAST CANCER CELL LINES ......................................................................................................................... 91
4.1 ABSTRACT ............................................................................................................................................. 91
4.2 INTRODUCTION .................................................................................................................................. 92
4.3 RESULTS ............................................................................................................................................... 93
4.3.1 Development and confirmation of acquired radioresistance in human ER+ and ER− breast cancer cell lines .......................................................................................................................................... 93
4.3.2 Development and confirmation of acquired radioresistance in a canine ER− breast cancer and an ovine lung cancer cell line ................................................................................................................. 97
4.3.3 Gene expression analysis identifies inherent similarities between radioresistant cell lines derived from ER+ cells .............................................................................................................................. 99
4.3.4 Radioresistant cell lines have concurrent lower expression of cell cycle associated genes and modified basal proliferation rates ......................................................................................... 101
4.3.5 Radioresistant cell lines have increased invasion and migration potential ........................................ 103
4.3.6 WNT signalling is increased in radioresistant cell lines derived from ER+ cells .............................. 110
4.3.7 Radioresistant MCF-7 and ZR-751 cell lines show loss of ERα and PgR expression and gain in EGFR expression ................................................................................................................. 113
4.3.8 Radioresistant MCF-7 and ZR-751 cell lines show activation of PI3K and MAPK pathways ................. 119
4.3.9 ERα knockdown in MCF-7 cells results in EGFR expression, reduced proliferation and enhancement of radiosensitivity .................................................................................................................................. 123
4.3.10 Radioresistant cell lines exhibit cellular plasticity within the context of intrinsic breast cancer subtyping ................................................................................................................................... 127
4.3.11 Radioresistant cell lines derived from ER+ cells show reduced activation of the PERK/eIF2α signalling pathway .................................................................................................................. 128
4.4 DISCUSSION .......................................................................................................................................... 131
4.5 CONCLUSION ....................................................................................................................................... 139

5 IDENTIFICATION OF BIOMARKERS RELEASED FROM CANCER CELLS IN RESPONSE TO RADIATION – A PILOT STUDY .................................................................................................................. 141
5.1 ABSTRACT ............................................................................................................................................. 141
5.2 RESULTS ............................................................................................................................................... 144
5.2.1 Characterisation of the MCF-7 secretome ............................................................................................ 144
5.2.2 Criteria used for candidate biomarker selection .................................................................................. 147
5.2.3 MCF-7 preliminary biomarker selection based on increased secretion at 24 hours post-radiation identified 33 candidate biomarkers ......................................................... 148
5.2.4 No common set of biomarkers were identified between different cancer types ...... 150
5.2.5 MCF-7 final biomarker selection based on functional analysis of the 33 biomarkers identified 9 candidate biomarkers ................................................................. 151
5.2.6 Similarities in secretion patterns of the 4 biomarkers between ER+ and ER- cell lines were identified ................................................................. 154
5.2.7 Radioresistant cell lines have lower gene and intra-cellular protein expression of the 4 biomarkers ................................................................. 155
5.2.8 Differential secretion patterns of the candidate biomarkers occur between sensitive and radioresistant cell lines in multiple species in response to radiation ........................................... 161
5.2.9 Increased expression of genes encoding EIF3G, SEC24, YBX3 and those involved in ER stress and the UPR is seen in breast cancer tissue following radiotherapy treatment ........ 167
5.3 DISCUSSION ............................................................................................................. 169
5.4 CONCLUSION ......................................................................................................... 177

6 BIOCOMPATIBILITY ASSESSMENT OF COMMON IMPLANTABLE SENSOR MATERIALS IN A TUMOUR XENOGRAFT MODEL .................................................. 179

6.1 ABSTRACT ............................................................................................................... 179
6.2 INTRODUCTION .................................................................................................. 180
6.3 RESULTS ................................................................................................................ 184
6.3.1 Development of a percutaneous biomaterial implantation technique ................. 184
6.3.2 Development of an IHC sectioning protocol for xenograft tumours containing implanted biomaterials ................................................................. 184
6.3.3 Refined procedure for biomaterial implantation into xenograft tumours ............... 185
6.3.4 The percutaneous implantation procedure resulted in a high success rate of biomaterial delivery into xenograft tumours ......................................................... 188
6.3.5 Implanted biomaterials have no effect on mouse body weights and tumour volumes 189
6.3.6 Implanted biomaterials have no effect on tumour necrosis and CA9 staining .......... 191
6.3.7 Implanted biomaterials have no effect on xenograft cancer cell proliferation and apoptosis ......................................................................................... 194
6.3.8 Implanted biomaterials have no effect on neutrophil and macrophage infiltration within xenograft tumours ........................................................................ 197
6.3.9 Implanted biomaterials have no effect on fibroblast infiltration and collagen deposition within xenograft tumours ................................................................. 201
6.4 DISCUSSION ............................................................................................................. 204
6.5 CONCLUSION ......................................................................................................... 212

7 VALIDATION OF FUNCTIONALITY OF THE IMPACT OXYGEN SENSOR TO MEASURE TISSUE OXYGEN TENSION FOR CLINICAL APPLICATIONS ........ 215

7.1 ABSTRACT ............................................................................................................... 215
7.2 INTRODUCTION .................................................................................................. 216
7.3 RESULTS ................................................................................................................ 219
7.3.1 Development of a model to measure intestinal tissue oxygen tension ............... 219
7.3.2 Protocol 1: Control group .................................................................................. 221
7.3.3 Protocol 2: Intestinal tissue responses to superior mesenteric arterial occlusion .... 222
7.3.4 Protocol 3: Intestinal tissue responses to alterations in inspired oxygen concentrations, progressive haemorrhage and autotransfusion ............................................. 222
7.3.5 Current generated by the sensor remained stable in control rats ....................... 223
7.3.6 Current generated by the sensor rapidly decreased following occlusion of the superior mesenteric artery which was reversible upon reinstatement of blood flow ......................... 224
7.3.7 Current generated by the sensor responded rapidly to alterations in inspired oxygen concentrations ........................................................ 226
7.3.8 Current generated by the sensor remained stable following haemorrhage ........... 227
8 DEVELOPMENT OF A PRE-CLINICAL OVINE PULMONARY ADENOCARCINOMA MODEL FOR HUMAN LUNG CANCER AND VALIDATION OF INTRA-TUMOURAL FUNCTIONALITY OF THE IMPACT OXYGEN SENSOR ........................................... 241

8.1 ABSTRACT .................................................................................................................. 241
8.2 INTRODUCTION .......................................................................................................... 242
8.3 RESULTS ...................................................................................................................... 245
8.3.1 Development of a percutaneous technique for sensor implantation into lung tissue. 245
8.3.2 Post-mortem cases allowed mapping of accessible regions of the thoracic cavity for sensor implantations .................................................................................................................. 248
8.3.3 Development of a CT-guided trans-thoracic percutaneous technique for sensor implantation into OPA tumours ........................................................................................................ 249
8.3.4 Refined procedure for OPA lesion localisation and CT-guided trans-thoracic percutaneous sensor implantation ................................................................. 252
8.3.5 Refined procedure for CT-guided implantation of multiple sensors .................... 258
8.3.6 CT-guided trans-thoracic percutaneous sensor implantation resulted in a high success rate of delivery of sensors into OPA lesions ............................................................................. 259
8.3.7 Iatrogenic pneumothorax is a potential complication following percutaneous sensor implantation ....................................................................................................................... 261
8.3.8 Appropriate anaesthetic protocols enable OPA sheep to remain physiologically stable throughout anaesthesia ........................................................................................................ 263
8.3.9 Current generated by the sensor responded to alterations in inspired oxygen concentrations ......................................................................................................................... 264
8.3.10 All implantation sites were identified during post-mortem examination ............ 266
8.3.11 Histopathology of OPA tissue and implant site identified variable amounts of intra-pulmonary haemorrhage .......................................................................................... 267
8.4 DISCUSSION .............................................................................................................. 270
8.5 CONCLUSION ............................................................................................................ 278
9 FUTURE WORK ............................................................................................................ 279
10 REFERENCES .............................................................................................................. 287
11 APPENDIX .................................................................................................................. 341
11.1 GENE LISTS USED IN CHAPTER 4 FOR CHARACTERISATION OF THE PARENTAL AND RADIOTHERAPIC RESISTANT CELL LINES ........................................................................... 341
11.2 PROTEIN LISTS GENERATED IN CHAPTER 5 FOR CHARACTERISATION OF MCF-7 SECRETOME ........................................................................................................ 343
11.3 JOURNAL ARTICLES ................................................................................................. 349
11.3.1 Published articles ................................................................................................ 349
11.3.2 Submitted articles ............................................................................................... 350


1 Introduction

This introduction chapter is an expanded version of 2 published review articles:

1.1 The hallmarks of cancer

Cancer (also referred to as a malignant tumour or neoplasm) is a term used to describe a large group of heterogeneous diseases characterised by aberrant growth of abnormal cells with a potential to spread from the primary site of origin throughout the body (metastasis). Genetic and environmental factors (lifestyle, pathogens or carcinogens) can influence cancer development (carcinogenesis) and progression; however, carcinogenesis is likely due to a multistep process beginning with the accumulation of somatic mutations that eventually lead to an altered genome resulting in the transformation of normal cells into malignant ones1-3.

Carcinogenesis can potentially occur in any cell in the human body that has replicative capabilities, because of this more than 100 different cancer types have been identified, each of which can have multiple subtypes4. Tumours originating from different tissues will be composed of specific cell types and stromal components; these factors in combination with malignant cells possessing unique genetic alterations make trying to understand cancer as a single disease entity very difficult. To overcome these issues Hanahan and Weinberg originally described 6 essential cell physiology capabilities applicable to all cancer types that can cause malignant transformation. These ‘hallmarks’ are: growth signal self-sufficiency,
insensitivity to growth suppressors, resisting apoptosis, replicative immortality, increased angiogenesis and tissue invasion and metastasis\textsuperscript{3}. With advances in understanding tumour biology, 2 further ‘hallmarks’ were subsequently described as energy metabolism reprogramming and avoiding immune system destruction\textsuperscript{5}.

These 8 functional capabilities are likely to develop in different tumour types through various mechanisms and at different stages in the process of carcinogenesis, these factors ultimately influence how cancer cells survive, proliferate, invade and metastasise. The development of these malignant capabilities requires certain cellular enabling characteristics, among which genomic instability and tumour promoting inflammation are considered important. Hanahan and Weinberg proposed that the study of tumour biology should not simply focus on cancer cells but should also include the investigation of recruited normal cells that make up the tumour-associated stroma and the tumour microenvironment (TME), as these factors can also play roles in carcinogenesis and the development of hallmark capabilities\textsuperscript{5}.

1.2 Worldwide cancer incidence and mortality

Cancer is a disease that occurs throughout the world, creating social and economic burdens for both developed and developing countries alike. Although advances in pre-clinical and clinical research are improving cancer diagnosis and treatment, the disease remains the most common cause of death throughout the world. It is estimated that 18.1 million new cancer cases and 9.6 million cancer-related deaths occurred in 2018; combined data for both sexes showed that lung, breast, prostate and colon cancers account for approximately 40\% of all newly diagnosed cases\textsuperscript{6}. In males, lung cancer is the most frequently diagnosed cancer and leading cause of cancer-related deaths, whereas in females, breast cancer is the most common. Overall, the top 10 cancer types account for over 65\% of newly diagnosed cases and deaths (Figure 1.1). If current trends in global population growth combined with the effects of an aging population continue, these figures could increase to 20.3 million new cancer cases and 12.7 million deaths by 2030\textsuperscript{7}.

1.3 United Kingdom cancer incidence and mortality

Cancer incidence and mortality rates can vary between countries and continents. In the United Kingdom, approximately 360,000 new cancer cases and
165,000 cancer-related deaths occurred in 2015. Approximately 36% of these new cases were diagnosed in people above 75 years of age, giving an indication of the effect that the aging population can have on cancer incidence rates. In line with global incidences, the 4 most common cancer types in the UK are breast, prostate, lung and bowel, which account for approximately 53% of all new cancer cases and approximately 45% of all cancer-related deaths. Lung cancer is a major contributor to this mortality rate accounting alone for approximately 20% of deaths. The scale of the health problem that cancer creates is highlighted by the estimate that in 2016 cancer accounted for 28% of all UK deaths; these figures are only likely to increase as UK cancer incidence rates are expected to rise by 2% by 2035.

![Pie charts](image)

**Figure 1.1.** Pie charts representing the distribution of cancer cases and deaths for the 10 most common cancer types in the world in 2018. For each sex, the area of the pie chart reflects the percentage of the total number of cases or deaths.
1.4 Precision medicine

The terms precision and personalised medicine are interchangeable; however, concerns amongst clinicians that the term ‘personalised’ could be interpreted as treatments/drugs being developed specifically for individual patients has led to the term precision medicine being favoured\(^8\)\(^9\). Precision medicine is defined as the incorporation of disease biomarkers, phenotype, molecular signatures, lifestyle and environment into the prevention, investigation and treatment of diseases\(^10\). Patients can be classified according to their differences in disease susceptibility, treatment response and prognosis, information which can be used to select patients that are most likely to benefit from specific treatments to improve clinical outcome\(^11\). Precision medicine has gained increased awareness in recent years aided by world leaders such as the former President of the United States Barack Obama. His ‘Precision Medicine Initiative’, announced in 2015 aimed ‘to bring us closer to curing diseases like cancer and diabetes – and to give us all access to the personalised information we need to keep ourselves and our families healthier’\(^12\).

Dedicated centres such as The Personalised Medicine Coalition in the USA and The Centre for Personalised Medicine in the UK will help to improve the use of precision medicine into healthcare practices\(^13\); however, for precision medicine to be integrated into the field of oncology we will need to understand and map tumour heterogeneity at genomic, epigenomic and microenvironmental levels\(^14,15\).

1.5 Breast cancer

Breast cancer is the most common female cancer in the world, with approximately 2 million new cases and 0.7 million cancer-related deaths occurring per year\(^6\). Following a diagnosis of breast cancer, immunohistochemistry (IHC) is used to classify the tumour based on the expression of certain cellular receptors. These receptors typically include human epidermal growth factor receptor 2 (HER2), oestrogen receptor \(\alpha\) (ER\(\alpha\)), progesterone receptor (PgR) and epidermal growth factor receptor (EGFR) which can classify the tumour as hormone dependant or independent\(^16\). ER\(\alpha\) is the most important predictive biomarker, with approximately 85% of breast cancers expressing this receptor. PgR is expressed in approximately 67% of breast cancers and is known to regulate epithelial proliferation\(^17\) and can alter
which genes are stimulated by ER binding\textsuperscript{18,19}. PgR expression is strongly dependent on the presence of ER, so the majority of ER\textsuperscript{+} cancers are also PgR\textsuperscript{+}\textsuperscript{20}. ER\textsuperscript{+} breast cancers are hormone dependent which rely on oestrogen for both carcinogenesis and tumour progression.

1.5.1 Oestrogen signalling

Oestrogen can modulate gene expression and promote cancer progression either directly through the genomic signalling pathway termed nuclear-initiated steroid signalling (NISS)\textsuperscript{21} or indirectly through the non-genomic signalling pathway termed membrane-initiated steroid signalling (MISS)\textsuperscript{22}. In NISS oestrogen binds directly to ER\textsubscript{α} causing the formation of an oestrogen-ER\textsubscript{α} complex. This complex translocates to the nucleus where it interacts with co-activators and binds specific DNA regions called oestrogen response elements (EREs). These ERS regulate transcription of oestrogen responsive genes involved in angiogenesis, apoptosis, proliferation and invasion\textsuperscript{21}. In MISS, following ligand binding, the oestrogen-ER\textsubscript{α} complex can interact with and activate other transcription factors and signal transduction pathways, such as nuclear factor-κB (NF-κB), activating protein 1 (AP1), p53, PI3K/AKT and ERK/MAPK. Following their recruitment and activation transcription of their target genes can occur\textsuperscript{22-24}. Both the genomic and non-genomic pathways can also be activated through cross talk with other oncogenic pathways such as those involving the EGFR and HER tyrosine kinases\textsuperscript{23,25,26}. Such interactions can lead to ER\textsubscript{α} signalling activation even in the absence of oestrogen.

1.5.2 Endocrine therapy

Typically, early and locally advanced breast cancer is treated with surgery followed by adjuvant radiotherapy (RT), chemotherapy and/or endocrine therapy (ET). ET plays an important role in the treatment of patients with ER\textsuperscript{+} breast cancers and can be used either to stop oestrogen synthesis or reduce its effect by preventing its binding to ER. Although there are various ET strategies, treatment selection is usually based on menopausal status, clinicopathological factors and the presence of co-morbidities\textsuperscript{27,28}. In pre-menopausal women, as the ovaries are the main source of oestrogen production, oestrogen synthesis blockade can be achieved either through removal of the ovaries (oophorectomy) or by chemical suppression (luteinising
hormone releasing hormone agonists, such as goserilin)\textsuperscript{16}. In post-menopausal women the ovaries cease to be the main source of oestrogen production with oestrogen instead being synthesised from androgens in bone, fat, and breast tissue through a reaction catalysed by the enzyme aromatase\textsuperscript{29,30}. Oestrogen synthesis can therefore be blocked through the administration of aromatase inhibitors such as anastrazole, letrozole, or exemestane. These inhibitors work either by competing with substrates binding to aromatase or by mimicking the substrates of aromatase and inactivating the enzyme. The overall result is to reduce the amount of oestrogen produced, thus inhibiting tumour growth\textsuperscript{31}. To reduce the effect that oestrogen has on cancer cells ER function can also be chemically blocked in both pre- and post-menopausal women using anti-oestrogens. These drugs include selective ER modulators (SERMs) and selective ER down-regulators or degraders (SERDs). Tamoxifen is an example of a SERM that acts as a partial oestrogen agonist which blocks the ER and removes the growth-promoting effects that oestrogen has on the tumour. Fulvestrant is an example of a SERD that acts as a full oestrogen antagonist, that both inhibits the ER and accelerates its degradation\textsuperscript{16}.

Overall, both ER and PgR have been used as diagnostic and predictive markers for response to ET treatment since the 1970s\textsuperscript{32,33} and their assessment by IHC is now a mandatory requirement in all breast cancer patients to assist treatment selection\textsuperscript{34}.

1.6 Radiotherapy

RT remains a commonly used treatment modality for many different cancer types with approximately 50\% of cancer patients receiving radiation either as a sole means of treatment or combined with surgery, ET or chemotherapy\textsuperscript{35}. RT can be given as a neoadjuvant treatment with curative intent, such as in prostate\textsuperscript{36} or laryngeal cancers\textsuperscript{37}, or to shrink a tumour before definitive surgery in cases such as locally advanced rectal cancer and various forms of head and neck cancers\textsuperscript{38}. RT can also be given after surgery as an adjuvant treatment to improve patient outcome\textsuperscript{39}. Unfortunately, not all patients obtain a therapeutic benefit from RT; factors such as innate\textsuperscript{40} and acquired radioresistance\textsuperscript{41} can contribute to treatment failures, resulting in local recurrences or metastatic disease. RT is also not a benign procedure; for example, in breast cancer known radiation-associated side effects include cardiac and
skin toxicities, lymphedema, secondary cancers, rib fractures and brachial plexopathy\textsuperscript{42}. The use of RT in a patient’s treatment plan must therefore consider the potential therapeutic benefits against the potential patient risks.

1.6.1 Breast cancer and radiotherapy

RT with curative intent or as a palliative treatment is estimated to benefit up to 83\% of breast cancer patients\textsuperscript{43}. Multiple studies have also shown that whole breast RT following breast conserving surgery provides local control and survival rates equivalent to mastectomy\textsuperscript{39,44,45}, with added advantages of improved cosmetic outcomes and reduced side effects. Although overall 5-year survival rates after RT are approximately 80\%, it is estimated that 30\% of these patients will develop loco-regional recurrences or metastatic disease, the majority of which will die within 5 years\textsuperscript{46}. RT treatment plans typically involve the delivery of radiation to the tumour in multiple fractions over a period of several weeks; the standard adjuvant RT fractionation regime following breast conservation surgery is 25 fractions of 2 Gy over a 5 week period, or hypofractionated regimes consisting of a total of 40 Gy delivered in 15 fractions over 3 weeks\textsuperscript{47}.

Regardless of whether RT is given as a neoadjuvant or adjuvant treatment, the clinical effects of RT are only seen towards the end or even after the treatment course has finished, therefore patients who fail to respond to RT will initially go undetected. This delay in identifying non-responding tumours will expose patients to the risk of developing RT-induced side effects for no therapeutic gain, allow tumour progression, impact on long-term survival and delay the provision of alternative treatments\textsuperscript{48}. One method being used in the management of cancer patients is the measurement of tumour-related biomarkers in serum and plasma.

1.6.2 Using tumour biomarkers for precision radiotherapy

Biomarkers can be defined as a characteristic which can be objectively measured and evaluated as indicators of normal biological processes, pathogenesis, or responses to therapy\textsuperscript{49}. Biomarkers can be diagnostic and prognostic (estimating the likelihood of disease recurrence) but can also be used for predicting (identifying patients likely respond to a specific treatment) and monitoring treatment responses\textsuperscript{50}. Post-operative reductions in the levels of the serum biomarkers carcinoembryonic
antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) have been shown to be prognostic for disease-free and overall survival in breast cancer patients\(^5\) and can improve the detection of recurrent/metastatic disease by 5–6 months\(^5\). However, these biomarker assays have limitations. For example, low biomarker concentrations in the presence of high abundance proteins (albumin and immunoglobulins) can make their detection difficult. Typically, biomarkers are also not specific for one cancer type and their levels can be altered in various disease conditions. The assays can also have low sensitivity and/or specificity and may not reflect a tumour’s response to therapy whilst a patient is on treatment.

The ability of a biomarker to provide information on a tumour’s response to radiation could represent an important tool to help tailor a patient’s treatment plan; patients not responding to traditional RT regimens could be given alternative therapies at an earlier stage of the treatment process. This would help direct health services resources, ease the burden on RT machines and ultimately reduce the economic cost of cancer treatment. More importantly, this could potentially improve patient outcomes and survival rates. Unfortunately, at present, no robust or validated secreted biomarkers for monitoring a tumour’s response to RT whilst a patient is on treatment are available. To address this unmet clinical issue, research using the secretome of cancer cells/tissue is becoming more popular for the discovery of novel, clinically relevant biomarkers.

### 1.6.3 Secretome analysis for biomarker discovery

The term secretome was first used to describe both secretory pathways and secreted substances\(^5\), but has since been refined to include only the latter\(^5\). Approximately 10-15% of proteins encoded by the human genome are secreted, which play important roles in various cellular functions including immune responses, cell signaling and extra-cellular matrix remodeling. As research into the secretome of normal cells has increased, it has become clear that cancer cells have their own unique set of secreted substances. The term cancer secretome was first used in 2006 in a study comparing the secretome of pancreatic cancer cells with that of non-neoplastic pancreatic ductal cells\(^5\). Substances within the cancer secretome are now known to play roles in cancer pathogenesis including angiogenesis, differentiation, invasion and metastasis\(^5\). For proteins to be secreted into the extra-cellular space
they must pass through either the classical or non-classical secretory pathways. To undergo classical secretion, proteins are synthesised as precursors containing N-terminus signal peptides that direct them to the translocation apparatus of the rough endoplasmic reticulum. Subsequent transfer to the Golgi apparatus allows the proteins to be released into the extracellular environment through fusion of Golgi-derived secretory vesicles with the plasma membrane. In contrast to this, at least 4 non-classical secretory pathways have been identified for the release of proteins that lack the signal peptide for endoplasmic reticulum/Golgi-dependent secretion. Examples of non-classical secretion include intra-cellular vesicles undergoing endosomal recycling, direct translocation across the plasma membrane using transporter systems, membrane-anchored flip-flop mechanisms or exosomal secretion. Exosomes are intraluminal vesicles (ILV) formed from inward budding of the membrane of multivesicular bodies (MVB). During their formation, cytosolic proteins and substances such as lipids, microRNAs and mRNA may be incorporated into the invaginating membrane and become contained within the ILV. As a result, when the MVB fuse with the plasma membrane, both ILV and their cytosolic contents are released into the extra-cellular space.

1.7 The tumour microenvironment

Tumour physiology differs from normal tissue physiology in that tumours typically have areas of varying O₂ tension, glucose and energy deprivation, extra-cellular acidosis and high lactate levels. This TME, influenced by the tumours abnormal vasculature and heterogeneous microcirculation, can affect a tumour’s response to RT and chemotherapy. The concepts of precision medicine are applicable to the idea of monitoring the TME. If TME parameters such as biomarkers, cancer metabolites, chemotherapeutic drug concentrations or intra-tumoural pH and O₂ could be safely and continuously measured throughout therapy without any or with minimal intervention from the patient or clinician, then this information could influence the management of a patient’s treatment.

1.7.1 Tumour hypoxia

Tissue oxygenation is a balance between O₂ supply and its use through cellular metabolic demands. Most normal mammalian tissues function in O₂
concentrations of 2-9%, whereas hypoxic and severely hypoxic conditions are defined as ≤ 2% O₂ and ≤ 0.02% O₂ respectively. Intra-tumoural hypoxia is an important and common component of many cancers, with up to 60% of solid tumours containing heterogeneously distributed areas of hypoxic tissue. Multiple pathogenic mechanisms can influence the formation of these hypoxic regions, largely due to the abnormal tumour vasculature. The first to be described in the literature was diffusion-limited hypoxia, when a connection between increasing distance from blood vessels and the development of necrotic tumour tissue was identified. Diffusion-limited hypoxia largely influences the development of chronic hypoxia and occurs as a result of viable aerobic tumour cells near blood vessels utilising the available O₂ carried in red blood cells (RBCs). O₂ concentrations decrease as the distance from blood vessels increase, resulting in hypoxia. Although the diffusion distance of O₂ from a blood vessel is approximately 150-180 μm, the point at which hypoxia develops will depend upon the O₂ carrying capacity of RBCs and the metabolic demands from cells closest to the blood vessel. The second hypoxic mechanism is perfusion-limited or cycling hypoxia caused by interruptions to blood flow. These interruptions can be acute and transient in nature and relate to the structural and functional abnormalities of tumour micro-vessels and collapse/blockade of these vessels by tumour cells. Anaemic hypoxia is caused by tumour-associated and/or therapy-induced anaemia, leading to a reduced RBC O₂ transport capacity. Macroscopic regional hypoxia is a recent term used to describe the situation where hypoxic cancer cells are found situated near a blood vessel. This occurs due to the production of an O₂ gradient along the length of a blood vessel contained within the tumour. Blood at the arterial end of a vessel will contain the highest O₂ concentration which will be readily used by cells present in this region. As the distance from the arterial end of the blood vessel increases the O₂ concentration of blood will decrease, so cells situated at the distal end of the vessel, even if near it, may still be hypoxic.

1.7.2 Hypoxia and its effect on treatment responses

The abnormal tumour blood supply leading to hypoxia can affect the response of a tumour to RT and chemotherapy. The irregular tumour vasculature can reduce the effective delivery of systemic drugs such as chemotherapeutic, hormone or
targeted therapies, leading to heterogeneous drug distribution within the tumour\(^7\). Hypoxic conditions can also reduce cancer cells proliferation rates\(^7\) which can reduce the effectiveness of cytotoxic agents that predominantly target rapidly dividing cells\(^7\). Tissue O\(_2\) concentrations at the time of radiation can also influence the degree of cellular radiosensitivity; studies have demonstrated that radiated anoxic cells are less sensitive to the effects of radiation than those which are well oxygenated\(^7\). When exposed to a given dose of radiation, cancer cells in low O\(_2\) conditions can withstand a dose 2-3 times higher than aerobic cells. This phenomenon is known as the O\(_2\) enhancement effect. The pivotal role of O\(_2\) in the effectiveness of RT is described through the O\(_2\) fixation hypothesis\(^6\),\(^7\). The clinical effects from RT arise largely through its DNA damaging ability which occurs via the indirect route due to the production of free radicals or through the direct route due to DNA ionisation. O\(_2\) present at the time of radiation can react with radiation-induced DNA radicals producing chemically irreparable peroxy radicals; however, in the absence of O\(_2\) this reaction cannot occur, and DNA damage can be repaired by radical scavengers such as endogenous thiols\(^7\), giving these hypoxic cells a significant survival advantage.

1.7.3 Cellular response to hypoxia

Although it seems intuitive that hypoxia would generate an unfavourable environment for cellular survival, cancer cells can produce a hypoxic response through changes in gene expression, which protect them against cell death\(^7\). Those cancer cells not able to adapt to hypoxia will die, leading to the selection of cancer cells with genetically-fixed features of this ‘hypoxic phenotype’\(^7\). This process, termed hypoxia-driven malignant progression, can cause cancer cells to become more invasive, metastatic and treatment resistant\(^7\).

Key transcription factors involved in the hypoxic response are the hypoxia-inducible factors (HIF). The most extensively studied is hypoxia inducible factor-1 (HIF-1), composed of a constitutively expressed HIF-1\(\beta\) subunit and a regulated HIF-1\(\alpha\) subunit. In normoxic conditions HIF-1\(\alpha\) is degraded by the von Hippel-Lindau (VHL)-mediated ubiquitin-proteasome pathway; however, in hypoxic conditions VHL cannot bind to HIF-1\(\alpha\), preventing its degradation. Accumulation and nuclear translocation of HIF-1\(\alpha\) leads to heterodimerisation with HIF-1\(\beta\) and
binding to specific DNA sequences within hypoxia-response elements to promote target gene transcription. Approximately 40 HIF-1 regulated genes have been identified\(^8\). In combination with other inducible transcription factors\(^8\) it is estimated that approximately 1.5% of the genome is transcriptionally responsive to hypoxia\(^8\). These hypoxia-regulated genes are involved in processes such as angiogenesis, erythropoiesis, iron homeostasis, cell survival, proliferation, apoptosis, glucose metabolism and invasion; it is these adaptive changes that improve a cancer cell’s ability to survive in the hostile hypoxic TME\(^8\).

1.7.4 Endoplasmic reticulum stress and the unfolded protein response

The unfolded protein response (UPR) consists of signalling pathways that attempt to protect a cell from the accumulation of misfolded or unfolded proteins within the endoplasmic reticulum\(^8\). Accumulation of these proteins can occur as a result of cellular stress from hypoxia, alterations in pH and nutrient deprivation\(^8\). The UPR can also be activated by radiation\(^8\) and can promote cancer cell survival in hypoxic conditions by regulating the translation of angiogenic factors\(^8\). The UPR is mediated through protein kinase RNA (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1α (IRE1α) and activating transcription factor 6 (ATF6)\(^9\) signalling pathways. These endoplasmic reticulum membrane-bound transducer proteins are inactive under non-stressed states through binding of their luminal domains with chaperone immunoglobulin heavy-chain binding proteins (BiP). However, during endoplasmic reticulum stress unfolded proteins bind directly to the transducer proteins or to BiP (causing their sequestration) leading to transducer activation (Figure 1.2).

PERK homodimerises and autophosphorylates when activated, which mediates the phosphorylation of the eukaryotic initiation factor 2α (eIF2α), leading to translation suppression and reduced protein transport into the endoplasmic reticulum\(^9\). PERK activation can also induce the translation of activating transcription factor 4 (ATF4) which controls the transcription of endoplasmic reticulum chaperone proteins, along with those involved in amino acid production and transport. IRE1α activation splices X-box-binding protein 1 (XBP1) mRNA, leading to the transcription of endoplasmic reticulum stress genes that promote
misfolded protein degradation, correct protein folding and secretion. Activated ATF6 functions as a transcription factor; following its transport to the Golgi apparatus in COPII vesicles it is cleaved by proteases before translocating to the nucleus and inducing the transcription of endoplasmic reticulum stress genes.

The combined function of these pathways is to reduce endoplasmic reticulum protein translocation, increase misfolded protein degradation and improve endoplasmic reticulum protein folding and secretion. However, prolonged stress with insurmountable accumulation of misfolded proteins can overwhelm these responses, causing a switch of UPR signalling to initiate apoptosis. Typically, endoplasmic reticulum stress-induced apoptosis is mediated by the PERK/eIF2α/ATF4 UPR pathway. ATF4 can induce expression of the transcription factor C/EBP homologues protein (CHOP), which increases the expression of Bim, (pro-apoptotic member of the Bcl-2 family) and decreases the expression of Bcl-2 (an anti-apoptotic protein). Radiation-induced PERK activation can also cause cell death through autophagy in caspase 3/7-deficient cells.

Figure 1.2. PERK, IRE1 and ATF6 pathways of the unfolded protein response. The UPR is comprised of 3 signalling pathways: protein kinase RNA (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1α (IRE1α), X-box binding protein 1 (XBP1) and activating transcription factor 6 (ATF6) (GADD34, growth arrest and DNA damage-inducible protein 34; CHOP, C/EBP homologous protein; JNK, JUN N-terminal kinase; RIDD, regulated IRE1-dependent decay; XBP1s transcriptionally active XBP1, XBP1u; P, phosphorylation).

1.7.5 Clinical relevance of tumour hypoxia

Tumour hypoxia has been shown to influence tumour progression and prognosis in a range of tumour types. One large international study demonstrated that
pre-treatment tumour O₂ status for head and neck cancer patients was prognostic for survival after RT (+/- surgery, chemotherapy, or radiosensitiser)\textsuperscript{104}. Another study showed that low O₂ levels measured in squamous cell carcinoma lymph node metastasis was associated with poor or no response to RT; this study concluded that O₂ levels could be used to identify patients who would benefit most from additional treatments\textsuperscript{105}. The prognostic significance of tumour hypoxia has also been shown in cervical cancer\textsuperscript{106} where patients with hypoxic tumours had worse disease-free and overall survival rates compared to patients with non-hypoxic tumours\textsuperscript{107}. Similar results have been observed in patients with soft tissue sarcomas\textsuperscript{108}.

### 1.7.6 Tumour hypoxia functional imaging

To target hypoxic, treatment-resistant tumour areas, clinicians need to be able to detect them. Multiple direct or indirect methods are available to detect hypoxic areas within tumours, but none are used routinely either due to their invasive nature or difficulties in incorporating them into clinical practice (Table 1.1). One of the first approaches for direct measuring of intra-tumoural O₂ levels used polarographic electrodes, such as the Eppendorf O₂ electrode\textsuperscript{109}. This technique showed associations between hypoxia and treatment responses in numerous cancer types\textsuperscript{105,107,110-113} and that O₂ concentrations within breast cancer tissue can be lower than that of normal breast tissue\textsuperscript{109}. However, this technique is invasive and only applicable to readily accessible tumours and is not used routinely in the clinic.

Indirect methods for assessing tumour hypoxia include the use of molecular reporters of O₂ such as pimonidazole, which forms adducts with intra-cellular macromolecules at low O₂ levels\textsuperscript{114}. Pimonidazole has been used in trials for hypoxia assessment to determine the use of hypoxia modifying drugs with accelerated RT; results demonstrated that patients with hypoxic laryngeal tumours benefited from additional treatments\textsuperscript{115}. Other indirect assessment methods include the evaluation of genes and proteins whose levels are regulated by O₂ (HIF-1, CA9 and GLUT1)\textsuperscript{116,117}. Hypoxic gene signatures have also been identified which can be prognostic\textsuperscript{118} and predictive of response to radiosensitising agents\textsuperscript{119}. All these indirect methods require a biopsy sample which can be challenging or impossible to obtain; recurrent measurements using repeat biopsies are also difficult to perform and justify clinically. Blood samples assessing biomarkers of hypoxia, such as osteopontin, can
be used to circumvent the issue of repeat biopsy sampling. These ‘liquid biopsies’ have been used to assess head and neck patients undergoing RT. Results showed that high osteopontin plasma concentrations were associated with a poor prognosis which could be improved with O₂ mimetic drugs. However, hypoxia assessment through biopsy samples only allows the analysis of specific tumour areas at specific times and hypoxia assessment through blood samples does not analyse the tumour at all. These limitations mean that the hypoxic heterogeneity of the entire tumour and the changing distribution of O₂ that occurs during treatment are not evaluated.

Advanced imaging techniques provide a non-invasive way of assessing hypoxia throughout the whole tumour volume and a means by which serial measurements can be obtained. The most common methods used are positron emission tomography (PET) and magnetic resonance imaging (MRI). PET hypoxia imaging uses tracers such as nitroimidazoles, copper-complexed dithiosemicarbazone (Cu-ATSM) derivatives, fluorodeoxyglucose or endogenous markers such as CA9 labelled with radioisotopes that allow images depicting hypoxia to be obtained. Each tracer has its own specific disadvantages; for example, the expression of CA9 can be induced by factors other than hypoxia and at reduced O₂ levels that are not low enough to have a radiobiological effect. Nitroimidazole-based tracers also require cells to be hypoxic for significant periods of time, meaning levels of acute hypoxia may be underestimated. Resolution may also be a problem; voxel size (3D representation of a pixel – determined by slice thickness and pixel size) tends to be much larger than potential hypoxic areas, so areas of low hypoxia that contain hypoxic hotspots could be classified as negative if the average value for that region falls below a cut-off point. Therefore, the actual PET image may not accurately reflect tumoural hypoxic heterogeneity at the microregional level.

Most MRI-based techniques use either dynamic contrast-enhanced MRI (DCE-MRI) or blood O₂ level-dependent (BOLD) imaging. In DCE-MRI, a gadolinium-based contrast agent is injected into a vein and its passage is tracked through the tumour vasculature; signal changes identified by MRI give an estimation of perfusion. BOLD techniques detect signal differences induced by regional changes in deoxygenated haemoglobin levels and are carried out with dynamic challenges to alter oxygenated and deoxygenated haemoglobin ratios to map hypoxic regions.
Table 1.1. Methods used for measuring tumour hypoxia. Advantages and disadvantages of each method used to measure tumour hypoxia\textsuperscript{121}.

<table>
<thead>
<tr>
<th>Method</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Microelectrode</strong></td>
<td>An O\textsubscript{2} electrode is placed directly into a solid tumour.</td>
<td>Invasive. Can only be used in accessible tumours. Inability to distinguish tumour areas with viable hypoxic cells from regions of necrosis.</td>
</tr>
<tr>
<td><strong>Tissue based biomarkers</strong></td>
<td>Nitroimidazole compounds (pimonidazole) are administered systemically which are converted into protein adducts in hypoxic cells. Proteins are detected by IHC using biopsy samples.</td>
<td>Indirect measurement of pO\textsubscript{2}. Invasive as requires a biopsy. Compounds may not be sensitive enough to detect intermediate hypoxic phenotypes as HIF-1 is stabilised at higher pO\textsubscript{2} than those at which nitroimidazole adducts are formed. Does not provide real-time measurements.</td>
</tr>
<tr>
<td><strong>Tissue based biomarkers</strong></td>
<td>Evaluating the expression levels of hypoxia-induced proteins (CA9, GLUT1).</td>
<td>Indirect measurement of pO\textsubscript{2}. Invasive as requires a biopsy. Protein expression can be influenced by other factors not just hypoxia. Antibody specificity and sensitivity can limit the technique to a small number of biomarkers. Does not provide real-time measurements.</td>
</tr>
<tr>
<td><strong>Tissue based biomarkers</strong></td>
<td>Measurement of serum biomarkers (osteopontin, hepatocyte growth factor, IL-8).</td>
<td>Non-invasive. Real-time measurements can be obtained.</td>
</tr>
<tr>
<td><strong>Positron emission tomography</strong></td>
<td>Nitroimidazole or copper-complexed dithiosemicarbazone compounds are administered systemically which are taken up by hypoxic cells. Compounds are labelled with radiotracers (F-fluoromisonidazole used for nitroimidazole compounds) which can be detected using PET imaging.</td>
<td>Indirect measurement of pO\textsubscript{2}. Invasive as requires a biopsy. Genes can be up/down-regulated by other factors not just hypoxia. Does not give information about hypoxia heterogeneity within different areas of a tumour.</td>
</tr>
<tr>
<td><strong>Magnetic resonance imaging</strong></td>
<td>Most MRI studies either use dynamic contrast-enhanced MRI (DCE-MRI), blood oxygen level-dependent (BOLD) imaging or oxygen-enhanced MRI (OE-MRI).</td>
<td>Potential for artefacts. The biological meaning of the parameters used to reflect hypoxia and the link with the hypoxic phenotype has yet to be established.</td>
</tr>
</tbody>
</table>

1.7.7 Using hypoxic imaging for precision radiotherapy

Identification of tumours containing significant levels of hypoxia would enable patient selection for additional treatments to overcome hypoxia-related radioresistance. Options include increasing tumour oxygenation through patients
breathing O\(_2\) at higher than normal partial pressures (hyperbaric O\(_2\) treatment), improving haemoglobin levels with blood transfusions, erythropoietin, and erythropoiesis-stimulating agents and administering hypoxia targeting drugs. Hyperbaric O\(_2\) treatment, largely from studies conducted in the 1970s, has been shown to have a therapeutic benefit in patients with head and neck squamous cell carcinomas (HNSCC)\(^{122}\); however, inconsistent clinical trial data for other cancer types and logistical issues have impeded its widespread use. Another approach to increasing tumoural oxygenation is by administering carbogen with nicotinamide. Carbogen, a mixture of O\(_2\) and CO\(_2\) gas, can reduce diffusion-limited hypoxia, whereas nicotinamide, an amide derivative of vitamin B6, is a vasoactive agent which counteracts perfusion-related acute hypoxia. Accelerated RT with carbogen and nicotinamide (ARCON) has been evaluated in numerous clinical trials with studies showing improved loco-regional control and disease-free survival rates\(^{115,123}\).

Similarly, clinical trials of nitroimidazole derivatives that act as O\(_2\) mimetics such as doranidazole and nimorazole have yielded survival benefits when used in combination with chemoradiotherapy in HNSCC patients\(^{124}\) and non-small cell lung cancer (NSCLC) patients\(^{125}\) or with RT alone\(^{126,127}\). Nimorazole in combination with RT is a standard of care treatment in Denmark for head and neck cancers\(^{128}\).

Prodrugs have been developed that are given to patients in an inactive form and are converted to their pharmacologically active form within hypoxic cells, thus enabling the selective killing of hypoxic cells. Numerous prodrugs are undergoing preclinical or clinical trials\(^ {129}\). Although studies involving the prodrug tirapazamine have shown disappointing results in terms of improving progression-free or overall survival\(^ {130,131}\); these studies failed to identify patients with hypoxic tumours that may gain the most benefit from this treatment. Another hypoxia-activated prodrug, TH-302, is showing promise in improving progression-free survival in phase II trials in combination with chemotherapy for pancreatic cancer\(^ {132}\) and soft tissue sarcomas\(^ {133}\), providing evidence for further evaluation in phase III trials.

An important aspect of clinical trials evaluating the potential benefit of hypoxia-modifying therapies is case selection. Most historical studies failed to specifically identify hypoxic tumours and so treatments would inevitably be given to patients who were unlikely to benefit from hypoxic modification. A hypoxic tumour
classifier based on a hypoxic gene signature has been used in a large cohort of HNSCC patients; tumours classified as hypoxic were associated with a significantly poorer outcome; however, outcomes were improved for patients with hypoxic tumours who received nimorazole. These results are also supported by studies that specifically identified hypoxic tumours in HNSCC patients through methods such as 18F-fluoromisonidazole–positron emission tomography (FMISO-PET) imaging, osteopontin or immunohistochemical analysis of pimonidazole labelling, with their results showing better tumour responses to nimorazole, tirapazamine, or ARCON, compared with standard treatments emphasising the need for accurate assessment of tumour hypoxia before treatment. One large meta-analysis study looked at the results of 64 clinical trials from HNSCC patients who received RT with curative intent and found that the addition of hypoxic modification improved loco-regional control, disease-free and overall survival.

Hypoxic imaging can also be used to enable more effective delivery of radiation to a tumour. Tumours identified as having large areas of hypoxia could be treated with increased radiation doses across the entire gross tumour volume (GTV); however, this technique could increase the risk of damage to the surrounding tissues. A more refined approach would be to determine a biological target volume (BTV) based on hypoxia. In this situation, the total radiation dose delivered to the GTV would remain the same, but the dose redistributed; raising the dose received by the hypoxic regions while reducing that received by the higher oxygenated regions. Alternatively, the BTV could receive boost doses of radiation either uniformly spread throughout the hypoxic sub-volume or varied according to the regional levels of hypoxia. Advancements in radiation-delivery machines, such as image-guided RT (IGRT) and intensity-modulated RT (IMRT), that allow highly conformal and accurate radiation delivery have meant that dose painting by numbers (DPBN) or sculpturing techniques are becoming more attainable. These techniques also have the advantage of limiting the radiation dose received by the nearby normal tissues.

If GTV or BTV dose escalation is to be used clinically, then determining how much additional radiation is required to obtain an increase in the benefit-to-risk ratio will need to be determined. Modelling studies have begun to investigate this question. One study combined PET imaging with IMRT planning as a means of
delivering a boost dose of 10 Gy to the hypoxic sub-volume of patients with HNSCC for those prescribed 70 Gy to the planned target volume (PTV). This study reported that this boost dose would provide a tumour control probability (TCP) increase of 17% without increasing complication risks within the surrounding normal tissues\textsuperscript{138}. Another study has shown that dose escalation using DPBN to the BTV would provide improved TCP compared with uniform dose escalation (both methods used the same mean dose). This study also showed that DPBN may be especially beneficial in cases with tumour regions of chronic hypoxia\textsuperscript{139}. Uniform BTV dose escalations of 10% have also been compared with DPBN in 13 scans from patients with HNSCC. DPBN again showed significantly improved TCP (70.2%) compared to conventional IMRT (55.9%) and uniform BTV (57.7%) dose escalation\textsuperscript{140}. These improved TCP rates are comparable with that seen using ARCON.

Although these results are promising, they are only radiobiological modelling studies and validation in clinical trials is needed. A potential significant limitation to using dose escalation plans based on functional imaging such as PET or MRI is that they fail to account for the dynamic nature of tumour hypoxia and the spatial and temporal changes that occur to the hypoxic volume during treatment. Serial images before and during treatment may provide an indication of changes but they still only provide a static indication of hypoxia at the time of image capture. Real-time data acquisition is currently not possible, and these techniques do not provide information on acute versus chronic hypoxia. Therefore, despite advances, approaches that give an accurate 3D map of hypoxic areas within the entire tumour volume in real-time are still not available. A potential solution to this unmet clinical need is the use of an implantable sensor that is designed to measure intra-tumoural O\textsubscript{2} tension at the time of treatment, which would also be able to provide information on the spatial and temporal changes that can occur during a patient’s treatment course.

1.7.8 Electrochemical oxygen sensors

The electrochemical reduction of O\textsubscript{2} was first demonstrated at the end of the 19\textsuperscript{th} century by Danneel and Nerst\textsuperscript{141}. However, in 1965 Clark was the first to be credited with the development of the amperometric ‘Clark electrode’ O\textsubscript{2} sensor capable of detecting O\textsubscript{2} at a platinum electrode\textsuperscript{142}. Here, at the electrode, O\textsubscript{2} undergoes electrochemical reduction which generates a measurable electric current.
proportional to the partial pressure of O\textsubscript{2} contained in the environment surrounding the sensor. This sensor used a gas permeable membrane to separate the electrodes and the liquid electrolyte in which they worked from the external environment. This technique prevented environmental proteins and electrolytes interfering with O\textsubscript{2} detection and reduction thus improving the sensor’s function in biological media\textsuperscript{141}. Unfortunately, these conventional Clark electrodes are unsuitable as implantable medical devices due to their large size and use of liquid electrolytes.

The Implantable Microsystems for Personalised Anti-Cancer Therapy (IMPACT) project is developing a miniaturised implantable solid-state Clark O\textsubscript{2} sensor to overcome limitations with conventional Clark-type electrodes\textsuperscript{143}. The project’s primary aim is to develop an implantable sensor that can monitor intra-tumoural O\textsubscript{2}. However, the ability of a sensor to continually measure tissue O\textsubscript{2} tension could prove to be a valuable monitoring tool for clinicians in a wide range of pathological and traumatic conditions where the measurement of organ perfusion is required. The IMPACT sensor is a 3-electrode cell composed of a platinum working electrode (WE), a Ag/AgCl reference electrode (RE) and a platinum counter electrode (CE), all microfabricated on silicon wafers\textsuperscript{143}. Oxygen reduction occurs at the WE against a fixed electrochemical potential provided by the RE. The function of the CE is to supply current to balance the WE reactions\textsuperscript{144}. A potential of -0.5 V (measured against the RE) is typically required to cause O\textsubscript{2} reduction at the WE. Nafion, a perfluorinated ion exchange resin, is O\textsubscript{2} permeable and can conduct protons between the electrodes and is used to coat the sensor surface, acting as both a gas permeable membrane and as a replacement for the traditional liquid electrolyte; this solid polymer membrane also helps prevents rapid electrode deterioration, increasing the sensors longevity\textsuperscript{145,146}. The silicon wafers are diced into 2.0 mm x 3.0 mm chips which each carry a single sensor. Individual chips are then bonded to a 1.7 mm x 200 mm long flexible printed circuit board (lead wire) and the chips are sealed in epoxy resin, resulting in an overall sensor size of approximately 2.6 mm x 5.0 mm x 1.4 mm (width x length x height). A window clear of epoxy resin over the central active sensor area permits interaction with the tissue environment (Figure 1.3).

Although several previous studies have designed microfabricated electrochemical O\textsubscript{2} sensors\textsuperscript{147-150}, IMPACT’s use of silicon-based microfabrication
techniques is currently unique. As well as having reproducibility and reduced manufacturing costs, silicon-based systems allow the integration of built-in complementary metal oxide semiconductor instrumentation electronics. This can create a fully autonomous ‘smart sensor’ eliminating the requirement of bulky external equipment, both of which are desirable characteristics for its use as an implantable medical device.

Figure 1.3. Microscopic and macroscopic images of the IMPACT O₂ sensor. (a) High magnification image documenting the position of the working, reference and counter electrodes covered by the Nafion membrane. (b) Macroscopic image documenting the chip covered in epoxy resin and bonded to the lead wire (images kindly provided by Dr J. Marland).

1.7.9 Cancer treatment and implantable technology

The concept of integrating implantable medical devices into cancer diagnosis, treatment and disease monitoring is becoming attainable due to advances in electronics and microfabrication techniques. Although most cancer studies using implantable devices are experimental or pre-clinical, promising results highlight their potential use in the field of precision medicine.

Pre-clinical studies have investigated the use of short-term implantable devices for high-throughput drug sensitivity testing within tumours. One study used a device containing multiple reservoirs which were capable of releasing drugs into distinct tumour regions at systemically achievable concentrations. Removal of tumour tissue surrounding the device 24 h after implantation allowed assessment of the anti-neoplastic effect of each drug through immunohistochemical analysis. This type of device could be employed to improve the identification of optimal drug
treatment before definitive systemic treatment commences. Releasing drugs directly within the TME could also reduce the severity of side effects seen with systemically administered drugs, whilst still achieving effective therapeutic doses. A tumour type that would benefit from a localised drug delivery system would be malignant brain tumours. The presence of the blood-brain barrier is a limitation to the development of effective brain tumour therapies, as it prevents the transfer of substances larger than 500 KDa and non-lipid soluble molecules into the brain. Because of this, chemotherapeutic systemic toxicity is often reached before obtaining effective therapeutic concentrations in the brain. The use of an implanted intra-cranial micro-electro-mechanical system (MEMS) to deliver the chemotherapy drug temozolomide to gliosarcoma brain tumours in rats has shown that implantation was safe and that drug delivery from the MEMS improved survival times. This silicon microchip was composed of 3 separate temozolomide containing reservoirs; each reservoir was covered by a membrane that could be independently opened by applying an electrical current. This study provided evidence that drugs can be locally administered to brain tumours at specific time points, allowing for active control over drug release rates. This concept could have applications for a range of tumours that require additional local treatments.

This MEMS type of implantable drug delivery systems also has potential for use in a wide range of diseases in which treatment regimens are difficult to implement. The first-in-human testing of a wirelessly-controlled drug delivery silicon microchip was used in the treatment of osteoporosis as a means of overcoming long-term daily injections of human parathyroid hormone fragment 1-34 (hPTH(1-34))154. The device consisted of multiple individual reservoirs filled with concentrated hPTH(1-34) solution. Even though a fibrous capsule developed around the device following implantation, pharmacokinetic evaluation showed similar bone formation results as compared to repeated daily hPTH(1-34) injections. This study provided evidence of an implantable device being utilised to overcome difficult treatment regimens and poor patient compliance15.

Implantable devices are not restricted to chemotherapeutic applications; they also have potential to be used in combination with RT. As previously mentioned, newer external beam RT techniques, such as 3D conformal RT can accurately
conform and deliver radiation to the shape of the PTV. As the clinical success of RT will depend upon the accuracy of delivering the calculated dose to the target area, it is important to be able to verify that the planned radiation dose is accurately delivered to the tumour. This has traditionally been achieved through regular calibration of the radiation source, using predictive algorithms and through placing diodes, thermo-luminescence dosimeters or metal oxide semiconductor field-effect transistor (MOSFET) dosimeters on the patient’s skin surface\textsuperscript{155,156}. However, a novel and potentially more accurate way to achieve dose monitoring has been achieved using an implantable dosimeter. This dose verification system (DVS) has undergone clinical testing and received Food and Drug Administration (FDA) approval for use in breast and prostate cancer. This device can verify the radiation dose received by the PTV for each fraction\textsuperscript{157} and provides the ability for radiation oncologists to verify and optimise radiation treatment on an individual basis.

As well as influencing a patient’s treatment, implantable sensors are suited for sampling the local tissue environment. Placed within a tumour or in surrounding tissue at the time of surgery or biopsy, sensors could play a role in monitoring the response of a tumour to treatment or in detection of recurrence or metastasis by measuring specific biomarkers. This would be especially useful in areas where imaging (MRI/CT) makes it difficult to distinguish between tumour recurrence, fibrosis, necrosis or benign lesions from previous surgery or chemoradiotherapy (gliomas)\textsuperscript{158}. The first \textit{in vivo} description of such a device was used to detect the $\beta$ subunit of human chorionic gonadotrophin (hcG-$\beta$)\textsuperscript{159}, a known soluble cancer biomarker, which shows elevated secretion levels in testicular and ovarian cancers. This study used an implantable device containing nanoparticle magnetic relaxation switches (MRSw) conjugated with antibodies for hcG-$\beta$. The device was implanted in tissue near hcG-$\beta$ producing JEG-3 (human choriocarcinoma) xenografts. Aggregation of these MRSw through hcG-$\beta$ antibody binding was detected through MRI, showing that the device was able to detect the biomarker in peri-tumoural tissue. MRSw can be functionalised to detect a variety of molecules, providing opportunities for their use in a variety of monitoring purposes\textsuperscript{160}. 

23
1.7.10 Regulations governing implantable medical devices

In 1992, Canada, the USA and Great Britain formed the International Standards Agency (ISO), which developed and published international standards on the Biological Evaluation of Medical Devices: ISO 10993. These standards classify implantable sensors as devices that are in contact with body tissues for greater than 30 days and describes pre-clinical in vitro and in vivo biocompatibility testing. *In vitro* tests include those for genotoxicity, cytotoxicity, carcinogenicity, developmental and reproductive toxicity, haemocompatibility, degradation assessment and biofunctionality (cellular adhesion and spreading); whereas *in vivo* tests focus on evaluating ethylene oxide residues, material degradation, sensitisation and irritation, local tissue effects and systemic toxicity\(^{161}\).

The Active Implantable Medical Devices Directive 90/385/ECC, developed by the Medicines and Healthcare products Regulatory Agency, aims to protect patient safety by ensuring manufacturers provide evidence of device safety and performance. This is essential for devices to gain market approval but also continues through post-market surveillance so adverse incidents can be identified by clinicians and patients. For a device to gain market approval manufactures can use ‘equivalence data’ and published clinical work of similar devices. This can decrease costs and the time required to get a product to market but can potentially lead to safety concerns, as each device is not fully evaluated; even high risk medical devices have been certified as safe without any supporting evidence in human trials\(^{162}\).

1.8 Biocompatibility and the foreign body response

During the development of implantable medical devices they must undergo biocompatibility evaluation to assess the device in terms of its biofunctionality (performance) and biosafety (local and systemic tissue responses and the absence of carcinogenesis, mutagenesis and cytotoxicity)\(^{15,163-165}\). Following implantation medical devices can lose functionality, this failure is largely due to biofouling (non-specific protein adsorption) that occurs around the device. This process results in a tissue reaction known as the foreign body response (FBR)\(^{165-167}\) and represents a clinical challenge in implantable technology design and development. It is the surface properties of the device that will influence the extent of the FBR that occurs
during the initial weeks following implantation, although the reaction at the tissue/surface interface will be present for the in vivo lifetime of the device.

1.8.1 Acute inflammatory response

Acute inflammation starts immediately after the implantation of a medical device within the body and typically resolves within 5 days\textsuperscript{168}. The magnitude of this initial response is related to the trauma caused by the insertion device, whereas the subsequent chronic inflammatory responses and fibrous encapsulation are largely affected by sensor size\textsuperscript{169}. Tissue injury at the implantation site will activate the intrinsic and extrinsic coagulation systems, complement and fibrinolytic system, kinin-generating system and platelets, causing the formation of a provisional matrix around the device\textsuperscript{170}. The device surface characteristics will affect the extent and type of proteins, such as albumin, fibrinogen, complement, fibronectin, vitronectin, and \( \gamma \) globulin that adhere to it\textsuperscript{167,171-173}. These proteins at the tissue/device interface provide structural, biochemical and cellular components that contribute to the ongoing inflammation through cytokine, chemoattractant and growth factor release\textsuperscript{174}. These substances can further regulate activation of the coagulation cascade, complement system, platelets and the subsequent immune responses through interacting with adhesion receptors present on inflammatory cells. Mast cell degranulation, with histamine release and fibrinogen adsorption, is also important during this stage for the recruitment of inflammatory cells\textsuperscript{175,176}.

Polymorphonuclear (PMN) leukocytes (neutrophils, granulocytes) are the predominant inflammatory cell type present for up to 2 days post-implantation\textsuperscript{167}. These cells play roles in microorganism phagocytosis and pathogen killing through the secretion of proteolytic enzymes and reactive O\(_2\) species. However, these enzymes may also be damaging to implanted materials and increase the duration of the acute inflammatory response. Prolonged PMN activation, due to the continual presence of the implanted medical device, can lead to metabolic exhaustion and depletion of oxidative resources. This situation can reduce their microbial killing ability and can contribute to the development of implant-related infections\textsuperscript{177}. PMNs secrete immunoregulatory signals such as IL-8\textsuperscript{178,179}, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1\( \beta \), which recruit further PMNs, monocytes, macrophages, lymphocytes and immature dendritic cells into the
Continued chemokine release leads to suppression of PMN infiltration and their numbers begin to fall as they are engulfed by macrophages or become apoptotic.

1.8.2 Chronic inflammatory response

The continued presence of an implanted medical device within the body leads to the development of chronic inflammation; this phase is characterised by the presence of monocytes, macrophages, fibroblasts, neovascularisation and the production of granulation and fibrous tissue around the implanted device. Macrophages are the predominant cell type present for up to 3 weeks following resolution of acute inflammation and will drive the ongoing immune response, enhancing the propagation of chemoattractive signals through the production of factors such as: PDGF, fibroblast growth factor, tumour necrosis factor-α (TNF-α), IL-1, IL-6, granulocyte-colony stimulating factor (G-CSF), transforming growth factor-β, transforming growth factor-α, chemokine (C-C motif) ligand 2 (CCL2) and granulocyte macrophage colony stimulating factor (GM-CSF). Macrophages are only capable of phagocytosing particles up to 5 μm in size; as a consequence of this, macrophages, in an attempt to deal with large implanted materials, fuse together to form foreign body giant cells (FBGCs) which spread over the material’s surface through integrin binding.

In vitro and in vivo studies have shown that FBGC formation can be induced by the cytokines IL-4 and IL-13; although, the exact source of these cytokines is under debate, natural killer cells (NK), natural killer-T cells (NKT) cells, mast cells, eosinophils, and basophils are all potential sources. However, the functions of these cell types in FBGC formation is unknown, as mouse models deficient in NK or NKT lymphocytes, mast cells or IL-4 receptor-α can still form FBGC in response to implanted materials. Activated T lymphocytes (CD4+ cells), transiently present at the implant site during chronic inflammation, are another possible source of these cytokines. In vivo lymphocyte/macrophage co-cultures have shown the ability of lymphocytes to increase macrophage adhesion to material surfaces and enhance FBGC formation, while macrophages can stimulate lymphocytes to proliferate. However, as the FBR has been shown to occur in the absence of T cells, the role of lymphocytes in FBGC formation remains unclear.
1.8.3 Consequences of foreign body giant cell formation

A unique environment exists between the device surface and the FBGC/macrophage cell membranes. Following failed attempts of classically activated macrophages and FBGC to phagocytose the material, they release degradative substances such as reactive \( \text{O}_2 \) intermediates, free radicals, enzymes and acids into the microenvironment; this process is termed ‘frustrated phagocytosis’ 195-197. The slow rate at which buffers and inhibitors of these substances gain access to this environment results in the surface of the device being exposed to high concentrations of these degradative agents 198. It is these reactions that can lead to material degradation and device failure 167.

1.8.4 Extracellular matrix remodelling

Macrophages are involved in angiogenesis, fibroproliferation and tissue remodelling through the secretion of growth and angiogenic factors and matrix metalloproteinases 167,199. Alternatively activated macrophages produce profibrogenic factors leading to fibrogenesis by fibroblasts 200, which can lead to the deposition of a collagenous and vascular fibrous capsule around the device. This capsule is the end stage of the FBR 201 and can be 50–200 µm thick 165. It is this capsule, in combination with FBGC on the device surface, that can contribute to loss of device function through the creation of a barrier that confines and prevents the implant from interacting with the surrounding tissues (Figure 1.4).
Figure 1.4. Sequence of inflammatory responses leading to FBGC formation and fibroblast infiltration. The result of the FBR is the production of granulation tissue with subsequent fibrous capsule formation. This reaction causes ‘walling-off’ of the sensor from its immediate surrounding area. This reaction combined with the degradative chemicals released from the FBGC can lead to loss of sensor function. 

1.9 Pre-clinical in vitro models used in the development of cancer therapeutics

The development and assessment of anti-cancer agents follow a stepwise process from in vitro and in vivo testing through to phase 0, I, II, III and IV clinical trials. A typical development plan would involve the assessment of compounds through in vitro cell-based assays investigating cell survival, proliferation, death, migration and invasion. Compounds would then progress onto in vivo studies assessing anti-tumour activity and pharmacological studies to define drug absorption, distribution, metabolism and elimination before progressing into clinical trials. This process is expensive and time consuming; from concept to completion of phase III trials, may take over 10 years and several hundred million pounds. Time and expense are not the only issues with cancer drug development; attrition rates for new cancer therapeutics are very high, with only 5% of agents that show pre-clinical promise gain a license to be used in patients.

Most pre-clinical studies assessing the efficacy of cancer agents rely on cancer cells grown in 2D cultures. Unfortunately, these models lack tumour heterogeneity and extended culturing may select for clones which survive and grow best in these
conditions. Using large panels of cell lines, such as the National Cancer Institute-60 panel (NCI-60)\textsuperscript{204}, or the expansion of cell lines derived directly from tumour tissue may partially overcome this problem\textsuperscript{205}. However, 2D cultures cannot replicate complex stromal components, interactions with immune cells/inflammatory mediators/growth factors or the acidic/hypoxic TME\textsuperscript{206}. The development of 3D cell culture and co-culture systems such as multicellular tumour spheroids (MTS) and organoids aim to better mimic the structural and functional properties of normal and tumour tissue and to bridge the gap between cell-based assays and animal studies\textsuperscript{207}. High-throughput assays have also been developed using MTS cultured in microwells with non-adherent hydrogels\textsuperscript{208,209}. MTS from cervical, breast and HNSCC cells form within 3-6 days, allowing high-throughput drug assays to be performed\textsuperscript{210}.

The National Cancer Institute’s (NCI) Developmental Therapeutics Program has developed in vivo rodent screening models to select agents for evaluation as clinical candidates. Common in vivo models include the hollow fibre assay\textsuperscript{211}, human tumour xenograft models, carcinogen-induced models, genetically-engineered models and inbred strains with high rates of spontaneous tumour development\textsuperscript{212}. Murine models have historically dominated medical research due to ease of breeding and housing and the availability of a large number of genetically identical strains and genetically-engineered models.

Subcutaneous and orthotopic xenograft murine tumour models can be established by inoculating human tumour cells grown in vitro or by implantation of patient tumour tissue into immunodeficient mice (athymic, severe combined immunodeficient (SCID), or non-obese diabetic/SCID); these models allow in vivo monitoring of tumour growth, drug toxicity, efficacy and pharmacokinetic studies, and reflect the O\textsubscript{2} and pH gradients found in solid tumours\textsuperscript{213}. These models have increased our molecular understanding of cancer and have been used successfully in pre-clinical cancer drug development; their use as predictors of clinical activity has also been validated for numerous cytotoxic agents\textsuperscript{214,215}. A retrospective analysis of 39 compounds using data from both xenograft testing and phase II clinical trials was performed by the NCI. This study showed that 15/33 agents with activity in more than one-third of cell line derived xenografts showed clinical activity. However, with the exception of NSCLC, activity within a particular xenograft histological type did
not predict for clinical activity in the same tumour type in patients\textsuperscript{216}. A further study using patient-derived xenografts (PDX) showed similar results\textsuperscript{217}.

Unfortunately, these murine models have limitations and reliance on them has contributed to high attrition rates in cancer drug development. Subcutaneous xenografts, particularly those established from cell lines, do not represent the primary tumour from which they are derived in terms of heterogeneity, tumourigenesis and metastasis\textsuperscript{218,219}. Orthotopic transplantation models are thought to be more representative of clinical tumours in terms of the development of metastatic disease\textsuperscript{220}. However, stromal tumour components in both models will be murine in origin and therefore the effects of drugs on the TME may not be representative of human tumours. This limitation may be minimised by using PDX, although even in this model human stromal elements are progressively lost over time. Other limitations include poor uptake of PDX and difficulties in obtaining patient material\textsuperscript{221}. Importantly, the growth rates of human xenografts are higher than that of primary tumours, as a result of this, they are much more likely to respond to anti-proliferative agents and so might provide a false indication of drug efficacy\textsuperscript{219}. The use of immunocompromised models hinders the testing of immunomodulatory agents; although immunocompetent genetically-engineered murine models, carcinogen-induced models or strains that have spontaneously-occurring tumours can overcome some of these limitations they still suffer from having murine-derived stroma. It can also be difficult to extrapolate drug doses to human trials as maximum tolerated murine doses may be far higher than those used in human patients\textsuperscript{222}.

Rodents also differ considerably from humans in size, physiology, anatomy, lifespan and immunology, all of which can reduce their usefulness\textsuperscript{215}. Their small size precludes their use for the development of human surgical procedures\textsuperscript{223}. It is also difficult to scale down equipment such as imaging technologies or surgical instrumentation. Samples can also only be collected in small quantities, which can be insufficient for detailed analyses. Modelling treatment protocols commonly used in human patients such as RT is hampered in rodents by uncertainties regarding the scaling of energy doses. An approach to overcome these limitations would be to combine murine studies with comparative cancer studies in other species to optimise the development of the most effective cancer therapies.
1.10 Comparative oncology

Comparative oncology is a field of research that uses naturally occurring cancers in animals as a means of investigating similar cancers in human patients. This approach can include all aspects of cancer research including pathogenesis and the evaluation of cancer treatments. Dogs, cats and large animals with naturally-occurring tumours that have incidence rates, clinicopathological features and risk factors similar to specific human cancers are regarded as excellent translational models of human disease\textsuperscript{224-226}. These models are particularly important as these cancers develop in the presence of an intact immune system where tumour, TME and host have developed together\textsuperscript{227}.

Dogs and sheep have many features that make them suitable for a range of comparative studies. The shorter lifespan of these species compared to humans enables tumours that develop after a few years instead of decades to be studied more readily; this can allow clinical trials to be performed rapidly whilst still providing a sufficient time course to allow comparison of treatment responses. Similarities in anatomy, size, physiology, immunology and metabolism to humans allow procedures or drugs that are commonly used in human medicine to be used in translational studies. Recent canine genome sequencing\textsuperscript{228} has also shown significant similarities between dog and human genetic sequences; which is far greater than that seen between human and mice sequences\textsuperscript{229}. Dogs have also been shown to be a highly predictive model for human drug development\textsuperscript{224,226,230}. As a result of these factors various canine and ovine translational models have become popular in pre-clinical trials as they can overcome the limitations associated with murine models.

1.11 Comparative human and canine breast cancer

Mammary tumours are the most commonly diagnosed cancer in female dogs with the disease accounting for approximately 50% of all canine neoplasms\textsuperscript{231}. The peak incidence age for dogs to develop mammary tumours is between 8-11 years old which is comparable to that seen in humans (50-58 years)\textsuperscript{232-236}. Canine mammary tumours (CMT) are known to have a hormonal aetiology with one study showing that the disease developed in approximately 0.5% of female dogs that were spayed before their first season compared with 8% and 26% of dogs spayed after their first or
Other risk factors for disease development include diet and obesity. In humans, obesity has been suggested to increase the risk of breast cancer by raising circulating oestrogen levels and increasing local oestrogen production by aromatases. Approximately 50% of canine mammary carcinomas will metastasise to regional lymph nodes, lungs and bone. This clinical course is similar to that seen in humans where approximately 37% of women will either present with or develop metastatic disease. In both human and canine patients, tumour size, age, clinical stage, the presence of local/distant metastases and histological subtype can be used as prognostic markers that can identify patients at higher risk of recurrence or mortality. Studies have also shown that there are significant similarities in the transcriptome and proteome of metastatic canine and human mammary carcinomas. These results suggest that similar mechanisms of mammary carcinogenesis may occur between the 2 species and that metastatic canine carcinomas are a suitable model for human breast tumours in order to identify prognostic molecular signatures and potential therapeutic targets.

1.11.1 Molecular markers and signalling pathways

The assessment of hormone or signalling receptor expression in human breast cancer has been shown to provide prognostic information and predict which patients will most likely respond to certain treatments. Although these markers are not routinely used in veterinary medicine, increasing evidence suggests that these human-derived molecular markers might be similarly useful for CMT evaluation.

ER and PgR expression occur in approximately 70% of benign and 60% of malignant CMT, this is similar to that seen in human breast cancer where approximately 85% express ER and 67% express PgR. Several studies have now shown that ER and PgR expression can be prognostic and predictive of disease-free and overall survival, with a decrease in hormonal dependency commonly seen in canine malignant mammary tumours and metastatic disease. One recent study showed that dogs with ER+/PgR+ tumours had better survival rates compared with ER/PgR+ tumours and that ER/PgR+ tumours had the worst prognosis of all.

HER2 expression occurs in approximately 30% of all human breast cancers and is associated with high metastatic rates and poor prognosis. Several studies
have identified HER2 expression in approximately 35% of malignant CMT\textsuperscript{257-259}; however, the use of HER2 as a marker of CMT malignancy is unclear. Although some studies have shown HER2 expression is associated with high proliferation rates, histological grade, tumour size and poor prognosis\textsuperscript{257,259-261} others have shown no difference in HER2 expression between benign and malignant tumours\textsuperscript{258,262,263}. EGFR has been suggested as a prognostic marker in human triple negative breast cancer (ER\textsuperscript{−}/PgR\textsuperscript{−}/HER2\textsuperscript{−})\textsuperscript{264}. In CMT high EGFR expression has been associated with tumour size, angiogenesis, proliferation rate, tumour necrosis, histological grade and clinical stage\textsuperscript{265-267}. However, its role in carcinogenesis or prognosis is unclear. Although a tendency toward shorter disease-free survival and overall survival has been identified in dogs with CMT expressing EGFR, these associations failed to reach statistical significance\textsuperscript{266}. EGFR downstream signalling pathways have also been implicated in human breast cancer pathogenesis; results from the first genome-wide comparative analysis of canine and human mammary cancers demonstrated that tumours from both species had up-regulation of pathways related to proliferation, whereas pathways related to cell development, cell matrix adhesion and cell communication were down-regulated. Furthermore, this study demonstrated a great degree of homology between human and canine mammary tumours with respect to many cancer-related pathways including PI3K/AKT, KRAS, PTEN, WNT-\(\beta\)-catenin, and MAPK\textsuperscript{268}. Other molecular markers which have been investigated for similarities between human and canine mammary tumours include insulin-like growth factor, growth hormone, mucins, heat shock proteins, P53, CEA, CA 15-3, VEGF and cyclooxygenases\textsuperscript{261,269-272}. The similarities in aetiology, histopathology, pathogenesis, oncogenic drivers, target genes and molecular signalling pathways observed between canine and human mammary cancers supports the use of spontaneously occurring canine mammary tumours as a model for human disease. This model has great potential to not only advance the molecular understanding of breast cancer, but also improve pre-clinical research and treatment of canine and human breast cancer patients.
1.12 Comparative human and ovine lung anatomy and physiology

Sheep are excellent models for investigating human lung function and disease largely due to their similarities in terms of lung physiology and anatomy\textsuperscript{273}. Both species have 2 lungs, in humans the left is divided into superior and inferior lobes and the right is divided into superior, inferior and middle lobes; whereas, in sheep the left divided is into cranial and caudal lobes and the right is divided into cranial, caudal, middle and accessory lobes\textsuperscript{274} (Figure 1.5). Although the right cranial lobe bronchus originates proximal to the tracheal bifurcation\textsuperscript{275} and bronchioles are less well developed in sheep\textsuperscript{274}, the remaining tracheobronchial anatomy is very similar to humans. Both species show an irregular dichotomous tracheobronchial branching pattern with similar distribution of differentiated respiratory epithelial cells\textsuperscript{276}, mast cells\textsuperscript{277} and airway smooth muscle\textsuperscript{278}. Although fewer intra-vascular pulmonary macrophages are seen in human lungs, increased numbers can be induced after endotoxic insults\textsuperscript{279}. Lung development between the species is also comparable, with lamb and human infant lungs showing prenatal alveologenesis and the same tracheobronchial branching pattern. Type II alveolar epithelial cell (pneumocytes) development and number of bronchiolar club cells and airway submucosal glands is also similar\textsuperscript{280}. Similarities in lung size also allow sheep to be used in ways not achievable using rodent models. Techniques used in the treatment of human patients such as endoscopy, advanced imaging\textsuperscript{281}, ultrasound\textsuperscript{282} and surgery can be performed in sheep, providing the model with excellent translational potential\textsuperscript{283}. Repeated blood and tissue collection are easier in sheep and their increased lifespan compared to rodents allows chronic conditions to be modelled whilst enabling long-term treatments to be evaluated. These factors have made sheep excellent models for human respiratory diseases\textsuperscript{275} such as asthma\textsuperscript{284}, cystic fibrosis, chronic obstructive respiratory disease\textsuperscript{285}, respiratory syncytial virus infection\textsuperscript{286} and now cancer\textsuperscript{287}. 


1.12.1 Human lung cancer

Global estimates indicate that lung cancer accounts for approximately 2 million new cases and 1.8 million cancer-related deaths per year, making it the most commonly diagnosed cancer in the world\(^6\). Unfortunately, 5-year survival rates are only 15%; this low rate is largely due to patients being diagnosed with advanced disease, when poor responses to chemotherapy and RT are seen. Lung cancer is a highly heterogenous disease and is divided into multiple subtypes\(^{273}\). These subtypes undergo periodic review and in 2011 a multidisciplinary classification system was suggested by the European Respiratory Society (ERS) and International Association for the Study of Lung Cancer (IASLC)\(^{288}\). Based on pathogenesis, biology and histopathology, this system rendered previous terms such as bronchioloalveolar carcinoma (BAC), including its non-mucinous and mucinous forms redundant. Lung cancer is broadly classified into non-small cell lung cancer (NSCLC), originating from epithelial lung cells and small-cell lung cancer (SCLC), originating from neuroendocrine bronchial cells. NSCLC accounts for 80% of lung cancer cases and is further subtyped into adenocarcinomas, squamous cell carcinomas, large-cell carcinomas, undifferentiated and mixed tumours\(^{289}\). Adenocarcinomas are the most common form of lung cancer, accounting for 40% of all cases.

Adenocarcinoma tumourigenesis is complex but is thought to begin with cellular changes occurring through hyperplasia of lung epithelial cells. The cells making up these pre-malignant lesions, known as ‘atypical adenomatous hyperplasia’\(^{290}\), accumulate genetic abnormalities causing them to become pleomorphic resulting in a lepidic, non-invasive, growth pattern along alveolar walls.
Lesions less than 30 mm in diameter are known as adenocarcinoma-in-situ; if treated at this stage by complete surgical resection, almost 100% of cases will achieve 5-year disease-free survival. Untreated/undiagnosed lesions will continue to grow and develop into invasive adenocarcinomas. Minimally invasive adenocarcinoma is a term used to describe lesions less than 30 mm in diameter with an invasive component of less than 5 mm; lesion resection is still likely to give excellent disease-free survival rates. Invasive adenocarcinomas greater than 30 mm in diameter are classified on the predominant cellular growth pattern present within the lesion (lepidic, acinar, papillary or solid); it is these invasive subtypes that are most commonly diagnosed in patients. Lepidic-predominant adenocarcinoma describes an invasive adenocarcinoma subtype that has a predominant lepidic growth pattern with an invasive component greater than 5 mm; these subtypes can be non-mucinous or mucinous (previously termed non-mucinous and mucinous BAC). The mucinous form can be non-invasive, minimally-invasive or invasive and is often bilateral and multifocal with extensive mucous production. Patients suffering from this subtype present with a cough and extensive mucous production which can lead to death from respiratory failure without any evidence of invasive disease.288

1.12.2 Models of human lung cancer

Although numerous animal models are available for lung cancer research (hamsters, mice, dogs, primates)291,292, mice have been considered the model of choice due to their ease of genetic manipulation and cost-effectiveness293. These factors have led to numerous mouse models being developed. Inbred strains with high rates of spontaneous lung tumour development are commonly used in chemoprevention studies294-296. Chemical297, carcinogen291 and environmental-induced lung cancer models allow for the study of tumourigenesis and progression298, whereas orthotopic xenograft models are used to investigate both primary and metastatic disease299-302. Transgenic mouse strains incorporating genetic mutations that occur in human lung cancers such as tumour suppressor gene inactivation (p53, retinoblastoma and p16), oncogene activation (K-ras), altered growth factor expression303 and amplification of specific chromosomal regions304,305 will produce tumours with greater similarity to those seen in humans and can be used to identify genes that drive lung cancer development and progression304. Mouse
models using fluorescent or bioluminescent reporters have also been described\textsuperscript{306,307} which can be used for the identification of oncogenes involved in tumourigenesis and determination of tumour cell type origin\textsuperscript{308}.

Despite their uses, these mouse models do not accurately represent advanced stages of human lung cancer and suffer from the same general limitations as mouse models for other cancer types, as described in section 1.9. The perceived advantages of having numerous models available can also be a significant limitation, as no one single model can be used to investigate all stages of the disease.

1.12.3 Ovine pulmonary adenocarcinoma

Ovine pulmonary adenocarcinoma (OPA) is becoming regarded as a valuable translational model for studying human lung cancer\textsuperscript{309}. OPA is a naturally occurring neoplastic lung disease caused by the jaagsiekte sheep retrovirus (JSRV)\textsuperscript{310-313}; the disease was first described in the 19\textsuperscript{th} century in sheep flocks in South Africa\textsuperscript{314}. Since then, JSRV infection has been identified throughout the world in numerous sheep breeds and small ruminants (including goats) but has never been identified in humans\textsuperscript{315,316}. Endemic within the UK, OPA is an economic and animal welfare concern\textsuperscript{317}. Although within-flock disease incidence can be as high as 30\%, levels of 2-5\% are more common\textsuperscript{309}. Mortality rates tend to reduce from 50\%, following initial disease diagnosis within the flock\textsuperscript{318}, to approximately 1-5\% as it becomes endemic\textsuperscript{314,319}. Apart from increased mortality, production losses occur through decreased weight gain and reduced fertility\textsuperscript{312}. Disease transmission occurs most commonly through the aerosol route\textsuperscript{314,318,320}, although the virus has also been isolated from the milk and colostrum of infected ewes\textsuperscript{321}.

1.12.4 JSRV biology

JSRV is the only known betaretrovirus capable of lung adenocarcinoma tumourigenesis. Each JSRV particle contains 2 single-stranded positive sense RNA copies containing a genome of approximately 7,460 nucleotides. Four genes encode viral proteins\textsuperscript{312}, gag (encoding structural proteins), pro (encoding aspartic protease), pol (encoding reverse transcriptase and integrase enzymes) and env (encoding surface and transmembrane envelope glycoproteins)\textsuperscript{322,323}. Although an additional open reading frame, known as orfX, has also been identified, its function remains
unclear as it is not required for cellular transformation\textsuperscript{324} or oncogenesis\textsuperscript{325-327}. The cellular mechanism underlying neoplastic transformation following JSRV infection involves the Env glycoprotein acting as a viral oncoprotein; this transforming ability has been shown using \textit{in vitro} systems\textsuperscript{324,328} and \textit{in vivo} mice\textsuperscript{327} and sheep\textsuperscript{326} models. It is thought that plasma membrane localised Env glycoprotein may interact with protein kinases, adapter proteins and signalling molecules that are capable of triggering cellular proliferation and survival pathways\textsuperscript{329}. The Ras-MEK-ERK and PI3K-AKT-mTOR\textsuperscript{287} pathways are commonly activated in OPA and human lung adenocarcinomas but others may include RON-HYAL2, EGFR and heat shock proteins\textsuperscript{330}. Further mutations such as telomerase activation\textsuperscript{331}, inactivation of tumour-suppressor genes or activation of additional oncogenes\textsuperscript{287} are likely to be required if tumours are to develop following initial pathway activation\textsuperscript{273}.

\section*{1.12.5 Endogenous retrovirus and immune responses}

Endogenous retroviruses are viruses that have become integrated into host germ-line DNA and are passed to subsequent generations. Numerous endogenous JSRV (enJSRV) have been found in the sheep genome which have over 90\% sequence homology to exogenous JSRV (exJSRV)\textsuperscript{332,333}. Although enJSRV are non-oncogenic\textsuperscript{310,322,334,335}, viral RNA and proteins have been identified in the female reproductive tract and in foetal tissues, providing evidence of their transcriptional potential\textsuperscript{335,336}. Viral proteins may protect from exJSRV infection by receptor competition or through the prevention of exJSRV transport and cellular exit\textsuperscript{336,337}.

Although JSRV infection can induce the production of neutralising antibodies\textsuperscript{338,339}, cellular or humoral adaptive immune responses typically do not occur. This is likely the result of immunological tolerance to JSRV antigens due to enJSRV protein expression in the foetal thymus during T lymphocyte development. Ineffective immune responses are also thought to occur through overproduction of surfactant proteins combined with tumour cells down-regulating major histocompatibility complex class I antigens preventing cellular recognition by CD8\textsuperscript{+} T lymphocytes. Alveolar macrophages can also produce large amounts of interferon gamma, which can inhibit T cell activation and JSRV-specific immune responses\textsuperscript{340}. 
1.12.6 OPA diagnosis

OPA cases are typically diagnosed in sheep aged 2-4 years of age. Diagnosis of clinical cases can be obtained from a physical examination; common clinical signs include weight loss, pneumonia, tachypnoea and dyspnoea\textsuperscript{341}. Thoracic auscultation may identify adventitious lung sounds\textsuperscript{342}; however, a pathognomonic sign of OPA is copious amounts of fluid draining from the nostrils\textsuperscript{343} which typically occurs when tumours occupy more than 30\% of the lung volume\textsuperscript{341}. Although these advanced stage tumours may develop over many months or years\textsuperscript{341}, new evidence indicates that some tumours can develop quickly\textsuperscript{344}. Pre-clinical antemortem OPA diagnosis is important for removing infectious sheep from flocks but also for identifying cases for research. Unfortunately, this pre-clinical diagnosis is difficult to achieve, as many sheep never develop clinical signs during their commercial lifespan\textsuperscript{345}. Diagnostic serological assays are not useful, as JSRV-infected sheep fail to produce humoral immune responses\textsuperscript{346}. Virus detection in the blood is possible through PCR technology\textsuperscript{347} but due to low numbers of virally infected blood cells (monocytes, T and B lymphocytes) high false negative results are seen\textsuperscript{348}. Despite this, PCR testing is useful for identifying infected flocks rather than individual animals. The same PCR technique has been used successfully to detect JSRV-infected cells in bronchoalveolar\textsuperscript{343} and lung fluid\textsuperscript{349} samples. This PCR test offers better sensitivity compared to blood samples; although, early cases can be missed as the procedure only samples a small region of the lung. The procedure also requires sedation and so is not practical for routine large-scale on-farm testing. Because of these factors, the standard diagnostic test for pre-clinical and clinical OPA cases is gross pathology and histology performed at the post-mortem examination.

1.12.7 OPA histology and comparison with human lung adenocarcinomas

Histological examination of OPA lesions reveal non-encapsulated tumours originating from JSRV-transformed alveolar and bronchiolar epithelial cells\textsuperscript{273,350,351}. Lesions are composed predominantly of type II pneumocytes, involved with alveolar surfactant production, with smaller numbers of undifferentiated cells and bronchiolar club cells that are involved with producing proteins that line bronchioles\textsuperscript{352}. Tumours can be highly heterogenous, with typical areas composed of columnar or cuboidal
cells with a low mitotic rate, whereas other areas show higher degrees of malignancy with high mitotic rates and necrosis\textsuperscript{352,353}. Tumour cells become surrounded by fibrovascular connective tissue which aids the influx of inflammatory cells. Although large numbers of macrophages are seen\textsuperscript{340}, neutrophil numbers can be variable, which is largely determined by whether a bacterial infection is present. Cancer cells spread along alveolar septa (lepidic growth) before forming acinar or papillary proliferations within bronchioles. JSRV virions, released from infected cells, cause the formation of new foci of infection throughout the lung\textsuperscript{354} and as neighbouring neoplastic foci enlarge, they coalesce to form a single large tumour. Although not common, intra-thoracic and extra-thoracic metastasis has been identified in approximately 10\% of cases\textsuperscript{355-358}. Initial histological classification systems described OPA as having similarity to human BAC; however, under the revised lung classification system early OPA lesions closely resemble those of minimally invasive adenocarcinoma or lepidic-predominant adenocarcinoma, whereas advanced disease would fit a description of adenocarcinoma with an acinar or papillary growth pattern with or without mucinous features. An important consideration is that OPA has significant similarities to the rare non-invasive, multifocal subtypes of human lung adenocarcinoma (such as the mucinous forms), where clinical samples are difficult to obtain, and is less similar to the more common metastatic forms of the disease\textsuperscript{287}.

1.13 Hypothesis and aims

The radiation response of a tumour depends not only on innate radiosensitivity but also on the TME and the development of acquired radioresistance. For RT to become integrated into the concept of precision medicine we require a detailed understanding of the mechanisms that contribute to cancer cells gaining radioresistance, as well as the development of novel methods by which tumour hypoxia can be monitored in real-time. This would provide a means by which these treatment resistant areas can be targeted. Monitoring patients during therapy would allow assessment of response to treatment and would assist the early identification of non-responding patients; more effective therapies could then be instigated sooner whilst sparing the patient from RT-induced side effects. With these currently unmet clinical issues in mind, the following hypothesis was devised and specific research aims identified.
1.13.1 Hypothesis

The overriding hypothesis that forms the basis for the body of work within this thesis is that complementary *in vitro* and *in vivo* research is required to advance the understanding of radioresistance and investigate means by which RT can become tailored to individual patients.

We hypothesise that developed *in vitro* radioresistant (RR) cell lines will undergo phenotypic and genotypic changes with respect to their original parental cell lines. Alterations in signalling pathways are hypothesised to identify therapeutic targets to reverse radioresistance; whereas changes in secretion profiles can be used to identify biomarkers related to radiation response and radioresistance. These biomarkers, when validated, could provide a means by which the radiation response of a tumour can be monitored either through blood samples or more locally using a sensor implanted into the tumour itself.

For medical devices to be implanted into tumours the *in vivo* biocompatibility of sensor components must be assessed. We hypothesise that a murine xenograft model can be developed to obtain intra-tumoural biocompatibility data for materials being consideration for use in the IMPACT O₂ sensor. Previous studies have suggested that these materials, commonly used in medical devices, have good biocompatibility when implanted into healthy tissues. We therefore hypothesise that these materials when implanted into xenografted tumours will be biocompatible and produce a minimal FBR. These results could be used in conjunction with previous studies to justify the use of these materials in the construction of implantable devices for a range of medical conditions. For validation of ability of the IMPACT O₂ sensor to be able to be implanted into a tumour and provide real-time intra-tumoural O₂ measurements we hypothesise that an ovine lung cancer model would not only answer these questions but would also be an excellent novel translational model of human lung cancer.

Our final hypothesis is that although the IMPACT O₂ sensor was originally designed for intra-tumoural use, this sensor could also be utilised for real-time monitoring of visceral surface O₂ levels in a range of medical conditions. One such application would be monitoring post-operative intestinal perfusion following an intestinal resection and anastomosis. The use of the sensor in this way could detect
peri-anastomotic tissue hypoxia and enable goal-directed treatments to be provided to restore intestinal oxygenation and prevent anastomotic dehiscence. We hypothesis that a developed murine model will provide proof-of-concept for this application.

1.13.2 Aims

1. **To develop and characterise radioresistant breast cancer cell lines**
   - Develop novel RR breast cancer cell lines using ER$^+$ and ER$^-$ cell lines representing different molecular breast cancer subtypes.
   - Undertake genotypic, phenotypic and functional characterisation of parental and RR cell lines to demonstrate cellular differences at gene, protein and functional levels.
   - Identify differential phenotypic and signalling pathways between parental and RR cell lines to highlight potential mechanisms of radioresistance.

2. **To develop a method to identify and validate radiation-induced cancer cell secreted biomarkers**
   - Obtain secretome samples from cancer cells up to 24 h post-radiation treatment from a variety of species and cancer types.
   - Use liquid chromatography-mass spectrometry to characterise the MCF-7 secretome in both untreated and radiation-treated samples.
   - Select candidate radiation-induced secreted biomarkers for further validation and examine their secretion patterns in other human and canine breast and ovine lung cancer cell lines.
   - Combine secretomic results with whole-transcriptome gene expression data from both radiation-treated parental and RR cell lines to identify biomarkers of radiosensitivity and validate them through western blot, immunofluorescence and immunohistochemistry.

3. **To develop a method to investigate the biocompatibility of implantable sensor materials in a tumour model**
   - Assess the intra-tumoural biocompatibility of materials under consideration for use in the IMPACT O$_2$ sensor.
   - Develop a novel *in vivo* murine biocompatibility model whereby materials are implanted into human breast cancer xenograft tumours and their effects
assessed through tumour immunohistochemistry (necrosis, proliferation, apoptosis, hypoxic markers, innate immune responses and fibrosis).

- Provide evidence to justify the use of these materials in the IMPACT O₂ sensor.

4. **To validate functionality of the IMPACT O₂ sensor to measure tissue O₂ tension for clinical applications**
   - Develop an *in vivo* murine model for validation of the IMPACT O₂ sensor to provide real-time measurements of intestinal and muscular ptO₂.
   - Investigate the sensor’s ability to detect changes in intestinal ptO₂ following ischaemic, hypoxic and haemorrhagic challenges and its ability to detect changes in muscular ptO₂ following hypoxic challenges.
   - Provide evidence to justify further development of the IMPACT O₂ sensor towards clinical applications in man.

5. **To develop a pre-clinical translation large animal model of human lung cancer and validate functionality of the IMPACT O₂ sensor to measure tissue O₂ tension within a solid tumour**
   - Develop a novel *in vivo* ovine pulmonary adenocarcinoma model for the surgical implantation and validation of the IMPACT O₂ sensor.
   - Develop a novel CT-guided trans-thoracic percutaneous implantation procedure with integration of techniques such as ultrasound, general anaesthesia, CT and surgery into the model.
   - Assess the sensor’s ability to detect changes in intra-tumoural ptO₂ following hypoxic challenges.
   - Provide evidence to justify further development of the IMPACT O₂ sensor towards clinical applications in man.
2 Materials and Methods: In Vitro Experiments

2.1 Introduction

All cell tissue culture and laboratory experiments were performed in the Division of Pathology Laboratories, Western General Hospital (University of Edinburgh).

2.2 Cell tissue culture

2.2.1 Cell lines

A panel of 4 human breast cancer cell lines, MCF-7, ZR-751, MDA-MB-231 and HBL-100, were chosen for this study due to their differing molecular classifications and phenotypic traits. For comparative studies involving different species and cancer cell types, 1 canine breast cancer cell line, REM-134, and 1 ovine lung cancer cell line, JS7, were chosen. The characteristics of these cell lines are outlined in Table 2.1.

All human breast cancer cell lines were obtained from the American Type Culture Collection (LGC Standards, Teddington, UK) and were authenticated by short tandem repeat (STR) profiling performed at Health England (Porton Down, Salisbury, UK). All cell line DNA samples matched 9 of 9 tested core alleles in DNA from known cell line samples confirming their identity. The canine breast cancer cell line was a kind gift from Professor R.W. Else (College of Veterinary Medicine, University of Edinburgh) and the ovine lung cancer cell line was a kind gift from Dr D. Griffiths (Moredun Research Institute, Pentlands Science Park, UK). All cells were maintained at a low passage number from frozen stocks with mycoplasma testing performed at 6 monthly intervals.
Table 2.1. Human, canine and ovine cell lines used in this study. (ER, oestrogen receptor; wt, wild type; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; SV40, Simian Virus 40).

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Origin</th>
<th>Classification</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7</td>
<td>Human breast cancer: pleural effusion from a 69-year-old female suffering from metastatic disease originating from a luminal mammary adenocarcinoma&lt;sup&gt;359&lt;/sup&gt;</td>
<td>Luminal A</td>
<td>ER&lt;sup&gt;+&lt;/sup&gt; (wt and variants)/PgR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;-&lt;/sup&gt;&lt;sup&gt;360&lt;/sup&gt;</td>
</tr>
<tr>
<td>ZR-751</td>
<td>Human breast cancer: ascitic effusion from a 63-year-old female suffering from metastatic disease originating from a ductal mammary adenocarcinoma&lt;sup&gt;361&lt;/sup&gt;</td>
<td>Luminal A</td>
<td>ER+/PgR+/HER2&lt;sup&gt;-&lt;/sup&gt;</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>Human breast cancer: pleural effusion from a 51-year-old female suffering from metastatic disease originating from a basal mammary adenocarcinoma&lt;sup&gt;362&lt;/sup&gt;</td>
<td>Basal B</td>
<td>ER/PgR/HER2&lt;sup&gt;-&lt;/sup&gt; (TNBC)</td>
</tr>
<tr>
<td>HBL-100</td>
<td>Human breast cancer: primary cultures of epithelial cells from an early lactation sample of human milk&lt;sup&gt;363&lt;/sup&gt;</td>
<td>Basal B</td>
<td>ER/PgR/HER2&lt;sup&gt;-&lt;/sup&gt; (TNBC) HBL-100 harbours the SV40 genome and exhibits characteristics of transformation including the ability to form colonies in soft agar, an aneuploid chromosome complement and continuous replication in culture</td>
</tr>
<tr>
<td>REM-134</td>
<td>Canine breast cancer: primary cultures of a mammary carcinoma&lt;sup&gt;364&lt;/sup&gt;</td>
<td>Unknown</td>
<td>ER/PgR/HER2&lt;sup&gt;-&lt;/sup&gt; (TNBC)</td>
</tr>
<tr>
<td>JS7</td>
<td>Ovine lung cancer: primary cultures of a pulmonary adenocarcinoma&lt;sup&gt;365&lt;/sup&gt;</td>
<td>Retrovirally induced</td>
<td>Known activated pathways: Ras-MEK-ERK and PI3K-AKT-mTOR&lt;sup&gt;287&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

2.2.2 Cell culture

Cell culture procedures were performed inside a category II biological safety hood using aseptic techniques. Media was stored at 4°C and was used or discarded within 4 weeks of the addition of supplements. Foetal calf serum (FCS) used for cell culture was inactivated by heating for 15 min at 37°C, then for 30 min at 56°C. For routine cell culture, all cell lines were grown using the appropriate media (Table 2.2) in an incubator at 37°C in a humidified atmosphere at 21% O<sub>2</sub> with 5% CO<sub>2</sub>. Media was changed every 48-72 h. Cells were used for no more than 15 passages, after which new cells were obtained from frozen stocks. Periodic recording of morphology and doubling times was undertaken to ensure maintenance of phenotype. Phase
contrast images of cells were captured with a monochrome digital Axiocam camera fitted to a Zeiss Axiovert S100 (Carl Zeiss Ltd, UK) microscope.

Table 2.2. Growth media and supplements required for each cell line.

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Media</th>
<th>Supplements</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7 ZR-751 MDA-MB-231 HBL-100</td>
<td>Dulbecco’s Modified Eagle Media (Gibco Life Technologies, Invitrogen, UK)</td>
<td>10% heat-inactivated FCS 1% Penicillin/Streptomycin (100 IU/ml)</td>
</tr>
<tr>
<td>REM-134</td>
<td>Dulbecco’s Modified Eagle Media-high glucose (Gibco Life Technologies, Invitrogen, UK)</td>
<td>10% heat-inactivated FCS 1% Penicillin/Streptomycin (100 IU/ml)</td>
</tr>
<tr>
<td>JS7</td>
<td>Iscove's Modified Dulbecco's Media (Sigma-Aldrich, UK)</td>
<td>10% heat-inactivated FCS 1% Penicillin/Streptomycin (100 IU/ml) 4mM L-glutamine</td>
</tr>
</tbody>
</table>

2.2.3 Recovery of cells from liquid nitrogen storage

Cell stocks were stored in freezing mix media (90% FCS, 10% DMSO) within cryovials in liquid nitrogen storage tanks at -196°C. To recover cells from storage, cryovials were defrosted as rapidly as possible in a water bath at 37°C. Cells were transferred into 10 ml of warmed media and centrifuged at 1000 x g for 5 min. The supernatant containing DMSO was removed and the cell pellet re-suspended in 8 ml of media and transferred to a T25 flask. Cells were used in experiments after a minimum period of 2 weeks after recovery from liquid nitrogen storage.

2.2.4 Cell passage

Cells were passaged when they reached 75-85% confluency. Media was removed and cells were washed twice with sterile phosphate-buffered saline (PBS). An appropriate volume of 0.05% trypsin ethylenediaminetetraacetic acid (EDTA) (Table 2.3) was added and the cells incubated for 3-5 min at 37°C until they detached from the flask surface. FCS-containing media was then added to neutralise the trypsin. Cells were centrifuged at 1000 x g for 5 min and the supernatant removed. Cells were then re-suspended in media and seeded into new culture vessels (Table 2.3) or counted as required. All experiments were performed using sub-confluent cultures in the log-phase of growth.
Table 2.3. Summary of culture vessels used. Data includes volumes of media and trypsin EDTA required for each culture vessel.

<table>
<thead>
<tr>
<th>Culture container</th>
<th>Surface area (mm²)</th>
<th>Cell number seeded</th>
<th>Trypsin EDTA (ml)</th>
<th>Media used to curtail trypsinisation (ml)</th>
<th>Total vol. of media (ml)</th>
<th>Approx. cell number at 100% confluency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Flasks</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T25</td>
<td>2,500</td>
<td>0.1-1x10⁶</td>
<td>1</td>
<td>5</td>
<td>3–5</td>
<td>2.5x10⁶</td>
</tr>
<tr>
<td>T75</td>
<td>7,500</td>
<td>1-3x10⁶</td>
<td>2</td>
<td>7</td>
<td>8–15</td>
<td>8x10⁶</td>
</tr>
<tr>
<td>T175</td>
<td>16,200</td>
<td>4x10⁶</td>
<td>3</td>
<td>7</td>
<td>15–30</td>
<td>18x10⁶</td>
</tr>
<tr>
<td><strong>Plates</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>75 mm</td>
<td>2,100</td>
<td>1x10³</td>
<td>2</td>
<td>5</td>
<td>5–10</td>
<td>3x10⁶</td>
</tr>
<tr>
<td>150 mm</td>
<td>15,200</td>
<td>1-2x10⁶</td>
<td>3</td>
<td>7</td>
<td>15–30</td>
<td>20x10⁶</td>
</tr>
<tr>
<td>6 well</td>
<td>900</td>
<td>0.23-1x10⁶</td>
<td>1</td>
<td>3</td>
<td>2–5</td>
<td>1x10⁶</td>
</tr>
<tr>
<td>96 well</td>
<td>320</td>
<td>1.5-10x10³</td>
<td>N/A</td>
<td>N/A</td>
<td>0.2</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Spinner Flasks</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 ml</td>
<td>N/A</td>
<td>1.5-3x10⁶</td>
<td>N/A</td>
<td>N/A</td>
<td>90</td>
<td>N/A</td>
</tr>
<tr>
<td>250 ml</td>
<td>N/A</td>
<td>3-6x10⁶</td>
<td>N/A</td>
<td>N/A</td>
<td>150</td>
<td>N/A</td>
</tr>
</tbody>
</table>

2.2.5 Cell counting and determination of cell viability

Following trypsinisation and the addition of FCS-containing media the cell suspension was transferred to a Falcon tube and centrifuged at 1000 x g for 5 min. The supernatant was removed, and the cell pellet re-suspended in media. A single cell suspension was created by passing the cell suspension 3 times through a 21G needle attached to a 10 ml syringe. 10 µl of this cell suspension was added to 10 µl of 0.4% trypan blue (Sigma-Aldrich, UK) and incubated for 2 min. 10 µl of this trypan blue cell suspension was then added to a haemocytometer. The total number and the number of dead cells were then counted (Table 2.4).

Table 2.4. Formulas used for cell counting and viability assessment. (*0.1 µl is the volume contained within the haemocytometer counting chamber).

- **Dilution factor** = (volume of cell suspension + volume of trypan blue)/volume of new cell suspension
- **Cell density (cells/ml)** = total cell count/0.1 µl* x dilution factor x10³
- **Total number of cells** = cells/ml x volume of cell suspension
- **Percentage cell viability** = total number of live cells/total cell count x100

2.2.6 Cryopreservation of cells and storage into liquid nitrogen

Surplus cells were allowed to reach 80-90% confluency in a T175 flask before undergoing routine trypsinisation and counting as described in sections 2.2.4.
and 2.2.5. Cells were re-centrifuged at 1000 x g for 5 min and the supernatant removed. Cells were then re-suspended in freezing media at a density of 2.5x10^6 cells per 0.5 ml freezing media, transferred into separate cryovials and placed into a freezing container (Nalgene Mr. Frosty, Sigma-Aldrich, UK) containing 100% isopropyl alcohol and stored overnight at -70°C. Cryovials were then transferred to a liquid nitrogen tank for long term storage (Institute of Genetics and Molecular Medicine, University of Edinburgh).

2.2.7 Irradiation of cells

Cells were irradiated using a Faxitron cabinet X-ray system 43855D (Faxitron X-ray Corporation, IL, USA). Dosimetry and dose-rate [mGy/s] checks were conducted at least once a year (NHS Medical Physics Department, Western General Hospital, Edinburgh, UK) using an Innovision Dosimeter 35050A and 150cc ion chamber 96020C. The Faxitron cabinet used no extra filtration, with x-rays passing through a 1.6 mm beryllium window. Culture vessels were placed in the centre of the glass shelf which rotates at 2 rpm to ensure uniform dosing. The distance from the focal spot of the x-ray tube to the culture vessels was 40.6 cm and when operated at 130 kV it produces a central dose of 1 Gy/min. For all experiments that involved radiation treatment, control cells were included that consisted of cells undergoing mock radiation treatment being placed within the Faxitron cabinet for the desired length of time without undergoing radiation treatment.

2.2.8 Development of radioresistant cell lines

Radioresistant cell lines (MCF-7 RR, ZR-751 RR, MDA-MB-231 RR, REM-134 RR and JS7 RR) were developed from their respective parental cell lines by weekly exposure to single fractions of radiation. An initial dose of 2 Gy was followed by weekly incremental doses of 0.5 Gy for 12 weeks. During this period cells received a total radiation dose of 57 Gy. Cells were subsequently maintained with further weekly doses of 5 Gy. Radioresistant cell lines were maintained in routine media. Following exposure to radiation, cells were left at least 24 h before undergoing trypsinisation and passage.
2.2.9 Generation of multicellular tumour spheroids

Numerous cancer cell line models are available to increase the complexity of cell culture systems that more accurately replicate the in vivo TME. The use of multicellular tumour spheroids (MTS) represents one such commonly used model\(^{366}\).

A single cell suspension from a T175 flask (approximately 15x10\(^6\) cells) was created and transferred into a spinner flask (Cellcontrol Spinner Flask, Integra, Switzerland) containing 100 ml of media and incubated routinely on a magnetic stirrer platform (Cellspin, Integra, Switzerland) to provide convective mixing of the culture media and cell suspension to generate MTS. Flasks were checked daily for MTS formation, the media was changed as required. When MTS had reached a sufficient size (generally 7-14 d) they were removed from the spinner flask using a 25 mL serological pipette.

2.3 Cellular assays

2.3.1 Sulforhodamine B proliferation (SRB) assay

The SRB assay was originally described in 1990 as a new technique for anti-cancer drug screening\(^{367}\). The SRB assay measures cellular proliferation based on the ability of the SRB dye to bind the basic amino acids of fixed proteins in a pH-dependent manner\(^{367}-369\); colorimetric evaluation provides an estimate of total protein, which is related to cell number\(^{369}\).

Due to differences in proliferation rates between cell lines, initial optimisation experiments were conducted to identify cell seeding numbers to ensure optical density (OD) saturation did not occur over the time course of the experiments. If the OD values produced by the assay are below 3.5, the relationship between OD and cell number is linear. However, if the OD values are greater than 3.5 there is a risk saturation may be occurring with values becoming inaccurate.

Seeding densities used for each cell line gave a confluency of approximately 10-30\% at 24 h post-seeding and produced OD values less than 3.5 up to 144 h post seeding.

Cells were seeded into flat-bottom 96 well plates and incubated for 24 h before treatment with drugs or radiation in a final volume of 200 µl in each well. Controls included untreated and drug vehicle (DMSO or ethanol) treated cells. Drug vehicle controls were treated corresponding to the highest drug concentration used in
each experiment (final concentration of DMSO/ethanol was not greater than 1%). Media only controls were also included to allow background readings to be assessed. Six replicates of each treatment group were performed in each experiment. Cellular proliferation was assessed at 0, 24, 48, 72, 96, 120 and 144 h following drug or radiation treatment. To perform the SRB assay, cells were fixed with 50 µl/well of cold 25% trichloracetic acid (TCA) (Sigma-Aldrich, UK) for 60 min at 4°C and subsequently washed 10 times with water to remove the TCA, media, metabolites and serum proteins. Plates were dried, and the fixed cells stained with 50 µl of 0.4% SRB dye solution (Sigma-Aldrich, UK) dissolved in 1% acetic acid (VWR International) for 30 min at room temperature. The SRB solution was removed and the plates washed in 1% glacial acetic acid 4 times to remove unbound dye. Once the plates were dry, the protein-bound SRB was solubilised with 150 µl of 10 mM Tris-NaOH buffer (pH 10.5) for 60 min at room temperature before measuring the OD of each well at 540 nm using a Biohit BP800 spectrophotometer (Biohit Ltd, UK) and Wallac 1420 Manager. OD values were corrected by subtracting average values of blanks and normalising to vehicle controls. Mean values and standard deviations were calculated from the technical replicates. IC₅₀ values were generated through sigmoidal concentration response curves fitted using Prism 7 (GraphPad Software, San Diego, CA, USA).

2.3.2 Colony formation assay

Cells were seeded into 75 mm plates (1x10³ cells/plate) and incubated for 24 h before radiation treatment. Untreated cells were used as controls; once visible colonies (approximately 50 cells/colony) had formed in the untreated control group (approximately 10-14 d post-seeding) the cells were fixed and stained for counting. The media was discarded, and the cells washed twice in PBS. Clonogenic reagent (1,9-dimethyl-methylene blue zinc chloride double salt, Sigma Aldrich, UK; 0.5 g methylene blue dissolved in 100 ml ethanol and 100 ml H₂O) was added to the plates, which were then left to incubate for 45 min at room temperature. The plates were washed twice in H₂O then left to dry before manually counting the colonies; only colonies greater than 50 cells were counted. Analysis was performed by calculating plating efficiencies (PE) and survival fractions (SF) for untreated and radiation treated cells. PE, which indicates the proportion of cells seeded into the
plate that grew to form a colony, was calculated by dividing the number of colonies counted by the initial number of cells seeded. Following determination of PE, the fraction of cells surviving a given radiation treatment was calculated; this SF was calculated by dividing the PE of the treated cells by that of the PE of the untreated control cells.

2.3.3 Scratch (migratory) assays

The migratory capabilities of parental and RR cell lines were investigated through 2D scratch assays. Cells were seeded into 6 well plates to achieve 100% confluence after 24 h. Scratch assays were performed as described by Liang et al., 2007\(^{370}\). A scratch was made in the monolayer of cells using a p1000 pipette tip. Media was discarded and the cells were washed in PBS until all floating cells were removed and a clean, sharp edged scratch could be identified by phase contrast light microscopy. 0.1% FCS-supplemented media was then added (lower percentage FCS-supplemented media was used to minimise cell proliferation while preventing apoptosis and/or cell detachment). Controls included untreated and drug vehicle (DMSO or ethanol) treated cells. For drug assays, the drug or drug vehicle was added to the 0.1% FCS-supplemented media. Photographs were taken using the 2.5x objective lens at regular intervals until the cells had migrated across the scratch (or up to a maximum of 48 h post-scratch). At each time point the area remaining of the scratch was calculated using FIJI software and expressed as a percentage of the scratch area at 0 h, giving a final relative migratory distance at each time point.

2.3.4 MTS invasion assays

The invasive capabilities of parental and RR cell lines were investigated through 3D invasion assays as the movement of cells through a 3D matrix more closely mimics in vivo invasion\(^{371}\). A collagen gel solution was made by mixing 0.1% filtered acetic acid, cell matrix type 1-A (an acid soluble type 1 collagen solution produced from porcine tendon, pH 3, 3 mg/ml, Alphalabs, UK), 0.22 M NaOH (Sigma-Aldrich, UK), FCS and 10x DMEM (Sigma-Aldrich, UK) at concentrations of 45%, 25%, 10%, 10% and 10% respectively. All solutions were kept on ice to prevent collagen polymerisation. A single MTS was added with 500 ul of collagen mix into a well of a 24 well plate and incubated for 1 h at 37°C to allow
the collagen to polymerise. Following polymerisation, a p200 pipette tip was used to release the collagen gel from the edges of the well and a further 500 ul of DMEM was added to each well. Controls included untreated and drug vehicle (DMSO or ethanol) treated cells. For drug assays, the drug or drug vehicle was added to both the collagen mix and the media. Photographs were taken using a 2.5x objective lens at regular intervals up to 120 h post-seeding. MTS invasion was measured using a macro programme developed by Matthew Pearson (Light Microscopy Application Specialist, IGMM, University of Edinburgh). This macro processes the image to find the edges of the MTS and highlights the cells using morphological filters and intensity thresholding. This macro programme provided 3 readings after analysis; the total area, the MTS area and the invasive area. To assess invasion the total MTS area at each time point was expressed as a percentage of the MTS area at 0 h (Figure 2.1).

![Figure 2.1. MTS invasion measurement.](image)

**Figure 2.1. MTS invasion measurement.** MCF-7 RR MTS are shown at (a) 0 h and (b) 96 h post-seeding into collagen. Images are shown pre- and post-macro analysis using FIJI software. The green lines outline the MTS and the invasive front.

### 2.4 Protein recovery and detection

#### 2.4.1 Whole cell protein extraction from adherent cells

Protein extraction was carried out on ice to minimise protein degradation. Cells were washed twice in ice cold PBS before the addition of ice-cold isotonic lysis buffer (Table 2.5). Using a cell scraper, the cells were scraped off the surface of the culture vessel and mixed with the lysis buffer. The cells were left on ice for 10-15 min to allow lysis to occur. The lysate was collected and transferred to a cold 1.5 ml Eppendorf tube then centrifuged at 13,000 x g for 6 min at 4°C. The supernatant (lysate) was removed and transferred to a new Eppendorf tube, which was then either frozen and stored at -70°C or placed on ice for immediate use.
Table 2.5. Lysis buffer. Volumes of lysis buffer used were dependent on the size of culture vessel: 400 µls per T175 flask or 150 mm petri dish; 200 µl per T75 flask or 75 mm petri dish; 100 µl per well in a 6 well plate.

<table>
<thead>
<tr>
<th>Lysis buffer</th>
<th>Lysis buffer additives per 10 ml lysis buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mM Tris (pH 7.5), 5 mM EGTA (pH 8.5), 150 mM NaCl</td>
<td>• 1 complete ‘protease inhibitor tablet’ (Roche, UK)</td>
</tr>
<tr>
<td></td>
<td>• 100 µl phosphatase inhibitor cocktail 2 (Sigma-Aldrich, UK)</td>
</tr>
<tr>
<td></td>
<td>• 100 µl phosphatase inhibitor cocktail 3 (Sigma-Aldrich, UK)</td>
</tr>
<tr>
<td></td>
<td>• 50 µl aprotinin (Sigma-Aldrich, UK)</td>
</tr>
<tr>
<td></td>
<td>• 100 µl Triton-X (Sigma-Aldrich, UK)</td>
</tr>
</tbody>
</table>

2.4.2 Protein quantification using the bicinchoninic acid assay

Protein concentrations from cellular lysates were determined using the bicinchoninic acid (BCA) assay. A 1 mg/ml bovine serum albumin (BSA) (Sigma-Aldrich, UK) standard was used to create an 8-point standard curve. Known BSA protein standards were made up to a final volume of 50 µl. The standard curve was produced using the same plate on which the samples were assayed. 5 µl of each protein sample was diluted into 45 µl of distilled water in borosilicate glass tubes. Fresh BCA solution was made by adding 1 ml of copper (II) sulphate (Sigma-Aldrich, UK) into 49 ml of BCA (Sigma-Aldrich, UK). 1 ml of this BCA solution was added to each 50 µl aliquot of sample or BSA standard. The samples were briefly vortexed and incubated for 15 min at 60°C then allowed to cool. In a 96 well plate, 200 µl of each solution (sample or known BSA protein standard) was added to a designated well. All samples were performed in duplicate. OD values were measured at 540 nm using a Biohit BP800 spectrophotometer (Biohit Ltd, UK) and Wallac 1420 Manager program (PerkinElmer, UK). Protein concentrations were determined from the standard curve generated using the known BSA concentrations.

2.4.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)

Protein samples were resolved in sodium dodecyl sulphate-polyacrylamide gels using electrophoresis. Different percentage SDS-polyacrylamide gels (5-15%) were used according to the size of the protein of interest. Lower percentage gels were used to separate high molecular weight proteins and higher percentage gels were used for lower molecular weight proteins. All SDS-polyacrylamide gels were prepared using the Bio-Rad Protean II mini-gel system (Bio-Rad Laboratories, UK). The resolving gel was prepared (Table 2.6) and approximately 8 ml was poured...
between the plates; this was overlaid with isopropanol to remove air bubbles. The gel was allowed to set at room temperature, the isopropanol was discarded, and the top of the gel was washed with dH$_2$O. The stacking gel (Table 2.6) was prepared and approximately 1.5 ml was poured on top of the resolving gel. A loading comb was then inserted into the stacking gel and allowed to set at room temperature. Once set, the comb was removed, and the wells were washed with dH$_2$O. The gel was placed into a running module which was then immersed in SDS-PAGE running buffer (Table 2.6). Protein samples were prepared into 40 µg aliquots by adding the appropriate volume of 4x Laemmli sample buffer (Bio-Rad Laboratories, UK) and lysis buffer to cell lysates as determined by the BCA assay. Samples were heated for 5 min at 95°C to denature the proteins, which were then loaded into the wells in the stacking gel. A pre-stained protein marker (broad range ladder, 11-190 KDa, Cell Signalling Technology, UK) was run in parallel to allow identification of the protein bands by size. The gel was subjected to electrophoresis at 80 V for 15 min (which allows the samples to move through the stacking gel), then at 150 V until the dye front had run off the bottom of the resolving gel (approximately 45 min).

2.4.4 Immunoblotting

Resolved proteins were electrophoretically transferred onto methanol-activated polyvinylidene difluoride nitrocellulose membranes (Immobilon-P PVDF, 0.45 µm, Merck Millipore, UK) in ice-cold transfer buffer (Table 2.6) using the Protean Transfer Cell equipment (Bio-Rad laboratories, UK). Transfer was performed at 100 V for 90 min at 4°C. Nitrocellulose membranes were stained with Revert total protein stain for 5 min, then washed twice in Revert wash solution for 30 s each time to allow visualisation of protein bands and confirm equal loading (Li-COR Biotechnology, UK). Membranes were visualised using the LI-COR Odyssey Infrared Imager (LI-COR, Bioscience, UK) using the 700 nm channel (as described below). Membranes were then washed with Revert reversal solution (Li-COR Biotechnology, UK) for 10 min until the stain was no longer visible. Non-specific antibody binding was blocked by incubating membranes in Li-COR Odyssey blocking buffer solution (Li-COR Biotechnology, UK) for 1 h at room temperature. Primary antibodies (targeting the protein of interest and loading control) were diluted
in Li-COR Odyssey blocking buffer solution (Table 2.7). The membranes were subsequently probed with primary antibodies and incubated overnight at 4°C.

**Table 2.6. Gels and solutions required for SDS-PAGE and immunoblotting.**

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Resolving gel</strong></td>
<td>5-15% acrylamide gels were made according to the size of protein of interest, 390mM Tris-HCL (pH 8.8), 0.1% SDS. Polymerisation was initiated by the addition of 0.1% ammonium persulphate and 0.08% TEMED immediately prior to pouring the gel</td>
</tr>
<tr>
<td><strong>SDS-PAGE running buffer</strong></td>
<td>25mM Tris, 190mM glycine, 0.1% (v/w) SDS</td>
</tr>
<tr>
<td><strong>Stacking gel</strong></td>
<td>5% acrylamide, 123mM Tris-HCL (pH 6.8), 0.1% SDS. Polymerisation was initiated by the addition of 0.1% ammonium persulphate and 0.1% TEMED immediately prior to pouring the gel</td>
</tr>
<tr>
<td><strong>Transfer buffer</strong></td>
<td>25mM Tris, 190mM glycine, 20% (v/v) methanol</td>
</tr>
</tbody>
</table>

Following overnight incubation, the primary antibodies were removed, and the membrane washed 3 times in phosphate-buffered saline-Tween 20 (PBST, 1:1000 solution of Tween20) 5 min per wash. Fluorescently labelled secondary antibodies IRDye 800CW and IRDye 680LT (LI-COR, Bioscience, UK) were diluted in Li-COR Odyssey blocking buffer solution (1:10,000) with the addition of 0.01% SDS. These fluorescently labelled secondary antibodies are susceptible to photo-bleaching, therefore subsequent steps were performed in the dark. The membranes were probed with the secondary antibodies and incubated for 45 min at room temperature. Following incubation, the secondary antibody was removed, and the membrane washed 3 times in PBST, followed by a further 3 washes with PBS (5 min per wash). Membranes were visualised using the LI-COR Odyssey Infrared Imager (LI-COR, Bioscience, UK) using the 700 and 800 nm channels to detect the loading control and protein of interest bands respectively. Images were saved as TIFF files for quantification. For storage, membranes were washed in PBST for 10 min and frozen at -20°C. Membranes required the following day were covered in PBS and stored at 4°C.

**2.4.5 Protein quantification using infra-red radiation**

Relative protein intensities were measured by quantifying infra-red radiation emitted from labelled antibodies using Odyssey software (Image Studio Lite, LI-COR Biosciences, UK). Protein intensities were normalised to loading controls.
Table 2.7. Primary antibodies. Primary antibodies used for western blotting (WB), immunocytochemistry (ICC) and immunohistochemistry (IHC).

<table>
<thead>
<tr>
<th>Primary antibody target antigen</th>
<th>Antibody details</th>
<th>Dilutions and applications</th>
<th>Antigen retrieval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-α tubulin</td>
<td>Mouse mAb; Abcam; ab7291</td>
<td>1:10,000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-β actin</td>
<td>Rabbit pAb; Abcam; ab8227</td>
<td>1:10,000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-GAPDH</td>
<td>Mouse mAb; Abcam; ab8245</td>
<td>1:5000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-ERα</td>
<td>Mouse mAb; Dako; M7047</td>
<td>1:50 (WB, ICC, IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-EGFR</td>
<td>Mouse mAb; Abcam; ab24918</td>
<td>1:1000 (WB)</td>
<td>EDTA</td>
</tr>
<tr>
<td>Anti-HER2</td>
<td>Rabbit mAb; Cell Signaling Technology; 2242</td>
<td>1:1000 (WB); 1:50 (ICC, IHC)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-PgR (A/B)</td>
<td>Rabbit mAb; Cell Signaling Technology; 8757</td>
<td>1:1000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-PgR</td>
<td>Mouse mAb; DAKO; M3569</td>
<td>1:150 (ICC, IHC)</td>
<td>EDTA</td>
</tr>
<tr>
<td>Anti-AKT</td>
<td>Mouse mAb; Cell Signaling technology; 2920</td>
<td>1:1000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-Phospho AKT</td>
<td>Rabbit pAb; Cell Signaling technology; 9271</td>
<td>1:1000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-ERK</td>
<td>Rabbit pAb; Cell Signaling Technology; 9102</td>
<td>1:1000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-Phospho ERK</td>
<td>Mouse mAb; Cell Signaling Technology; 9106</td>
<td>1:1000 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-Ki67</td>
<td>Mouse mAb; DAKO; M7240</td>
<td>1:150 (ICC, IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-E-cadherin</td>
<td>Mouse mAb; BD Transduction; 610182</td>
<td>1:50 (ICC, IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-N-cadherin</td>
<td>Mouse mAb; BD Transduction; 610921</td>
<td>1:150 (ICC, IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-vimentin</td>
<td>Mouse mAb; Abcam; ab8069</td>
<td>1:50 (ICC, IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-SNAIL</td>
<td>Rabbit pAb; Abcam; ab128530</td>
<td>1:250 (ICC, IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-SEC24C</td>
<td>Rabbit pAb; Atlas Antibodies; HPA040196</td>
<td>1:500 (WB); 1:500 (IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti YBX3</td>
<td>Mouse mAb; Novus biologicals; H00008531-MO6</td>
<td>1:500 (WB); 1:100 (IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-EIF3G</td>
<td>Rabbit pAb; Atlas Antibodies; HPA041997</td>
<td>1:1000 (WB); 1:250 (IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-TK1</td>
<td>Rabbit mAb; Abcam; ab76495</td>
<td>1:500 (WB); 1:500 (IHC)</td>
<td>Sodium citrate</td>
</tr>
<tr>
<td>Anti-PERK</td>
<td>Rabbit mAb; Cell Signaling Technology; 5683</td>
<td>1:500 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-Phospho PERK</td>
<td>Rabbit pAb; Thermo Scientific; PA5-30294</td>
<td>1:500 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-PhosphoEIF2α</td>
<td>Rabbit pAb; Cell Signaling Technology; 9721</td>
<td>1:500 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-Phospho IRE1</td>
<td>Rabbit pAb; Thermo Scientific; PA1-16927</td>
<td>1:500 (WB)</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-WNT5a</td>
<td>Mouse mAb; Thermo Scientific; MA5-15502</td>
<td>1:500 (WB, ICC)</td>
<td>Sodium citrate</td>
</tr>
</tbody>
</table>
2.4.6 Membrane Stripping

Membranes required for re-probing were stripped using NewBlot PVDF Stripping Buffer (LI-COR Biosciences, UK). Membranes were first washed in PBST then covered in stripping buffer (diluted 1:5 with dH₂O) for 20 min at room temperature. The membranes were visualised using the LI-COR Odyssey Infrared Imager to ensure the secondary antibodies had been removed. Blots were then re-probed with secondary antibodies for 45 min at room temperature and re-visualised to ensure the primary antibody had also been removed. Blots were washed in PBS then blocked and probed as previously described in section 2.4.4.

2.4.7 Assessment of the effects of radiation on pathway activation

Cells were seeded into 75 mm plates at a density of 1x10⁶ cells per plate and incubated for 24 h. Cells were washed twice with PBS before 7 ml of FCS-free media was added into the wells. The cells were serum starved for 2 h then exposed to 2 Gy radiation (control cells were not treated with radiation). All cells underwent routine harvesting and lysis collection at 0, 5, 10- and 30-min post-radiation. The lysate was snap frozen on dry ice and stored at -70°C for subsequent western blot (WB) analysis.

2.5 Immunohistochemistry

2.5.1 Fixation and sectioning of MTS and tissue for immunohistochemistry

MTS were fixed for 24 h in 4% formaldehyde (Genta Medical, UK). After fixation, the formaldehyde was removed and 100-200 µl of molten 2% agarose was added. A 1 ml pipette tip was then used to gently stir the agarose and MTS, being careful to conserve the integrity of the MTS. The suspension was allowed to set at room temperature before being processed. Harvested xenograft tumours and OPA tissue were fixed for at least 24 h (depending on tissue thickness) in 4% formaldehyde before being processed. Processing of MTS and tissue for IHC was performed using the Thermo Scientific Excelsior AS Tissue Processor (Thermo Scientific, UK). Once processed, MTS and tissue were embedded in paraffin blocks and stored at room temperature. Sectioning of samples was performed using the Leica RM2235 rotary microtome (Leica Microsystems Ltd, UK). Microtome sections
of 4 µm were placed on SuperFrost Plus glass slides (Thermo Scientific, UK) and allowed to dry for a minimum of 4 h at 53°C for H&E and Mason's trichrome staining or overnight at 37°C for IHC. Sections cut for IHC were stored at 4°C.

2.5.2 Haematoxylin and eosin staining

Sections were deparaffinised by 3 changes in 100% xylene for 5 min each time, then rehydrated by placing into decreasing concentrations of alcohol; 2 changes in 100% ethanol, followed by 80% then 50% for 2 min each time. The slides were then washed in running water for 2 min, before placing in haematoxylin (Shandon Harris Haematoxylin, Thermo Scientific, UK) for a maximum of 10 min. Slides were washed in running water for 2 min before being placed into Scott’s tap water substitute for a maximum of 10 min until the tissue sections turned blue. Sections were counterstained by placing them into Eosin Y (Shandon Eosin Y Cytoplasmic Counterstain, Thermo Scientific, UK) for 5 min. The slides were dehydrated by placing them into increasing concentrations of alcohol; 50% ethanol for 30 s, 80% ethanol for 30 s, then 2 changes in 100% ethanol for 2 min each time. The slides were placed in xylene for 10 min before being mounted with coverslips using DXP mountant (Sigma-Aldrich, UK). Mounted slides were given a brief wash in 100% xylene before being left to dry at room temperature.

2.5.3 Masson’s trichrome staining

All solutions for Masson’s Trichrome staining were obtained from TCS Biosciences Ltd, UK. Sections were routinely deparaffinised and rehydrated then washed in running water for 2 min. Slides were mordanted with Bouin solution for 24 h at room temperature, before washing in running water for 60 s or until free of yellow colouration. Slides were then stained in Weigert iron haematoxylin for 5 min, washed for 5 min in running water and rinsed in distilled water. Slides were stained with Masson’s Trichrome for 5 min, rinsed in distilled water and then treated with phosphotungstic/phosphomolybdic acid solution for 5 min. Slides were counterstained in aniline blue for 5 min, immersed in 1% acetic acid, then routinely dehydrated and mounted.
2.5.4 **Vertical immunohistochemistry for paraffin embedded MTS and tissue samples**

Sections were routinely deparaffinised and rehydrated. The slides were washed in running water for 10 s before being placed into a pressure cooker and covered with pre-warmed antigen retrieval solution. The pressure cooker was placed into a microwave and heated on maximum power for 5 min. Following heating, the slides were left to cool for 20 min, then washed twice in PBST for 5 min. Cover plates were added and the slides placed into a Sequenza rack (Thermo Scientific, UK) before washing in PBST for 5 min. Following this wash endogenous peroxidase activity was blocked by the addition of 120 µl of 3% H₂O₂ (Dako, UK) for 10 min, followed by 2 washes in PBST for 5 min each time. Non-specific staining was blocked by the addition of Total Protein Block (Dako, UK) for 10 min at room temperature. Primary antibodies were diluted in Dako antibody diluent (Dako, UK), added to the slides and incubated for 1 h at room temperature. Negative controls consisted of adding antibody diluent containing no primary antibodies. Following incubation, the slides were washed twice in PBST for 5 min each time and then incubated with Dako Envision labelled polymer or IgG specific secondary antibody for 30 min at room temperature. Following incubation, the slides were washed twice in PBST for 5 min followed by the addition of Dako chromophore/substrate solution (1:50) to the slides, which were incubated for 10 min at room temperature. The slides were then removed from the Sequenza rack and cover plates and placed into a slide rack submerged in water. The slides were counterstained in haematoxylin for 60 s, rinsed in water for 60 s until the purple colour had washed away then placed in Scott’s tap water substitute for 30 s before rinsing in water. The slides were then routinely dehydrated and mounted.

2.5.5 **Horizontal immunocytochemistry and immunofluorescence using chamber slides**

Cells were seeded into 2-well chamber slides (Lab-Tek II, Scientific Laboratory Supplies, UK) to achieve confluenes of approximately 80% at 24 h (total of 2 ml media/chamber). Following incubation, the media was discarded, and the cells washed twice in cold PBS. The cells were fixed in cold acetone (500 µl/chamber) for 10 min at 4°C and then washed twice in PBS for 10 min each time.
For immunocytochemistry the slides underwent the same protocol as described for paraffin embedded MTS/tissue starting with the addition of the H$_2$O$_2$ solution. To perform immunofluorescence the slides also underwent the same protocol as described for paraffin embedded MTS/tissue starting with the addition of the H$_2$O$_2$ solution, continuing up to the addition of the labelled polymer. At this point secondary antibodies conjugated with fluorescent dyes (AlexaFluro 568, IgG. Life Technologies, UK), diluted to 1:300 in Dako antibody diluent (Dako, UK), were added to the chambers and incubated in the dark for 1 h at room temperature. Following incubation, the slides were washed 3 times in PBST for 5 min each time. Slides were then mounted using anti-fade mounting media containing DAPI (Vetorshield, Vector Laboratories Inc, Burlingame, CA, USA).

2.5.6 Image acquisition

High resolution digital scans of the entire microscope slide were obtained using the NanoZoomer ER slide scanner (Hamamatsu Photonics, UK) and viewed using NanoZoomer Digital Pathology software. All mounted slides were stored at room temperature.

2.6 RNA interference

2.6.1 ERα knockdown using siRNA

An individual pre-designed ERα siRNA (J-003401-12; ESR1), a combined mixture of 4 siRNAs (L-003401-00-0005; Smart pool ESR1) and a non-targeting siRNA (D-001810-01) were purchased from the ON-TARGET plus series (GE Healthcare Dharmacon, UK). siRNAs were re-suspended to create 20 µM stock solutions using siRNA buffer (Dharmacon, UK) and RNase-free water. The solutions were mixed by pipetting and placed on an orbital shaker for 30 min at room temperature. The concentration of the reconstituted siRNA was then verified using the NanoDrop Spectrophotometer ND1000 (Thermo Fischer Scientific, UK) at 260 nm (for siRNAs 1 µM = 13.3 ng/µl). Aliquots of the stock solution were made and stored at -20°C. Freeze-thaw events were limited to no more than 5 for each stored siRNA.
2.6.2 Liposome-mediated transfection optimisation

MCF-7 cells were seeded into either 96 or 6 well plates at a density of 1.5x$10^3$ or 2.3x$10^5$ respectively using antibiotic-free, 10% FCS-supplemented DMEM. Cells were seeded to achieve confluences of approximately 20-30% by 24 h. Transfections were performed using the manufacturer’s transfection protocol; briefly, 24 h post-seeding the media was removed, and the cells washed in PBS. Antibiotic-free DMEM was then added to the wells (1 ml for 6 well plate, 100 µl for 96 well plate). The transfection protocol consisted of diluting DharamaEFECT 1 transfection reagent (GE Healthcare Dharmacon, UK) into serum and antibiotic-free DMEM and incubating the solution for 5 min at room temperature. Required amounts of siRNA were also diluted into serum and antibiotic-free DMEM which was also incubated for 5 min at room temperature. siRNA was diluted to achieve the desired concentration in the wells (Table 2.8). The 2 solutions were combined and incubated for 20 min at room temperature. The solution was diluted with antibiotic-free 10% FCS-supplemented DMEM then added drop wise to the appropriate wells. Cells were incubated routinely with the media changed to routine DMEM (containing antibiotics and FCS) 24 h post-transfection.

For each experiment controls included; untreated cells, mock transfected cells (cells treated only with transfection reagent but no siRNA) and non-targeted transfected cells (cells transfected with a non-targeting siRNA sequence). Lysates of transfected samples were collected, and efficiency of knockdown was assessed at protein level through western blotting. The expression of the targeted protein in the transfected cells was compared to the expression in the mock and non-targeted treated cells. All transfection reactions were optimised for individual experiments to achieve the maximum knockdown while preserving cell viability.
Table 2.8. siRNA transfection concentrations and volumes required for 96 and 6 well plate formats. Data provided is to achieve siRNA end concentrations of 25 nM.

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Concentration/volume per well</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>96 Well Plate</td>
</tr>
<tr>
<td>siRNA</td>
<td>0.25 µl</td>
</tr>
<tr>
<td>Volume of FCS and antibiotic-free DMEM used for siRNA dilution</td>
<td>9.75 µl</td>
</tr>
<tr>
<td>Total volume of diluted RNA</td>
<td>10 µl</td>
</tr>
<tr>
<td>DharmaFECT 1 transfection reagent</td>
<td>0.1 µl</td>
</tr>
<tr>
<td>Volume of FCS and antibiotic-free DMEM used for DharmaFECT 1 transfection reagent dilution</td>
<td>9.9 µl</td>
</tr>
<tr>
<td>Total volume of diluted transfection reagent</td>
<td>10 µl</td>
</tr>
<tr>
<td>Volume of antibiotic-free 10% FCS DMEM added to the combined transfection mixture</td>
<td>80 µl</td>
</tr>
<tr>
<td>Total end volume of media, transfection reagent and siRNA solution per well</td>
<td>200 µl</td>
</tr>
</tbody>
</table>

2.7 Nucleic acid isolation and quantification

2.7.1 RNA extraction and assessment of nucleic acid purity

The RNeasy Mini Kit using QIAshredder technology (Qiagen, UK) was used to extract total RNA from cells following the manufacturer’s protocol for the purification of RNA from cells using spin technology. The protocol included the addition of a genomic DNA (gDNA) eliminator column for the removal of gDNA.

Cells were seeded into 75 mm plates at a density of 3x10^6 cells per plate and incubated for 24 h. Cells were washed twice with PBS before 7 ml of FCS-free media was added. The cells were serum starved for 2 h after which the treatment groups were exposed to 2 Gy radiation. The cells underwent routine trypsinisation at 0, 2 and 8 h post-radiation. A cell suspension containing up to 1x10^7 cells (the maximum number of cells recommended for each spin column) was centrifuged at 1000 x g for 5 min. The supernatant was removed, and the cell pellet was snap frozen on dry ice and stored at -70°C for subsequent RNA extraction.

For RNA extraction the cell pellet was defrosted on ice and re-suspended in 350-600 µl (depending on cell number) of RLT lysis buffer. The lysate was transferred into a QIAshredder placed into a 2 ml collection tube; the assembled QIAshredder was centrifuged for 2 min at full speed. To eliminate gDNA contamination the homogenised lysate was then transferred to a gDNA eliminator
spin column placed into a 2 ml collection tube and centrifuged for 30 s at 13000 x g. The spin column was discarded but the flow through was saved.

Depending on cell number, 350 or 600 µl of 70% ethanol was added to the homogenised and gDNA-removed lysate before the solution was transferred to a RNeasy spin column placed in a 2 ml collection tube and centrifuged for 15 s at 13000 x g. The flow through was discarded and 700 µl of buffer RW1 was added to the RNeasy spin column and centrifuged for 15 s at 13000 x g to wash the spin column membrane. The flow through was discarded and care was taken to ensure the RNeasy spin column collection tube did not contact the flow through. Two further washes using 500 µl of buffer RPE containing 80% ethanol with centrifugation steps of 15 s and 2 min at 13000 x g were performed to wash the spin column membrane. The RPE buffer dissolves RNA salts but nucleic acids are left behind. After each wash the flow through was discarded. To ensure that no RPE buffer was carried over, the RNeasy spin column was placed in a new 1.5 ml collection tube and centrifuged at full speed for 1 min. The RNeasy spin column was then placed in a new 1.5 ml collection tube and 30-50 µl of RNase-free water was added directly to the spin column membrane, the RNA was eluted by centrifugation for 1 min at 13000 x g. The eluted RNA was used immediately or stored at -20°C.

Extracted RNA samples were assessed for quality and quantified using the NanoDrop Spectrophotometer ND1000 (Thermo Fischer Scientific). Nucleic acid purity was assessed using the A_{260}/A_{280} and A_{260}/A_{230} ratios. An A_{260}/A_{280} ratio value of approximately 2.0 is accepted as pure for RNA. Only good quality RNA with acceptable A_{260}/A_{280} ratios were used in subsequent experiments.

### 2.7.2 Whole-transcriptome gene expression analysis

Gene expression analysis was performed using Lexogen QuantSeq sequencing (Edinburgh Clinical Research Facility, University of Edinburgh). Analysis was performed by Dr A. K. Turnbull (Cancer Research UK, University of Edinburgh). Full genome expression read-counts were generated using Lexogen QuantSeq 3’ FWD sequencing technology on an Illumina flow cell which was scanned using an Illumina HiScanSQ system. NGS reads were generated towards the poly(A) tail and read 1 directly reflects the mRNA sequence. RNA integrity number (RIN) was generated for each sample to assess RNA quality (Agilent Bioanalyzer);
all samples had RIN values above 9.7. FASTQ files of raw read-count data were preprocessed using the Lexogen recommended BlueBee high-performance NGS analysis software which implemented poly(A) tail trimming and alignment to the Genome Reference Consortium Human genome build 38 reference genome using the Spliced Transcripts Alignment to a Reference (STAR) algorithm. Prior to analysis, data were log2 transformed and quantile normalised in R (Bioconductor) software and packages. Differentially expressed genes were identified using a log2 fold-change increase or decrease cut-off of greater than 1. Gene enrichment and multi-dimensional scaling analysis were performed using R (Bioconductor) software and packages. Pathway-focused analyses, heatmap and cluster analysis were performed using TM4 MeV (multiple experiment viewer) software. Heatmap clustering was carried out using Pearson correlation with average linkage. For integration of gene expression data with public datasets, correction for integration batch effects was performed in R using ComBat. Hierarchical clustering of parental and RR cell lines was performed using a published list of genes whose expression profile denotes the breast cancer intrinsic subtypes (basal, normal-like, HER2, luminal A and luminal B). Assignment of individual samples to intrinsic subtypes was performed using the genefu R package. Genefu implements a Single Sample Predictor algorithm which is a nearest-centroid classifier. The centroids representing the breast cancer molecular subtypes were identified through hierarchical clustering using the same intrinsic gene list that were used for cluster analysis. Venn diagrams were generated using jvenn. All datasets generated and/or analysed during the study are available in the NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE120798.

2.8 Cancer cell secretome analysis

2.8.1 Assessment of the effects of radiation on secretome profiles of cancer cells

Cells were seeded into 6 well plates to achieve approximately 40–50% confluence at 24 h. Cells were washed 3 times with PBS before 2 ml of FCS-free media was added. The cells were serum starved for 2 h. Cells were then exposed to radiation (0, 2, 4, 6, 8 or 10 Gy) and the conditioned media (CM) was harvested at 1, 2, 4, 8 and 24 h post-radiation for each radiation dose. Secretome samples underwent
processing for liquid chromatography-mass spectrometry (LC-MS) or WB analysis immediately following collection. Following CM harvesting cells were routinely trypsinised and counted using a haemocytometer with trypan blue exclusion (Sigma-Aldrich, UK). Secretome samples were stored at -80°C.

2.8.2 Secretome sample preparation

CM samples were centrifuged at 1000 x g for 5 min at 4°C to remove dead cells and large debris then passed through a 0.22 µm filter (Millex, Merck Millipore, UK). The samples were further centrifuged at 100,000 x g for 60 min at 4°C (Beckman Coulter Optima L-90K Ultracentrifuge with SW 55 Ti rotor); the supernatant was removed and placed into a new universal container. Proteins were concentrated from the supernatant using the Amicon Ultra-0.5 Centrifugal Filter Unit with Ultracel-3 membrane (Merck Millipore, UK) as per the manufacturer’s protocol. Briefly, 500 µl of the CM was added to the Amicon Ultra filter device and the sample was centrifuged at 14,000 x g for 30 min at 4°C. The filter was removed and placed upside down into a new 1.5 ml microcentrifuge tube. The sample was centrifuged at 1000 x g for 2 min at 4°C to elute the concentrated protein. Protein concentrations were determined using the BCA assay. The ultrafiltrate was then stored at -80°C prior to undergoing LC-MS or WB analysis.

2.8.3 Liquid chromatography-mass spectrometry (LC-MS) and sample analysis

Secretomic samples underwent in-solution digests for LC-MS analysis, which was performed by Dr J. Wills (Mass Spectrometry Facility, IGMM, University of Edinburgh). Using 96 well plates with silicon lids, 50 µg of protein was added to 2 M urea/100 mM tris/10 mM DTT and heated for 30 min at 50°C. 55 mM iodoacetamide was then added and incubated in the dark for 30 min at room temperature. Trypsin at 1:100 was then added and incubated overnight at room temperature. 10 µg of the resulting peptide solution was loaded onto an activated (20 µl methanol) and equilibrated (100 µl 0.1% trifluoroacetic acid (TFA)) C18 StAGE tip, and washed with 100 µl of 0.1% TFA. Bound peptides were eluted into Protein LoBind tubes with 20 µl of 80% acetonitrile (ACN) and 0.1% TFA solution and concentrated to less than 4 µl in a vacuum concentrator. The final volume was adjusted to 6 µl with
0.1% TFA. Online LC was performed using a Dionex RSLC Nano. Following the C18 clean-up, 5 μg of the peptide solution was injected onto a C18 packed emitter and eluted over a gradient of 2-80% ACN for 120 min with 0.1% TFA. Eluted peptides were ionised at +2 kV before data-dependent analysis on a Thermo Q-Exactive Plus. MS1 was acquired with mz range 300-1650 and resolution 70,000, and the top 12 ions were selected for fragmentation with normalised collision energy of 26, and an exclusion window of 30 s. MS2 were collected with resolution 17,500. The AGC targets for MS1 and MS2 were 3x 10^6 and 5x 10^4 respectively, and all spectra were acquired with 1 microscan without lockmass.

Pre-processing and analysis of data was performed by Dr A. K. Turnbull (Cancer Research UK, University of Edinburgh). Data were analysed using MaxQuant in conjunction with uniport fasta database with match between runs. Prior to analysis all data were log2 transformed. For fold change analysis, data were normalised to untreated controls at each time point using R (Bioconductor) software and packages. Venn diagrams were generated using jvenn. Heatmap and cluster analysis were performed using TM4 MeV (multiple experiment viewer) software. Heatmap clustering was carried out using Pearson correlation with average linkage. For integration of gene expression data with public datasets, correction for integration batch effects was performed in R using ComBat. Protein interaction networks of candidate biomarkers were generated using the STRING protein interaction database and Markvo clustering algorithms.

### 2.9 Immunohistochemistry and statistical analysis

Image analysis software QuPath version 0.1.2 was used to analyse Ki67, ERα and WNT5a target protein expression. Two-way ANOVA with Holm-Šídák multiple comparisons test was used to test for differences between 2 groups in CF, SRB, invasion and migration assays and WB experiments. Unpaired two-sample t-test was used to test for differences between 2 groups in IHC analysis. p values <0.05 were deemed statistically significant. Data are shown as mean ± SEM with all statistical analysis and graphs generated using Prism 7 (GraphPad Software, San Diego, CA, USA).
3 Materials and Methods: In Vivo Experiments

3.1 Introduction

The murine and ovine experiments were performed in accordance with a UK Home Office Project Licence. The murine study was carried out in the BRF facility (University of Edinburgh), with the ovine study performed at the Large Animal Research and Imaging Facility (LARIF) at Dryden Farm (University of Edinburgh) and at the Royal (Dick) School of Veterinary Studies (University of Edinburgh). The rat experiments were conducted at the Institute for Biomedical Research (University College London). All studies were performed using my own personal licence gained through the Scottish Accreditation Board in accordance with the Animals (Scientific Procedures) Act 1986. All projects were approved by either the University of Edinburgh or University College London Animal Ethics Committee. The recommended guidelines for welfare and use of animals in research were followed.

The following materials and methods sections will cover general procedures relating to each animal model. The development of specific novel techniques will be described in-depth in the relevant result chapters.

3.2 Biocompatibility assessment of common implantable sensor materials in a tumour xenograft model

3.2.1 Background

CD-1 female nude mice (Charles River Laboratories, Tranent, UK) were used in all experiments. The mice were allowed a period of adaptation of at least 7 days before use in experiments and were housed in cages of 6 on an alternating 12 h light cycle in a sterile and specific pathogen-free environment, with ad libitum access to food and water. As nude mice are immunocompromised, they were housed in individually ventilated cages in a barrier environment.

3.2.2 Generation of MDA-MB-231 stock xenograft tumours

MDA-MB-231 cells were grown routinely, trypsinised and counted as previously described in sections 2.2.4 and 2.2.5. Approximately $2 \times 10^9$ cells were resuspended in 1 ml of FCS-free DMEM. Using a 21G needle, 0.1 ml of this cell suspension was injected bilaterally into subcutaneous tissue of the flanks of 5 mice.
Mice were monitored for the development of xenograft tumours which occurred within 6-8 weeks post-injection.

### 3.2.3 Generation of MDA-MB-231 xenograft tumours for biomaterial implantation

Once stock tumours had grown to an adequate size (approximately 0.7-1.2 cm in length), mice were euthanised by cervical dislocation. In a sterile cabinet, xenograft tumours were harvested and placed into DMEM with no additives and sectioned into small fragments, approximately 1-2 mm in length. Implantation of tumour fragments into experimental mice was performed under local anaesthetic (ethyl chloride) using a 12G trocar. Each mouse received 1 tumour fragment injected bilaterally into subcutaneous tissue of the flanks. Mice were monitored for the development of xenograft tumours which occurred within 6-8 weeks post-implantation. The tumour uptake success rate was approximately 90%.

### 3.2.4 General anaesthesia for biomaterial implantation procedures

Mice underwent general anaesthesia using 5% isoflurane (IsoFlo, Abbot Animal Health, Maidenhead, UK) gaseous anaesthesia delivered in room air. Animals were positioned onto a heat mat to maintain rectal temperature between 36.5–37.5°C and adequate depth of anaesthesia was maintained using end-tidal concentrations of 1.5-2.0% isoflurane. All animals were euthanised when required by cervical dislocation.

### 3.2.5 Biomaterial fabrication

The outward-facing materials of the IMPACT sensor were selected for testing; the materials chosen were silicon dioxide (SiO₂), silicon nitride (Si₃N₄), Parylene-C, Nafion, OG116-31 resin (Epoxy Technology) and platinum (Pt). Materials were prepared in the Scottish Microelectronics Centre Class 10 cleanroom facility (Kings Buildings, University of Edinburgh) and comprised of 3–7 mm long pieces of titanium (Ti) wire, diameter 0.4 mm, coated with the material to be tested. Copper (Cu) wire (99.999% purity; Sigma Aldrich, UK) was used for positive control samples.
3.2.6 Biomaterial manufacture

Manufacture of materials for xenograft implantation was performed by Dr E. Blair and Dr J. Marland (School of Engineering, University of Edinburgh). For all coated materials Ti wire was first cleaned in isopropyl alcohol at 50°C with ultrasonic agitation for 15 min, followed by the same treatment in deionised water, then dried using an N₂ gun; Cu wire was also cleaned using the same protocol. Parylene-C samples were produced using a vapour deposition system SCS (Speciality Coating Systems 2010 Labcoater), ensuring a conformal coating of 5 μm of Parylene-C. SiO₂ and Si₃N₄ samples were prepared using Plasma Enhanced Chemical Vapour Deposition (PECVD); a 1 μm layer of each material was deposited. Pt samples were produced using electron-beam evaporation in an ANS Cluster tool which deposited a 50 nm thick Pt film onto the wire. Nafion samples were created by dipping Ti wire in a solution of 5% by weight Nafion in lower aliphatic alcohols and water, before air curing for 5 min; the process was repeated 5 times before curing for 1 h at 120°C. Resin samples were produced by dip coating the Ti wire in OG116-31 resin which were then cured for 800 s under ultraviolet light. After completion of each coating process wires were optically inspected to ensure uniformity. All wires were sterilised prior to implantation. Nafion coated wires were sterilised by routine autoclaving; all other biomaterials were sterilised in 100% ethanol for 10 min, rinsed in deionised water and stored in penicillin and streptomycin. All wires were washed in sterile distilled water immediately before implantation.

3.2.7 Immunohistochemistry

Sections for IHC underwent routine vertical IHC and counterstaining in haematoxylin as described in section 2.5.4. Primary antibodies used in the murine study are described in Table 3.1. Appropriate positive and negative controls were included in all IHC staining protocols (Figure 3.1). The staining pattern of each antibody was verified by a board-certified veterinary pathologist (Dr L. Morrison, The Royal (Dick) School of Veterinary Studies, University of Edinburgh). Additional sections were also routinely stained with haematoxylin and eosin (H&E) or Masson’s Trichrome as described in sections 2.5.2 & 2.5.3.
## Table 3.1. Primary antibodies used in the murine experiments.

<table>
<thead>
<tr>
<th>Primary antibody target antigen</th>
<th>Histological marker/cited publications</th>
<th>Antibody details and antigen retrieval solution</th>
<th>Manufacturer</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Ki67</td>
<td>Proliferation(^{384-387})</td>
<td>Rabbit mAb Sodium citrate</td>
<td>Abcam; ab92742</td>
<td>1:1000</td>
</tr>
<tr>
<td>Anti-carbonic anhydrase 9</td>
<td>Hypoxia(^{117,388,389})</td>
<td>Rabbit pAb Sodium citrate</td>
<td>Abcam: ab15086</td>
<td>1:750</td>
</tr>
<tr>
<td>Anti-cleaved caspase 3</td>
<td>Apoptosis(^{390-393})</td>
<td>Rabbit pAb Sodium citrate</td>
<td>Cell Signaling Technology; 9661</td>
<td>1:150</td>
</tr>
<tr>
<td>Anti-Ly-6G</td>
<td>Neutrophil(^{394-397})</td>
<td>Rat mAb EDTA</td>
<td>Abcam; ab25377</td>
<td>1:50</td>
</tr>
<tr>
<td>Anti-F4/80</td>
<td>Macrophage(^{398-401})</td>
<td>Rat mAb Enzymatic</td>
<td>Biolegend; 123101</td>
<td>1:100</td>
</tr>
<tr>
<td>Anti-ER-TR7</td>
<td>Fibroblast(^{402-405})</td>
<td>Rat mAb Enzymatic</td>
<td>Novus Biologicals; NB100-64932</td>
<td>1:50</td>
</tr>
</tbody>
</table>

### 3.2.8 Immunohistochemical analysis

QuPath version 0.1.2\(^{383}\) was used to analyse target protein expression and the percentage area of tumour necrosis using the entire tumour area contained within whole slide images. The image analysis pipeline was comprised of several steps. The initial step required, for both target protein expression and percentage area of tumour necrosis analysis, was to isolate the diagnostically relevant areas within the tissue in each whole slide image. Extraneous tissue such as subcutaneous fat and skin was excluded from image analysis and all areas of necrosis were identified. H&E stained sections were used to calculate the percentage area of tumour necrosis; the area of necrosis was divided by the total tumour area (tumour tissue and necrotic area) and then multiplied by 100 (Figure 3.2 & Figure 3.3). Further steps were required for target protein expression analysis. Intensity thresholds and detection parameters for positive and negatively stained cells for each antibody were optimised (Table 3.2). DAB-positive cells were detected using positive cell detection and negative cells were detected by haematoxylin staining. These antibody specific parameters were then applied to every section stained using that antibody. All results were visually assessed for accuracy in all tumour sections following analysis. Examples of this method of cell detection are shown for each antibody in Figure 3.4-Figure 3.15. To calculate the percentage of positively stained cells, the number of positively stained cells was divided by the total number of cells and then multiplied by 100.
Table 3.2. QuPath parameters for cell detection. Intensity threshold values were optimised for each specific antibody other values remained as default settings.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Setting</th>
<th>Parameter</th>
<th>Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scan magnification</td>
<td>20x</td>
<td>Max. background intensity</td>
<td>2</td>
</tr>
<tr>
<td>Stain vectors</td>
<td>QuPath default</td>
<td>Split by shape</td>
<td>on</td>
</tr>
<tr>
<td>Detection image</td>
<td>Haematoxylin OD</td>
<td>Exclude DAB</td>
<td>off</td>
</tr>
<tr>
<td>Pixel size</td>
<td>0.5 μm</td>
<td>Cell expansion</td>
<td>5</td>
</tr>
<tr>
<td>Background radius</td>
<td>8 μm</td>
<td>Include cell nucleus</td>
<td>on</td>
</tr>
<tr>
<td>Median filter radius</td>
<td>0 μm</td>
<td>Smooth boundaries</td>
<td>on</td>
</tr>
<tr>
<td>Sigma</td>
<td>1.5 μm</td>
<td>Make measurements</td>
<td>on</td>
</tr>
<tr>
<td>Minimum area</td>
<td>10 μm</td>
<td>Score compartment</td>
<td>Nucleus DAB OD mean</td>
</tr>
<tr>
<td>Maximum area</td>
<td>400 μm</td>
<td>Threshold 1+</td>
<td>Antibody specific</td>
</tr>
<tr>
<td>Intensity threshold</td>
<td>0.1</td>
<td>single threshold</td>
<td>on</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Threshold 1+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki67, CA9, Ly-6C, F4/80</td>
</tr>
<tr>
<td>Caspase 3</td>
</tr>
<tr>
<td>ER-TR7</td>
</tr>
</tbody>
</table>

Image J (NIH, Bethesda, MD, USA) was used to analyse the percentage area of collagen using the entire tumour area contained within whole slide images. A colour deconvolution macro programme developed by Dr L. Murphy (IGMM, University of Edinburgh) was used in conjunction with Image J for this purpose. Following the isolation of the diagnostically relevant areas (as was performed with the QuPath analysis) and colour deconvolution, thresholds were set to detect collagen appearing as red on a white background. This stain specific threshold was then applied to every section. All results were visually checked for accuracy in all tumour sections following analysis. Examples for collagen detection using whole slide images are shown in Figure 3.16 & Figure 3.17. To calculate the percentage area of collagen, the stained area was divided by the total area and then multiplied by 100.
Figure 3.1. Positive controls used for verifying murine immune antibodies. (a) Liver used for F4/80 (macrophage), (b) SKOV xenograft tumour used for ER-TR7 (fibroblast), (c) Spleen used for Ly-6G (neutrophil). Negative controls underwent the same IHC procedure as for positive controls, with the exception that antibody diluent containing no primary antibodies was added to the slides. Positive DAB staining is seen for each antibody at the expected cellular localisation region and in the correct cell type: positive F4/80 staining is seen predominately at the cell membrane in hepatic macrophages, ER-TR7 staining is seen predominately in the cytoplasm in fibroblasts, Ly-6G staining is seen in the cytoplasm of neutrophils.
Figure 3.2. Representative H&E stained sections from tumours harvested at day 7. (a) Untreated, (b) Parylene-C implanted.

Figure 3.3. Representative H&E stained sections for QuPath analysis of the area of necrosis. Yellow line is outlining the total tumour area including the necrotic area, but with the removal of skin and subcutaneous tissue. Red line is outlining the area of necrosis.
Figure 3.4. Representative CA9 stained sections from tumours harvested at day 7. (a) Negative control, (b) Untreated, (c) Nafion implanted.

Figure 3.5. Representative CA9 stained sections for QuPath analysis of hypoxia. CA9 staining, as expected, is predominantly localised to the cell membrane.
Figure 3.6. Representative Ki67 stained sections from tumours harvested at day 7. (a) Negative control, (b) Untreated, (c) Silicon dioxide implanted.

Figure 3.7. Representative Ki67 stained sections for QuPath analysis of proliferation. Ki67 staining, as expected, is localised to the cell nucleus.
Figure 3.8. Representative caspase 3 stained sections from tumours harvested at day 7. (a) Negative control, (b) Untreated, (c) Copper implanted.

Figure 3.9. Representative caspase 3 stained sections for QuPath analysis of apoptosis. Caspase 3 staining, as expected, is predominantly localised to the cytoplasm.
Figure 3.10. Representative Ly-6G stained sections from tumours harvested at day 7. (a) Negative control, (b) Untreated, (c) Silicon nitride implanted.

Figure 3.11. Representative Ly-6G stained sections for QuPath analysis of neutrophil numbers. Ly-6G staining, as expected, is predominantly localised to the cytoplasm.
Figure 3.12. Representative F4/80 stained sections from tumours harvested at day 7. (a) Negative control, (b) Untreated, (c) Parylene-C implanted.

Figure 3.13. Representative F4/80 stained sections for QuPath analysis of macrophage numbers. F4/80 staining, as expected, is predominantly localised to the cell membrane.
Figure 3.14. Representative ER-TR7 stained sections from tumours harvested at day 7. (a) Negative control, (b) Untreated, (c) Platinum implanted.

Figure 3.15. Representative ER-TR7 stained sections for QuPath analysis of fibroblast numbers. ER-TR7 staining, as expected, is predominantly localised to the cytoplasm.
Figure 3.16. Representative Masson’s trichrome stained sections from tumours harvested at day 7. (a) Untreated, (b) Silicon dioxide implanted.

Figure 3.17. Representative Masson’s trichrome stained sections for Image J analysis of collagen deposition. Following colour devolution, the collagen is highlighted in red against a white background.
3.3 Validation of functionality of the IMPACT oxygen sensor to measure tissue oxygen tension for clinical applications

3.3.1 Background

Male Wistar rats (Charles River Laboratories, Margate, UK) of approximately 400 g body weight were used in all experiments. Prior to instrumentation, the rats were allowed a period of adaptation of at least 7 days and were housed in cages of 4 on an alternating 12 h light cycle in a specific pathogen-free environment, with ad libitum access to food and water.

3.3.2 Anaesthesia, arterial and venous cannulation and tracheostomy tube placement

Rats underwent general anaesthesia using 5% isoflurane (IsoFlo, Abbot Animal Health, Maidenhead, UK) gaseous anaesthesia delivered in room air and were positioned onto a heat mat to maintain rectal temperature between 36.5–37.5°C, which was continuously recorded using a temperature sensor (Harvard Apparatus, Cambridge, UK). Adequate depth of anaesthesia was maintained using end-tidal concentrations of 1.5-2.0% isoflurane. Placement of arterial and venous cannulas was performed in accordance with a previous study. A 2 cm ventral midline cervical incision was made with cervical dissection to identify the right internal jugular vein and left common carotid artery. Both vessels were cannulated using 0.96 mm external diameter PVC catheters (Scientific Commodities Inc., Lake Havasu City, AZ, USA) (Figure 3.18 & Figure 3.19) and secured in place with 1 metric braided silk (Ethicon, UK). The arterial line was subsequently connected to a pressure transducer (Powerlab, AD Instruments, Chalgrove, UK) for continuous monitoring and recording of mean arterial blood pressure and heart rate; this was performed by connecting the transducer to a computer using a 16-channel Powerlab system and Chart 5 acquisition software (AD Instruments, Chalgrove, UK). The arterial line was also used for intermittent blood sampling; when required, 0.1 ml of arterial blood was taken into heparinised capillary tubes for immediate blood-gas (pH, pCO₂, pO₂, HCO₃⁻, arterial base deficits and paO₂), biochemical (glucose, lactate, Na⁺, K⁺, Cl⁻, Ca²⁺) and haematological (tCO₂, Hct, Hgb) analysis (ABL90 Analyser; Radiometer, Copenhagen, Denmark). The venous line was used for the
administration of fluids; all animals received surgical doses of crystalloid fluids throughout the procedures, which consisted of a continuous infusion of 10-20/ml/kg/h compound sodium lactate (Aqupharm No 11, Animalcare, York, UK) to sustain cardiac preload and replace lost fluids and electrolytes. Mean arterial blood pressure was maintained at approximately 100 mmHg. A tracheostomy was created using 2.08 mm external diameter polythene tubing (Portex Ltd, Hythe, UK); this was attached to a T-piece breathing circuit to secure the airway, maintain anaesthesia and allow changes in the inspired fractional oxygen concentration (FiO₂) to be delivered (Figure 3.20). All animals were euthanised with intravenous sodium pentobarbitone (Pentoject; Animalcare, York, UK).

Figure 3.18 Intra-operative photographs depicting cannulation of the right jugular vein. (a) A 2 cm ventral cervical skin incision is made. (b&c) Cervical dissection is performed to allow identification and mobilisation of the right jugular vein. (d) One untied suture is placed distally around the jugular vein and a second is placed proximally and tied securely, leaving about 1 cm of vein between the 2 sutures. (e) A venotomy is created just distal to the proximal suture; the cannula is inserted and advanced 2-3 cm into the vein before tying the distal suture around the vein and cannula.
Figure 3.19. Intra-operative photographs depicting cannulation of the left carotid artery. (a) Cervical dissection is performed to allow identification of the left carotid artery. (b) The carotid artery is dissected from the vagus nerve. (c) One untied suture is placed distally around the carotid artery and a second is placed proximally and tied securely leaving about 1.5 cm of artery between the 2 sutures. A clamp is added just proximal to the distal suture before placing a third untied suture. (d) An arteriotomy is created between the 2 sutures and the cannula is inserted and advanced up to the clamp. (e) The third suture is tied loosely over the cannula and the clamp is removed. (f) The cannula is advanced a further 2 cm before tying the distal suture around the artery and cannula.

Figure 3.20. Intra-operative photographs depicting placement of a tracheostomy tube. (a) Cervical dissection is performed to allow identification of the trachea. (b) The trachea is elevated and maintained in position with a piece of sterile paper and an untied suture is placed distally. (c) An incision is made between tracheal cartilage rings through which the tracheostomy tube is inserted. The tubing is advanced 1 cm before tying the distal suture around the trachea and tracheostomy tube. The tubing is attached to a 3-way tap connected to the inflow of anaesthetic gases.
3.4 Development of a pre-clinical ovine pulmonary adenocarcinoma model for human lung cancer and validation of intra-tumoural functionality of the IMPACT oxygen sensor

3.4.1 Background

For initial protocol development, post-mortem carcasses were obtained through the Royal (Dick) School of Veterinary Studies Large Animal Practice (University of Edinburgh). All experimental OPA sheep were obtained in collaboration with Dr C. Cousens at the Moredun Institute (Pentland Science Park, UK) through an on-farm ultrasound eradication programme run by Dr P. Scot.

Eight post-mortem carcasses were used for initial protocol development. A total of 12 adult female sheep diagnosed with OPA were used in the study. Of these cases, 3 were used to refine the model and 9 were used in experimental procedures. All sheep weighed between 39-76 kg and were transported direct from the farm of origin to Dryden farm. Sheep were bedded on straw, with ad libitum access to food and water in groups of at least 2 animals and were allowed a period of adaptation of at least 24 h before undergoing anaesthesia. Anaesthesia, CT imaging, sensor placement and post-mortem examinations were carried out at the Large Animal Research and Imaging Facility (LARIF) at Dryden Farm (University of Edinburgh).

3.4.2 General anaesthesia for CT imaging and sensor implantations

All sheep underwent pre-anaesthetic assessment, which included distant observation of demeanour and breathing, followed by physical examination. Only animals that passed veterinary assessment underwent anaesthesia and surgery. Food was withheld for 12 h before anaesthesia, but access to water was permitted until pre-anaesthetic medication was administered. Anaesthesia was managed by a specialist team of anaesthetists at the LARIF.

All sheep received pre-anaesthetic sedation to reduce stress, facilitate the induction of anaesthesia and decrease induction agent dose requirements. To limit the risk of sedation-induced respiratory decompensation, intravenous sedative administration was followed by induction of general anaesthesia within 10 min. This pre-anaesthetic sedation was achieved by the intravenous injection of medetomidine in combination with midazolam. Following sedation, the head was elevated to limit
respiratory secretions and rumen contents entering the upper airway. Once sedative effects were evident, generally within 5 min, intravenous propofol was given to effect to allow endotracheal intubation. Intubation was assisted by a laryngoscope with a long (350 mm) blade and a rigid atraumatic stylet; suction was also used when required to aid larynx visualisation; once intubated, the endotracheal tube cuff was inflated and secured in place. Generally, a 10 mm internal diameter endotracheal tube was required for a 30-60 kg sheep. Oropharyngeal and tracheobronchial suction was used as required. Morphine in combination with flunixin was given pre-emptively, either at the time of sedation or immediately post-induction, to provide analgesia for the duration of anaesthesia (Table 3.3).

Anaesthesia was maintained with isoflurane (IsoFlo, Abbot Animal Health, Maidenhead, UK) vaporised in an O2/air mixture administered via a Bain or circle breathing system connected to the endotracheal tube; end-tidal concentrations of 1.5-2.0% isoflurane were used to maintain adequate depth of anaesthesia. After tracheal intubation, intermittent positive pressure, volume controlled, ventilation was provided using a mechanical ventilation system to achieve adequate tidal volumes of 8-10 ml/kg. Respiratory rate was adjusted to maintain normocapnia (PaCO2 range 4.7–6 kPa). To aid ventilation sheep were positioned in sternal recumbency; however, animals were placed temporarily in lateral recumbency, with OPA lesion(s) uppermost, for CT imaging and sensor implantation (Figure 3.21).

Body temperature was monitored using rectal and oesophageal temperature sensors and maintained between 38.5–39.5°C. A central (jugular) venous 14G cannula was placed which was used for the administration of drugs and crystalloid fluids. Animals received surgical doses of fluids throughout anaesthesia and surgery, which consisted of a continuous infusion of 5-10/ml/kg/hr compound sodium lactate (Aqupharm No 11, Animalcare, York, UK) to maintain cardiac preload and replace lost fluids and electrolytes. Mean arterial blood pressure was maintained at approximately 70-80 mmHg. An arterial cannula was placed in the central auricular artery which was used for intermittent blood sampling; when required, 1 ml of arterial blood was taken into heparinised syringes for immediate blood-gas (pH, pCO2, pO2, HCO3-, arterial base deficits and paO2), biochemical (glucose, lactate, creatinine, Na+, K+, Cl-, Ca2+) and haematological (tCO2, Hct, Hgb) analysis (Epoc
portable blood-gas electrolyte and critical care analyser; Woodley Equipment Company Ltd, Lancashire, UK). A multiparameter patient monitoring device (Datex-Ohmeda S/5, SOMA Technology, Madison, USA) was used to continuously monitor pulse rate and blood pressure along with pulse oximetry, capnography, temperature, spirometry, electrocardiography and inspired and expired gases (O₂, CO₂ and inhalant anaesthetic agent). All animals were euthanised with intravenous sodium pentobarbitone (Pentoject; Animalcare, York, UK).

**Table 3.3. Anaesthesia and analgesia options in sheep diagnosed with OPA.**

*Until conditions for endotracheal intubation are present (i.m., intramuscular; i.v., intravenous) (information provided by Professor E. Clutton and Dr S. Greenhalgh).

<table>
<thead>
<tr>
<th>Phase</th>
<th>Drug</th>
<th>Manufacturer</th>
<th>Dose (mg/kg)</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedation</td>
<td>Medetomidine</td>
<td>‘Sedator’; Dechra Veterinary Products, Shrewsbury, UK</td>
<td>0.003-0.01</td>
<td>i.v.</td>
</tr>
<tr>
<td></td>
<td>in combination with</td>
<td>Midazolam ‘Hypnovel’; Roche, Welwyn Garden City, UK</td>
<td>0.25-0.5</td>
<td>i.v.</td>
</tr>
<tr>
<td>Induction</td>
<td>Propofol</td>
<td>‘Propofol’; Fresenius Kabi, Welwyn Garden City, UK</td>
<td>To effect* (e.g. 3-10)</td>
<td>i.v.</td>
</tr>
<tr>
<td>Maintenance</td>
<td>Isoflurane</td>
<td>‘IsoFlo’; Abbot Animal Health, Maidenhead, UK</td>
<td></td>
<td>inhaled</td>
</tr>
<tr>
<td>Analgesia</td>
<td>Flunixin</td>
<td>‘Flunixin Injection’; Norbrook, Newry, UK</td>
<td>2.2</td>
<td>i.v.</td>
</tr>
<tr>
<td></td>
<td>Morphine</td>
<td>‘Morphine Sulphate’; Martindale Pharmaceuticals, Essex, UK</td>
<td>0.1-0.3</td>
<td>i.v./i.m</td>
</tr>
</tbody>
</table>

**Figure 3.21. Photographs of an anaesthetised sheep undergoing sensor readings.** Sheep are positioned in sternal recumbency with the head elevated above the thorax.
3.4.3 Computed tomography

CT imaging was performed by Mrs L. Grant (The Royal (Dick) School of Veterinary Studies, University of Edinburgh). A single-section SOMATOM Definition AS 64 slice helical CT machine (Siemens Healthcare Ltd, Camberley, UK) was used for all advanced imaging procedures. Imaging parameters of the scanner were 120 kVp, 35 mA, 3-5 mm collimation with 1 mm section thickness. The window width and level were approximately 2000 and -500 HU respectively, allowing simultaneous visualisation of the implantation needle, blood vessels, lesions, pneumothorax, bone, muscle and fat. All scans were obtained through the entire thoracic cavity from the first to the last rib using a section thickness of 1 mm to improve the visualisation of the needle tip and sensor in relation to the OPA lesion (Figure 3.22).

Figure 3.22. Photographs of imaging and surgical facilities. (a) The sheep is anaesthetised and positioned on the gantry, rump first, for CT scanning in lateral recumbency, with the OPA affected lungs uppermost. (b) Surgical equipment required for sensor implantation including a general surgical kit and Jamshidi insertion needle. An IMPACT O2 sensor can be seen in a bottle of sterile saline at the top right-hand side of the image.

3.4.4 Oxygen sensor recordings

Oxygen sensor recordings in both the rat and ovine experiments were performed by Dr J. Marland (School of Engineering, University of Edinburgh). Following sensor implantation, the lead wire was connected to an EmStat3 Blue potentiostat (PalmSens BV, Netherlands). Periodic O2 measurements were performed using chronoamperometry at -0.5 V (versus the on-chip Ag/AgCl reference electrode) for 20 s, followed by a rest period of 20 s. These cycles were repeated
continuously for the duration of the experiments. The working electrode current over the final 5 s of each 20 s chronoamperometry recording was analysed using MATLAB R2017a (MathWorks, Natick, MA, USA) to derive the mean current. The measured working electrode current is directly proportional to the ptO$_2$ at the sensor surface.

### 3.4.5 Statistical Analysis

Data for all murine and ovine experiments were analysed with either one-way or two-way ANOVA with Holm-Šidák multiple comparisons tests to test for differences between 2 groups; $p$ values <0.05 were deemed statistically significant. Data are shown as mean ± SEM with all statistical analysis and graphs generated using Prism 7 (GraphPad Software, San Diego, CA, USA).
4 Development and Characterisation of Acquired Radioresistant Breast Cancer Cell Lines

This results chapter is an expanded version of a published research article: Gray M, Turnbull AK, Ward C, Meehan J, Martínez-Pérez C, Bonello M, Pang LP, Langdon SP, Kunkler IH, Murray A, Argyle D. Development and characterisation of acquired radioresistant breast cancer cell lines. Radiation Oncology 2019; 14(64): 1-19. This article is open access with the authors retaining copyright to their work with permission to use published figures in this thesis. Sections of text and figures used from this article have been referenced accordingly.

4.1 Abstract

**Background:** The response of a tumour to radiotherapy will be influenced by the tumour’s innate radiosensitivity and the development of acquired radioresistance. Research into understanding and targeting the mechanisms involved in acquired radioresistance is required if patient outcomes are to be improved. **Methods:** Radioresistant breast cancer cell lines (RR) were established by treating ZR-751, MCF-7 and MDA-MB-231 parental cells with weekly fractions of radiation. Parental and radioresistant cell lines underwent phenotypic, functional and genotypic characterisation. Intrinsic differences between parental and RR cells were investigated by gene expression analysis to identify differentially expressed or activated signalling networks. **Results:** Radioresistance was confirmed through colony formation and proliferation assays. Radioresistant cells exhibited evidence of epithelial-to-mesenchymal-transition with enhanced invasion and migration. ZR-751 RR and MCF-7 RR cell lines demonstrated loss of ERα and PgR expression with an increase in EGFR expression. Based on gene analysis, these cell lines changed classification from luminal A (parental) to normal-like (ZR-751 RR) or HER2-overexpressing (MCF-7 RR) subtypes. Gene expression analysis identified that RR cell lines derived from ER+ cells demonstrated down-regulation of ER signalling genes and up-regulation of genes associated with WNT, MAPK and PI3K pathway activation; this was confirmed by western blot. **Conclusions:** This study has successfully developed 3 novel radioresistant breast cancer cell lines which underwent phenotypic, functional and genotypic characterisation. Comparisons made
with their parental cells identified multiple differentially expressed or activated signalling networks which warrant further investigation as potential targets for overcoming acquired radioresistance.

4.2 Introduction

Tumour recurrence following RT can be due to the survival of a population of cells that have either greater intrinsic (innate) resistance to radiation (e.g. hypoxic or cancer stem cells) or acquire resistance. Ultimately, through clonal selection, it is these radioresistant cells that can repopulate the tumour site, leading to recurrence and treatment failure. Research into understanding and targeting the mechanisms involved in cancer cells acquiring radioresistance is therefore required to improve patient outcome. Previous studies have identified multiple factors which are likely to be involved in radioresistance development, including increased oncogenic miRNA production, epithelial-to-mesenchymal transition (EMT), signalling pathway activation (EGFR, PI3K/AKT, MAPK, NF-ƙB), improved DNA damage responses, cancer stem cell repopulation and changes in cancer cell metabolism. The TME (including hypoxia) can also influence the effectiveness of RT. Unfortunately, these studies tend to focus on isolated pathways which fail to appreciate the complex and likely interconnected cellular changes that are required for cancer cells to become radioresistant. Hypoxia, for example, can cause cancer cells to adopt a more undifferentiated phenotype characterised by increased stem cell marker expression and can also affect the expression of genes and pathways controlling stemness, such as Oct4, Notch and EMT.

In comparison with studies investigating chemoresistance, research into understanding radioresistance is currently limited; this is partly due to a lack of radioresistant model systems. To overcome this, RR models are required that can be used with techniques capable of studying multiple pathways simultaneously. This research could provide an overview of complex interrelated biological systems and a detailed understanding of cellular changes involved in the development of radioresistance. This could ultimately lead to a more effective way of identifying pathways which could be targeted to overcome radioresistance.

This chapter describes the development of novel in vitro radioresistant ER positive (ER\(^+\)) and ER negative (ER\(^-\)) breast cancer cell lines. Analysis of gene
expression data was performed by Dr A. K. Turnbull (Cancer Research UK, University of Edinburgh). Parental cell lines were chosen to represent different molecular subtypes of breast cancer and included MCF-7 and ZR-751 cell lines (ER\(^+\), PgR\(^+\), HER2\(^-\)), which are hormone-dependent, and the MDA-MB-231 cell line, which is triple negative (ER\(^-\), PgR\(^-\), HER2\(^-\)) and consequently hormone-independent. Genotypic, phenotypic and functional characterisation of the RR model was undertaken, allowing validation of results at gene, protein and functional levels. This approach identified multiple differences between paired parental and RR cell lines and between the different breast cancer subtypes (ER\(^+\) and ER\(^-\)), resulting in an in-depth characterisation of the RR model. To our knowledge, this is the first description of a developed ZR-751 RR cell line and the use of MTS derived from RR cells in IHC and functional assays.

4.3 Results

4.3.1 Development and confirmation of acquired radioresistance in human ER\(^+\) and ER\(^-\) breast cancer cell lines

Parental cells (MCF-7, ZR-751 and MDA-MB-231) were used to develop radioresistant cell lines (MCF-7 RR, ZR-751 RR and MDA-MB-231 RR). Parental cells were exposed to weekly single fractionated doses of radiation, increasing by 0.5 Gy per week over a 12-week period; cells were subsequently maintained by weekly doses of 5 Gy. Although this maintenance radiation dose still caused cell death in all 3 RR cell lines, this was significantly less than the level seen during the 12-week development period and did not appear to change with chronic radiation exposure.

Following the 12-week development period, CF and SRB assays were used to confirm radioresistance. All RR cell lines had significantly higher CF ability than their parental cell lines when exposed to a single dose of radiation up to 6 Gy (Figure 4.1). Proliferation of the RR cell lines was inhibited less than that of their parental cell lines when exposed to a single dose of radiation up to 10 Gy (Figure 4.2, Figure 4.3 & Figure 4.4), with correspondingly higher IC\(\text{50}\) values seen in the RR cell lines (Table 4.1). MCF-7 RR and MCF-7 rr cells (a MCF-7 RR cell line which had not received radiation for 6 months), showed comparable radioresistance when exposed to a single dose of radiation up to 6 Gy in CF assays and up to 4 Gy in SRB assays. Both cell lines showed significantly greater resistance to the effects of radiation in
terms of proliferation and CF ability compared to the parental MCF-7 cell line, suggesting maintenance of their acquired phenotype (Figure 4.5).

**Figure 4.1. Radioresistant cell lines have increased colony formation ability.** Colony formation assays at 10-14 d post-radiation comparing MCF-7 RR, ZR-751 RR and MDA-MB-231 RR cell lines with their respective parental cell lines (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001).

**Figure 4.2. Proliferation of the ZR-751 RR cell line is inhibited less than its parental cell line following exposure to radiation.** SRB proliferation assay comparing ZR-751 RR with its parental cell line at 144 h post-radiation (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001).
Figure 4.3. Proliferation of the MCF-7 RR cell line is inhibited less than its parental cell line following exposure to radiation. SRB proliferation assays comparing MCF-7 RR with its parental cell line up to 120 h post-radiation (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05).
Figure 4.4. Proliferation of the MDA-MB-231 RR cell line is inhibited less than its parental cell line following exposure to radiation. SRB proliferation assays comparing MDA-MB-231 RR with its parental cell line up to 120 h post-radiation (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05).

Table 4.1. IC₅₀ values for each parental and RR cell line up to 144 h post-radiation. If no value is recorded this indicates that a reduction in proliferation by 50% had not occurred at that time point; MCF-7 and MDA-MB-231 cell lines were evaluated up to 120 h post-radiation, whereas the ZR-751 cell line was evaluated up to 144 h post-radiation.

<table>
<thead>
<tr>
<th>Time post-radiation (h)</th>
<th>MCF-7</th>
<th>MCF-7 RR</th>
<th>ZR-751</th>
<th>ZR-751 RR</th>
<th>MDA-MB-231</th>
<th>MDA-MB-231 RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>48</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>72</td>
<td>4.98</td>
<td>9.64</td>
<td>-</td>
<td>-</td>
<td>3.53</td>
<td>9.71</td>
</tr>
<tr>
<td>96</td>
<td>3.27</td>
<td>5.36</td>
<td>3.53</td>
<td>9.71</td>
<td>3.13</td>
<td>7.11</td>
</tr>
<tr>
<td>120</td>
<td>3.74</td>
<td>5.22</td>
<td>-</td>
<td>3.13</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>144</td>
<td>N/A</td>
<td>N/A</td>
<td>4.38</td>
<td>6.91</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
4.3.2 Development and confirmation of acquired radioresistance in a canine ER⁻ breast cancer and an ovine lung cancer cell line

Parental cells (REM-134 and JS7) were used to develop radioresistant cell lines (REM-134 RR and JS7 RR). These cell lines were developed for use in the secretomic experiments (described in chapter 5). Following the 12-week radiation protocol, as previously described, SRB assays were used to confirm radioresistance (CF assays were not used, as both cell lines would not form colonies from single cells). Proliferation of the JS7 RR and REM-134 RR cell lines was inhibited less than that of their parental cell lines when exposed to a single dose of radiation up to 4 and 10 Gy respectively (Figure 4.6 & Figure 4.7), with corresponding higher IC₅₀ values seen in the RR cell lines (Table 4.2). REM-134 RR and REM-134 rr cells (a REM-134 RR cell line which had not received radiation for 6 months), showed comparable radioresistance when exposed to radiation doses of up to 10 Gy in SRB assays. Both cell lines showed significantly greater resistance to the effects of radiation in terms of proliferation compared to the parental REM-134 cell line, suggesting maintenance of their acquired phenotype (Figure 4.8).
Figure 4.6. Proliferation of the JS7 RR cell line is inhibited less than its parental cell line following exposure to radiation. SRB proliferation assay comparing JS7 RR with its parental cell line at 144 h post-radiation (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, **p≤0.01; *p≤0.05).

Figure 4.7. Proliferation of the REM-134 RR cell line is inhibited less than its parental cell line following exposure to radiation. SRB proliferation assays comparing REM-134 RR with its parental cell line up to 120 h post-radiation (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05).
Table 4.2. IC₅₀ values for each parental and RR cell line up to 144 h post-radiation. If no value is recorded this indicates that a reduction in proliferation by 50% at that time point had not occurred; REM-134 cell line was evaluated up to 120 h post-radiation whereas JS7 cell line was evaluated up to 144 h post-radiation.

<table>
<thead>
<tr>
<th>Time post-radiation (h)</th>
<th>REM-134</th>
<th>REM-134 RR</th>
<th>JS7</th>
<th>JS7 RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>48</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>72</td>
<td>3.85</td>
<td>10.34</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>96</td>
<td>3.32</td>
<td>4.98</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>120</td>
<td>1.7</td>
<td>3.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>144</td>
<td>N/A</td>
<td>N/A</td>
<td>2.82</td>
<td>4.12</td>
</tr>
</tbody>
</table>

Figure 4.8. SRB assays comparing REM-134, REM-134 RR and REM-134 rr cell lines. REM-134 rr is a radioresistant cell line not radiated for 6 months (24 passages). (a) SRB assay at 96 h post-radiation. (b) SRB assay at 120 h post-radiation (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3).

4.3.3 Gene expression analysis identifies inherent similarities between radioresistant cell lines derived from ER⁺ cells

A large number of genes were found to be inherently differentially expressed (using a log2 fold-change cut-off of 1) between ER⁺ parental and RR cell lines. These changes were consistent between both MCF-7 RR and ZR-751 RR cell lines. Fewer differentially expressed genes were observed between the MDA-MB-231 parental and RR cell lines. Cluster analysis using differentially expressed genes (n=8796) identified that the MDA-MB-231 and RR cell lines clustered closely together, having similar expression patterns. Parental ZR-751 and MCF-7 cells also had a similar pattern of gene expression to the MDA-MB-231 cells except for 2 gene clusters, 1 enriched for focal adhesion and tight junctions and 1 enriched for glycan biosynthesis. MCF-7 RR and ZR-751 RR cell lines clustered together and separately from all the other cell lines, with lower expression of ribosomal genes and genes involved in proliferation, metabolism and DNA repair and higher expression of genes involved in WNT and MAPK signalling (Figure 4.9).
Figure 4.9. Global gene expression analysis identifies significant inherent similarities between RR cell lines derived from ER+ cells. (a) Venn-diagrams comparing all 3 cell lines, showing the overlap of up-regulated (left) and down-regulated (right) genes with log2 fold changes > 1 between paired parental and RR untreated cell lines. (b) Log2 mean-centered gene expression heatmap, labelled with cluster-enriched gene ontology, showing expression of the most differentially expressed genes, taken from the Venn-diagram analysis (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.
4.3.4 Radioresistant cell lines have concurrent lower expression of cell cycle associated genes and modified basal proliferation rates

SRB assays using cells grown in 2D cultures showed lower proliferation rates in the MCF-7 RR and MDA-MB-231 RR cell lines and higher rates in the ZR-751 RR cell line in comparison to their respective parental cells (Figure 4.10a). Gene expression analysis from 2D cultures characterised the MCF-7 RR and ZR-751 RR cell lines as having lower expression of genes involved in DNA repair and replication and those related to G1/S-phase transition and cell cycle regulation, along with higher expression of cell cycle arrest genes. Changes were less marked in the MDA-MB-231 parental and RR cell lines, both of which clustered next to each other and to the MCF-7 and ZR-751 parental cell lines (Figure 4.10b). To investigate the apparent differences between the gene expression and SRB proliferation data in the ZR-751 RR cell line, Ki67 staining by IHC was performed using MCF-7 and ZR-751 parental and RR MTS (MDA-MB-231 cells failed to form MTS that could withstand IHC processing). Quantitative analysis showed that RR MTS contained lower percentages of positively stained Ki67 cells compared with parental MTS, suggesting lower basal proliferation rates (Figure 4.11).
Figure 4.10. Radioresistant cell lines have modified proliferation rates relative to their parental cells. (a) SRB assays showing differences in proliferation rates between parental and RR cell lines grown in 2D cultures over 120 h (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; *p≤0.05). (b) Log2 mean-centered gene expression heatmap showing differences in expression between parental and RR cell lines in respect of proliferation genes taken from the KEGG database cell cycle pathway (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.
Figure 4.11. MCF-7 RR and ZR-751 RR MTS show decreased expression of Ki67. IHC of MTS stained for Ki67 using MCF-7 and ZR-751 parental and RR cell lines with quantitative analysis of the % of positively stained cells. Ki67 staining, as expected, is localised to the cell nucleus (unpaired two-sample t-test; data expressed as mean ± SEM, n=3, ****p≤0.0001).

4.3.5 Radioresistant cell lines have increased invasion and migration potential

Considered to be a normal feature of embryonic development, epithelial-to-mesenchymal transition (EMT) is a process involved in cellular movement and morphogenesis. However, cancer cells can also undergo EMT, causing them to develop a more invasive and migratory phenotype. Here, using a 3D collagen invasion assay, we showed a statistically significant increase in the invasive potential of MTS derived from MCF-7 RR and ZR-751 RR cells compared to parental MTS (which demonstrated no invasive capabilities); although at 72 h the MDA-MB-231 RR MTS showed a small increase in invasiveness, this was not statistically significant (Figure 4.12). However, results from 2D scratch assays demonstrated that
all 3 RR cell lines had significantly enhanced migratory ability compared to their parental cells (Figure 4.13, Figure 4.14 & Figure 4.15).

The morphology of parental ER+ cell lines was typically epithelial-like, consisting of clumps of tightly packed cells forming cobblestone-like monolayers. The cells themselves consisted of a small amount of cytoplasm and a single large nucleus. However, following the initial 12 weeks of radiation exposure significant morphological changes were evident in the RR derivatives. Single cells or those within small clusters gained a spindle-shaped morphology with cellular contact between cells occurring via focal points rather than along their entire perimeter. Parental MDA-MB-231 cells originally exhibited a mesenchymal-like phenotype, therefore phenotypic changes in its RR derivate were not obvious (Figure 4.16).

These morphological changes that occurred with the acquisition of radioresistance were consistent with EMT and this process was initially investigated using IHC and ICC to examine the expression levels of EMT markers. Increased expression of vimentin, N-cadherin and SNAIL, along with the partial down-regulation of E-cadherin was identified in the MCF-7 RR and ZR-751 RR cell lines compared with their parental cells. No differences between the MDA-MB-231 parental and RR cell lines were identified, with these cell lines exhibiting high vimentin along with low N-cadherin and E-cadherin expression (Figure 4.17). The IHC results were mirrored in the gene expression data, firstly by investigating the expression of the vimentin, E- and N-cadherin genes (VIM, CDH1 and CDH2) (Figure 4.18a) and secondly by using a published EMT signature (Figure 4.18b). This pan-cancer EMT-associated gene expression signature was from a study that combined bioinformatic expression data from 7 tumour types using The Cancer Genome Atlas and Cancer Cell Line Encyclopaedia databases (the gene lists used are provided in the appendix). In our analysis, as expected, MCF-7 and ZR-751 parental cell lines had a gene expression pattern consistent with an epithelial genotype, whereas the MDA-MB-231 parental and RR cell lines had higher mesenchymal gene expression. A mixed pattern of gene expression was identified in the MCF-7 RR and ZR-751 RR cell lines, with higher expression of both epithelial and mesenchymal genes; this suggested a transition from an epithelial towards a more mesenchymal-like gene expression profile.
Figure 4.12. Radioresistant cell lines have increased invasion potential. 3D invasion assays comparing MCF-7 RR, ZR-751 RR and MDA-MB-231 RR MTS with their respective parental MTS. Following placement in collagen MTS invasion was assessed up to 120 h. Area of MTS at each time point was calculated and expressed as a % of the initial MTS area at day 0 (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001).
Figure 4.13. MCF-7 RR cell line has increased migration potential. 2D migration scratch assays comparing MCF-7 RR with its parental cell line. Relative migratory distance was calculated at each time point and expressed as a % area devoid of cells based on the initial scratch area at day 0 (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001).

Figure 4.14. ZR-751 RR cell line has increased migration potential. 2D migration scratch assays comparing ZR-751 RR with its parental cell line. Relative migratory distance was calculated at each time point and expressed as a % area devoid of cells based on the initial scratch area at day 0 (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001).
Figure 4.15. MDA-MB-231 RR cell line has increased migration potential. 2D migration scratch assays comparing MDA-MB-231 RR with its parental cell line. Relative migratory distance was calculated at each time point and expressed as a % area devoid of cells based on the initial scratch area at day 0 (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001).

Figure 4.16. MCF-7 RR and ZR-751 RR cells show phenotypic changes consistent with EMT. H&E staining of parental and RR cell lines detailing their morphology (representative images, n=3).
Figure legend on following page.
Figure 4.17. MCF-7 RR and ZR-751 RR cell lines show increased expression of vimentin, N-cadherin and SNAIL with partial down-regulation of E-cadherin. IHC staining for EMT markers (vimentin, N-cadherin, SNAIL and E-cadherin) in MCF-7, ZR-751 and MDA-MB-231 parental and RR cells. Positive DAB staining is seen for each antibody at the expected cellular localisation region: positive vimentin and SNAIL staining is seen predominately in the cytoplasm whereas E and N-cadherin staining is seen predominantly in the cell membrane and cytoplasm (representative images, n=3).
Figure 4.18. MCF-7 RR and ZR-751 RR cell lines show increased gene expression of vimentin and N-cadherin with the partial down-regulation of E-cadherin. (a) Log2 mean-centered gene expression heatmap showing relative inherent gene expression differences between parental and RR cell lines in respect of classical EMT markers; VIM=vimentin, CDH1=E-cadherin, CDH2=N-cadherin (red=higher expression, green=lower expression). (b) Log2 mean-centered gene expression heatmap showing expression differences in respect of a published cancer cell EMT-signature\textsuperscript{414} (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage. The gene list and the order in which they appear in the heatmap is shown in the appendix.

4.3.6  WNT signalling is increased in radioresistant cell lines derived from ER$^+$ cells

WNT signalling has been reported to be involved in EMT and radioresistance\textsuperscript{415}. To investigate this, the expression levels of WNT pathway-related genes was determined in the ER$^+$ parental and RR cell lines. To perform this analysis panels of WNT signalling pathway members and their down-stream targets were taken from the KEGG database\textsuperscript{411} (the gene lists used are provided in the appendix). The majority of genes in these panels, including WNT5a, WNT5b and FRIZZLED family members 1/2/5/7/8, showed increased expression in the RR cell lines derived from ER$^+$ cells (Figure 4.19a & Figure 4.19b); WNT5a showed a log2 5-fold and 15-
fold increase in count-number in the ZR-751 RR and MCF-7 RR cell lines respectively when compared to their parental cell lines. IHC and quantitative analysis using MCF-7 and ZR-751 parental and RR MTS showed increased WNT5a expression in the RR cell lines (Figure 4.20a). Further validation through WB experiments using whole cell lysates from serum-starved cells (in accordance with conditions for the gene expression experiments) also showed increased WNT5a expression in the RR cell lines at 0 and 24 h post-serum starvation (Figure 4.20b).

Figure 4.19. WNT signalling is increased in RR cell lines derived from ER+ cells. Log2 mean-centered gene expression heatmaps showing differences between parental and RR cell lines. (a) WNT pathway-related genes with highlighted WNT and FRIZZLED genes. (b) WNT target genes, taken from the KEGG pathway database\textsuperscript{411} (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage. The gene list and the order in which they appear in the heatmap is shown in the appendix.
Figure 4.20. WNT signalling is increased in RR cell lines derived from ER⁺ cells. (a) IHC of WNT5a expression using MCF-7 and ZR-751 parental and RR MTS; WNT5a staining, as expected, is predominantly localised to the cytoplasm. (b) WB analysis showing the levels of WNT5a in untreated MCF-7 and ZR-751 cell lines in comparison with their RR derivatives (samples were obtained at 0 and 24 h after 2 h serum starvation), (unpaired two-sample t-test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001, **p≤0.01).
4.3.7 Radioresistant MCF-7 and ZR-751 cell lines show loss of ERα and PgR expression and gain in EGFR expression

Breast cancers can be characterised into subtypes by the expression of certain signalling receptors (ERα, PgR, HER2 and EGFR)\textsuperscript{416-418}. IHC showed that the phenotype of the RR cell lines derived from ER\textsuperscript{+} cells was characterised by ERα and PgR expression loss in combination with a gain in EGFR expression (Figure 4.21 & Figure 4.22). MDA-MB-231 parental and RR cells maintained their TNBC phenotype with no significant EGFR expression changes (Figure 4.23); these IHC results were confirmed by WB (Figure 4.24a). ICC with quantitative analysis confirmed reduction in the percentage of ERα positive staining cells in the MCF-7 RR cell line (0.27 ± 0.17\%) compared with the parental MCF-7 cell line (81 ± 1.1\%) and in the ZR-751 RR cell line (0.52 ± 0.36\%) compared with the parental ZR-751 cell line (96.5 ± 1.8\%). Loss of ERα in the MCF-7 RR cell line was associated with tamoxifen resistance; after 72 h of tamoxifen treatment a statistically significant increase in proliferation of the MCF-7 RR cell line was evident compared to the parental cells at concentrations ranging from 0.01–3 \(\mu\)M (Figure 4.24b). Tamoxifen at concentrations of 1 and 3 \(\mu\)M had no effect on migration in the MCF-7 RR cells, whereas an inhibition of migration was seen in the parental cell line (Figure 4.24c).

To investigate the cellular effects of increased EGFR expression on proliferation, invasion and migration, parental and RR cells were treated with the EGFR inhibitor, gefitinib (Selleckchem, Munich, Germany). A statistically significant decrease in MCF-7 RR proliferation was seen after 72 h of treatment with gefitinib at concentrations ranging from 0.1–15 \(\mu\)M compared to MCF-7 parental cells. A significant reduction in migration of the MCF-7 RR cells was also seen, with a concentration of 5 \(\mu\)M decreasing their migratory potential to that of the parental cells (Figure 4.25a & Figure 4.25b). Similar results were also seen in the ZR-751 parental and RR cell lines (Figure 4.25c & Figure 4.25d). Although only a small decrease in MDA-MB-231 RR proliferation was seen at higher gefitinib concentrations compared to the parental cells, a significant reduction in migration was seen, with a concentration of 5 \(\mu\)M decreasing the migratory potential of the RR cell line below that of the parental cells (Figure 4.25e & Figure 4.25f). IC\textsubscript{50} values were reduced in all RR cell lines but were more pronounced in the MCF-7 RR and
ZR-751 RR cell lines (Table 4.3). The effects of gefitinib on invasion were also investigated in the ER+ cell lines, with results showing a significant reduction in invasion of the MCF-7 RR and ZR-751 RR cell lines with a concentration of 5 μM (Figure 4.26).

**Figure 4.21.** MCF-7 RR cells show loss of ERα and PgR and gain in EGFR expression. ICC and IHC expression profiles of signalling receptors, ERα, PgR and EGFR in MCF-7 and MCF-7 RR cell lines using 2D monolayer of cells and MTS. Positive DAB staining is seen for each antibody at the expected cellular localisation region: positive ERα and PgR staining is seen in the nucleus whereas EGFR is seen predominantly in the cell membrane (representative images, n=3).
Figure 4.22. ZR-751 RR cells show loss of ERα and PgR and gain in EGFR expression. ICC and IHC expression profiles of signalling receptors, ERα, PgR and EGFR in ZR-751 and ZR-751 RR cell lines using 2D monolayer of cells and MTS. Positive DAB staining is seen for each antibody at the expected cellular localisation region: positive ERα and PgR staining is seen in the nucleus whereas EGFR is seen predominantly in the cell membrane (representative images, n=3).
Figure 4.23. MDA-MB-231 parental and RR cells show similar EGFR expression. ICC expression profiles of EGFR in MDA-MB-231 and MDA-MB-231 RR cell lines using 2D monolayer of cells. Positive DAB staining is seen at the expected cellular localisation region: positive EGFR staining is seen predominantly in the cell membrane (representative images, n=3).

Figure 4.24. MCF-7 RR and ZR-751 RR cell lines show loss of ERα and PgR expression and gain in EGFR expression. (a) WB analysis showing parental and RR cell lines. The ZR-751 Rr cell line shows results from cells only receiving 6 weeks radiation as opposed to the 12 week course of radiation required for the development of confirmed radioresistance. (b) SRB at 72 h and (c) scratch assay up to 24 h showing the effects of tamoxifen in MCF-7 and MCF-7 RR cell lines (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05).
Radioresistant cell lines show increased sensitivity to gefitinib. (a) SRB at 72 h and (b) scratch assay up to 48 h showing the effects of gefitinib in MCF-7 and MCF-7 RR cell lines. (c) SRB at 72 h and (d) scratch assay up to 24 h showing the effects of gefitinib in ZR-751 and ZR-751 RR cell lines. (e) SRB at 72 h and (f) scratch assay up to 24 h showing the effects of gefitinib in MDA-MB-231 and MDA-MB-231 RR cell lines (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01).

Table 4.3. IC₅₀ values of gefitinib for each parental and RR cell line 72 h post-treatment.

<table>
<thead>
<tr>
<th>Time post gefitinib treatment (h)</th>
<th>MCF-7</th>
<th>MCF-7 RR</th>
<th>ZR-751</th>
<th>ZR-751 RR</th>
<th>MDA-MB-231</th>
<th>MDA-MB-231 RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>72</td>
<td>13.37</td>
<td>6.43</td>
<td>22.02</td>
<td>13.12</td>
<td>14.45</td>
<td>12.16</td>
</tr>
</tbody>
</table>
Figure 4.26. Gefitinib inhibits MCF-7 RR and ZR-751 RR invasion. 3D invasion assay showing the effects of gefitinib in (a&b) MCF-7 and MCF-7 RR MTS and (c&d) ZR-751 and ZR-751 RR MTS. MTS were placed in collagen and invasion was assessed up to 120 h post-seeding. Area of MTS at each time point was calculated and expressed as a % of the initial MTS area at day 0 (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05).
4.3.8 Radioresistant MCF-7 and ZR-751 cell lines show activation of PI3K and MAPK pathways

Increased total EGFR expression was further investigated through the evaluation of downstream signal transduction pathways of the HER/ERBB tyrosine-kinase receptor family. WB analysis of time course experiments up to 30 min after 2 Gy radiation showed increased p-ERK levels in MCF-7 RR and ZR-751 RR cell lines 5 min post-radiation, whereas only smaller increases were seen in the parental cells at a much later time point (Figure 4.27). Although p-AKT did not show a response with radiation, the MCF-7 RR and ZR-751 RR cell lines had overall higher expression levels compared to those of their parental cell lines (Figure 4.28). No differences were seen in the MDA-MB-231 and RR cell lines.

MAPK pathway activity was investigated by integrating the transcriptomic data with a published gene expression signature\(^{419}\), whereas PI3K activity was assessed using genes taken from the KEGG pathway database\(^{411}\) in combination with FOXO-regulated genes (which have an inverse expression pattern to PI3K activity)\(^{420}\). Analysis suggested that active MAPK and inactive PI3K signalling were constitutive in the MDA-MB-231 parental and RR cell lines and expression of genes related to these pathways were not affected by radiation. Untreated ER\(^+\) cell lines were characterised by inactive MAPK and PI3K pathway signalling, whereas their RR derivatives showed significant changes in gene expression patterns suggesting a switch to active MAPK and PI3K signalling (Figure 4.29 & Figure 4.30).
Figure 4.27. Western blot results showing activation of MAPK signalling in RR cell lines derived from ER⁺ cells. WB analysis showing the levels of p-ERK in response to 2 Gy of radiation in MCF-7, ZR-751 and MDA-MB-231 cell lines in comparison with their RR derivatives (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; *p≤0.05).
Figure 4.28. Western blot results showing activation of PI3K signalling in RR cell lines derived from ER⁺ cells. WB analysis showing the levels of p-AKT in response to 2 Gy of radiation in MCF-7, ZR-751 and MDA-MB-231 cell lines in comparison with their RR derivatives (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****ₚ≤0.0001; *ₚ≤0.05).
Figure 4.29. Gene analysis showing activation of MAPK signalling in RR cell lines derived from ER\(^+\) cells. Log2 mean-centered gene expression heatmap showing differences between parental and RR cell lines in respect to a MAPK pathway activity gene signature\(^{419}\) (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.

Figure 4.30. Gene analysis showing activation of PI3K signalling in RR cell lines derived from ER\(^+\) cells. Log2 mean-centered gene expression heatmap showing differences between parental and RR cell lines in respect of the PI3K pathway; associated genes taken from the PI3K KEGG pathway\(^{411}\) (upper heatmap) and FOXO-regulated genes\(^{420}\) (lower heatmap) (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.
4.3.9 ERα knockdown in MCF-7 cells results in EGFR expression, reduced proliferation and enhancement of radiosensitivity

siRNA optimisation was performed using SRB and WB analysis to select the appropriate transfection reagent concentration and the most efficient ERα siRNA to achieve maximum knockdown while preserving cell viability. Using the MCF-7 cell line, 0.1 µl of transfection reagent had no detrimental effect on proliferation up to 96 h post-transfection in mock and non-targeting transfected cells. This volume was sufficient to produce a significant reduction in proliferation when transfected with ERα siRNA (Figure 4.31). The J-003401-12, ESR1 siRNA was chosen for use in siRNA experiments over the Smart pool siRNA as lower concentrations could be used to achieve the same knockdown efficiency. WB results showed that ERα siRNA transfection lasted for 120 h, although at 120 h post-transfection ERα expression began to increase. No statistical difference in ERα expression was identified between the mock and non-targeting transfected cells, whereas ERα expression was statistically lower in the ERα siRNA transfected cells (Figure 4.32 & Table 4.4).

**Figure 4.31.** SRB assay showing proliferation of the MCF-7 cell line when exposed to different volumes of transfection reagent. Transfection volumes of 0.1, 0.14 and 0.25 µl were used in (a) Mock transfected, (b) Non-targeting transfected (25 nM) and (c) ERα siRNA transfected (25 nM) (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; *p≤0.05).
Figure 4.32. Validation of ERα siRNA knockdown in MCF-7 transfected cells. (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ***p≤0.001; **p≤0.01; *p≤0.05).

Table 4.4. ERα percentage knockdown compared to non-targeting transfected cells. Excellent reductions in ERα expression was seen using both the Smart pool and J12 ESR1 siRNAs based on WB analysis.

<table>
<thead>
<tr>
<th>Time post-ERα siRNA transfection (h)</th>
<th>24</th>
<th>48</th>
<th>72</th>
<th>96</th>
<th>120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smart pool ERα siRNA (50 nM)</td>
<td>62.51</td>
<td>78.45</td>
<td>70.55</td>
<td>74.55</td>
<td>40.64</td>
</tr>
<tr>
<td>J12 ERα siRNA (25 nM)</td>
<td>75.63</td>
<td>82.68</td>
<td>73.30</td>
<td>73.07</td>
<td>43.59</td>
</tr>
<tr>
<td>J12 ERα siRNA (50 nM)</td>
<td>79.45</td>
<td>86.70</td>
<td>83.71</td>
<td>85.83</td>
<td>63.08</td>
</tr>
</tbody>
</table>
ERα loss in the MCF-7 RR cell line was further investigated using ERα siRNA knockdown. At 72 h post ERα siRNA knockdown (25 nM) or tamoxifen treatment (0.05 µM) results showed significant reductions in MCF-7 proliferation, whereas no change was identified in the MCF-7 RR cell line (Figure 4.33). An additional reduction MCF-7 proliferation was observed when ERα knockdown or tamoxifen treatment was combined with radiation 24 h post-transfection/tamoxifen treatment, suggesting acute loss of ERα provides a radiosensitising rather than a radioprotective effect (Figure 4.34). WB analysis also showed increased EGFR expression at 96 and 120 h post-ERα knockdown (Figure 4.35).

Figure 4.33. ERα siRNA transfection or tamoxifen treatment reduces MCF-7 proliferation. SRB assays showing the effect of ERα siRNA (25 nM) or tamoxifen (0.05 µM) on proliferation 72 h after treatment in (a) MCF-7 cells and (b) MCF-7 RR cells (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; **p≤0.01).
Figure 4.34. Radiation treatment combined with either ERα siRNA transfection or tamoxifen treatment results in an additional reduction in MCF-7 proliferation. Cells were exposed to 1.5 Gy radiation 24 h following either (a) ERα siRNA transfection or (b) tamoxifen treatment (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01).

Figure 4.35. EGFR expression increases in MCF-7 cells following ERα siRNA transfection. WB results showing EGFR and ERα expression following ERα siRNA knockdown (5, 10 and 25 nM) with quantitative analysis at 96 and 120 h post-transfection (graphs document the relative intensity of EGFR normalised to the loading controls) (one-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; **p≤0.01).
Radioresistant cell lines exhibit cellular plasticity within the context of intrinsic breast cancer subtyping

ER signalling was investigated further through the integration of a published ER signalling gene expression signature with the transcriptomic data\textsuperscript{421}. As expected, both ER\textsuperscript{+} parental cell lines were characterised by high expression of ER signalling genes in comparison to the ER\textsuperscript{-} parental and RR cell lines which had several-fold lower expression of the same genes. Interestingly, using hierarchical clustering analysis both MCF-7 RR and ZR-751 RR cell lines clustered closely with the ER\textsuperscript{-} cell lines, although they still maintained higher expression levels for a subset of these genes, similar to their parental cells. Radiation treatment did not affect the expression of these genes (Figure 4.36a).

Gene expression data was further integrated with a public gene expression dataset (GSE50811) of 67 breast cancer cell lines\textsuperscript{422}. Untreated and radiation treated MDA-MB-231 parental and RR cell lines clustered tightly with each other in the dendrogram branch enriched for the basal breast cancer subtype. MCF-7 and ZR-751 parental cell lines obtained a luminal A classification whereas their RR derivates clustered independently and were enriched for HER2-overexpressing (MCF-7 RR) and normal-like (ZR-751 RR) intrinsic subtypes (Figure 4.36b).
Figure 4.36. Radioresistant cell lines derived from ER\(^+\) cells exhibited a change in oestrogen signalling associated genes and a change in intrinsic breast cancer subtype classification. (a) Log2 mean-centered gene expression heatmap showing differential expression of oestrogen-signalling associated genes\(^{421}\) (red=higher expression, black=no change, green=lower expression). Heatmap clustering was carried out using Pearson correlation with average linkage. (b) Transcriptomic data integrated with a public gene expression dataset (GSE50811). Hierarchical clustering of parental and RR cell lines based on Pearson correlation to centroids of Sørlie 2003 intrinsic genes\(^{377}\) (red=basal, dark blue=luminal A, light blue=luminal B, purple=HER2-overexpressing, green=normal-like, n=1).

4.3.11 Radioresistant cell lines derived from ER\(^+\) cells show reduced activation of the PERK/eIF2\(\alpha\) signalling pathway

Endoplasmic reticulum stress leading to the UPR has been shown to be implicated in radiation-induced cell death\(^{88,89,102}\). To investigate the 3 arms (PERK, IRE1, ATF6) of the UPR, gene and/or protein expression levels of UPR transducers and mediators were investigated, assessing both their inherent levels and changes in response to radiation between MCF-7 and ZR-751 parental and RR cell lines. Selected UPR components included: endoplasmic reticulum chaperone BIP, primary UPR transducer IRE1\(\alpha\) and its target XBP1, UPR transducer ATF6, UPR transducer PERK and its target eIF2\(\alpha\) and UPR mediators of the PERK/eIF2\(\alpha\) pathway ATF4 and CHOP.
Gene analysis of endoplasmic reticulum stress markers identified inherently higher expression of genes encoding for BiP, ATF4, ATF6, XBP1 and PERK in MCF-7 cells compared to MCF-7 RR cells. Gene expression in both parental and RR cell lines was not altered by 2 Gy radiation at either 2 or 8 h post-treatment. Conversely, the expression of CHOP and IRE1 was inherently higher in the MCF-7 RR cells compared with their parental cells and again their expression levels did not change in response to radiation (Figure 4.37a). To investigate activation of components of the UPR, phosphorylated levels of IRE1, total PERK and its down-stream target EIF2α were examined through WB analysis in both MCF-7 and ZR-751 parental and RR cell lines. Results confirmed statistically higher levels of total PERK ($p \leq 0.0001$), p-PERK ($p \leq 0.0083$), and p-EIF2α ($p \leq 0.0068$) in the MCF-7 parental cells compared to the MCF-7 RR cell line. These results were mirrored in the ZR-751 parental and RR cell lines, with statistically higher levels of total PERK ($p \leq 0.0001$), p-PERK ($p \leq 0.0056$), and p-EIF2α ($p \leq 0.0469$) in the ZR-751 parental cell line. An almost complete loss of total and p-PERK was seen in both RR cell lines. MCF-7 parental cell lines also demonstrated increased p-PERK expression at 8 h post-radiation returning to baseline levels at 24 h; this radiation response did not occur in the MCF-7 RR cell line. Statistically lower levels of p-IRE1 were seen in MCF-7 ($p \leq 0.0009$) and ZR-751 ($p \leq 0.0114$) parental cells compared with their RR derivatives (Figure 4.37b & Figure 4.38).
Figure 4.37. Gene expression and western blot analysis show inherent differences in UPR pathway activation between MCF-7 and MCF-7 RR cell lines. (a) Log2 mean-centered gene expression heatmap showing differences in respect of endoplasmic reticulum markers between untreated and radiation treated MCF-7 and MCF-7 RR cell lines (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage. (b) WB analysis showing the levels of p-PERK, p-eIF2α and p-IRE1 in untreated MCF-7 and MCF-7 RR cell lines in comparison to 2 Gy treated cells at 0, 8 and 24 h post-radiation (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, **p≤0.01).

Figure 4.38. Western blot analysis shows inherent differences in UPR pathway activation between ZR-751 and ZR-751 RR cell lines. WB analysis showing the levels of p-PERK, p-eIF2α and p-IRE1 in untreated ZR-751 and ZR-751 RR cell lines in comparison to 2 Gy treated cells at 0, 8 and 24 h post-radiation (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3).
4.4 Discussion

Cancer cells that possess innate radioresistance or those that acquire it can contribute to treatment failures and poor patient outcomes. Treatment failures can occur through tumours not responding or only partially responding to RT or due to the development of recurrent loco-regional and/or metastatic disease. Through the identification of genes, proteins and signalling pathways that are related to the acquisition of radioresistance, targets can be identified, and therapeutic approaches developed to overcome the clinical issue of radioresistance. The generation of in vitro RR cancer cell line models can help study, and subsequently target, the mechanisms involved in the development of acquired radioresistance. However, only a small number of previous studies have developed RR cell lines to investigate acquired radioresistance and these focused on single specific pathways, which limited their ability to determine the complex interrelated systems that govern radioresistance development.

This chapter describes the development of novel RR breast cancer cell lines from both ER+ hormone-responsive (MCF-7 and ZR-751) and ER- hormone non-responsive (MDA-MB-231) molecular subtypes and the characterisation of their inherent differences and responses to radiation. Using genetic, molecular and functional assays, in 2D and 3D model systems, a more global characterisation of this RR model was achieved. 3D culture systems were incorporated into the experiments to increase the complexity of the RR model. These MTS models more accurately represent the TME within a solid tumour, as they develop O2, nutrient and pH gradients, producing a central necrotic core with an outer mantle of proliferating cells. The novel MTS derived from RR cells developed in this study have not been described before in the literature and serve as excellent in vitro RR tumour models which were used to investigate invasiveness and protein expression through IHC.

Following the 12-week development period, all RR cell lines were confirmed as radioresistant through proliferation and CF assays with respect to their sensitivity to a single, clinically relevant, dose of radiation. These initial experiments validated the use of these cell lines as in vitro models to characterise the radioresistant phenotype and investigate the mechanisms involved in its development. Using the same assays, the radioresistant phenotype was also shown to be maintained in MCF-
7 RR (and REM-134 RR) cells that had not been exposed to radiation for 6 months. This indicated RR models were generated in which the acquisition of radioresistance was not transient. This is in contrast to a previous study that showed that radioresistant MCF-7 cells lost their resistant phenotype 12 weeks after a final dose of radiation\textsuperscript{424}. The difference in maintenance of the RR phenotype could be due to the fact that we developed our model by increasing weekly radiation doses by 0.5 Gy or due to cell lines being exposed to radiation over a longer period of time. These factors could contribute to the generation of a more stable phenotype. Varying results from different RR models highlights the importance of regular confirmation of maintained radioresistance through CF/SRB assays.

The cell cycle of a cancer cell can significantly influence the effects of radiation. Cells during the G2/M phase are most sensitive to radiation-induced DNA damage whereas those in late S-phase are most resistant. Fractionated RT treatment plans can help overcome this cell cycle-associated radioresistance by allowing radioresistant S-phase cells to progress into a more sensitive cell cycle phase in between the daily fractions of radiation. Quiescent cells or those that only progress slowly through the cell cycle are known to be more radioresistant, as they have more time to activate DNA damage response pathways and repair DNA damage before cellular division occurs. Results from our study suggested reduced proliferation in terms of cell cycle arrest genes and Ki67 staining in MTS, which is in accordance with other studies showing reduced proliferation rates of \textit{in vitro} prostate cancer RR cell lines\textsuperscript{429}. In clinical terms, reduced cancer cell proliferation rates as demonstrated by Ki67 staining has been associated with poor local control of HNSCC tumours\textsuperscript{430}.

Among breast cancer patients, metastatic disease accounts for more than 90% of cancer-related deaths\textsuperscript{431}, so understanding the processes involved in breast cancer metastasis and treatment failure is of clinical importance. Results obtained using functional assays identified that MCF-7 RR and ZR-751 RR cell lines had significantly increased migration and invasion ability compared with their parental cells, whereas the MDA-MB-231 RR cell line exhibited increased migration with only a marginal and non-significant increase in invasion compared to its parental cell line. These results suggested that the RR cell lines had developed a more aggressive phenotype, which was more evident in the RR cell lines derived from ER\textsuperscript{+} cells.
Clinically these results could lead to a greater potential for local tissue invasion and metastasis. These functional changes are likely to be orchestrated by EMT. EMT is a critical process involved in malignant cellular transformation leading to reduced cell–cell contacts, increased cell motility and metastasis. In addition, EMT can influence other cellular processes such as enhanced survival, genomic instability, cancer stem cells and resistance to chemotherapy and RT. The loss of epithelial morphology that occurs during EMT has been shown to be a prognostic indicator that correlates with poor prognosis. We evaluated known biomarkers for breast cancer EMT in our RR model and demonstrated, at both gene and protein levels, down-regulation of E-cadherin and up-regulation of vimentin, N-cadherin and SNAIL in the MCF-7 RR and ZR-751 RR cell lines. These results supported the morphological and functional changes identified in these RR cells, which developed a more mesenchymal-like phenotype with increased invasive and migratory potential. In contrast to the epithelial-like ER+ cell lines, the MDA-MB-231 cell line has a much more mesenchymal-like phenotype with constitutively low E-cadherin and high vimentin expression; because of this, further development of EMT in its RR derivative was difficult to ascertain. Multiple signalling pathways can activate EMT in both normal and cancer cells, including receptor tyrosine kinase signalling, WNT-β-catenin and Notch signalling. Radiation alone can also induce EMT through the expression of TGFβ. Both EGFR downstream signalling pathways and WNT signalling were found to be activated in MCF-7 RR and ZR-751 RR cell lines suggesting possible mechanisms by which EMT may be activated. WNT signalling has been shown to play a role in EMT, with one study using MCF-7 cells showing that WNT signalling could inhibit Snail phosphorylation, causing an increase in Snail protein and activity levels resulting in the MCF-7 cells gaining a mesenchymal-like phenotype. It is interesting to note that in our results the same population of cells, predominantly those around the periphery of the MTS formed from RR cells from ER+ cell lines, showed increased co-expression of vimentin, Snail, N-cadherin and WNT5a.

Breast cancers can be characterised and subtyped using IHC and gene expression analysis. Expression of receptors such as HER2, ERα, PgR and EGFR can be assessed by IHC, whereas gene expression profiling can be used to identify
cancer cell molecular profiles and classify them into 5 specific tumour subtypes: basal, luminal A, luminal B, HER2-overexpressing and normal-like$. These subtypes exhibit differential sensitivities to radiation and have distinct clinical outcomes$. The clinical usefulness of breast cancer molecular subtyping is undeniable, as it can help influence a patient’s treatment plan and give an indication of prognosis. However, its usefulness in subtyping in vitro cell lines remains controversial. This issue has been previously investigated by comparing genomic and transcriptional characteristics of primary breast tumours with those of cancer cell lines. One study showed that genome aberrations and transcriptional changes identified in 51 cancer cell lines (including MCF-7, ZR-751 and MDA-MB-231) were well preserved compared to those found in primary tumours of a similar subtype$. Although the cell lines carried more genome aberrations, possibly related to certain cell lines having been derived from pleural effusions or late stage tumours, the study concluded that cell lines can show stable genomic patterns which do not necessarily accumulate significant numbers of new mutations during extended culture. This study also reported that cell lines are well suited to assess the functional consequences of genome aberrations-mediated gene deregulation and are useful in the identification of molecular features that predict sensitivity/resistance to agents targeting these changes. However, it is important to understand that profiling cell lines does not consider the TME, which includes normal stromal tissue and epithelial cells, nor will it reflect intra-tumoral heterogeneity. With these caveats in mind, the purpose of subtyping the parental and RR cell lines in this study was to demonstrate that radioresistance development is consistent with a change in intrinsic subtype to a prognostically less favourable classification$.

Transcriptional profiles of the parental and RR cell lines were used to assign each one to an intrinsic breast cancer subtype. Both parental and RR MDA-MB-231 cell lines were triple negative and transcriptional subtyping identified them both as basal$. Treatment of basal breast cancers mainly relies on chemotherapy, as targeted therapies are lacking. Unfortunately, basal breast cancer is associated with lower disease-specific survival rates and a higher risk of local and regional recurrence compared with luminal subtypes$. It is therefore not surprising that no significant changes were identified in the MDA-MB-231 RR cell line as the
parental MDA-MB-231 cell line is inherently aggressive in nature. A change in subtype classification was identified in both RR cell lines derived from ER+ cells, with a shift from luminal A for both MCF-7 and ZR-751 cell lines towards a non-luminal classification. The MCF-7 RR cell line closely correlated with the HER2-overexpressing subtype while the ZR-751 RR cell line correlated with the normal-like subtype. Although the MCF-7 RR cell line did not express HER2 in IHC assessment, it is likely that it gained its HER2-overexpressing classification due to its gain in EGFR expression in combination with MAPK and PI3K activity, which are also found in HER2 positive breast cancers. Normal-like breast cancers resemble normal breast tissue with high expression of genes associated with adipocytes and non-epithelial cell types, and low expression of genes related to luminal epithelial cells. Both HER2-overexpressing and normal-like subtypes carry a worse prognosis compared to luminal A tumours, with HER2-overexpressing tumours having a higher risk of locoregional recurrence. Luminal A tumours also respond well to hormone and radiation treatment, and so a shift away from this subtype would be consistent with endocrine therapy resistance, reduced radiosensitivity and a more aggressive phenotype. These results show that the acquisition of radioresistance can be linked with cellular plasticity through extensive alterations in gene expression resulting in a change in molecular subtype classification.

Investigation of common breast cancer signalling receptors demonstrated that MCF-7 RR and ZR-751 RR cell lines lost ERα and PgR expression and gained EGFR expression. Furthermore, when siRNA transfection was used in the MCF-7 cell line to knockdown ERα this resulted in increased EGFR expression, suggesting a direct relationship between ERα loss and EGFR expression. Gene analysis also corroborated ERα loss, with lower expression of ER driven genes in the RR cell lines derived from ER+ cells. An inverse relationship between ER activity and EGFR and HER2 expression has been reported in clinical breast cancers and overexpression of these receptor tyrosine kinases is associated with reduced sensitivity to endocrine therapy and worse prognosis. This apparent switch from ER signalling to EGFR-mediated signalling in the RR cell lines derived from ER+ cells was investigated using the EGFR inhibitor gefitinib and the anti-oestrogen tamoxifen.
Gefitinib treatment produced greater concentration-dependent reductions in cell proliferation, migration and invasion in the MCF-7 RR and ZR-751 RR cell lines compared with their parental cells. The calculated IC₅₀ values were 6.43 (MCF-7 RR) and 13.12 µM (ZR-751 RR); although these values were approximately half that of the parental cells (13.34 µM for the MCF-7 and 22.02 µM for the ZR-751), these concentrations are still relatively high compared to clinically relevant doses. Therefore, these results suggest that, although the MCF-7 RR and ZR-751 RR cell lines are still relatively insensitive to the effects of gefitinib, a significant sensitisation was seen in comparison to their parental cell lines. Results also showed that the MCF-7 RR cells developed simultaneous resistance to tamoxifen at clinically relevant doses. In the clinic, patients with ER⁺ breast cancer may be treated with tamoxifen for 5-10 years following surgery and RT. If radioresistant cells survive following completion of the RT course then, as our results suggest, these radioresistant cells may also gain tamoxifen resistance. Repopulation of the tumour site with endocrine therapy-resistant and radioresistant cancer cells could significantly limit treatment options and have a negative impact on patient outcome. Mechanisms for acquired tamoxifen resistance are complex, since resistant tumours do not usually lose ERα expression and the receptor remains functional. This is demonstrated by patient cohorts with recurrent disease still being able to respond to second line endocrine therapy. Studies have suggested that this form of resistance could work through ER function modification by growth factor pathways. Another study investigated tamoxifen resistance in MCF-7 RR cells, showing resistance occurred without a change in the expression levels of ER but with enhanced AKT phosphorylation. This study suggested that sequential tamoxifen treatment post-radiation treatment could be more effective than providing the treatments concurrently. Conversely, results from our study showed an additional inhibition of proliferation when radiation was delivered 24 h after tamoxifen treatment or ERα knockdown in the MCF-7 cells. Suggesting that the use of tamoxifen before and during a patient’s RT treatment would be advantageous. Another study determined that tamoxifen-resistant MCF-7 cells showed increased EGF sensitivity, with oestradiol stimulating MAPK activation. Tamoxifen was able to elicit rapid MAPK phosphorylation in the MCF-7 resistant cells, whereas
inhibition of the EGFR/MAPK pathway caused a significant inhibition of proliferation. Although ERα was not lost in these tamoxifen-resistant cells, it became redistributed to extra-nuclear sites (cytoplasmic translocation). It was postulated that the enhanced function of ERα was due to cooperation with EGFR and is a possible mechanism for the development of acquired resistance to tamoxifen\textsuperscript{460}. Similar results have also been shown in anti-oestrogen-resistant MCF-7 cell lines developed through continuous culture in fulvestrant. These resistant cells developed reduced ERα expression and loss of PgR with a shift towards dependence on EGFR/MAPK-mediated signalling\textsuperscript{461}. Our RR model is the first to report a link between acquired radioresistance and the loss of ERα and PgR and resistance to tamoxifen. Therefore, this suggests that tamoxifen resistance secondary to acquired radioresistance may involve different pathways compared to the development of tamoxifen resistance from chronic drug exposure and that additional targeted therapy may be required in these cells to overcome both endocrine and radiation resistance.

Following the identification of increased EGFR expression in the RR cell lines, downstream signal transduction pathways of the HER tyrosine-kinase receptor family were investigated. Increased activation of the PI3K/AKT/mTOR cascade is frequently seen in a wide range of cancer types and can trigger downstream pathway responses related to cell survival, apoptosis, proliferation, migration, invasion, and metabolism\textsuperscript{462,463}. This pathway can be activated by radiation and has been associated with resistance mechanisms, with constitutively activated AKT being linked to intrinsic radioresistance\textsuperscript{464,465}. In this study we found that the gene expression signature in the MCF-7 RR and ZR-751 RR cell lines fitted with activation of the PI3K pathway. Although p-AKT did not increase in response to radiation, expression levels were statistically higher than in the parental cell lines, suggesting a constitutively activated PI3K/AKT/mTOR signalling pathway in these RR cell lines, which may play an important role in their radioresistant phenotype. These pathways have also been shown to be activated in RR prostate cancer cell lines (androgen responsive and non-responsive) in combination with enhanced EMT/cancer stem cell phenotypes and activation of checkpoint proteins\textsuperscript{425}.

In breast and other cancers, EGFR activation with stimulation of the downstream components of the MAPK cascade, including phospholipase-C, Ras, and
Raf-1, has been linked with radiation-induced cancer cell proliferation\textsuperscript{466-469} and is considered to be a cytoprotective response\textsuperscript{470} and a mechanism by which cancer cells can cause tumour repopulation during fractionated RT. Results at gene and protein level from this study suggest that MAPK signalling is activated in the MCF-7 RR and ZR-751 RR cell lines. Basal expression levels of p-ERK1 and p-ERK2 were significantly higher in MCF-7 RR and ZR-751 RR cell lines compared with their parental cells. Radiation-induced ERK1 and ERK2 phosphorylation also occurred more quickly and to a greater degree following a 2 Gy dose of radiation in these RR cell lines. These results suggest that EGFR signalling, and multiple components of its downstream pathways are activated in the MCF-7 RR and ZR-751 RR cell lines. This finding could have clinical implications, as multiple pathways may need to be targeted to improve therapeutic responses to radiation and overcome resistance\textsuperscript{409}.

The UPR is an important cellular process that enables cells to respond to endoplasmic reticulum stress, resulting in either restoration of normal cellular functions and endoplasmic reticulum homeostasis or cell death\textsuperscript{471}. The UPR of ER\textsuperscript{+} parental and RR cell lines was characterised because previous studies have shown that radiation can induce endoplasmic reticulum stress and UPR activation\textsuperscript{88,89}. If differential pathway activation is occurring in the RR cell lines, then this may provide a radiation-induced pro-survival mechanism rather than activating endoplasmic reticulum-induced apoptotic or autophagic cell death pathways. The most striking finding from our results was an almost complete loss of total and p-PERK expression and significantly reduced expression of eIF2α in both RR cell lines derived from ER\textsuperscript{+} cells. A previous study using MDA-MB-231 cells showed that, although endoplasmic reticulum stress markers and CHOP levels were not elevated following radiation, the PERK-eIF2α pathway did become activated; these results led the authors to conclude that PERK-dependent radiation-induced apoptosis was not CHOP mediated. Furthermore, PERK down-regulation using siRNA resulted in lower levels of radiation-induced apoptosis, leading to increased radioresistance\textsuperscript{472}. Although this study used an ER\textsuperscript{−} cell line, it provides an important comparison with our results, as our RR cell lines derived from ER\textsuperscript{+} cells have some ER\textsuperscript{−} phenotypic characteristics. As endoplasmic reticulum stress-induced apoptosis is primarily mediated by the PERK/eIF2α UPR pathway\textsuperscript{90,97}, these results support our findings.
that a reduction in PERK-eIF2α pathway activation may be contributing to the RR phenotype.

Although apoptosis is considered the main mechanism by which irreversibly endoplasmic reticulum stressed cells are removed, typical apoptotic pathways may not occur in the MCF-7 cell line since, although it possesses caspase 6 and 7, it is deficient in functional caspase 3. One study showed that PERK and radiation-induced phosphorylation of eIF2α were essential for autophagy and radiosensitivity in caspase 3/7-deficient cells. Although our study reported almost identical results for MCF-7 and ZR-751 cell lines, further work would be required to determine if they are undergoing similar caspase 3-independent autophagy or some other cell death mechanism. The increased gene and protein expression levels of IRE1 in the RR cell lines warrant further investigation, as this part of the UPR can be protective or lead to apoptosis. If the MCF-7 and MCF-7 RR cell lines are predominantly relying on PERK-mediated radiation-induced autophagy, then IRE1 activation may suggest the pathway is being used as a pro-survival mechanism, as this pathway has not been shown to be involved in cell death through autophagy. Although expression signatures of the major UPR genes differ among tissues and diseases, BiP, PERK, IRE1α and ATF6 have been shown to have increased expression in breast carcinomas. Inherent expression of these markers could explain the base line gene and protein levels seen in our experiments, especially in the MCF-7 and ZR-751 parental cells.

4.5 Conclusion

This chapter has described the development of novel RR models which incorporated the use of both 2D and 3D culture systems. Characterisation of these RR breast cancer cell lines was performed using multiple different techniques including gene, protein and functional experiments. This in-depth characterisation allowed results to be validated through independent means and provided a more global approach to understanding the cellular changes that occur following the acquisition of radioresistance. The development of RR cells from both ER+ and ER- parental cell lines allowed for comparisons to be made between not only paired parental and RR cell lines but also between the different molecular breast cancer subtypes. The most striking cellular changes were identified in the RR cell lines.
derived from ER\(^+\) cells; these RR cells were characterised by a shift towards a more invasive mesenchymal phenotype, with changes in oestrogen-regulated signalling pathways, gain of EGFR signalling and a change in subtype classification. The ER\(^+\) cell line possessed these characteristics at the outset and hence its phenotype changed relatively little with radioresistance development.

Well characterised models of resistant disease, as developed and examined in this chapter, are needed if continued progress is to be made in understanding the mechanisms and signalling pathways involved in the development of radioresistance. Future studies using this RR model can now target the differentially activated pathways identified in the RR cell lines to focus on radioresistance reversal. The use of paired parental and RR cell lines can also be used to identify genetic and secretomic signatures to assess a tumour’s response to radiation. This type of study will likely be instrumental in the development of new therapeutic strategies for patients who either fail to respond to treatment or develop recurrent disease.
5 Identification of Biomarkers Released from Cancer Cells in Response to Radiation – A Pilot Study

5.1 Abstract

**Background:** Identification of patients that fail to respond to radiotherapy during treatment could decrease the number of patients receiving radiation treatment for no therapeutic gain and allow the use of alternative therapies at an earlier stage. Monitoring radiation-induced secreted cancer biomarkers could assess a tumour's response to radiotherapy, determine radiosensitivity and provide a means of identifying non-responding patients. **Methods:** To identify radiation-induced secreted biomarkers, cancer cells were exposed to radiation and liquid chromatography-mass spectroscopy was performed on conditioned media samples. To identify biomarkers related to radiosensitivity, gene expression analysis was performed using parental and radioresistant cell lines. **Results:** Using the MCF-7 cell line, 33 biomarkers were identified as having up to a 12-fold increase in secretion in response to radiation compared to controls at 24 h. Based on secretion profiles and functional analysis 9 candidate biomarkers were selected (YBX3, TK1, SEC24C, EIF3G, EIF4EBP2, NAP1L4, VPS29, GNPNAT1 and DKK1), of which the first 4 underwent in-lab validation. Gene analysis identified higher expression of genes encoding 7 of the candidate biomarkers in the MCF-7 cell line compared to its radioresistant derivative. Western blot identified increased levels of the 4 biomarkers in the conditioned media of parental cells 24 h post-radiation which was not seen in the RR cell lines. **Conclusions:** The identification of biomarkers that have differential gene expression and secretion profiles in response to radiation between sensitive and RR cell lines has provided initial evidence that these biomarkers may be useful for predicting and/or monitoring the response to radiotherapy.

5.1 Introduction

Monitoring a tumour's response to radiation whilst a patient is undergoing RT could provide a means by which a patient’s treatment could become tailored, with patients not responding to traditional RT given alternative therapies at an earlier stage of the treatment process. One method through which response could be
measured is through the detection of tumour secreted biomarkers, either in the blood or within the tumour itself using an implanted sensor. Research using the secretome of cancer cells is likely to aid the discovery of these clinically relevant biomarkers.

Although the term ‘cancer secretome’ should be used to describe all substances secreted by cancer cells and cancer-associated stromal cells through the classical or non-classical pathways it is more commonly applied to proteins identified by mass spectrometry in the conditioned media (CM) of cancer cell lines. Although these types of experiments do not accurately re-create the complex TME, the CM obtained with these experiments is less complex than that of biological fluids, which increases the likelihood of identifying low abundance substances. Several secretomic studies have used CM from breast cancer cell lines as in vitro model systems. Many of these studies are comparative, using non-tumourigenic and tumourigenic cell lines to investigate differentially secreted proteins related to malignant transformation, with the aim of identifying secreted biomarkers for early breast cancer diagnosis. The MCF-10 isogenic cell line has been used in various secretomic studies to help identify differentially secreted proteins from cell lines representing different tumourigenic stages, ranging from the non-tumourigenic MCF-10A through to the tumourigenic/metastatic MCF-10CA cl. Differential secretome profiles between non-tumorigenic and malignant cell lines have been confirmed in numerous studies, providing evidence that secreted proteins within the cancer secretome can be used to predict the aggressiveness of breast cancer cells. Cancer cell line in vitro secretomic results have also been validated using clinical samples; following in vitro identification that activated leukocyte cell adhesion molecule (ALCAM) was secreted in higher levels in non-invasive and metastatic breast cancer cell lines compared with breast epithelial cells, a clinical study investigated its use as a serum biomarker for breast cancer diagnosis. This study showed ALCAM serum concentrations were statistically higher in breast cancer patients compared with normal women, with the test having higher diagnostic sensitivity compared to other serum biomarker assays currently used (CA15-3 and CEA).

Secretomic studies have also been used for the investigation of predictive biomarkers of chemotherapy resistance. For example, one study characterised the secretomes from MCF-7 doxorubicin sensitive and resistant cell lines, a total of
2084 proteins were identified in the 2 cell lines, of which 89 were differentially secreted. *In vitro* validation showed that doxorubicin resistance could be induced by IL-18, whereas doxorubicin sensitivity was restored upon IL-18 inhibition. *In vivo* validation using breast cancer lysates from patients resistant to neoadjuvant doxorubicin showed higher IL-18 levels compared to responding patient samples, demonstrating the functional role of IL-18 in doxorubicin resistance.

Although these secretomic studies have identified novel biomarkers of aggressive phenotypes or as therapeutic predictors, no study has investigated the immediate effects of radiation on the cancer secretome as a means of assessing a cancer cells response to RT and/or determining their radiosensitivity. This chapter describes the development of an *in vitro* secretomic screening and validation method to identify such biomarkers. Analysis of gene expression and secretomic data was performed by Dr A. K. Turnbull (Cancer Research UK, University of Edinburgh). Parental cell lines were used to investigate the secretome of cancer cells and characterise the changes that occur in response to radiation. These cell lines, unlike their RR derivatives, have not received any prior exposure to radiation and therefore could be considered a more appropriate model for monitoring a naive cellular response to radiation as would be the case in most tumours in patients receiving RT for the first time. Characterisation of the cancer secretome was performed using LC-MS on CM samples from untreated and radiation-treated parental cells up to 24 h post-treatment. Secretion patterns of candidate biomarkers were initially identified using the MCF-7 cell line, which were then investigated in CM samples obtained from other human breast, canine breast and ovine lung cancer cell lines. The aim was to identify differentially secreted biomarkers that were secreted in response to radiation within 24 h of treatment, and to investigate whether these biomarkers could be found in different cancer types and species. Further investigations were performed using both parental and RR cell lines to assess the expression of candidate biomarkers at gene and intra-cellular protein level, along with their secretion levels up to 24 h following 2 Gy radiation. The aim was to assess the biomarkers potential for use as an indicator of radiosensitivity. To our knowledge, this is the first description of the use of secretomic experiments to identify radiation-induced secreted biomarkers which are released from cancer cells within 24 h of treatment.
5.2 Results

5.2.1 Characterisation of the MCF-7 secretome

The ER+ MCF-7 cell line was chosen as the initial model system for biomarker discovery as it is an extremely well characterised cell line, with previous studies successfully demonstrating and validating its use in secretomic experiments. Preliminary characterisation of the untreated MCF-7 secretome identified a total of 927 secreted proteins in CM samples up to 24 h post-serum starvation (provided in the appendix). Although at each secretomic analysis time point (1, 2, 4, 8 and 24 h) a unique set of proteins (proteins detected only at one specific time point) were identified, the number of unique proteins remained low up to 8 h post-serum starvation (Figure 5.1a). By 24 h, 160 unique proteins were identified. In total, 239 secreted proteins (provided in the appendix) were common to all time points, and although their secretion levels did vary over time, overall absolute changes in secretion were minimal (only around 2-fold). At later time points lower secretion was seen for proteins functionally enriched for metabolism, including glycolysis and the citrate cycle, whereas higher secretion was found for proteins associated with glycogen biosynthesis and lipid metabolism (Figure 5.1b).
Figure 5.1. Characterisation of the untreated MCF-7 secretome identified 927 unique proteins up to 24 h post-serum starvation. (a) Venn diagram showing the overlap between the total number of detected secreted proteins in the CM of untreated MCF-7 cells at each time point. (b) Log2 mean-centered protein heatmap showing secretion levels for the 239 proteins common to all time points (yellow=higher secretion, black=no change, blue=lower secretion, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.
Following characterisation of the MCF-7 untreated secretome we wished to identify differentially secreted proteins in response to radiation. To achieve this MCF-7 cells were treated with a single dose of radiation (2–10 Gy) and CM samples were obtained up to 24 h post-radiation. To ensure that radiation treatment was not causing significant cell death, cell counts using trypan blue exclusion were performed at the time of the experiments. Although some cell lines did show a statistically significant increase in cell number between untreated samples at 0 h and 24 h, no difference in total cell number or number of dead cells was seen between any of the untreated and radiation treated (up to 10 Gy) groups at 24 h (Figure 5.2) (the proportion of dead cells in each treatment group was less than 5%).

Figure 5.2. Cell numbers were not affected by a single dose of radiation up to 10 Gy at 24 h post-treatment. Cells were seeded at varying numbers to achieve a confluency of 40% at 24 h (MCF-7 and MCF-7 RR 40x10^4; ZR-751 and ZR-751 RR 60x10^4; MDA-MB-231, MDA-MB-231 RR, HBL-100 and REM-134 30x10^4; JS7 20x10^4). After secretome collection, cells were counted routinely using trypan blue exclusion (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001; **p≤0.01; *p≤0.05).

MCF-7 secretomic analysis subsequently focused on CM samples obtained at 24 h post-radiation treatment. This time point was chosen as it was deemed most suitable for use in clinical situations where patients routinely receive daily radiation doses approximately 24 h apart. Characterisation of untreated and radiation treated
CM samples at 24 h identified a total of 765 secreted proteins, of which 530 were common to both the untreated and radiation treated samples (Figure 5.3). Investigation of protein secretion fold changes between untreated and radiation treated samples identified 147 proteins which had a >2-fold increase in secretion levels in radiation treated cells (provided in the appendix).

**Figure 5.3. Characterisation of the untreated and radiation treated MCF-7 secretome identified 530 common proteins at 24 h.** Venn diagram showing the overlap between the total number of detected secreted proteins in the CM of MCF-7 untreated and radiation treated cells (2-10 Gy) at 24 h.

### 5.2.2 Criteria used for candidate biomarker selection

Using secretomic data initially obtained from the MCF-7 model, several criteria were applied to the biomarkers in order to identify those most appropriate to be taken forward for validation. We had already focused on biomarkers that were released by cells which were detectable at 24 h post-radiation exposure, as this was likely to be the most clinically relevant time point; patients typically receive daily radiation fractions, therefore biomarkers detectable at 24 h post-radiation would allow for ease of monitoring between daily doses. We also wished to identify biomarkers that showed a simple secretion profile whereby levels were low at early time points, then showed a dramatic increase at 24 h, as this would potentially increase the likelihood of successful validation. Selected biomarkers were also
investigated in multiple radiosensitive cancer types from different species. The identification of common biomarkers in several species would give the biomarkers wider application and would allow for large animal model testing, and possible veterinary uses. Following the initial selection based on secretion profiles, final biomarker selection was performed using functional analysis; any biomarkers that played roles in common pathways were preferentially selected.

Although not part of the selection process, further assessment of candidate biomarkers at gene and intra-cellular protein level in parental and RR cell lines was performed to investigate whether a gene/protein expression signature could be obtained to predict radiosensitivity.

5.2.3 MCF-7 preliminary biomarker selection based on increased secretion at 24 hours post-radiation identified 33 candidate biomarkers

Using the 147 biomarkers with >2-fold increase in secretion levels in radiation treated cells, hierarchical clustering with Euclidean distance was performed. A cluster of 33 biomarkers emerged which had higher (up to 12-fold) secretion levels at all radiation doses in treated compared to untreated controls (Figure 5.4) (provided in the appendix). Secretion levels of all 33 biomarkers were then investigated at the earlier time points. Although a small number of the biomarkers had early increased or decreased secretion compared to untreated controls the secretion levels of most of the biomarkers did not change with radiation at the earlier time points (Figure 5.5). A literature search of these 33 candidates was performed to investigate whether these biomarkers were previously known to be secreted either through the classical or non-classical routes. Cross referencing through Vesiclepedia\textsuperscript{482} identified that all 33 biomarkers have previously been shown to be secreted in microvesicles or exosomes by cancer cells.
Hierarchical clustering identified a cluster of 33 biomarkers with dramatic increase in secretion in response to radiation. Heatmap of log2 fold changes showing the 147 proteins whose increased secretion had fold changes greater than 2 between controls and matched treated samples at 24 h across all doses. Hierarchical clustering identified a cluster of 33 proteins, shown at the top of the heatmap in red, which had increased (up to 12-fold) secretion at all radiation doses in treated compared to untreated controls (red=higher secretion, blue=no change, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.
Figure 5.5. MCF-7 secretion patterns of the 33 candidate biomarkers remained stable up to 8 hours post-radiation treatment. Heatmap of log2 fold changes showing secretion levels of the 33 biomarkers compared to untreated controls at each time point up to 24 h post-radiation for each radiation dose (red=higher secretion, green=no change, blue=lower secretion, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.

5.2.4 No common set of biomarkers were identified between different cancer types

To investigate whether the 33 candidate biomarkers could be found in different cancer types and species, their secretion patterns up to 24 h post-radiation exposure were investigated using secretomic data generated from ER− human breast (MDA-MB-231 and HBL-100), canine breast (REM-134) and ovine lung (JS7) cancer cell lines. In total across all time points, 20 of the 33 biomarkers were identified in both MDA-MB-231 and HBL-100 cell lines; however, this number reduced to 12 and 6 respectively when including the criteria of increased secretion at the 24 h time point, as was done with the MCF-7 secretomic data. Across all time points only 5 and 4 of the 33 biomarkers were identified in the REM-134 and JS7 cell lines respectively. Most of the biomarkers also had more complicated secretion patterns with increased levels at both 4 and 24 h post-radiation (Figure 5.6).
Figure 5.6. Secretion patterns of the 33 candidate biomarkers in multiple cancer cell types and species identified no common set of candidate biomarkers. Heatmap of log2 fold changes showing secretion levels of the 33 biomarkers compared to untreated controls at each time point up to 24 h post-radiation for each radiation dose (yellow=higher secretion, black=no change, blue=lower secretion, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.

5.2.5 MCF-7 final biomarker selection based on functional analysis of the 33 biomarkers identified 9 candidate biomarkers

Final candidate biomarkers were selected based on secretion profiles and functional analysis. Using the Markov clustering algorithm\(^\text{382}\), incorporating the initial 33 candidate biomarkers selected based on secretion profiles, this program identified 3 functionally enriched clusters that included protein transport, transcription and translation (Figure 5.7).
Figure 5.7. Protein interaction networks identified protein transport, transcription and translation as enriched clusters within the 33 candidate biomarkers. Protein interaction network of the 33 candidate biomarkers plus the 10 most closely associated interacting partners using the STRING protein interaction database\textsuperscript{381}. Using the Markov clustering algorithm\textsuperscript{382}, 3 functional clusters were identified: protein transport (green), transcription (yellow) and translation (red).

Any biomarkers identified as playing roles within these 3 functional pathways were selected. Biomarkers involved in signalling pathways that were determined as inherently different between the MCF-7 parental and RR cell lines (described in chapter 4) were also considered as these could potentially be used as biomarkers to determine radiosensitivity; these included UPR, WNT and proliferation. This analysis identified 9 candidate biomarkers that either had excellent secretion profiles (GNPNAT1, YBX3), or played roles in translation (EIF3G,
EIF4EBP2, NAP1L4), proliferation (TK1), protein transport from the ER to the Golgi (SEC24C, VPS29) or WNT signalling (DKK1).

Out of these 9 candidate biomarkers, 4 were selected for initial validation. These were EIF3G, TK1, SEC24C and YBX3. MCF-7 log2 secretion levels were calculated relative to untreated controls at each time point and for each radiation dose (Figure 5.8). The secretion of both TK1 and YBX3 increased 4-fold at 24 h with all doses of radiation, with no detected secretion at the earlier time points. Both EIF3G and SEC24C also had approximately a 4-fold increase in secretion by 24 h. EIF3G had an early secretion peak at 4 h post-radiation at higher doses (6-8 Gy) and increased secretion at 8 h with lower doses (2 and 4 Gy) which was maintained at 24 h. SEC24C had reduced secretion at 8 h compared to the untreated controls prior to a dramatic increase by 24 h post-radiation.

Figure 5.8. The 9 candidate biomarkers show increased secretion levels at all radiation doses at 24 h post-treatment. Graphs of log2 secretion levels of each of the candidate biomarkers relative to untreated controls at each time point and for each radiation dose.
5.2.6 Similarities in secretion patterns of the 4 biomarkers between ER− and ER+ cell lines were identified

To specifically investigate the 4 candidate biomarkers in the different cancer types and species their secretion patterns at 8 and 24 h post-radiation were investigated using the secretomic data presented in Figure 5.6. These 4 biomarkers alone are shown in Figure 5.9. Whereas YBX3 was detected in all these cell lines, the other biomarkers were detected only in some of them (Figure 5.9a). In the MDA-MB-231 cell line, except for YBX3, all biomarkers were found to have increased secretion above that of the untreated controls at all doses of radiation at 24 h and at the earlier time point of 8 h for SEC24C and TK1. Only EIF3G was found to have increased secretion in HBL-100 cells at 24 h with all doses of radiation. In the REM-134 cell line only EIF3G and YBX3 were detected, both of which had increased secretion with 3 of the 5 radiation doses. In the JS7 cell line only YBX3 was detected, with increased secretion at 24 h with all doses of radiation. In total 14 members of the EIF family were detected at 24 h in CM samples in the MCF-7, MDA-MB-231 and HBL-100 cell lines, several of which had higher secretion levels in radiation-treated samples compared to untreated controls. Investigation of SEC family members showed that only SEC24C had consistently higher secretion levels at 24 h in the radiation treated samples compared to untreated controls (Figure 5.9b).
Figure 5.9. Similarities in secretion patterns of the 4 biomarkers at 24 h post-radiation treatment were identified between ER− and ER+ cell lines. (a) Heatmap of log2 fold changes showing changes in secretion levels of each of the 4 candidate biomarkers compared to untreated controls in MDA-MB-231, HBL-100, REM-134 and JS7 cell lines at 8 and 24 h for all radiation doses (yellow=higher secretion, black=no change, blue=lower secretion, n=1). (b) Heatmap of log2 fold changes showing secretion levels compared to untreated controls at 24 h for detected members of the EIF family (upper) and Sec23/24 family (lower) in MCF-7, MDA-MB-231 and HBL-100 cell lines (red=higher secretion, white=no change, and green=lower secretion, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.

5.2.7 Radioresistant cell lines have lower gene and intra-cellular protein expression of the 4 biomarkers

To investigate the potential of the biomarkers for use as an indicator of radiosensitivity, parental and RR cell lines were used to assess differential expression of candidate biomarkers at gene and intra-cellular protein level. Although these results would not give an indication of secretion, increased gene expression levels may suggest higher amounts of intra-cellular protein, which may lead to increased secretion. As our secretomic results have shown that at least in the MCF-7 model the biomarkers all have increased secretion at 24 h post-radiation, we investigated whether gene changes could be detected up to 8 h post-exposure to 2 Gy.

Analysis of gene expression data investigating the 33 secreted biomarkers from ER+ and ER− human breast cancer cell lines using both parental and their RR
derivatives identified higher YBX3, EIF3G, EIF4EBP2, TK1, DKK1, NAP1L4 and GNPNAT1 gene expression in the MCF-7 parental cell line compared with the MCF-7 RR cell line; conversely the expression of SEC24C was the opposite with higher levels in the RR cells compared with the parental cells, VPS29 showed little change between the cell lines. These results showed that in total 7 of the 9 candidate biomarkers had higher gene expression levels in the parental cell line. Similar results were seen in the ZR-751 parental and RR cell lines, although higher gene expression levels for both SEC24C and DKK1 were seen in the RR cell line. Gene expression differences between the MDA-MB-231 parental and RR cell lines identified higher YBX3, EIF3G, EIF4EBP2, VPS29, DKK1 and GNPNAT1 expression in the MDA-MB-231 parental cell line. Again, the expression of SEC24C as well as TK1 and NAP1L4 was the opposite with higher levels in the RR cells compared with the parental cell line. A single radiation dose of 2 Gy had little/no effect on gene expression at 2 and 8 h post-treatment in all cell lines (Figure 5.10).

To compare basal intra-cellular protein expression levels of each of the 4 biomarkers in parental and RR cell lines IF was performed using untreated MCF-7 and MCF-7 RR cell lines grown in 2D monolayers. Higher expression levels for all 4 biomarkers were identified in the parental cell line in comparison to the RR derivative (Figure 5.11). To investigate this result further, expression levels were also evaluated using MCF-7, ZR-751 and REM-134 parental and RR MTS (MDA-MB-231 cells failed to form MTS that could withstand IHC processing). Experiments produced similar results to those seen using IF, with higher expression levels identified in the parental cell lines compared to the RR derivatives; the exception was for EIF3G in which the parental MCF-7 cell line had lower expression compared with its RR derivative (Figure 5.12).
Figure 5.10. MCF-7 and ZR-751 show higher expression of genes encoding 7 of the 9 candidate biomarkers compared with their RR derivatives. Log2 mean-centered gene expression heatmap showing differences in expression of the genes encoding the 33 candidate biomarkers in the human parental and RR breast cancer cell lines at 2 and 8 h post-2 Gy radiation treatment (red=higher expression, black=no change, green=lower expression, n=1). Heatmap clustering was carried out using Pearson correlation with average linkage.
Figure 5.11. MCF-7 cells grown in 2D monolayers show higher intra-cellular expression of EIF3G, SEC24C, TK1 and YBX3 compared with its RR derivative. IF of the 4 candidate biomarkers in MCF-7 and MCF-7 RR cell lines. For each antibody immunofluorescence signal is detected at the expected cellular localisation region: the strongest signal for EIF3G, SEC24C, TK1 and YBX3 is seen predominately in the cytoplasm (representative images, n=3).
Figure legend on following page.
Figure 5.12. MCF-7, ZR-751 and REM-134 MTS show higher intra-cellular expression of SEC24C, TK1 and YBX3 compared with their RR derivatives. IHC of the 4 candidate biomarkers in MCF-7, ZR-751 and REM-134 parental and RR cell lines. Positive DAB staining is seen for each antibody at the expected cellular localisation region: positive EIF3G, SEC24, TK1 and YBX3 staining is seen in the cytoplasm (representative images, n=3).
5.2.8 Differential secretion patterns of the candidate biomarkers occur between sensitive and radioresistant cell lines in multiple species in response to radiation

To validate the secretomic results and to further investigate the potential use of these proteins as biomarkers of radiosensitivity, parental and RR cell lines were used in WB experiments. To achieve this, WB analysis was performed using CM samples to assess the secretion levels obtained from parental and RR cell lines 24 h after the cells had received a single radiation dose of 2 or 4 Gy. Unfortunately, due to time restraints and antibody availability only EIF3G, SEC24C and TK1 validation was performed. GAPDH was used with CM samples to assess for the presence of intra-cellular proteins that could be released into the CM from cell lysis; 2 µg of whole cell lysates were also run in parallel to CM samples to act as positive controls. Revert total protein stain (Li-COR Biotechnology, UK) was used to confirm equal loading of the samples.

Secretion levels of SEC24C, EIF3G and TK1 were found to be significantly increased from MCF-7 cells treated with 2 Gy of radiation at 24 h compared to 24 h untreated controls. Biomarker levels in the CM from radiation-treated and untreated MCF-7 RR cells remained low (Figure 5.13). Similar results were found in ZR-751 parental and RR cell lines with secretion levels of SEC24C and TK1 found to be significantly increased from ZR-751 cells treated with 2 or 4 Gy of radiation at 24 h compared to the 24 h untreated controls. A dose dependent effect was seen for TK1. Biomarker levels in CM from radiation-treated and untreated ZR-751 RR cells remained low. EIF3G was not detected in the CM from the ZR-751 or ZR-751 RR cell lines (Figure 5.14).
Figure 5.13. MCF-7 secretion levels of SEC24C, EIF3G and TK1 increase in response to radiation. WB analysis of candidate biomarkers in MCF-7 and MCF-7 RR cell lines using CM samples obtained up to 24 h following exposure to a 2 Gy dose of radiation. NS is a non-specific band identified using the total protein stain used to confirm equal loading (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001).
Figure 5.14. ZR-751 secretion levels of SEC24C and TK1 increase in response to radiation. WB analysis of candidate biomarkers in ZR-751 and ZR-751 RR cell lines using CM samples obtained up to 24 h following exposure to a 2 or 4 Gy dose of radiation. NS is a non-specific band identified using the total protein stain used to confirm equal loading (two-way ANOVA with Holm-Sidak multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; ***p≤0.001).

Only SEC24C was detected in the CM of MDA-MB-231 and MDA-MB-231 RR cell lines. Although SEC24C secretion in the MDA-MB-231 cell line did occur in response to 2 Gy of radiation at 24 h compared to the 24 h untreated controls, a much larger and statistically significant increase was seen in the MDA-MB-231 RR cell line, demonstrating differences in the results obtained using the ER+ cell lines (Figure 5.15).
Figure 5.15. MDA-MB-231 RR secretion levels of SEC24C increase in response to radiation. WB analysis of candidate biomarkers in MDA-MB-231 and MDA-MB-231 RR cell lines using CM samples obtained up to 24 h following exposure to a 2 Gy dose of radiation. NS is a non-specific band identified using the total protein stain used to confirm equal loading (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, *p≤0.05).

Secretion levels of SEC24C and EIF3G were found to be significantly increased in the CM of REM-134 cells treated with 2 Gy of radiation at 24 h compared to the 24 h untreated controls. SEC24C and EIF3G levels in CM from radiation treated and untreated REM-134 RR cells remained low. TK1 was not detected in the CM from the REM-134 or REM-134 RR cell lines (Figure 5.16).

SEC24C was detected at all time points and treatment groups in both the JS7 and JS7 RR cell lines, however secretion levels were not altered with exposure to radiation. Although EIF3G secretion increased in both the JS7 and JS7 RR cell lines in response to 2 Gy of radiation at 24 h compared to the 24 h untreated controls, a larger and statistically significant increase was seen from the parental JS7 cells. TK1 secretion was also increased in both the JS7 and JS7 RR cell lines in response to 2 Gy of radiation, however these increases were not statistically significant (Figure 5.17). A summary of all validation experiments for all cell lines is provided in Table 5.1 & Table 5.2.
Figure 5.16. REM-134 secretion levels of SEC24C and EIF3G increase in response to radiation. WB analysis of candidate biomarkers in REM-134 and REM-134 RR cell lines using CM samples obtained up to 24 h following exposure to a 2 Gy dose of radiation. NS is a non-specific band identified using the total protein stain used to confirm equal loading (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, ****p≤0.0001; **p≤0.01).
Figure 5.17. JS7 secretion levels of EIF3G increase in response to radiation. WB analysis of candidate biomarkers in JS7 and JS7 RR cell lines using CM samples obtained up to 24 h following exposure to a 2 Gy dose of radiation. NS is a non-specific band identified using the total protein stain used to confirm equal loading (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=3, *p≤0.05).
Table 5.1. Summary of validation experiments in human breast cancer cell lines. The WB results show whether each biomarker had increased secretion (↑↑), low levels (-) or were not detected in the CM of cells 24 h following a 2 Gy dose of radiation. IF and IHC results show intra-cellular expression levels of each biomarker (results for WB, IF and IHC depict comparisons between each paired parental and RR cell line).

<table>
<thead>
<tr>
<th></th>
<th>MCF-7</th>
<th>MCF-7 RR</th>
<th>ZR-751</th>
<th>ZR-751 RR</th>
<th>MDA-MB-231</th>
<th>MDA-MB-231 RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>WB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEC24C</td>
<td>↑↑</td>
<td>-</td>
<td>↑↑</td>
<td>-</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>EIF3G</td>
<td>↑↑</td>
<td>-</td>
<td>Not detected</td>
<td>Not detected</td>
<td>Not detected</td>
<td>Not detected</td>
</tr>
<tr>
<td>TK1</td>
<td>↑↑</td>
<td>-</td>
<td>↑↑</td>
<td>-</td>
<td>Not detected</td>
<td>Not detected</td>
</tr>
<tr>
<td>IF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEC24C</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EIF3G</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TK1</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YBX3</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IHC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEC24C</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EIF3G</td>
<td>Lower levels</td>
<td></td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TK1</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YBX3</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 5.2. Summary of validation experiments in canine breast and ovine lung cancer cell lines. The WB results show whether each biomarker had increased secretion (↑↑), low levels (-) or were not detected in the CM of cells 24 h following a 2 Gy dose of radiation. IF and IHC results show intra-cellular expression levels of each biomarker (results for WB, IF and IHC depict comparisons between each paired parental and RR cell line).

<table>
<thead>
<tr>
<th></th>
<th>REM-134</th>
<th>REM-134 RR</th>
<th>JS7</th>
<th>JS7 RR</th>
</tr>
</thead>
<tbody>
<tr>
<td>WB</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEC24C</td>
<td>↑↑</td>
<td>-</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>EIF3G</td>
<td>↑↑</td>
<td>-</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>TK1</td>
<td>Not detected</td>
<td>Not detected</td>
<td>↑↑</td>
<td>↑</td>
</tr>
<tr>
<td>IHC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEC24C</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EIF3G</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TK1</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>YBX3</td>
<td>↑↑</td>
<td>Lower levels</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.2.9 Increased expression of genes encoding EIF3G, SEC24, YBX3 and those involved in ER stress and the UPR is seen in breast cancer tissue following radiotherapy treatment

Characterisation of the ER⁺ parental and RR cell lines previously identified differential activation of UPR pathways, with MCF-7 RR and ZR-751 RR cell lines showing reduced PERK/EIF2α signalling in comparison to their parental cells (described in chapter 4). The UPR is involved in the suspension of translation.
following endoplasmic reticulum stress and as we had identified translation components enriched in our candidate biomarkers, we sought to preliminarily investigate any potential relationship between the UPR and our candidate biomarkers. A publicly available data set (GSE59733) was analysed to investigate changes in gene expression that occur following RT. In that study, 9 patients with breast cancer who were at least 55 years old and diagnosed with invasive carcinomas received pre-operative partial breast RT of either 15, 18 or 21 Gy. Surgical resection was performed on patients within 10 days of treatment. As part of the study both pre- and post-radiation biopsy tumour samples were obtained and profiled using Affymetrix whole transcriptome expression analysis with HTA 2.0 arrays. For our analysis, expression of genes encoding the 4 candidate biomarkers and 6 genes involved with ER stress and the UPR were compared in patient samples taken before and after pre-operative RT. Hierarchical cluster analysis using the 4 candidate biomarkers produced 2 clear clusters, 1 enriched for pre-treatment and 1 enriched for post-treatment samples. The post-treatment cluster was characterised by higher expression levels of EIF3G, SEC24 and YBX3, and lower expression levels of TK1 when compared to the pre-treatment cluster. Higher expression of genes involved in ER stress and the UPR was seen in the cluster enriched for post-treatment samples (Figure 5.18).
Increased expression of genes encoding EIF3G, SEC24 and YBX3 is seen in patient breast cancer tissue following RT. Log2 mean-centered gene expression heatmap showing differential expression of genes encoding the 4 candidate biomarkers and 6 genes involved with ER stress and the UPR using a public gene expression dataset (GSE50811). Gene expression differences are shown from biopsy samples taken before and after pre-operative RT (red=higher expression, black=no change, green=lower expression). Heatmap clustering was carried out using Pearson correlation with average linkage.

5.3 Discussion

The cancer secretome is a potential source of biomarkers suitable for use not only in cancer diagnosis and prognosis but also as a monitoring tool to assess the response of a tumour to treatment. A major advantage of studying the secretome over the cellular proteome is that proteins secreted by tumour cells have the potential to be detected in the blood or locally through the implantation of a sensor into the tumour itself. This chapter describes the characterisation of the cancer secretome using untreated and radiation treated MCF-7 cells and the investigation of selected candidate biomarkers in various other cancer cell lines from multiple species. The aim was to identify biomarkers that were differentially secreted in response to radiation within 24 h of treatment. The incorporation of our novel RR cell lines into validation experiments also allowed the potential of the biomarkers to be used as indicators of radiosensitivity to be assessed.
Several secretomic studies have used CM from breast cancer cell lines as *in vitro* model systems. Most of these studies use non-tumourigenic and tumourigenic cell lines to investigate differentially secreted proteins related to malignancy; results from these studies have shown that secretomic analysis can identify biomarkers related to an aggressive phenotype or predict chemotherapeutic response. One study has investigated secreted biomarkers related to radiation sensitivity by analysing the secretome from various breast cancer cell lines 6 days after exposure to a single radiation dose of 10 Gy. Comparison of the secretomes between untreated cells and those cells that survived radiation identified 17 differentially secreted proteins, including cyclophilin A (CyPA), which was subsequently validated by WB. Further investigation using untreated cell lines with varying radiosensitivities showed that CyPA cellular protein expression was consistent between the cell lines, however higher secretion levels were observed in the most radiosensitive cell lines, demonstrating that CyPA secretion, independent of intra-cellular protein levels, is related to intrinsic radiosensitivity; this led the authors to suggest that secretion levels of CyPA were regulated by post-translation mechanisms. This study provided evidence that protein secretion can be increased following radiation treatment and can relate to radiosensitivity; however, the study did not assess acute changes to the cancer secretome following radiation exposure.

The first step in our experimental design was to obtain CM samples for LC-MS. We chose the technique of using CM from cells grown in serum-free media (SFM). This protocol is simple and can increase the identification of secreted proteins as the presence of serum proteins can mask and dilute the cancer secretome and confound the identification of secreted proteins due to its high abundance or close sequence homology. Although the effect that serum starvation has on cells is under debate, studies have shown that under correct culture conditions cell death is minimised and that serum-free culture does not significantly affect the composition of secreted proteins. In order to reduce cytosolic protein contamination from cell death, studies have suggested that optimal cell number and incubation times are required; SFM incubation up to 30 h with cell confluency under 70% are considered optimal cell culture conditions to minimise cell lysis and the release of cytoplasmic proteins. These culture conditions were adhered to in our
experiments. An extensive wash step was also performed prior to incubating cells in SFM to remove both cytosolic and serum proteins; this has been shown to reduce CM contamination by serum proteins and increase the number of secreted proteins identified, while not affecting cell growth or viability. As secreted proteins present in the CM are usually at low concentrations they were concentrated before secretomic analysis. All CM samples underwent filtering and centrifugation to reduce contamination by dead cells and debris, with ultrafiltration performed to enrich and concentrate secreted proteins; this method has been successfully used in numerous studies despite the potential for column blockade with prolonged centrifugation periods and the loss of low molecular weight proteins. In our experiments control samples were also included at each time point to account for the potential effects from serum starvation. Cell counts, using trypan blue, for each cell line following CM harvesting identified no significant differences in viable cell number between controls and samples treated with up to 10 Gy 24 h post-radiation. This method of assessing cell viability has been used in previous secretomic studies, the results of which are in accordance with our survival data, showing the absence of any significant cell death up to 24 h post 10 Gy radiation.

Initial analysis to identify MCF-7 radiation-induced secreted biomarkers involved the 24 h time point. As cancer patients typically receive daily radiation fractions, identification of biomarkers at this time point would be more applicable for use in the clinics; biomarker levels could in theory be measured just prior to daily treatment i.e. 24 h after a patient’s previous dose. Using only biomarkers whose levels dramatically rose at 24 h reduced the number of potential biomarkers from 765 to 33. Subsequent investigation of the secretion levels of the 33 biomarkers at earlier time points identified that the majority had low secretion levels up to 8 h post-radiation. Literature searches and cross referencing through Vesiclepedia identified that all 33 biomarkers have previously been shown to be secreted in microvesicles or exosomes by cancer cells. As our results had previously confirmed that the total number and percentage of dead cells did not change with radiation, and that the total number of unique secreted biomarkers also did not change with radiation, it is unlikely that the identified changes in the secretome up to 24 h post-radiation was related to radiation-induced membrane damage and cell death. Instead,
it is more likely that these biomarkers are either actively secreted or secreted via microvesicles or exosomes, and that the rate of secretion may be increased by radiation treatment. Exosomes (30-150 nm) and microvesicles (100-1000 nm), together with apoptotic bodies (>1 µm), are collectively termed extra-cellular vesicles and are utilised by normal cells for the transmission of proteins, lipids, mRNAs, microRNA and DNA\textsuperscript{495,496}. Cancer cells can also use these vesicles to communicate with other cancer and stromal cells through various cytokines and growth factors (VEGF, FGF, TGFβ), enabling then to modify the TME to sustain tumour progression, angiogenesis and promote metastasis\textsuperscript{497,498}. Exosome markers and exosome-related proteins have been found in the cancer secretome and in the blood of patients; this exosome cargo is one explanation for the identification of nuclear, cytoplasmic and unconventional secreted biomarkers found in tumour secretomes\textsuperscript{499}. Further investigations from our results would be to specifically isolate microvesicles and exosomes and validate the presence of our biomarkers within them; advantages of using the microvesicle/exosome proteome is that it is relatively stable in blood, making it suited for blood-based detection methods.

Although all 33 biomarkers identified from the preliminary MCF-7 characterisation could have been taken forward for validation based on their excellent secretion profiles, we wanted to reduce the numbers further; this was done first by investigating the secretion patterns in other cancer cell types from different species and then through functional analysis. A common set of biomarkers that are released from multiple cancer types and in different species that are sensitive to radiation would allow for wider applications of the biomarkers and would allow for large animal model validation and possible veterinary uses. Unfortunately, from the 33 MCF-7 candidate biomarkers only a small number were identified as having similar secretion patterns in the other cell lines. Using the ER\textsuperscript{-} human breast cancer cell lines (MDA-MB-231 and HBL-100) only EIF3G, SEC24C, CAP1 and VPS29 shared similar secretion patterns with those found in the MCF-7 secretome. Even fewer similarities in secretion patterns compared with the MCF-7 secretome were seen using the canine breast cancer (REM-134; YBX3 and EIF3G) and ovine lung cancer (JS7; YBX3, VPS29 and FAM49B) cell lines. These results suggest that secretome patterns may be cell line and species specific which is supported by...
previous studies that have identified specific secretomes related to aggressive phenotypes. Further investigation of this would require secretome characterisation of untreated and radiation treated samples to be performed from each individual cell line separately, with a subsequent analysis assessing for any biomarker similarities. Unfortunately, time restraints prevented this from being performed, but this analysis may in the future be a means of identifying common biomarkers across cell lines, or at least ones common to specific cancer subtypes i.e. ER- versus ER+.

Final candidate biomarker selection was based on those with known roles in the 3 functional pathways identified through Markov clustering. Biomarkers were also selected if they were involved in signalling pathways previously determined as inherently different between the MCF-7 parental and RR cell lines (consisting of proliferation, UPR and WNT pathways). Incorporating these factors into the biomarker selection process could enable the identification of biomarkers that may provide an indication of radiosensitivity. This analysis identified 9 candidate biomarkers that either had excellent secretion profiles (GNPNAT1, YBX3) or had roles in translation (EIF3G, EIF4EBP2, NAP1L4), proliferation (TK1), protein transport from the ER to the Golgi (SEC24C, VPS29) or WNT signalling (DKK1).

Following the selection of lead candidate biomarkers in-lab validation was conducted on 4 of the 9 biomarkers. Validation experiments aimed to confirm that biomarker secretion occurred in response to radiation and to assess whether differential secretion occurred between radiosensitive and radioresistant cell lines. This was achieved predominantly through WB experiments using CM samples and was supported through the investigation of gene and intra-cellular biomarker expression levels. All these validation experiments were performed using paired parental and RR cell lines which had been previously developed and characterised. A brief description of the function of the 4 biomarkers, highlighting their potential roles in cancer and secretion pathways, is discussed in the following sections.

The eukaryotic translation initiation factor 3 (EIF3) complex plays an essential role in RNA transport and protein synthesis through its control of translation initiation500. Although essential for normal cellular functions, aberrant EIF3 subunit expression has been shown in several cancer types to be associated with proliferation, invasion, metastasis and prognosis501-505. Specifically, increased
EIF3G expression has been shown in vitro to enhance the ability of breast cancer cells to proliferate, migrate and invade, whilst in vivo studies have shown increased expression to correlate with lymph node metastasis and drug resistance\(^5\). EIF3G has also been found to be secreted via extra-cellular vesicles in numerous cancer types\(^6\)\(^\text{--}\)\(^8\), breast milk\(^9\) and mesenchymal stem cells\(^10\). Validation using CM samples identified increased EIF3G secretion levels in response to radiation at 24 h in MCF-7, REM-134 and JS7 parental cell lines, whereas significantly lower or no secretion was observed in the RR cell lines. EIF3G gene expression was also higher in ER\(^-\) and ER\(^+\) parental cell lines compared with RR derivatives, which was supported by IHC and IF results. Overall these results provided evidence that EIF3G is secreted in response to radiation, but only in radiosensitive cell lines, and that EIF3G gene expression and intra-cellular protein levels may be related to radiosensitivity.

Protein transport from the endoplasmic reticulum to the Golgi apparatus is an essential component of the classical protein secretion pathway. Transport occurs through the production of Coat Protein Complex II (COPII) vesicles\(^11\), which are composed of 5 proteins (Sar1, Sec23, Sec24, Sec13 and Sec31) that assemble on the cytosolic face of the endoplasmic reticulum membrane\(^12\)\(^\text{--}\)\(^14\). Four isoforms of Sec24 exist (A-D) which serve as cargo-binding adaptor molecules in COPII vesicles\(^15\)\(^\text{--}\)\(^19\). Cellular kinases may also play a role in post-translational modification of Sec24; AKT has been shown in vitro to phosphorylate Sec24C which can decrease its binding affinity with SEC23, thus reducing correct COPII formation and transport ability\(^20\). This may be an important finding, as our previous characterisation of the MCF-7 RR cell line identified increased AKT pathway activity. The effects of AKT inhibition on SEC24 could warrant further investigation. Increased SEC24C expression has been shown in colorectal cancer\(^21\) and has been found to be secreted via extra-cellular vesicles in numerous cancer types\(^22\)\(^\text{--}\)\(^26\), breast milk\(^27\) and mesenchymal stem cells\(^28\). Validation using CM samples identified increased SEC24C secretion levels in response to radiation at 24 h in MCF-7, ZR-751, MDA-MB-231 and REM-134 parental cell lines, whereas significantly lower or no secretion was observed in the RR cell lines. The only exception was in the MDA-MB-231 RR cell line, which showed a significant increase in secretion levels. SEC24C gene expression was lower in ER\(^-\) and ER\(^+\) parental cell lines compared
with RR derivatives, although this result was not supported by IHC and IF results, which identified higher expression in the parental cell lines. Overall, these results provided evidence that SEC24C is secreted in response to radiation, but secretion may only provide evidence of radiosensitivity in ER\(^+\) cell lines. Differences between SEC24C gene expression and intra-cellular protein levels would require further investigation to determine if levels could relate to radiosensitivity.

Y-box binding protein 3 (YBX3) has been shown to act as a transcription factor, regulating translation\(^{527}\) and influencing processes such as differentiation, proliferation and survival\(^{528}\). YBX3 overexpression and nuclear localisation has been correlated with poor prognosis in hepatocarcinomas\(^{529-531}\) and is involved with the pathogenesis of gastric cancer through increased invasion and chemoresistance\(^{532}\). YBX3 has also been found to be secreted via extra-cellular vesicles in numerous cancer types\(^{507,533,534}\) and mesenchymal stem cells\(^{535}\). Unfortunately, time restraints did not allow for validation using CM samples; however, YBX3 gene expression was higher in ER\(^-\) and ER\(^+\) parental cell lines compared with RR derivatives, which was supported by IHC and IF results. Overall these results provided evidence that YBX3 gene expression and intra-cellular protein levels may be related to radiosensitivity.

TK1 is a cell cycle regulator\(^{536}\) which catalyses the addition of a gamma-phosphate group to thymidine creating thymidine monophosphate, which is the first step in the synthesis of deoxythymidine triphosphate and DNA replication\(^{537}\). Intra-cellular TK1 levels vary depending on the stage of the cell cycle, with low concentrations in the G1 phase and higher levels in S/G2 phases. A dramatic fall in concentration is seen in the M-phase as a result of degradation pathways\(^{538}\). Increased TK1 expression has been identified in breast tumours and has been shown to correlate with disease stage and grade\(^{539}\). TK1 has also been found to be secreted via extra-cellular vesicles in numerous cancer types\(^{507,526,533,534}\). Serum TK1 has shown promise as a biomarker of proliferation\(^{540}\) with diagnostic and prognostic potential in numerous cancer types\(^{536,541}\). Serum TK1 has also been investigated for monitoring the response of breast cancer patients to treatment\(^{542}\) and for predicting the risk of developing distant and/or regional recurrence post-surgery\(^{543}\). Validation using CM samples identified increased TK1 secretion levels in response to radiation at 24 h in MCF-7 and ZR-751 parental cell lines, whereas significantly lower or no
secretion was observed in the RR cell lines. Increased secretion levels were seen in both JS7 and JS7 RR cell lines. TK1 gene expression was also higher in the ER\(^+\) parental cell lines compared with RR derivatives, which was supported by IHC and IF results. Gene expression in the ER\(^-\) MDA-MB-231 parental and RR cell lines identified higher expression in the RR derivatives. Overall, these results provided evidence that TK1 is secreted in response to radiation but may only provide evidence of radiosensitivity (based on gene analysis) in ER\(^+\) cell lines.

Currently only 4 of the 9 lead biomarkers have undergone preliminary validation and further work will be needed to investigate the remaining candidates. Gene analysis of the REM-134 and JS7 parental and RR cell lines has also not yet been completed; performing this analysis would provide further information of the ability of these biomarkers to be used for predicting radiosensitivity. Another area of future research would involve investigating the mechanisms of biomarker secretion and what roles their secretion plays in terms of radiation response. One speculative mechanistic theory for biomarker secretion that incorporates both protein transport and translation would involve the UPR. From our previous characterisation of the ER\(^+\) parental and RR cell lines we know that there is differential activation in UPR pathways. MCF-7 RR and ZR-751 RR cell lines seemingly lose PERK/EIF2\(\alpha\) signalling as opposed to parental cells which show higher expression of total and p-PERK and EIF2\(\alpha\) at both gene and protein level. If parental radiosensitive cells block translation in response to radiation, then this could perhaps lead to a build-up of complexes required for translation initiation (EIF3G, EIF4EBP2, NAP1L4) and protein transport from the endoplasmic reticulum to the Golgi (SEC24C, VPS29) within the cytoplasm. While translation is inhibited these biomarkers are no longer required by the cell and so may be preferentially secreted. Although currently there is no direct evidence to support this theory, investigation of UPR associated genes and genes encoding the 4 biomarkers using a publicly available data set (GSE59733) provided preliminary evidence that radiation can increase the expression of UPR response genes and genes encoding EIF3G, SEC24C and YBX3. These results identified a gene signature similar to that seen in MCF-7 and ZR-751 parental cell lines as opposed to their RR derivatives. Further work investigating the UPR would
help to investigate the mechanisms of radioresistance and assess its potential role in radiation-induced secreted biomarkers.

5.4 Conclusion

This chapter has described the preliminary development of an in vitro secretomic experiment using CM from cancer cells with the aim of detecting and validating radiation-induced acutely secreted biomarkers. To our knowledge, this is the first description of secretomic experiments being used to identify radiation-induced secreted biomarkers which are released within 24 h of treatment, the results of which were validated using novel RR cell lines. By using these paired parental and RR cell lines we have shown that biomarkers can be released in response to radiation and that differential biomarker secretion profiles can indicate the radiosensitivity of a cancer cell. Furthermore, investigation of differential gene expression and intra-cellular protein levels of the candidate biomarkers also provided an indication of radiosensitivity. In clinical terms, the identification of a panel of biomarkers whose gene expression signature or intra-cellular expression levels predict the likelihood of a tumour responding to RT could be combined with measuring on-treatment secreted levels of the same biomarkers; this may provide a means by which the response of a tumour could both be predicted and also continually assessed. The use of biomarkers for both predicting and monitoring the response to treatment would provide a potential way in which RT could become tailored to an individual patient.
6 Biocompatibility Assessment of Common Implantable Sensor Materials in a Tumour Xenograft Model

This results chapter is an expanded version of a published research article: Gray M, Meehan J, Blair EO, Ward C, Langdon SP, Morrison L, Marland JRK, Tsiamis A, Kunkler IH, Murray A, Argyle D. Biocompatibility of common implantable sensor materials in a tumour xenograft model. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2018; 1-14. This article is open access with the authors retaining copyright to their work with permission to use published figures in this thesis. Sections of text and figures used from this article have been referenced accordingly.

6.1 Abstract

**Background:** Interest in the use of implantable devices for a wide range of medical conditions is increasing. Unfortunately, following implantation within the body these devices can lose functionality due to biofouling caused by the foreign body response (FBR). To accurately assess the FBR induced by an implanted medical device then biocompatibility evaluation should be performed within tissues where implantation is intended; sensors designed for implantation into solid tumours should be evaluated within a tumour microenvironment. **Methods:** A novel serial sacrifice murine xenograft model was developed to evaluate the potential of 6 biomaterials, used in the construction of the IMPACT O₂ sensor (silicon dioxide, silicon nitride, Parylene-C, Nafion, biocompatible EPOTEK epoxy resin and platinum), to trigger a FBR when implanted into human breast cancer xenograft tumours. Novel protocols were developed to process, and section harvested tumours that allowed identification of the implant site. **Results:** No detrimental effects from implantation of any of the biomaterials on mice body weight or on tumour growth were identified. Immunohistochemistry showed no significant changes in tumour necrosis, hypoxic cell number, proliferation, apoptosis, immune cell infiltration or collagen deposition. **Conclusions:** The lack of biofouling from the implantation of these biomaterials within a solid tumour supports their use in implantable medical devices. To our knowledge, this is the first documented investigation of the effects of modern
biomaterials used in the production of implantable sensors within a tumour microenvironment.

6.2 Introduction

Interest in the development and use of implantable medical devices has increased in recent years due to advances in microfabrication techniques and through the development of novel biocompatible materials. As precision medicine becomes integrated into healthcare practices, the roles of implantable medical devices as diagnostic, therapeutic and monitoring aids will likely become more important in achieving better patient outcomes in a variety of disease conditions. Major challenges in the development of any implantable medical device include the activation of tissue and immune responses that occur post-implantation. These reactions can contribute to device failure or host toxicity and are largely attributed to biofouling and the FBR\textsuperscript{165-167}. The extent of these processes can be influenced by the implantation procedure itself as well as the biocompatibility of the device.

Although \textit{in vitro} tests as outlined in the Biological Evaluation of Medical Devices: ISO 10993\textsuperscript{161} are excellent screening processes, \textit{in vivo} animal models are required to evaluate tissue reactions, the results of which can influence the selection of materials used in the development of implantable medical devices. \textit{In vivo} models provide a means by which the FBR can be evaluated in a situation similar to that which would occur following implantation into patients. Obtaining tissue or fluid exudates adjacent to the implanted material allows assessment of cellular interactions which occur in the presence of stromal and immune cells; these factors greatly increase the complexity of \textit{in vivo} models compared with \textit{in vitro} testing systems\textsuperscript{544}.

The cage implant system involves placing candidate materials into stainless-steel cages which are then subcutaneously implanted into an animal. Tissue exudates can be collected from the cage and examined for inflammatory cells, enzymes, fibrous encapsulation and infection\textsuperscript{545}. Although no tissue is obtained from this model, it allows for serial exudate samples to be obtained without animal sacrifice. Serial sacrifice models, such as the chamber system, allow for tissue harvesting for histological evaluation of the inflammatory response, fibrous encapsulation and vascularisation. This system utilises a lightweight aluminium or titanium frame fastened to 2 skin folds on the back of a rat or hamster. Candidate materials can then
be implanted into the skin fold. Real-time visualisation can also be achieved with this model by removing a skin section and replacing it with glass. The chorioallantoic membrane (CAM) of a developing chick embryo is a simple and cost-effective method of observing tissue responses to materials. Acute and chronic inflammatory responses have been shown to be elicited in a manner similar to that in other animal models. Materials coated in ovalbumin or egg white are placed on top of the CAM, which can become incorporated into it within 7 days. Visualisation of the material is also possible due to the transparent nature of the CAM.

These models have all been used to evaluate medical devices designed for implantation into normal healthy tissues. However, it has been suggested that biocompatibility is a characteristic of a system rather than of a material and that individual materials may affect different biological systems in different ways. Therefore, materials should undergo biocompatibility testing in the tissue they are designed to be implanted into. This is an important consideration for the IMPACT sensor, designed for implantation into solid tumours, or any device developed for intra or peri-tumoural implantation. For these devices, the FBR must be evaluated within the diseased tissues, rather than relying on published data from implantation studies within healthy tissues. The in vitro and in vivo biocompatibility of the constituent materials used in the construction of the IMPACT sensor has been previously documented. Various in vivo studies have shown that the materials are well tolerated and induce only a minimal FBR. Some of the materials have gained ISO 10993 accreditation, while all have been used in the construction of a variety of medical devices (Table 6.1). However, all these biocompatibility studies used in vivo models in which the materials were implanted into healthy, non-diseased tissue; their effects within a tumour have never been evaluated.

This chapter describes the assessment of the intra-tumoural biocompatibility of 6 modern biomaterials that were under consideration for use in the IMPACT sensor. The biomaterials investigated were silicon nitride, silicon dioxide, platinum, Parylene-C, biocompatible EPOTEK epoxy resin and Nafion. Copper was chosen as a positive control implantation material due to its recognised previously published cytotoxic effects. Through the development of a novel serial sacrifice murine model, biomaterials were implanted into human breast cancer xenograft tumours and...
their biocompatibility assessed up to 14 days post-implantation. Novel protocols were developed to process, and section harvested tumours that allowed identification of the implant site. The effects of the biomaterials were investigated through changes in mean tumour volumes and mouse body weights, while histopathology was used to assess proliferation, apoptosis, hypoxia and necrosis, as well as innate immune responses and collagen deposition occurring within the tumour. To our knowledge, this is the first description of the interaction of modern biomaterials, used in the fabrication of implantable devices within a TME.
Table 6.1. Previously published studies investigating the *in vivo* and *in vitro* biocompatibility testing of IMPACT component biomaterials. (taken from\textsuperscript{551}).

<table>
<thead>
<tr>
<th>Biomaterial</th>
<th><em>In vitro testing</em></th>
<th><em>In vivo testing</em></th>
<th>Implantable devices</th>
<th>Regulations</th>
</tr>
</thead>
</table>
| Parylene-C  | Haemocompatibility testing\textsuperscript{554}  
Cell culture biocompatibility\textsuperscript{555-557}  
Cytotoxicity, hemocompatibility testing\textsuperscript{161} | Systemic toxicity, sensitisation, intracutaneous reactivity testing\textsuperscript{161}  
Neural electrodes biocompatibility: mice\textsuperscript{556,558}, cat\textsuperscript{559}, monkey\textsuperscript{560}, rat\textsuperscript{561-563} | Cardiovascular implants\textsuperscript{564} | ISO 10993\textsuperscript{565} |
| Platinum    | Cell culture biocompatibility\textsuperscript{566} | | | |
| Silicon nitride | Cytotoxicity, haemocompatibility testing\textsuperscript{161}  
Non-toxic, encourage cell adhesion and cellular differentiation\textsuperscript{573-577} | Systemic toxicity, sensitisation and intramuscular reactivity testing\textsuperscript{161,578}  
Fracture repair and evaluation of osteoconductivity\textsuperscript{573,576,579,581}  
Cage implant biocompatibility testing\textsuperscript{582,583} | Orthopaedic and neurosurgical implants\textsuperscript{584-586} | ISO 10993\textsuperscript{574,578} |
| Silicon dioxide | Cytotoxicity testing\textsuperscript{161}  
Biocompatibility and antibacterial testing\textsuperscript{573,587} | Intramuscular reactivity testing\textsuperscript{161,578}  
Nerve electrodes biocompatibility: rat\textsuperscript{588}  
Cage implant biocompatibility testing\textsuperscript{582} | Nanomedicine drug delivery systems and diagnostic probes\textsuperscript{589,590} | ISO 10993\textsuperscript{577} |
| Nafion      | Biocompatibility and antibacterial testing\textsuperscript{591}  
Non-cytotoxic and allows cellular differentiation\textsuperscript{592} | Subcutaneous, intraperitoneal and intravenous biocompatibility: mice\textsuperscript{591,593}, dogs\textsuperscript{594}  
Intracerebral biocompatibility\textsuperscript{145,595,597}  
Nervous system biocompatibility\textsuperscript{592} | Electrochemical sensors and electrodes\textsuperscript{598,599} | |
| EPO-TEK OG116-31 resin | Cytotoxicity, haemocompatibility, genotoxicity testing\textsuperscript{161} | Systemic toxicity, sensitisation, intracutaneous and intramuscular reactivity testing\textsuperscript{161} | Pacemakers, ophthalmic and neurostimulators, insulin pumps, cochlear implants orthopaedic and neurological implants\textsuperscript{600} | ISO 10993\textsuperscript{600} |
6.3 Results

6.3.1 Development of a percutaneous biomaterial implantation technique

To develop a technique whereby biomaterials could be safely, reliably and quickly implanted into a xenograft tumour, we began to investigate protocols using ex-vivo MDA-MB-231 xenograft tumours. A 21G needle was introduced through the skin overlying the tumour but not into the tumour tissue itself. The needle was withdrawn, noting its skin entry position and any blood seeping from the wound. Using needle holders, a length of Cu wire (400 μm in diameter and approximately 7 mm in length) was introduced through the needle-created insertion hole and advanced into tumour tissue until the wire was completely buried under the skin (Figure 6.1). Tumours containing the implanted wires then underwent fixing in formalin, processing and edge embedding in paraffin for IHC.

![Figure 6.1. Photographs of ex-vivo MDA-MB-231 xenograft tumours used in the development of a biomaterial implantation protocol.](image)

(a) Dorsal aspect of MDA-MB-231 xenograft tumour, a 1 cm Cu wire is shown for implantation. (b) Ventral aspect of MDA-MB-231 xenograft tumour. (c) A 21G needle was introduced through the skin overlying the tumour. (d) A length of Cu wire was then introduced into the tumour through the insertion hole created by the needle.

6.3.2 Development of an IHC sectioning protocol for xenograft tumours containing implanted biomaterials

Blocks of paraffin-embedded xenograft tumours were sectioned until the tip of the implanted wire was reached. If the wire was flush with the cut surface of the block it was removed, and sectioning continued through the implant site. However, if the trajectory of the wire was directed further into the tumour, sectioning stopped, and the paraffin was melted. The tumour was then trimmed from its sectioned edge as parallel as possible to the path of the wire. The wire was then carefully removed before re-embedding the tumour in paraffin. Once cooled and set, sectioning continued through the block and implant site as previously described (Figure 6.2 & Figure 6.3).
Figure 6.2. Photographs depicting the position of an implanted biomaterial within a xenograft tumour following harvesting and processing for IHC. The dashed box is outlining an OG116-31 resin wire. (a) Lateral and (b) Dorsal views showing the biomaterial positioned centrally within the tumour; photographs were taken following tumour processing but before paraffin embedding. (c) Following edge embedding in paraffin, the tumour was sectioned until the biomaterial was identified. The wire was then removed, and sectioning continued through the implantation site.

Figure 6.3. Histological appearance of xenograft tumour sections containing the biomaterial implantation site. These H&E stained sections are from 2 xenograft tumours used for development of the sectioning protocol. The implant site can be clearly identified centrally positioned within the tumour.

6.3.3 Refined procedure for biomaterial implantation into xenograft tumours

Following development of the implantation procedure using *ex vivo* xenograft tumours we progressed onto experimental cases. All biomaterials were implanted under general anaesthesia using the same percutaneous technique. MDA-MB-231 human xenograft tumours were generated subcutaneously in CD-1 female nude mice as described in sections 3.2.2 & 3.2.3. Once tumours had developed to an adequate
size (0.7-1.2 mm) mice were randomly assigned into treatment or control groups. Treatment groups consisted of tumours implanted with a single biomaterial, whereas control groups consisted of untreated tumours and those that received a needle tract (NT) injury to mimic the implantation procedure. The generation of bilateral subcutaneous flank xenograft tumours enabled each mouse to act as its own control. This reduced the total number of mice required as 1 tumour received biomaterial implantation or NT injury whilst the contralateral tumour remained untreated.

All mice underwent general anaesthesia as described in section 3.2.4 (defined as day 0). Mice were positioned in dorsal recumbency and the skin immediately surrounding the xenograft tumour was aseptically prepared for surgery using chlorohexidine solution. The biomaterials were implanted using a percutaneous technique based on the developed protocol described in section 6.3.1. A 21G needle was used to penetrate the skin overlying the tumour but not into the tumour parenchyma itself. This entry point was positioned at the caudal aspect of the tumour, so introduction of the biomaterial would be along the long axis. The needle was removed, and a single biomaterial wire was then introduced into the tumour through the pre-made entry point and advanced until the entire length of the wire was within tumour tissue. Tissue adhesive (Vetbond, 3M, Bracknell, UK) was then applied to the skin (Figure 6.4). For NT injury control tumours, a 21G needle was used to penetrate the skin as previously described but was then advanced into the tumour tissue, stopping just short of penetrating the contralateral side of the tumour. The needle was removed, and tissue adhesive was applied to the skin (Figure 6.5). Following surgery all mice were placed into an incubator at 30-35°C until recovered. Anaesthetic duration, including induction and maintenance, aseptic skin preparation, implantation/NT injury and recovery lasted approximately 5 min. No anaesthetic complications were encountered.
Figure 6.4. *Intra-operative photographs depicting percutaneous biomaterial implantation.* (a) Under general anaesthesia mice were placed in dorsal recumbency and the skin surrounding the tumour was aseptically prepared. (b) A 21G needle was used to make an entry point in the skin overlying the tumour. (c) An appropriately sized length of biomaterial was chosen for each tumour. (d) Needle holders were used to introduce the biomaterial into the tumour through the pre-prepared hole.

Figure 6.5. *Intra-operative photograph depicting needle tract injury.* A 21G needle was introduced through the skin overlying the tumour and into the tumour parenchyma itself. The needle was advanced as far as possible through the tumour to ensure the creation of a long NT. The needle stopped short of penetrating the contralateral side of the tumour.

Day 0 mice were euthanised immediately following anaesthesia, whilst the remaining mice were monitored up to 14 days post-implantation. All mice were assessed for signs of ill health with body condition score, body weight and tumour size measured 3 times a week. Relative mouse body weight was calculated by dividing the body weight measured on each day by the weight on day 0. Tumour size (width and length) was measured using Vernier callipers and tumour volume was
calculated as $\pi/6 \times width^2 \times length$. Relative tumour volume was calculated by dividing the tumour volume on each day by its volume on day 0. Immediately following euthanasia, xenograft tumours were removed and fixed in formalin for subsequent processing and edge embedding in paraffin for IHC.

6.3.4 **The percutaneous implantation procedure resulted in a high success rate of biomaterial delivery into xenograft tumours**

The mean body weight of each mouse group at day 0 was similar, averaging 26.76 ± 1.2 g. The developed percutaneous implantation procedure resulted in a high success rate of delivering biomaterial wires to the centre of the xenograft tumours. Out of 47 implantations, following harvesting 1 wire was found to have migrated from within the tumour to lie in subcutaneous fat and 1 was found to be peripherally located within the tumour during sectioning; the remainder were all well positioned within central tumour tissue. The method for sectioning biomaterial-containing tumours was also highly successful, with all implant sites identified and every implanted wire successfully recovered (Figure 6.6 & Figure 6.7). The number of mice used in each control and treatment group is provided in Figure 6.8 & Figure 6.9.

![Figure 6.6. Representative H&E stained sections from untreated tumours harvested at day 7.](image)

![Figure 6.7. Representative H&E stained sections from biomaterial implanted tumours harvested at day 7 post-implantation. (a) Nafion implanted. (b) SiO$_2$ implanted. (c) Pt implanted.](image)
6.3.5 Implantable biomaterials have no effect on mouse body weights and tumour volumes

Body weights of biomaterial (Si$_3$N$_4$, SiO$_2$, Parylene-C, Nafion, Pt and OG116-31 resin) implanted and untreated mice remained stable throughout the 7-day experimental period, with no statistically significant changes in body weight identified within any individual treatment group (Figure 6.8). The body weights of mice whose xenograft tumours were implanted with Cu also remained stable. Furthermore, no statistically significant differences were identified between any of the groups measured at each time point. Mean tumour volumes for untreated, NT injury and all biomaterial implanted and Cu implanted tumours, all showed growth over the 7 days, with no statistically significant differences identified between any group at any time point (Figure 6.8). Similar results were found when Parylene-C was implanted for 14 days; body weights remained stable with no statistically significant changes in body weight observed between implanted and control tumours. Although at day 7 the mean tumour volume of NT injury tumours was statistically lower compared to the untreated control group ($p=0.0211$) their volumes increased on subsequent days with differences between the groups becoming non-significant. Tumour volumes for Parylene-C implanted tumours showed no statistical differences between untreated and NT injury tumours at any of the time points up to 14 days post-implantation (Figure 6.9).
Figure 6.8. Biomaterials have no effect on mice body weights or xenograft tumour growth up to 7 days post-implantation. (a&b) Mice body weights for untreated tumours and Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si₃N₄ and SiO₂ implanted tumours. Body weights are normalised to the day 0 measurement. (c&d) Mean tumour volumes for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si₃N₄ and SiO₂ implanted tumours. Tumour volumes are normalised to the day 0 measurement. Number of mice in each control and treatment group is provided in each figure legend.
Figure 6.9. Parylene-C has no effect on mice body weights or xenograft tumour growth up to 14 days post-implantation. (a) Mice body weights for untreated tumours and Parylene-C implanted tumours. Body weights are normalised to the day 0 measurement. (b) Mean tumour volumes for untreated and NT injury tumours, along with Parylene-C implanted tumours. Tumour volumes are normalised to the day 0 measurement. Number of mice in each control and treatment group is provided in each figure legend (two-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, *p≤0.05).

6.3.6 Implanted biomaterials have no effect on tumour necrosis and CA9 staining

The area of tumour necrosis was calculated as a percentage of the total xenograft tumour area. At 7 days post-implantation xenograft tumours implanted with Cu wires showed a statistically significant increase in the percentage area of necrosis compared to NT injury (p = 0.0288) and untreated (p = 0.0141) control groups. No significant differences in the area of necrosis were identified between biomaterial implanted xenograft tumours and the control tumours, including Parylene-C up to 14 days post-implantation (Figure 6.10 & Figure 6.11). As a hypoxic marker, CA9 expression was investigated to identify the number of hypoxic cancer cells in each xenograft tumour. No significant differences in the percentage of CA9 positive cells were identified between any of the biomaterial implanted, Cu implanted and control tumours up to 7 days post-implantation (Figure 6.12). CA9 staining was not undertaken in Parylene-C implanted tumours up to 14 days due to limited numbers of available sections.
Biomaterials have no effect on the percentage area of tumour necrosis up to 7 days post-implantation. (ai&aii) Representative H&E stained sections from tumours harvested at day 7. (ai) Untreated. (aii) Cu implanted. (bi&bii) Percentage area of necrosis for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si₃N₄ and SiO₂ implanted tumours (one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, *p≤0.05).
Figure 6.11. Parylene-C has no effect on the percentage area of tumour necrosis up to 14 days post-implantation. Percentage area of necrosis for untreated and NT injury tumours, along with Parylene-C implanted tumours.

Figure 6.12. Biomaterials have no effect on xenograft cancer cell CA9 staining up to 7 days post-implantation. (ai&aii) Representative CA9 stained sections from tumours harvested at day 7. (ai) Untreated. (aii) Nafion implanted. (bi&bii) Percentage of CA9 positive staining cells for untreated and NT injury xenograft tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and SiO2 implanted tumours.
6.3.7 Implanted biomaterials have no effect on xenograft cancer cell proliferation and apoptosis

As a marker of cells present in active phases of the cell cycle (G1, S, G2) and mitosis, Ki67 expression was investigated to identify the number of proliferating cancer cells in each xenograft tumour. No significant difference in the percentage of Ki67 positive staining cells was identified between any of the biomaterial implanted, Cu implanted and control tumours up to 7 days post-implantation. (Figure 6.13). When Parylene-C implantation was investigated up to 14 days a statistically significant higher percentage of Ki67 positive staining cells was identified in the Parylene-C implanted xenograft tumours compared with NT injury tumours at 2 days post-implantation ($p=0.0037$). The numbers of Ki67 positive staining cells increased in the NT injury control group on subsequent days with differences between the groups becoming non-significant (Figure 6.15). As a marker of cells activating death proteases, cleaved caspase 3 expression was investigated to identify the number of apoptotic cancer cells in each xenograft tumour. Only Cu implanted xenograft tumours had a statistically significant increase in the percentage of cleaved caspase 3 positive staining cells compared to untreated ($p=0.0025$) and NT ($p=0.0020$) control groups at 7 days post-implantation (Figure 6.14). Parylene-C implanted tumours showed no statistical differences in the percentage of caspase 3 positive staining cells between untreated and NT injury tumours at any of the time points up to 14 days post-implantation (Figure 6.15).
Figure 6.13. Biomaterials have no effect on xenograft cancer cell proliferation up to 7 days post-implantation. (ai & aii) Representative Ki67 stained sections from tumours harvested at day 7. (ai) Untreated. (a(ii) SiO$_2$ implanted. (bi & bii) Percentage of Ki67 positive staining cells for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si$_3$N$_4$ and SiO$_2$ implanted tumours.
Figure 6.14. Biomaterials have no effect on xenograft cancer cell apoptosis up to 7 days post-implantation. (ai&aii) Representative caspase 3 stained sections from tumours harvested at day 7. (ai) Untreated. (aii) Cu implanted. (bi&bii) Percentage of caspase 3 positive staining cells for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si₃N₄ and SiO₂ implanted tumours (one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, **p≤0.01).
Figure 6.15. Parylene-C has no effect on xenograft cancer cell proliferation and apoptosis up to 14 days post-implantation. (a) Percentage of Ki67 positive staining cells for untreated and NT injury tumours, along with Parylene-C implanted tumours. (b) Percentage of caspase 3 positive staining cells for untreated and NT injury tumours, along with Parylene-C implanted tumours (two-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, **p≤0.01).

6.3.8 Implanted biomaterials have no effect on neutrophil and macrophage infiltration within xenograft tumours

Using Ly6G, a glycosylphosphatidylinositol-anchored protein and the glycoprotein F4/80, cellular expression levels of each target was investigated to identify the number of murine neutrophils and macrophages within each xenograft tumour. No significant differences in the percentage of Ly6G or F4/80 positive staining cells were identified between any of the biomaterial implanted, Cu implanted and control tumours up to 7 days post-implantation or up to 14 days with Parylene-C implantation. Only small numbers of Ly6G positive cells were identified in any of the tumours (Figure 6.16, Figure 6.17 & Figure 6.18). Two types of macrophage distribution patterns were identified in implanted and control tumours. In approximately 50% of tumours, a localised region of F4/80 positive stained cells was identified round the periphery of the tumour, whereas the remaining tumours had a more uniform distribution throughout the tumour tissue (Figure 6.19).
Figure 6.16. Biomaterials have no effect on neutrophil infiltration within tumour tissue up to 7 days post-implantation. (ai & aii) Representative Ly6G stained sections from tumours harvested at day 7. (ai) Untreated. (aII) Parylene-C implanted. (bi & bii) Percentage of Ly6G positive staining cells for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si3N4 and SiO2 implanted tumours.
Figure 6.17. Biomaterials have no effect on macrophage infiltration within tumour tissue up to 7 days post-implantation. (ai & aii) Representative F4/80 stained sections from tumours harvested at day 7. (ai) Untreated. (a(ii) Si$_3$N$_4$ implanted. (bi & bii) Percentage of F4/80 positive staining cells for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si$_3$N$_4$ and SiO$_2$ implanted tumours.
Figure 6.18. Parylene-C has no effect on neutrophil and macrophage infiltration within tumour tissue up to 14 days post-implantation. (a) Percentage of Ly6G positive staining cells for untreated and NT injury tumours, along with Parylene-C implanted tumours. (b) Percentage of F4/80 staining cells for untreated and NT injury tumours, along with Parylene-C implanted tumours.

Figure 6.19. Macrophage distribution patterns within untreated xenograft tumours. (a) Macrophages are identified both at the periphery of the tumour and within the tumour tissue. (b) Macrophages are uniformly distributed within the tumour tissue.
6.3.9 Implant biomaterials have no effect on fibroblast infiltration and collagen deposition within xenograft tumours

Using ER-TR7, an antigen expressed in the cytoplasm of fibroblasts, cellular expression levels were investigated to identify the number of murine fibroblasts within each xenograft tumour. Compared to untreated tumours at day 0, there was a significantly higher percentage of ER-TR7 positive staining cells in both untreated ($p=0.0073$) and NT injury tumours ($p=0.0445$) at day 7. However, no significant differences in the percentage of ER-TR7 positive staining cells were identified between any of the biomaterial implanted, Cu implanted tumours and control tumours at 7 days post-implantation (Figure 6.20) or up to 14 days with Parylene-C implantation (Figure 6.22). Untreated tumours at 7 days post-implantation had a statistically significant higher percentage area of collagen compared to untreated tumours at day 0 ($p=0.0086$) (Figure 6.21). However, no significant differences in the percentage area of collagen were identified between any of the biomaterial implanted and control tumours at 7 days post-implantation. Cu implanted tumours, on the other hand, did have a statistically significant increase in collagen compared to untreated ($p=0.0217$) and NT ($p=0.0314$) control groups at day 7 post-implantation (Figure 6.21). Although a trend for an increase in the percentage area of collagen was noted over the 14-day period for Parylene-C implantation, this was not statistically significant (Figure 6.22).
Figure 6.20. Biomaterials have no effect on fibroblast infiltration within xenograft tumour tissue up to 7 days post-implantation. (ai & aii) Representative ER-TR7 stained sections from tumours harvested at day 7. (ai) Untreated. (aii) Pt implanted. (bi & bii) Percentage of ER-TR7 positive staining cells for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si$_3$N$_4$ and SiO$_2$ implanted tumours (one-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, **$p$≤0.01; * $p$≤0.05).
Figure 6.21. Biomaterials have no effect on collagen deposition within xenograft tumour tissue up to 7 days post-implantation. (ai&aii) Representative Masson’s trichrome stained sections from tumours harvested at day 7. (ai) Untreated. (aii) SiO$_2$ implanted. (bi&bii) Percentage area of collagen for untreated and NT injury tumours, along with Cu, OG116-31 resin, Parylene-C, Nafion, Pt, Si$_3$N$_4$ and SiO$_2$ implanted tumours (one-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM. **$p$≤0.01; *$p$≤0.05).
6.4 Discussion

Implantable medical devices are becoming increasing used in pre-clinical research for a variety of disease conditions (Table 6.1) including cancer\textsuperscript{151}. With the first implantable device for monitoring radiation dose delivery now used in the clinics\textsuperscript{157}, it is likely more and more devices will become available as their roles in precision medicine become more defined. However, for an implantable device to attain regulatory approval, component materials or, ideally, the complete working device must undergo pre-clinical in vitro and in vivo biocompatibility testing. Well documented and commonly used biocompatibility models typically implant devices into healthy, non-diseased tissue; to date only limited published information is available regarding biofouling and the FBR that occurs within tumour tissue. Only one historical paper, published in 1962, has investigated the FBR induced following the implantation of cotton into murine tumours. Results showed that following implantation, the FBR seen within the tumours was minimal compared to that of normal tissues, indicating that the induced FBR may be decreased within a TME\textsuperscript{601}.

This chapter describes the investigation of the effects of selected modern biomaterials within a solid tumour and provides important biocompatibility data. Using human breast cancer xenograft tumours, biocompatibility was assessed up to 14 days following implantation through the development of a novel percutaneous implantation technique and IHC processing and sectioning protocols. The implantation procedure was highly reproducible and minimally invasive.
Approximately 95% of implants were successfully placed within the centre of xenograft tumours with no mice showing signs of inflammation or discomfort around the implantation/NT injury site.

For validation of the results obtained from biomaterial implanted tumours positive control implants were required, Cu wires were used in the experiments for this purpose. Although not previously reported within a TME, Cu has been shown to be cytotoxic552,553,595, these toxic effects are mediated through a variety of different mechanisms602,603. Cu and Cu ions can be involved in the generation of ROS604, leading to DNA strand breaks, base oxidation and ultimately cell death605. Apoptosis induced by Cu2+ has also been shown to be mediated through the induction of Bax, NF-κB inactivation and ROS formation606. In accordance with these results, Cu implanted xenograft tumours in our study had increased percentages of caspase 3 positive staining cells and larger areas of tumour necrosis. Although the mechanisms by which Cu-induced apoptosis were not investigated, the increased levels of caspase 3 expression within Cu implanted tumours agrees with these previously published findings. In vivo models have also shown that Cu can generate more severe inflammatory responses and fibrosis compared to non-Cu containing materials201,607. Our results demonstrated that, although the absolute percentage of fibroblasts remained the same in Cu implanted tumours, the percentage area of collagen was higher compared to control tumours; increasing to 1.05% in Cu implanted tumours compared with 0.49% in NT injury tumours and 0.48% in untreated tumours. These changes identified in the Cu implanted tumours (apoptosis, necrosis and fibrosis), reflecting the known cytotoxic effects of Cu, provided confidence in the implantation procedure and the method used for quantitative analysis and validated our results seen in the biomaterial implanted xenograft tumours551.

Potential systemic effects caused by the implanted biomaterials was investigated by monitoring changes in body weight and condition score. No systemic toxicities were identified in mice that underwent biomaterial or Cu implantation, as indicated by maintenance of their body weight and condition score. Localised tumoural effects were investigated by calculating relative mean tumour volumes throughout the experimental period, results showed that all implanted tumours increased in size over 7 or 14 days in accordance with the controls. This result was
further assessed through histopathology by evaluating MDA-MB-231 cancer cell proliferation, apoptosis, necrosis and hypoxia within the xenograft tumours.

Assessment of proliferation and apoptosis was performed through Ki67 and caspase 3 staining respectively. Only Parylene-C implanted tumours had a statistically greater percentage of Ki67 positive cells compared to NT injury tumours at 2 days post-implantation. No further differences in cellular proliferation or apoptosis were observed between the other biomaterials at any of the remaining time points. CA9 is a protein whose expression is induced in hypoxic conditions\textsuperscript{117}; expression levels were investigated, as the IMPACT sensor is ultimately designed to monitor intratumoural O\textsubscript{2} concentrations. No significant differences in the percentage of CA9 positive staining cells were observed between any of the implanted and control tumours, indicating that the biomaterials did not affect intratumoural O\textsubscript{2} levels. MDA-MB-231 xenograft tumours are heterogeneous, containing areas that are normoxic, hypoxic and necrotic\textsuperscript{608}. The necrosis that develops can be a result of the tumour outgrowing its blood supply, increased levels of cell death and failure of clearance of these dead cells. Although necrotic areas were identified around the implanted biomaterials, the percentage area of necrosis was not significantly different from that of the control tumours. This suggests that the biomaterials did not increase the levels of necrosis from that seen within untreated xenograft tumours. Together, assessment of these 4 cellular parameters (Ki67, caspase 3, CA9 and necrosis) indicate that the implanted biomaterials did not affect the viability of the MDA-MB-231 cancer cells within the xenograft tumours\textsuperscript{551}.

Acute inflammation begins immediately after a material has been implanted within the body and can continue for 5 days\textsuperscript{168}. The initial trauma caused by the insertion device will largely determine the severity of the acute inflammatory response, whereas the size of the implanted device will have a more significant effect on chronic inflammation and fibrosis\textsuperscript{169}. During acute inflammation, polymorphonuclear leukocytes predominate, these cells are typically found in tissues at the implant site immediately following and up to 2 days post-implantation\textsuperscript{167}. This component of the acute inflammatory response was investigated through the measurement of murine neutrophil numbers in the xenograft tumours using a primary antibody targeting the Ly6G antigen, a glycosylphosphatidylinositol-anchored
protein (also known as the myeloid differentiation antigen Gr1). Although transiently expressed in eosinophils and bone marrow monocytes\(^6\), Ly6G is predominantly expressed on neutrophils and is a common marker used for murine neutrophil identification\(^6\). Our study showed that the percentage of Ly6G positive stained cells was considerably lower than that seen using the F4/80 antibody (murine macrophage marker), indicating that cross reactivity between these cell types was unlikely to have occurred. Minimal numbers of neutrophils were identified in both the implanted and control xenograft tumours at day 0 and day 7 post-implantation. Even in the Parylene-C serial sacrifice study at 2 days post-implantation minimal numbers were identified. These results suggest that the acute inflammatory response resolved normally in the presence of the biomaterials.

Chronic inflammation develops following the resolution of acute inflammation because the causative agent (the biomaterial) remains within the tissues at the implantation site. Monocytes, macrophages and fibroblasts are the major cell types present in the first 3 weeks of chronic inflammation, leading to neovascularisation with granulation and fibrous tissue production\(^16,195\). Macrophages take the lead role in orchestrating events involved with the ongoing immune responses through the formation of FBGCs\(^185\) and production of profibrogenic factors that lead to enhanced fibrogenesis by fibroblasts\(^200\). The potential of the implanted biomaterials for influencing these chronic immune responses was investigated through the measurement of murine macrophage and fibroblast numbers in the xenograft tumours using primary antibodies targeting the F4/80 and ER-TR7 antigens respectively, while also assessing the area of collagen deposition with Masson’s trichrome staining. No significant differences in the percentage of F4/80 positive staining cells were identified between any of the implanted and control tumours up to 7 days post-implantation or up to 14 days with Parylene-C implantation. Both tissue-resident macrophages and tumour-associated macrophages (TAMs) can be present within a tumour. Identification of the separate types can be advantageous, as TAMs have been shown to promote cancer cell invasion, migration, metastasis and angiogenesis; however, differentiating the 2 types of macrophages can be challenging\(^61\). In our study, macrophage identification was performed using an antibody reactive to murine F4/80, a protein that has been widely used as a pan-
macrophage marker\textsuperscript{612,613}; as a result of this, we did not distinguish between the different macrophage types. However, as the percentage of positive staining cells between implanted and control tumours was similar, our results indicated that the biomaterials did not lead to the recruitment of additional macrophages. An association between the percentage number of ER-TR7 positive staining cells and the percentage area of collagen was identified with a statistically significant increase in both parameters occurring between day 0 untreated and day 7 untreated/NT injury tumours, this result was likely due to ongoing tumour growth. Importantly no differences were identified in ER-TR7 positive staining cells and the percentage area of collagen between implanted and control tumours.

When considering the FBR generated by an implanted material, it has been suggested that the physical structure of the material, including its modulus (resistance to elastic (recoverable) deformation), mechanics and stiffness may influence the extent of the inflammatory reactions, with materials of lower moduli producing less fibrosis than more rigid materials\textsuperscript{614}. Tissue damage may also be increased in the presence of stiffer materials\textsuperscript{615}, therefore the use of softer materials with properties more similar to the tissue in which it is implanted may reduce interfacial strain and improve biocompatibility\textsuperscript{616}. However, as no significant differences were seen in the FBR between the softest (Nafion, Youngs modulus 600 MPa) and hardest (Pt, Youngs modulus 168 GPa) biomaterials in our study, the results indicate that a material’s modulus is not be a major contributing factor to the FBR in this tumour model\textsuperscript{551}.

Following implantation, a layer of host proteins immediately acquires on the materials surface. The specific types and amounts of these adsorbed proteins is determined by the materials surface charge and hydrophilicity\textsuperscript{617}. Adsorbed proteins such as such as albumin, vitronectin, fibronectin, fibrinogen, complement and $\gamma$ globulin are known influencers of the FBR as they can dictate the adhesion and survival of monocytes, macrophages and FBGCs on the materials surface\textsuperscript{167,618,619}. These proteins can also desorb rapidly from the materials surface causing time-dependent fluctuations in protein levels\textsuperscript{620}. Various methods could have been used to investigate differences in adsorbed proteins between the materials tested in our study. One method would have been to use the cage implant system whereby exudates
could be examined for these specific proteins. The advantage of using this method would have meant multiple samples could have been obtained without the need for animal sacrifice. Serial samples from the same animal would also mean that levels of specific proteins across time would be directly comparable to each other. A second method would have been to use the serial sacrifice IHC method we developed but harvest mice immediately following implantation and at a greater number of time points within the first 48 h post-implantation. These tumours could then be specifically stained for a range of these adsorbed proteins. These experiments would allow characterisation of the adsorbed proteins for each implanted material which could provide information with regards to the subsequent immune and FBRs that occurred in the surrounding tissues.

Adherent macrophages and FBGC can lead to degradation of materials with subsequent device failure. An important clinical example of this was seen following the replacement of silicon rubber as the insulating material on pacemaker leads for mechanically superior polyether polyurethane (PEU) elastomers\textsuperscript{167}. PEU was thought to be biocompatible but following its use in pacemaker leads increased rates of device failure were seen. Initial investigations suggested that environment stress cracking and metal ion oxidation were responsible for these failures with later studies demonstrating that adherent macrophages and FBGC were involved in the mechanisms underlying both these failure mechanisms\textsuperscript{621-626}. To investigate the effects of adherent macrophages and FBGC in our model, scanning electron microscopy could have been used on recovered implanted materials. This technique has been previously used to study the progression of the FBR in terms of monocyte adhesion, monocyte-to-macrophage development, macrophage fusion and FBGC formation and so could have been applied to our model\textsuperscript{167}. Scanning electron microscopy would also have provided visual information on the presence of any degradation occurring on the materials surface due to the ongoing FBR.

Numerous mouse models (including CD-1 nude mice, SCID and NOD SCID) have been developed specifically to investigate tumourigenesis and pathogenesis of human cancers through the production of xenograft tumours\textsuperscript{218,219}. Due to the relative ease, speed and reproducibility of producing human xenograft tumours, CD-1 nude mice were used in our model. Although this model uses athymic nude mice, deficient
in thymus-derived T lymphocytes, they are far from being immunodeficient. T lymphocytes can be produced via thymus-independent pathways (although in diminished numbers), allowing for some T cell-dependent immunity\(^6\). CD-1 nude mice also demonstrate near-normal responses to T cell-independent antigens, have high, naturally occurring antibody titres that can react with cancer cells\(^7\), have tumouricidal macrophages\(^8\) and have high levels of natural killer (NK) cell activity\(^9\). As a result of these studies demonstrating the ability of CD-1 nude mice to generate both innate and adapted immune responses, T cell-deficient mice (BALB/c nude mice) have been used in the investigation of the FBR to implanted materials\(^1\). This study demonstrated that, although the BALB/c nude mice had lower total leukocyte concentrations in the region of the implanted material, FBGC number and morphology were comparable to the control BALB/c mice. This suggests that pathways independent of thymus-matured T lymphocytes can still induce a normal FBR. Using non-immunosuppressed mice models, such as carcinogen-induced or spontaneously occurring tumours, would allow for the generation of tumours in the presence of an intact immune system. However, a significant disadvantage of these models would be the loss of using xenografted human cancer cells; this would mean the FBR induced by the implanted biomaterial would be assessed within murine rather than human cancer cells.

Functional differences between murine and human immune systems need to be considered when evaluating the data presented in this murine study if the results are to be considered comparable to what would be expected to occur in human tissue\(^5\). Immune system differences in a range of species, including human and CD-1 mice, have been previously investigated which identified significant species differences in circulating leukocyte populations\(^6\). This study demonstrated that the circulating leukocyte profile in human blood is neutrophilic, composed of approximately 50–70% neutrophils (3500–7000 cells/\(\mu\)l) and 20–40% lymphocytes (1400–4000 cells/\(\mu\)l) in comparison to CD-1 mice which is lymphocytic, composed of approximately 50–70% lymphocytes (1000–7000 cells/\(\mu\)l) and 15–20% neutrophils (300–2000 cells/\(\mu\)l). Neutrophil function and activity can also vary between humans and mice, with differences in mechanisms of leukocyte recruitment and composition of neutrophil granules\(^7\). As neutrophils are required in the initial
acute inflammatory phase and lymphocytes are transiently present in the chronic phase of the FBR, these species differences in circulating leukocyte number and function could potentially result in altered FBR initiation and progression.

The pathological equivalence between human xenografts in nude mice and naturally occurring human tumours needs to be considered, as changes in tumour characteristics such as proliferation rates, histological classification and cell type distribution patterns within the tumour can occur post-transplantation. In humans, TAMs are typically distributed uniformly throughout the tumour; while this distribution pattern was identified in approximately 50% of xenograft tumours in our study, the remainder were characterised by macrophages localising towards the periphery of the xenograft tumour. This type of macrophage distribution has been documented previously and may be due to macrophage-associated fibrous capsule formation around the tumour. Whether the distribution of immune cells within human xenograft tumours could influence the FBR is unknown; however, as similar numbers of implanted and control xenograft tumours were observed to present both macrophage distribution types, the effect is likely to be minimal.

When developing the percutaneous biomaterial implantation and NT injury techniques, the risks of introducing endogenous cutaneous bacteria or endotoxins into the tumour were considered, as these factors alone could induce an immune reaction within the tumour. The potential for these issues occurring was reduced by the use of aseptic skin preparation and wire sterilisation, along with minimal anaesthesia and surgery time. As all mice remained healthy throughout the experiments, with no visible signs of inflammation occurring at the implant sites, combined with similar levels of inflammation occurring in both implanted and control tumours our results suggest that these potential confounding factors were not an issue. One previous murine study has used a similar percutaneous method to evaluate the FBR to a subcutaneously implanted nylon mesh. This study used a 16G needle as the implantation device and for the creation of a NT injury in control tumours. The advantage of our model over this study is that smaller gauge biomaterial wires and needles were used for implantation and in the creation of NT injuries; this is an important consideration in any model for investigating the FBR, as
the extent of the acute inflammatory response is related to the initial trauma caused by the insertion device\textsuperscript{169}.

The potential for each biomaterial to induce a FBR was evaluated up to 7 days post-implantation. This length of time is long enough to evaluate the acute inflammatory response and the initial phases of chronic inflammation. Full evaluation of chronic inflammation would require biomaterials to be implanted for a minimum of 3 weeks. This increased experimental time frame is difficult to achieve using murine xenograft models, as continuous tumour growth typically leads to skin ulceration causing localised inflammation and ethical concerns. However, we were able to evaluate Parylene-C up to 14 days post-implantation, providing evidence that the model can be extended for longer periods. Parylene-C was chosen for this extended evaluation as functional sensors were initially designed to be covered with a layer of this material (except for the active sensing area); Parylene-C would therefore be in direct contact with surrounding tumour tissue (subsequent modifications to sensor design finally resulted in the device been encased in biocompatible epoxy resin). Unfortunately, time and resources were not available to evaluate all biomaterials up to 14 days post-implantation. Further investigation of the FBR and biomaterial biocompatibility within a solid tumour, could involve using functional sensors implanted into naturally occurring solid tumours in immunocompetent large animal models. This would enable longer implantation periods to be achieved whilst overcoming the perceived disadvantages of using immunocompromised mice models. These experiments would provide further confidence in the intra-tumoural biocompatibility of these biomaterials.

6.5 Conclusion

This chapter has described the development of a novel \textit{in vivo} murine xenograft biocompatibility model whereby biomaterials can be safely, reliably and quickly implanted into xenograft tumours. IHC protocols were also developed that allowed biomaterial implanted tumours to be sectioned in a way as to identify the implant site. These experiments document, for the first time in the literature, the biocompatibility assessment of SiO\textsubscript{2}, Si\textsubscript{3}N\textsubscript{4}, Parylene-C, Nafion, OG116-31 resin and Pt within a human xenograft tumour. The results demonstrated that these biomaterials had no significant effects on tumour viability and did not trigger a
significant FBR. These results have provided evidence for the use of these biomaterials in the construction of medical devices for implantation within solid tumours and have justified the progression of experiments to use working IMPACT sensors in \textit{in vivo} models to investigate sensor functionality and begin to evaluate their use for clinical applications.
7 Validation of Functionality of the IMPACT Oxygen Sensor to Measure Tissue Oxygen Tension for Clinical Applications

This results chapter is an expanded version of a published research article: Gray M, Marland JRK, Dunare C, Blair EO, Meehan J, Tsiamis A, Kunkler IH, Murray A, Argyle A, Dyson A, Singer M, Potter MA. In Vivo Validation of a Miniaturised Electrochemical Oxygen Sensor for Measuring Intestinal Oxygen Tension. American Journal of Physiology - Gastrointestinal and Liver Physiology 2019; 317: 242-252. This article is open access with the authors retaining copyright to their work with permission to use published figures in this thesis. Sections of text and figures used from this article have been referenced accordingly.

7.1 Abstract

Background: An anastomotic leak is a life-threatening complication that can occur following an intestinal resection and anastomosis. Although its aetiology is complex, a leak can occur through tissue hypoxia from compromised anastomotic blood flow. This can impair intestinal healing, resulting in anastomotic dehiscence. Post-operative monitoring of anastomotic oxygenation would provide a means by which intestinal hypoperfusion could be detected allowing the provision of treatments to improve intestinal perfusion and possibly prevent anastomotic breakdown. Methods: A novel murine intestinal ischaemic and hypoxic model was developed for validation of the ability of the IMPACT O₂ sensor to provide real-time measurements of intestinal oxygenation. The sensor was placed onto the serosal surface of the small intestine of anaesthetised (non-recovery) rats that underwent ischaemic, hypoxaemic and haemorrhagic insults. Results: Sensor readings identified decreased intestinal O₂ tension following occlusion of the superior mesenteric artery and reduction in inspired O₂ concentrations. Sensor readings increased back to baseline levels after reinstating blood flow or increasing inspired O₂ concentrations. Conclusion: These results demonstrate in vivo validation of the ability of the IMPACT O₂ sensor to detect dynamic changes in intestinal O₂ tension through ischaemia and hypoxaemia and provide evidence for their use as O₂ tension monitoring devices. Sensors placed and left in situ at an anastomotic site during surgery would provide a means of
monitoring post-operative intestinal perfusion. This approach, combined with current post-operative monitoring techniques, could allow for early detection of peri-anastomotic tissue hypoxia and enable goal-directed treatments to be provided to restore intestinal oxygenation and prevent anastomotic dehiscence.

7.2 Introduction

Following biocompatibility assessment of sensor materials, in vivo functional validation of working IMPACT O₂ sensors was undertaken to assess their suitability for clinical applications. To achieve this, we developed an in vivo murine model to investigate the sensor’s potential for measuring intestinal and muscular tissue O₂ tension (ptO₂). If successful, these sensors could be developed for use in clinical situations where monitoring tissue perfusion would improve patient outcome. One situation where assessment of tissue perfusion would be advantageous is in the peri-operative management of patients undergoing intestinal surgery.

Intestinal resection and anastomosis is an abdominal procedure used in the treatment of various diseases including diverticulosis, ulcerative colitis, Crohn’s disease and cancer. Surgery involves removal (resection) of the diseased segment of intestine followed by re-joining (anastomosis) of the healthy, disease-free intestinal ends, thus restoring intestinal mural and luminal integrity. Surgery can be performed via an open or laparoscopic approach using hand placed sutures or with a stapling device. The procedure is commonly performed, with estimates from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) indicating that every year in the UK and Ireland approximately 20,000 large bowel anastomoses are performed. Regardless of the underlying disease, patient outcomes for those undergoing this procedure have improved through advances in peri-operative management, neoadjuvant and adjuvant radiotherapy and chemotherapy and through refinement of the procedure itself. However, no matter how safe the procedure is regarded to be, surgical complications can still occur.

An anastomotic leak (AL) is a life-threatening complication that occurs as a result of failure of the anastomosis to heal. Anastomotic dehiscence can result in significant increases in morbidity and 30-day mortality rates and can result in higher local colorectal cancer recurrence rates and decreased long-term survival for cancer patients. Patients that develop an AL are also at an increased risk of
developing post-operative complications such as pneumonia, multi-organ failure, renal and cardiac complications, localised or generalised sepsis, enterocutaneous fistula, wound infections and dehiscence. Revision surgery will be required in approximately 85–95% of patients who develop an AL, of which 50% will need permanent stoma formation. The additional surgery and intensive care needed for the treatment of these patients will increase hospitalisation length and overall treatment costs.

AL aetiology is complex, with both patient specific and surgical factors being involved (Table 7.1). An important factor involved in AL development is intestinal ptO₂, which is a measure of the partial pressure of O₂ within the interstitial space and is dependent on the balance between O₂ supply and utilisation. If local intestinal O₂ requirements cannot be met due to compromised tissue perfusion from anastomotic tension and disruption of the peri-anastomotic blood supply, then intestinal ischaemia and necrosis can develop.

Table 7.1. Risk factors associated with the development of an anastomotic leak.

<table>
<thead>
<tr>
<th>Patient factors</th>
<th>Surgical factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, gender</td>
<td>Cardiovascular disease</td>
</tr>
<tr>
<td>Malnutrition</td>
<td>Suboptimal anastomotic blood supply</td>
</tr>
<tr>
<td>Steroid use</td>
<td>Concurrent surgical procedures</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Poor colonic preparation</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Peri-operative blood transfusion</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>Anastomotic ischaemia or tension</td>
</tr>
<tr>
<td>Leukocytosis</td>
<td>Poor surgical technique</td>
</tr>
<tr>
<td>Diverticulitis</td>
<td>Emergency resection</td>
</tr>
</tbody>
</table>

Although AL rates can be as high as 24% for surgery performed in the distal rectum, combined rates for surgery performed at any level of the intestinal tract are approximately 6-7%. Comprehensive peri-operative patient management is crucial, especially in the early post-operative period, as septic complications following an AL will cause the majority of patients to become clinically ill at 5-8 days post-surgery. Factors that can decrease morbidity and improve patient outcome after abdominal surgery include the preservation of normovolaemia, normothermia, provision of supplemental O₂ and goal-directed fluid therapy. These factors, acting largely through improvements in local tissue perfusion and ptO₂, are all applicable to the post-operative care of intestinal resection and anastomosis patients. One major influencer of tissue perfusion is intravenous fluid therapy and although there is debate about the volume and type of peri-
operative fluids that should be administered, intravenous colloid therapy has been shown in a pig model to significantly increase colonic \( \text{pO}_2 \) and perfusion in healthy and peri-anastomotic sites\(^{660}\). These peri-operative patient management strategies may help promote anastomotic healing and possibly decrease AL rates.

If anastomotic dehiscence does occur, then early diagnosis is critical in improving patient outcomes and decreasing mortality rates\(^{653,661-663}\). A delay of 2.5 days for definitive AL treatment can increase mortality rates from 24\% to 39\%\(^{639}\) whereas every hour of delay from septic shock onset to the administration of antibiotics is associated with a 7.6\% decrease in survival\(^{664}\). Research into anastomotic healing and dehiscence has been identified as a priority by the UK NHS National Institute for Health Research, Colorectal Therapies Healthcare Technology Co-operative and the ACPGBI. Unfortunately, no methods are currently available that allow monitoring of post-operative intestinal healing and there is no consensus as to the best approach to diagnose an AL.

AL has no pathognomonic signs and therefore diagnosis cannot be based solely on clinical symptoms. Symptoms range from pyrexia, ileus and cardiorespiratory abnormalities to acute sepsis with multi-organ failure or even faeces draining from the surgical wound. Although blood tests for AL diagnosis based on raised inflammatory markers such as C-reactive protein (CRP) levels may be helpful, these tests are non-specific and can point to a wide range of post-operative complications such as urinary, chest or surgical wound infections. Using a combination of clinically measurable parameters such as temperature, leukocyte count, CRP and creatinine levels as well as systemic inflammatory response syndrome components and urine output has been shown to decrease the delay from the first symptoms of AL to its treatment from 4 to 1.5 days\(^{639}\). Current practice for AL diagnosis remains imaging-based, predominantly through contrast-enhanced CT scans. Unfortunately, this technique has variable sensitivity and specificity\(^{665}\), with false negative rates as high as 47\%\(^{666}\). These false negative results are likely from CT scans being performed prior to a leak been radiologically visible. Reluctance to perform multiple scans due to cost, logistics and radiation exposure in combination with inherent delays incurred from the time of imaging to the interpretation of results can significantly hinder prompt AL diagnosis\(^{667}\).
As a result of the deficiencies in the current methods used for AL diagnosis, there is a need for novel monitoring and diagnostic techniques to overcome this unmet clinical issue. A device capable of detecting post-operative peri-anastomotic hypoperfusion could allow early remedial intervention to be instigated to improve tissue perfusion and potentially reduce the risk of an AL from developing. Devices which allow an AL to be diagnosed quicker than current tests allow could also enable repeat surgery to be performed before local sepsis makes surgical revision impossible. The use of an implantable sensor to provide real-time information on spatial and temporal changes in intestinal ptO$_2$ would be a novel approach to meet these diagnostic needs. Although the principle aim of the IMPACT O$_2$ sensor is to monitor tissue O$_2$ levels within a solid tumour, the technology is suitable to multiple applications in which monitoring visceral surface ptO$_2$ is clinically important and would appear well suited to monitoring peri-anastomotic ptO$_2$.

This chapter describes the development and use of a murine intestinal ischaemic and hypoxic model for functional validation of the IMPACT O$_2$ sensor. Following sensor placement onto the serosal surface of a segment of small intestine, we investigated the sensor’s ability to detect changes in intestinal ptO$_2$ following occlusion of the superior mesenteric artery (SMA), manipulation of the inspired fractional oxygen concentration (FiO$_2$), creation of acute haemorrhage and after euthanasia. This is, to the best of our knowledge, the first time that this developed murine model has been used for validation of a miniaturised Clark O$_2$ sensor to measure dynamic changes in intestinal ptO$_2$ which was further evaluated though measuring muscular ptO$_2$. These results provide robust evidence for further development of the IMPACT O$_2$ sensor towards clinical applications in man.

### 7.3 Results

#### 7.3.1 Development of a model to measure intestinal tissue oxygen tension

To develop an *in vivo* model whereby sensor validation for measuring intestinal ptO$_2$ could be performed, 3 experimental groups were required. One acted as the control group designed to assess sensor longevity and drift, whereas 2 treatment groups were designed to assess the sensor’s potential for detecting changes
in intestinal ptO₂ following local (SMA occlusion) or systemic (manipulation of blood O₂ levels and circulating blood volume) insults (Figure 7.1).

All rats underwent general anaesthesia, arterial and venous cannulation and tracheostomy tube placement as described in section 3.3.2. Following a routine ventral midline celiotomy, extending from the manubrium to the pubis, a tube cystotomy was performed. A stab incision was made at the apex of the bladder which was then cannulated with 1.57 mm external diameter polythene tubing (Portex Ltd, Hythe, UK) and sutured in place with a purse string suture. Urine was collected by placing the free end of the tubing into a 1.5 ml Eppendorf tube. To gain access to the abdominal vasculature and to allow sensor placement, the small intestine and caecum were exteriorised and placed to the left-hand side abdominal wall. To reduce evaporative fluid and convective heat loss these exteriorised organs were wrapped in cling film and kept moist via regular topical applications of saline. Using a proximal section of small intestine, the IMPACT O₂ sensor was placed on the antimesenteric serosal surface at the midpoint between small serosal blood vessels (Figure 7.2). Tissue adhesive (Vetbond, 3M, Bracknell, UK) was used to temporarily attach the lead wire to the intestine ensuring close contact between the sensor’s central active sensing area and the serosal surface was achieved. Following instrumentation, a stabilisation period of at least 30 min was provided to allow stable baseline physiological variables to be achieved, after which rats were randomly divided into control or treatment groups. Continuous sensor recordings were made throughout each experiment, commencing after the initial stabilisation period and continuing for 15 min following confirmation of death post-euthanasia.
Figure 7.1. Outline of experimental protocols and interventions. **Protocol 1:** Control animals with no interventions. **Protocol 2:** SMA occlusion. **Protocol 3:** Alterations in FiO₂, haemorrhage and autotransfusion (resuscitation). Instrumentation includes anaesthesia induction, surgical preparation, arterial and venous cannulation, tracheostomy, celiotomy and tube cystotomy.

7.3.2 **Protocol 1: Control group**

The control group consisted of instrumented rats that received no physiological challenges. Continuous sensor recordings were performed for 165 min. Arterial blood samples were obtained immediately prior to the commencement of sensor recordings, every hour thereafter and then just before euthanasia.

Figure 7.2. Intra-operative photograph depicting intestinal placement of the sensor. Placement of the sensor can be seen on the serosal surface of a section of small intestine.
7.3.3 Protocol 2: Intestinal tissue responses to superior mesenteric arterial occlusion

The SMA was identified as a vessel originating from the left side of the aorta at the level of the right renal vein. The artery was isolated, close to the aortic origin, from its associated vein and surrounding soft tissues. A loose suture of 1 metric braided silk (Ethicon, UK) was placed round the artery to aid vessel manipulation and localisation. Following SMA isolation, the vessel was temporarily and reversibly occluded with the use of a haemostatic clamp (Fine Science Tools, Linton, UK). Each occlusion lasted for 5 min with a 10 min reperfusion period between occlusions. Vessel occlusion was confirmed through the development of intestinal pallor with the loss of mesenteric arterial pulsations; these changes were reversible following removal of the haemostatic clamp. The occlusion-reperfusion cycle was performed 3 times. Arterial blood samples were obtained immediately prior to the start of continuous sensor readings and just before euthanasia.

Figure 7.3. Intra-operative photographs depicting SMA isolation, occlusion and release. (a) SMA identification. (b) Haemostatic clamp placed across the SMA providing temporary mechanical occlusion. Intestinal pallor was immediately evident upon vessel occlusion. (c) Following removal of the haemostatic clamp and re-instatement of blood flow, a hyperaemic intestinal flush was evident.

7.3.4 Protocol 3: Intestinal tissue responses to alterations in inspired oxygen concentrations, progressive haemorrhage and autotransfusion

Alterations in FiO₂ (1.0, 0.21, 0.1) were performed at 15 min intervals with each different O₂ concentration delivered through a flowmeter via the isoflurane vaporiser. The cycle of FiO₂ alterations was: 0.21 for 15 min (baseline), 0.1 for 15 min (inducing hypoxaemia), 0.21 for 15 min, 1.0 for 15 min (inducing
hyperoxaemia) before finally returning to 0.21 for 15 min. Arterial blood samples were taken at the end of each FiO₂ change.

Following completion of FiO₂ alterations, progressive haemorrhage was achieved by removing 15% of the circulating blood volume (estimated as 70 ml/kg) over a period of 5 min. Following a 10 min stabilisation period a further 15% was removed. The exsanguinated blood was collected into a heparinised syringe and maintained at 37°C. Ten min after completion of the second haemorrhage procedure autotransfusion was performed by administering the blood intravenously back to the rat over 10 min. Arterial blood samples were taken at the end of each haemorrhage procedure and just before euthanasia.

7.3.5 Current generated by the sensor remained stable in control rats

To assess the physiological stability of rats throughout the duration of anaesthesia that encompassed the longest experimental protocol, data from blood-gas, biochemical and haematological analysis was combined with variables such as heart rate (HR), respiratory rate (RR), core temperature (CT) and mean arterial blood pressure (MAP). All physiological parameters, blood-gas analysis and electrolytes remained stable throughout anaesthesia. Although blood glucose levels began to decrease towards the end of the procedure this was not statistically significant ($p=0.9304$) and was consistent with the fasting state and metabolic demands of the rat during anaesthesia (Figure 7.4a).

To assess stability of sensor measurements over a time period that encompassed the longest experimental protocol, continuous sensor recordings were performed in rats which were not subjected to physiological interventions. Results showed that currents generated in the O₂ sensors were extremely stable over 165 min, with mean currents ranging from $-1.14 \pm 0.03$ nA at 15 min to $-1.44 \pm 0.15$ nA at 135 min. Although a trend towards increasing currents over time was observed, this was not statistically significant ($p=0.7244$) (Figure 7.4b).
Figure 7.4. Sensor currents and physiological data remain stable in control rats. (a) Physiological data (Hb, haemoglobin; ABE, arterial base excess; SaO₂, haemoglobin O₂ saturation; PaO₂, arterial O₂ partial pressure; PaCO₂, arterial CO₂ partial pressure; CT, core temperature; RR, respiratory rate; HR, heart rate) (data expressed as mean ± SEM, n=3). (b) Current generated at the working electrode of the sensor during continuous sensor readings over a period of 165 min; results show mean current recordings from the final 5 min of each 15 min period (one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=3, p = 0.7244).

7.3.6 Current generated by the sensor rapidly decreased following occlusion of the superior mesenteric artery which was reversible upon reinstatement of blood flow

To assess the ability of the sensors to detect changes in intestinal ptO₂ through the generation of temporary and reversible intestinal ischaemia, we performed 3 cycles of SMA occlusion and release. Results showed an almost instantaneous decrease in sensor current after each occlusion, reducing from non-occluded recordings of -1.85 ± 0.05 nA to occluded recordings of -0.27 ± 0.08 nA.
(mean current ± SEM) (Figure 7.5a). Changes between the pre- and post-occlusion current measurements for each of the cycles were statistically significant ($p=0.0082$). Current reductions were maintained throughout the majority of each occlusion which quickly rose back to non-occluded current values following removal of the haemostatic clamp and re-instigation of blood flow (Figure 7.5b and Table 7.2). Following euthanasia, sensor recordings fell to the lowest recorded current measuring 0.04 ± 0.16 nA, which was statistically significant when compared to non-occluded currents ($p=0.0025$).

**Figure 7.5. Sensor currents rapidly decrease following superior mesenteric artery occlusion.** (a) Representative graph showing current generated at the working electrode of the sensor during continuous sensor recordings over a period of 70 min. Three cycles of 5 min occlusion followed by 10 min of reperfusion were performed in each animal before euthanasia. (b) Combined analysis comparing current generated at the working electrode of the sensor during periods of SMA occlusion and intestinal reperfusion; results show mean current recordings from the final 5 min of each occlusion and reperfusion period (one-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=4, **$p$$\leq$0.01).
Table 7.2. Current recordings during each SMA occlusion/reperfusion and euthanasia. (n=4; mean ± SEM).

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Occlusion (1)</th>
<th>Reperfusion (1)</th>
<th>Occlusion (2)</th>
<th>Reperfusion (2)</th>
<th>Occlusion (3)</th>
<th>Reperfusion (3)</th>
<th>Euthanasia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current</td>
<td>-1.98 ± 0.47</td>
<td>-0.12 ± 0.25</td>
<td>-1.73 ± 0.40</td>
<td>-0.41 ± 0.24</td>
<td>-1.85 ± 0.36</td>
<td>-0.28 ± 0.27</td>
<td>-1.84 ± 0.32</td>
<td>0.04 ± 0.16</td>
</tr>
</tbody>
</table>

7.3.7 Current generated by the sensor responded rapidly to alterations in inspired oxygen concentrations

To assess the ability of the sensors to detect changes in intestinal ptO₂ through changes in blood oxygenation we performed sequential alterations in FiO₂ ranging from 0.1-1.0 (Figure 7.6a). Baseline current recordings were first obtained using FiO₂ of 0.21. The mean sensor current during this baseline period was -1.35 ± 0.18 nA. Following a FiO₂ reduction to 0.1, sensor recordings decreased by more than 50%, to -0.60 ± 0.10 nA. This current reduction occurred over a period of 1-2 min, which was maintained throughout the hypoxaemic challenge and was statistically significant when compared to current recordings obtained during baseline measurements (p= 0.0396). Reversal of FiO₂ from 0.1 to 0.21 resulted in an increase in sensor current recordings back to baseline values. Upon increasing FiO₂ to 1.0 sensor currents rapidly increased to -6.53 ± 0.46 nA, which was statistically significant when compared to baseline currents (p< 0.0001). This increase in current was maintained throughout the hyperoxaemic challenge. A final reduction in FiO₂ back to 0.21 resulted in sensor currents returning to baseline levels. Following euthanasia, sensor recordings fell to the lowest recorded current measuring -0.08 ± 0.17 nA, which was statistically significant when compared to baseline currents (p= 0.0006) (Figure 7.6b and Table 7.3). At the end of each FiO₂ alteration arterial blood-gas analysis confirmed the expected physiological changes induced by each challenge. Haemoglobin O₂ saturation (SaO₂) and arterial O₂ partial pressure (PaO₂) both decreased at 0.1, increased at 1.0 (more prominent with PaO₂), and returned to baseline levels at 0.21. Expectedly, total haemoglobin (Hb) concentration remained the same throughout each challenge (Figure 7.6c & d).
Figure 7.6. Sensor currents change in accordance with alterations in FiO₂. (a) Representative graph showing current generated at the working electrode of the sensor during continuous sensor recordings over a period of 150 min. Each FiO₂ challenge was performed in 15 min blocks before removal of 30% of the circulating blood volume. (b) Combined analysis comparing current generated at the working electrode of the sensor during each FiO₂ challenge; results show mean current recordings from the final 5 min of each 15 min period (one-way ANOVA with Holm-Sidak multiple comparisons test; data expressed as mean ± SEM, n=5, ****p<0.0001; ***p<0.001; *p<0.05). (c&d) Arterial O₂ partial pressure, total haemoglobin and haemoglobin O₂ saturation measured at the end of each FiO₂ challenge.

Table 7.3. Current recordings during each FiO₂ challenge and euthanasia. (n=5; mean ± SEM).

<table>
<thead>
<tr>
<th>FiO₂</th>
<th>21% (1)</th>
<th>10%</th>
<th>21% (2)</th>
<th>100%</th>
<th>21% (3)</th>
<th>Euthanasia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current (nA)</td>
<td>-1.35 ± 0.18</td>
<td>-0.60 ± 0.10</td>
<td>-1.37 ± 0.12</td>
<td>-6.53 ± 0.46</td>
<td>-1.55 ± 0.20</td>
<td>-0.08 ± 0.17</td>
</tr>
</tbody>
</table>

7.3.8 Current generated by the sensor remained stable following haemorrhage

Following completion of FiO₂ challenges, the ability of the sensors to detect changes in intestinal PtO₂ through acute haemorrhage was assessed by performing...
progressive removal of 30% of the circulating blood volume (performed in 2 x 15% removal periods) (Figure 7.7a). Physiological data and arterial blood-gas analysis obtained 10 min after the end of each haemorrhage procedure confirmed the expected physiological changes induced by acute haemorrhage. Hb concentration, HR and MAP all showed moderate decreases following 15% haemorrhage which became more pronounced after 30% haemorrhage. Baseline values compared to those following 30% haemorrhage showed that Hb concentration decreased from 13.3 ± 0.6 g/dl to 11.4 ± 0.4 g/dl, HR decreased from 405 ± 22 bpm to 348 ± 16 bpm and MAP decreased from 118 ± 12 mmHg to 56 ± 3 mmHg. All these parameters returned to baseline levels following autotransfusion (Figure 7.7b & c). SaO₂ levels remained constant throughout each haemorrhage procedure.

Although physiological responses to acute haemorrhage were induced, only small decreases in sensor current measurements were observed, which were not statistically significant compared with baseline recordings. Baseline measurements at FiO₂ of 0.21 were -1.55 ± 0.20 nA; however, following 15% and 30% haemorrhage currents only decreased to -1.39 ± 0.13 nA and -1.33 ± 0.13 nA respectively. Following autotransfusion, sensor currents failed to increase back to baseline levels, measuring -1.22 ± 0.14 nA at the end of the transfusion (Table 7.4).
Figure 7.7. Sensor currents remain stable following progressive haemorrhage and autotransfusion. (a) Combined analysis comparing current generated at the working electrode of the sensor during the preceding 15 min baseline period at FiO₂ of 0.21 and 2 subsequent cycles of removal of 15% circulating blood volume followed by autotransfusion; results show mean current recordings from the final 5 min of each period (one-way ANOVA with Holm-Šidák multiple comparisons test; data expressed as mean ± SEM, n=5, ****p≤0.0001). (b&c) Mean arterial blood pressure, heart rate, total haemoglobin and haemoglobin O₂ saturation measured at the end of each of intervention period.

Table 7.4. Current recordings during each haemorrhage procedure and euthanasia. Baseline recordings were made at FiO₂ of 0.21 (n=5; mean ± SEM).

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>15% haemorrhage</th>
<th>30% haemorrhage</th>
<th>Autotransfusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current (nA)</td>
<td>-1.55 ± 0.20</td>
<td>-1.39 ± 0.13</td>
<td>-1.33 ± 0.13</td>
<td>-1.22 ± 0.14</td>
</tr>
</tbody>
</table>

7.3.9 Development of a model to measure muscular tissue oxygen tension

To develop an in vivo model whereby sensor validation for measuring muscular ptO₂ could be performed, 1 experimental group was required. The
treatment group was designed to assess the sensor’s potential for detecting changes in muscular pO2 following systemic insults (manipulation of blood O2 levels).

All rats underwent general anaesthesia, routine arterial and venous cannulation and tracheostomy tube placement as described in section 3.3.2. An incision was made through the skin and subcutaneous tissues of the lateral aspect of the thigh, mid-way between the patella and greater trochanter of the femur. The vastus lateralis was identified and fascia covering a small area of the muscle was removed. The IMPACT O2 sensor was placed onto these muscular fibres and the lead wire temporarily attached to the surface of the biceps femoris using tissue adhesive (Figure 7.8), ensuring close contact between the sensor’s central active sensing area and the muscular surface was achieved. To reduce evaporative fluid and convective heat loss exposed muscular tissues were covered in cling film and kept moist via regular topical applications of saline. Following instrumentation, a stabilisation period of at least 30 min was provided to allow stable baseline physiological variables to be achieved. Continuous sensor recordings were made throughout each experiment, commencing after the initial stabilisation period and continuing for 15 min following confirmation of death post-euthanasia.

Figure 7.8. Intra-operative photographs depicting muscular placement of the IMPACT sensor. (a-c) A cranial-to-caudal skin incision was made mid-way between the patella and the greater trochanter of the femur. The vastus lateralis (cranial) and biceps femoris (caudal) muscles were identified. (d) Fascia was removed from the vastus lateralis exposing the underlying muscular fibres. (e) Placement of the sensor on the muscular surface of the vastus lateralis.
7.3.10 Muscular tissue responses to alterations in inspired oxygen concentrations

Alterations in FiO\textsubscript{2} (1.0, 0.21, 0.1) were performed at 15 min intervals with each different O\textsubscript{2} concentration delivered through a flowmeter via the isoflurane vaporiser. The cycle of FiO\textsubscript{2} alterations was: 0.21 for 15 min (baseline), 0.1 for 15 min (inducing hypoxaemia), 0.21 for 15 min, 1.0 for 15 min (inducing hyperoxaemia) before finally returning to 0.21 for 15 min. Arterial blood samples were taken at the end of each FiO\textsubscript{2} challenge.

7.3.11 Current generated by the sensor responded to alterations in inspired oxygen concentrations

To assess the ability of the sensors to detect changes in muscular ptO\textsubscript{2} through changes in blood oxygenation, we performed sequential alterations in FiO\textsubscript{2} ranging from 0.1-1.0 (Figure 7.9a). Baseline current recordings were first obtained using FiO\textsubscript{2} of 0.21. The mean sensor current during this baseline period was -1.46 ± 0.25 nA. Following a FiO\textsubscript{2} reduction to 0.1, sensor current recordings decreased to -1.06 ± 0.18 nA. This current reduction occurred over a period of 5 min but was not statistically significant when compared to current recordings obtained during baseline measurements (p = 0.934). Reversal of FiO\textsubscript{2} from 0.1 to 0.21 resulted in an increase in sensor current recordings back to baseline values, again occurring over a period of 5 min. Upon increasing FiO\textsubscript{2} to 1.0, sensor currents rapidly increased to -3.47 ± 0.71 nA, which was statistically significant when compared to current recordings obtained during baseline measurements (p = 0.0282) and at FiO\textsubscript{2} of 0.1 (p = 0.0075). This increase in current was maintained throughout the hyperoxaemic challenge. A final reduction in FiO\textsubscript{2} back to 0.21 resulted in sensor currents returning to baseline levels of -1.74 ± 0.36 nA, which was statistically significant when compared to current recordings obtained at FiO\textsubscript{2} of 1.0 (p = 0.0393) (Figure 7.9b and Table 7.5). At the end of each FiO\textsubscript{2} alteration, arterial blood-gas analysis confirmed the expected physiological changes induced by each challenge. SaO\textsubscript{2} and PaO\textsubscript{2} both decreased at FiO\textsubscript{2} of 0.1, increased at 1.0 (more prominent with PaO\textsubscript{2}) and returned to baseline levels at 0.21. Expectedly, Hb concentration remained the same throughout each challenge (Figure 7.9c & d).
Figure 7.9. Sensor currents change in accordance with alterations in FiO₂. (a) Representative graph showing current generated at the working electrode of the sensor during continuous sensor recordings over a period of 80 min. A 20 min baseline recording at FiO₂ of 0.21 was performed prior to 15 min blocks of each FiO₂ challenge. (b) Combined analysis comparing current generated at the working electrode of the sensor during each FiO₂ challenge; results show mean current recordings from the final 5 min of each 15 min period (one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=4, **p≤0.01; *p≤0.05). (c&d) Arterial O₂ partial pressure, total haemoglobin and haemoglobin O₂ saturation measured at the end of each FiO₂ challenge.

Table 7.5. Current recordings during each FiO₂ challenge. (n=4; mean ± SEM).

<table>
<thead>
<tr>
<th>FiO₂</th>
<th>21% (1)</th>
<th>10%</th>
<th>21% (2)</th>
<th>100%</th>
<th>21% (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current (nA)</td>
<td>-1.46 ± 0.25</td>
<td>-1.06 ± 0.18</td>
<td>-1.59 ± 0.29</td>
<td>-3.47 ± 0.71</td>
<td>-1.74 ± 0.36</td>
</tr>
</tbody>
</table>

7.4 Discussion

An AL is a serious complication that can occur following intestinal resection and anastomosis. The condition is life-threatening and can have long-term life
changing consequences. Unfortunately, there is no ‘perfect’ post-operative diagnostic test for an AL or a device that can monitor anastomotic healing. Although AL aetiology is complex, it has been associated with peri-anastomotic tension and interruption of microvasculature blood flow. This situation can cause peri-anastomotic necrosis and poor intestinal healing through compromised tissue perfusion and decreased \( \text{ptO}_2 \). In accordance with this, our experiments focused on validating the ability of the IMPACT \( \text{O}_2 \) sensor to measure intestinal \( \text{ptO}_2 \) which could be developed as a means of assessing anastomotic healing.

Various intra-operative techniques are available to assess intestinal tissue perfusion (visible light and near infrared spectroscopy and laser fluorescence angiography)\(^{669,670}\) and \( \text{O}_2 \) tension (laser Doppler flowmetry and wireless hand held pulse oximeters)\(^{668,671}\), which have been shown to predict leak occurrence. An ongoing clinical trial is also currently assessing the potential benefits of measuring intra-operative anastomotic perfusion, using intravenous indocyanine green with near-infrared laparoscopy, to minimise leak occurrence compared with conventional white-light laparoscopy\(^{672}\). Unfortunately, these techniques are only applicable to intra-operative use and as yet have failed to gain interest with clinicians. Currently, surgeons typically rely on subjective macroscopic tissue appraisal to assess intra-operative intestinal perfusion. Adequate perfusion is deemed present if the intestine has a healthy pink colouration with the presence of intestinal bleeding and palpable mesenteric pulses. Unfortunately, these subjective techniques are only applicable to intra-operative use and are unable to predict the risk of a leak occurring\(^{635}\).

Clark \( \text{O}_2 \) electrodes have been previously investigated as a means of measuring intra-operative intestinal \( \text{ptO}_2 \) using pre-clinical rabbit and dog intestinal devascularisation models\(^{673,674}\). These studies created gradual reductions in intestinal perfusion through the sequential ligation of a marginal intestinal artery and demonstrated that intestinal serosal \( \text{ptO}_2 \) measured immediately before performing an anastomosis could predict leak occurrence. In humans, Clark \( \text{O}_2 \) electrodes have been used intra-operatively to provide \( \text{ptO}_2 \) reference ranges for the majority of the gastrointestinal tract (stomach, ileum, caecum and colon)\(^{675}\) and have been investigated in clinical trials for their ability to predict AL occurrence\(^{676}\). This clinical study measured peri-anastomotic colonic \( \text{ptO}_2 \) before, during and
immediately after performing a resection and anastomosis. The results demonstrated that colonic ptO$_2$ of less than either 20 mmHg, 50% of the pre-resection values, 15% of the PaO$_2$ or 40% of the ptO$_2$ at a control site were all associated with a post-operative AL. Adequate ptO$_2$ is required for collagen production, with levels lower than 15-20 mmHg associated with impaired synthesis. As submucosal collagen is the major holding layer for sutures/staples in the early stages of anastomotic healing, inadequate collagen synthesis due to low ptO$_2$ could lead to AL occurrence$^{676}$.

Although, these pre-clinical and clinical studies have provided evidence that Clark O$_2$ electrodes can be used intra-operatively to measure intestinal ptO$_2$ and predict AL occurrence, they fail to consider their potential post-operative use. The use of novel techniques such as an implantable device that can continuously measure intra- and post-operative peri-anastomotic ptO$_2$ would not only improve a surgeon’s intra-operative ability to identify sites at increased risk of dehiscence$^{670}$, but also provide a means for monitoring post-operative anastomotic healing. This concept would be an ideal clinical application for the IMPACT O$_2$ sensor.

For in vivo functional validation and proof-of-concept that the IMPACT O$_2$ sensor could measure changes in intestinal ptO$_2$, a rat model was developed. Physiological challenges through either manipulation of intestinal blood flow (through SMA occlusion) to induce ischaemia, alterations in blood oxygenation status (through changes in FiO$_2$) to cause hypoxaemia and hyperoxaemia and finally creation of a state of acute haemorrhage were developed for use in the model. We suspected that these physiological challenges would cause a change in intestinal ptO$_2$ that could be detected by the IMPACT O$_2$ sensor.

Control experiments were first performed to investigate whether the rats could remain physiologically stable for the duration of the longest experimental protocols. Through monitoring physiological variables and evaluating arterial blood-gas, biochemical and haematological data, results demonstrated that the rats could cope with the physiological demands from general anaesthesia for the duration of our experimental protocols; this was in accordance with a previous study$^{677}$. Using the same control group of rats, sensor recordings were performed to evaluate stability of the currents generated by the sensors and investigate any detrimental effects that the tissue environment and anaesthetic gases might have on sensor functionality. These
considerations are important, as halothane anaesthesia has been shown to affect Clark electrode function\textsuperscript{678,679}. Our results demonstrated, for the first time in the literature, continuous \textit{in vivo} recordings made using a miniaturised Clark-type electrochemical \textit{O}_2 sensor for 165 min. No statistically significant changes in measured current were recorded during this period, suggesting that the tissue environment or anaesthetic gases had no effect on sensor function. This result was important in providing confidence that current changes observed in the experimental protocols were due to alterations in intestinal pt\textit{O}_2 caused by the physiological challenges rather than from sensor drift/inaccuracy. Potential effects of anaesthetic agents and tissue metabolites on the functionality of the IMPACT \textit{O}_2 sensor are likely to have been minimised/prevented through its design and packaging, predominantly using Nafion as the outer protective coating of the active sensing area. Pore size within Nafion membranes is small enough to exclude proteins that may contaminate the electrode surface, while the presence of charged sulphonate groups causes the electrostatic exclusion of small anions\textsuperscript{680}.

In all control and experimental groups, intestinal pt\textit{O}_2 measurements were performed by positioning the sensors on the serosal surface of the small intestine and securing them in place with tissue adhesive. This technique ensured direct contact of the active sensing area with the intestinal serosal surface without the use of excessive pressure which could affect local microvascular blood supply, leading to alterations in pt\textit{O}_2\textsuperscript{675}. The size of the central active sensing area is also an important factor when considering the use of Clark \textit{O}_2 electrodes for clinical applications, as large sensing areas have the potential to reduce tissue \textit{O}_2 levels in the process of generating measurable currents. As the sensing area of the IMPACT \textit{O}_2 sensor is only 50 \textmu m in diameter, its potential for depleting tissue \textit{O}_2 levels will be minimal. In clinical situations the small sensor size also would allow surgeons to place single or multiple sensors accurately on specific tissue areas. Placement of multiple miniaturised sensors in the case of anastomotic surgery would be particularly advantageous as they could be placed on either side and around the circumference of the anastomosis enabling detailed peri-anastomotic pt\textit{O}_2 information to be obtained. This could not be achieved with a single sensor with a large sensing area that can only provide mean pt\textit{O}_2 readings from multiple capillary beds\textsuperscript{635}. 

235
Initial physiological challenges to validate sensor functionality were performed through intestinal blood flow manipulation to induce ischaemia. To do this, a SMA occlusion and reperfusion technique was developed. The SMA, a direct branch of the aorta, is the principle blood supply to the majority of the gastrointestinal tract, extending from the distal duodenum to the proximal two-thirds of the transverse colon. SMA identification is straightforward due to defined anatomical landmarks; with the small intestine and caecum exteriorised to the left-hand side of the abdomen the artery can be seen originating from the ventral aspect of the aorta at the level of the right renal vein. SMA identification was confirmed by observing small intestinal pallor immediately following vessel occlusion and a hyperaemic flush following vessel release.

SMA occlusion is the most direct way of causing intestinal ischaemia with significant histological changes occurring in the small intestine within 40 min of occlusion\textsuperscript{681}. Previous studies have used various SMA occlusion techniques to study ischaemia-reperfusion injuries\textsuperscript{682,683}, cytokine production and bacteria/endotoxin translocation\textsuperscript{684}; however, to our knowledge, this is the first report of the model being used for the validation of a miniaturised Clark O\textsubscript{2} sensor to measure intestinal ptO\textsubscript{2}. Our technique of temporary SMA ligation as close to its aortic origin as possible ensured no collateral blood supply to the small intestine could occur from SMA subsidiary branches (inferior pancreaticoduodenal, intestinal, ileocolic, right and middle colic). Our results demonstrated that sensor currents fell to almost 0 nA within 1-2 min of SMA occlusion, indicating a severely hypoxic state as a result of tissue utilisation of the residual available O\textsubscript{2}. Upon removal of the SMA occlusion, a rapid increase in sensor current was observed indicating a return of normal intestinal oxygenation as a direct consequence of intestinal reperfusion and flooding of the intestinal capillary beds with oxygenated blood. These results showed that the IMPACT O\textsubscript{2} sensor could quickly, reliably and reproducibly detect changes in intestinal ptO\textsubscript{2} through ischaemic and reperfusion challenges induced by SMA occlusion and release.

Further sensor validation was performed by manipulating intestinal ptO\textsubscript{2} through alterations in blood oxygenation levels, achieved through FiO\textsubscript{2} challenges. Arterial blood-gas analysis was used to confirm the expected physiological responses
to these FiO₂ alterations. Hypoxia caused reductions in both PaO₂ and SaO₂, whereas hyperoxia caused their levels to increase. Changes in sensor currents occurring with FiO₂ challenges matched the same pattern of results obtained using arterial blood-gas analysis with statistically lower and higher currents generated in hypoxaemic and hyperoxaemic conditions respectively. Time taken for sensor currents to change following a FiO₂ alteration was similar to that seen using the SMA model, with typical response times of 1-2 min. These results showed that the sensor could quickly, reliably and reproducibly detect changes in intestinal pO₂ through hypoxaemic and hyperoxaemic challenges caused by changes in blood oxygenation.

Although significant changes in intestinal pO₂ were detected through both ischaemic, hypoxaemic and hyperoxaemic challenges, similar results were not demonstrated with acute haemorrhage. Physiological parameters were used to confirm the expected responses caused by acute haemorrhage, which showed significant reductions in HR and MAP following acute removal of 30% of the circulating blood volume. This response is consistent with increased vagal activity and reduced sympathetic input (Bezold–Jarish-like reflex) resulting in a decrease in total peripheral resistance. HR typically only increases during continued and severe circulating blood volume loss in an attempt to maintain tissue perfusion and represents a transition from reversible to irreversible shock⁶⁸⁵. Arterial blood-gas analysis at the end of 30% haemorrhage did identify a slight decrease in Hb concentration. However, SaO₂ levels remained consistent due to the haemorrhage procedures being performed with a FiO₂ of 0.21. It is likely that in our induced model of acute haemorrhage that decreased peripheral resistance combined with stable SaO₂ could have maintained intestinal pO₂ at normal levels, which is why no changes in sensor current measurements were observed⁶³⁵.

Although the main aim of these experiments was to investigate the use of the IMPACT O₂ sensor for measuring intestinal pO₂, we also investigated its potential for measuring pO₂ in other tissues. Using our developed FiO₂ model we assessed changes in muscular pO₂ to hypoxaemic and hyperoxaemic challenges. The results showed changes similar to those documented in the intestinal experiments and provided evidence that the sensor may be used for measuring pO₂ in various tissues.
One significant advantage of our developed in vivo model over previous studies using Clark O2 electrodes is that it allowed not only the assessment of whether the IMPACT sensor could detect changes in intestinal and muscular ptO2 following the initial physiological challenge, but also whether sensor readings would return to baseline levels upon challenge removal. Previous studies have only reported on Clark O2 electrodes being used for making individual intestinal ptO2 measurements at specific time points; the continuous recording of data performed in our experiments provided an opportunity to dynamically measure changes in ptO2 before, during and after each challenge. Our results clearly demonstrated that currents measured by the IMPACT O2 sensor returned to baseline levels following repeated temporary ischaemic insults and reversible changes in FiO2. The ability to dynamically measure changes in intestinal ptO2 could have a significant impact on the peri-operative management of patients undergoing intestinal resection and anastomosis. Miniaturised Clark O2 sensors placed around the anastomotic site and left in situ following surgery could provide post-operative, minimally-invasive, rapid and highly localised continuous real-time data regarding transitory changes in peri-anastomotic intestinal ptO2. This method of monitoring ptO2 could detect early peri-anastomotic tissue hypoxia and identify patients that may benefit from treatments aimed at improving local ptO2 to prevent a leak, or failing that, diagnose a leak earlier than current diagnostic methods allow. The sensor’s ability to detect dynamic intestinal ptO2 changes could also be used to assess treatment responses and, when combined with information gained from conventional monitoring systems, would provide a more accurate assessment of the patient’s condition.

7.5 Conclusion

This chapter has described the development of a novel in vivo murine ischaemic, hypoxic and haemorrhagic model in which acute and reversible changes in intestinal and muscular ptO2 were produced. The results demonstrated that the IMPACT O2 sensor can accurately detect dynamic changes in intestinal ptO2 through ischaemic insults, alterations in FiO2 and euthanasia, with similar results also identified in muscular tissues in response to alterations in FiO2. These results have provided initial functional in vivo validation of the IMPACT O2 sensor and is the
first step in the process of evaluating its potential to be used as an advanced pO$_2$ monitoring device. Justification for progressing sensor validation experiments into more complex large animal tumour models has also been successfully achieved.
8 Development of a Pre-Clinical Ovine Pulmonary Adenocarcinoma Model for Human Lung Cancer and Validation of Intra-Tumoural Functionality of the IMPACT Oxygen Sensor

This results chapter is an expanded version of a published research article: Gray M, Sullivan P, Marland JRK, Greenhalgh SN, Meehan J, Gregson R, Clutton RE, Cousens C, Griffiths D, Murray A, Argyle D. A Novel Translational Ovine Pulmonary Adenocarcinoma Model for Human Lung Cancer. Frontiers in Oncology - Molecular and Cellular Oncology 2019; 9(534): 1-17. This article is open access with the authors retaining copyright to their work with permission to use published figures in this thesis. Sections of text and figures used from this article have been referenced accordingly.

8.1 Abstract

Background: Large animal models that accurately reflect human disease are regarded as excellent translational models which can be used in pre-clinical research. Ovine pulmonary adenocarcinoma (OPA) is a naturally occurring lung cancer that has a similar histological classification and oncogenic pathway activation with that of human lung adenocarcinomas; similarities such as these make it a valuable model for studying human lung cancer. Methods: A novel OPA model was developed for validation of the ability of the IMPACT O₂ sensor to provide real-time measurements of intra-tumoural O₂ tension. Sensors were implanted into OPA tumours of anaesthetised (non-recovery) sheep using a CT-guided trans-thoracic percutaneous implantation procedure. Results: Nine sheep underwent single or double sensor implantations. For single sensor implantations the time taken from initial CT scans to sensor placement was 45 ± 5 min. All implantations resulted in successful sensor delivery into OPA tumours. Post-implantation pneumothorax occurred in 4 sheep. Sensor recordings identified decreased intra-tumoural O₂ tension following a reduction in inspired O₂ concentrations, although these changes were not statistically significant. Conclusion: These results demonstrate the in vivo validation of the ability of the IMPACT O₂ sensor to detect dynamic changes in intra-tumoural O₂ tension caused by hypoxaemia. Through the integration of techniques used in the
treatment of human lung cancer patients, including ultrasound, general anaesthesia, CT and surgery into the OPA model, we have shown its translational potential. We believe this model can be used for a variety of other pre-clinical applications.

8.2 Introduction

Following initial validation of the ability of the IMPACT O_{2} sensor to detect changes in intestinal and muscular ptO_{2} in healthy tissues, our aim was to investigate its potential for measuring ptO_{2} within a solid tumour. To achieve this, we developed a novel translational large animal ovine model whereby sensors were implanted into naturally occurring OPA tumours. If successful, the aim would be to develop the sensors for use in clinical situations where a patient’s cancer treatment could be influenced by the assessment of intra-tumoural ptO_{2}. Although applicable to many solid tumours, one situation where assessment of intra-tumoural O_{2} levels could be advantageous is in the treatment of lung cancer.

Lung cancer is the most commonly diagnosed cancer in the world, with approximately 2 million new cases and 1.8 million cancer-related deaths occurring per year\(^6\). Historically lung cancer research has largely relied on \textit{in vivo} mouse models. Although these models have increased our molecular understanding of the disease, they have failed to lead to breakthrough advancements in lung cancer treatment. If progress is to be made in improving lung cancer prognosis, then the limitations with current \textit{in vivo} models must be addressed. One solution would be to use complex models that more accurately represent the disease\(^293\). Similarities in clinical presentation, activated signalling pathways and histological classification between OPA and human lung adenocarcinomas, combined with the availability of several \textit{in vitro} and \textit{in vivo} OPA model systems, has led to the disease being regarded as a valuable translational model for studying human lung cancer\(^309\).

\textit{In vitro} OPA models typically use either immortalised cell lines or primary cultures from OPA tumours\(^331,686,687\). Unfortunately, the lack of an \textit{in vitro} cell line that can support JSRV replication when cells are grown in 2D systems has limited the amount of research that has been performed in this manner. To overcome this limitation, \textit{in vitro} JSRV expression has been shown to be possible by culturing cells using 3D systems\(^686,688\) or by using OPA lung tissue explants\(^689,690\). These 3D model systems may more accurately recreate the oncogenic events that occur in OPA and
represent transitional models between \textit{in vitro} and \textit{in vivo} systems\textsuperscript{273}. \textit{In vivo} small animal OPA models have been developed using immunodeficient\textsuperscript{327} and immunocompetent mice\textsuperscript{691}. These studies show that intra-nasal administration of adeno-associated virus vectors encoding JSRV Env leads to the formation of lung adenocarcinomas that are comparable to those found in sheep and humans. Although these small animal systems are more widely available than large animal models and do not require specialised animal facilities, they suffer from the same limitations as other \textit{in vitro} cancer mouse models, as described in section 1.9.

To improve complexity and translational ability of OPA models there are 2 \textit{in vivo} ovine models available which use either experimentally induced tumours or naturally occurring disease\textsuperscript{273}. The first documented \textit{in vivo} OPA model demonstrated that the formation of lung tumours in healthy sheep could be induced following intra-tracheal injections of either OPA tumour homogenates or JSRV purified from lung fluid\textsuperscript{692,693}. Later studies using neonatal lambs improved infection rates and decreased the time required for tumours to develop\textsuperscript{351,694}. These improved results are likely due to JSRV preferentially infecting dividing cells, which are more common in younger animals\textsuperscript{695}. This model has been constantly refined, most recently through sequencing and cloning of the JSRV genome\textsuperscript{322,696} and through the generation of an oncogenic and infectious molecular clone. This has enabled \textit{in vitro} virus production to be achieved through the transfection of cell lines\textsuperscript{697}, which can be used to infect neonatal lambs. The main advantage of using the \textit{in vivo} lamb model is that it provides the opportunity for studying tumourigenesis and early stage disease. This is an important area of research in human lung cancer as clinical tissue from early cases is generally unavailable. However, while this model is useful for studying tumourigenesis and pathogenesis from infection to the formation of small tumours, for welfare reasons the disease cannot be allowed to reach advanced stages. The use of naturally occurring OPA cases provides the opportunity for studying advanced disease and overcomes the ethical concerns associated with the lamb model.

As OPA is endemic in the UK, this disease population represents a valuable translational research opportunity for assessing human lung cancer treatment strategies. Unfortunately, the lack of reliable ante-mortem, pre-clinical OPA diagnostic tests has limited the use of these naturally occurring cases for research.
Pre-clinical OPA diagnosis is difficult as clinical signs are often lacking. Although JSRV can be detected in blood, bronchoalveolar and lung fluid samples through PCR, these tests can suffer from poor sensitivity and are not easily applicable to routine large-scale on-farm testing. To overcome these issues, imaging techniques such as radiography, CT and now ultrasound are being investigated for use in pre-clinical OPA diagnosis. In human thoracic medicine, CT is the imaging modality of choice that allows detailed evaluation of lung tissue which can identify smaller lesions compared to conventional radiography. Its use in OPA models has been demonstrated for monitoring the development and progression of tumours in both naturally occurring and experimentally infected animals. Unfortunately, radiography and CT are cost prohibitive for commercial flocks and require specialised equipment and sedation/general anaesthesia.

Trans-thoracic ultrasonography has been proposed as a useful OPA diagnostic technique. One study performed trans-thoracic ultrasound examinations on 100 sheep as part of a series of diagnostic tests for the investigation of weight loss. Based on ultrasound examination alone, 41 sheep were diagnosed as OPA positive, with all cases having the diagnosis confirmed at post-mortem. All remaining sheep had no ultrasonographic changes characteristic of OPA and were diagnosed as OPA negative at post-mortem. These results demonstrated that diagnostic ultrasound was highly specific, producing no false positive or negative results. Trans-thoracic ultrasound can be performed in a sheep in less than 1 minute and can differentiate chronic lung lesions and detect OPA lesions as small as 1-2 cm. As trans-thoracic ultrasound can be performed quickly and in conscious animals the procedure lends itself to routine large-scale on-farm OPA diagnosis programmes. It is also an ideal method for identifying pre-clinical cases for experimental use as individual cases can be selected based on size and location of OPA lesions. These are the reasons why trans-thoracic ultrasound was chosen to select OPA cases for use in our study.

Until now the majority of in vivo and in vitro OPA models have focused on the investigation of JSRV biology and oncogenesis. One study however has investigated the impact of nutritional selenium on tumourigenesis and progression using naturally occurring OPA cases. Although this study demonstrated the potential for the OPA model to be integrated with techniques such as CT, post-mortem examination, trace...
element and liver enzyme activity analysis to provide comprehensive information on tumour pathogenesis, the use of OPA as a pre-clinical model for monitoring the TME, evaluation of chemotherapeutic agents or as a surgical model has yet to be documented.

This chapter describes the development, refinement and use of an anaesthetised OPA model for functional validation of the IMPACT O$_2$ sensor within a TME. A novel CT-guided trans-thoracic percutaneous implantation procedure was developed for sensor placement into OPA tumours. Following sensor implantation, we investigated the sensors ability to detect changes in intra-tumoural ptO$_2$ following manipulation of FiO$_2$. This is, to the best of our knowledge, the first description of the use of naturally occurring OPA cases as a pre-clinical surgical model for the validation of the ability of a miniaturised Clark O$_2$ sensor to measure dynamic changes in intra-tumoural ptO$_2$. Through the successful integration of techniques used in the treatment of human lung cancer patients, including ultrasound, general anaesthesia, CT and surgery into the OPA model, we have shown its translational potential. These results provide robust evidence for further development of the IMPACT O$_2$ sensor towards clinical applications in man.

8.3 Results

8.3.1 Development of a percutaneous technique for sensor implantation into lung tissue

To develop a technique whereby IMPACT O$_2$ sensors could be safely and reliably implanted into an OPA tumour we began to investigate protocols using sheep carcasses. Although these sheep did not have any lung pathology, we were able to develop the surgical protocol before moving onto experimental animals.

Post-mortem sheep were placed in lateral recumbency and the entire hemithorax was clipped. A 1 cm vertical skin incision was made approximately 1-2 intercostal spaces caudal to the desired site of penetration into the thoracic cavity. Artery forceps were used to develop a subcutaneous tunnel from the skin incision extending cranially to the desired intercostal space. An 8G x 15 cm Jamshidi biopsy needle (Carefusion, France), with its stylet in place, was introduced through the subcutaneous tunnel, then redirected perpendicular to the thoracic wall in the middle of the selected intercostal space. The needle was advanced to enter the thoracic
cavity, with the penetration of the parietal pleura appreciated as the feeling of a ‘pop’. Once the parietal pleura had been penetrated the needle was advanced through the visceral pleura and into lung parenchyma. Following penetration into lung tissue the stylet was removed, and the sensor and lead wire were introduced down the bore of the needle. The obturator was then introduced down the bore of the needle, advancing the sensor past the tip of the needle and positioning it within lung tissue. Once in place, the obturator and implantation needle were withdrawn, leaving the sensor and lead wire *in situ*. A purse string suture of 3 metric braided silk (Ethicon, UK) was placed around the incision, which continued as a Chinese finger trap suture around the lead wire, securing the sensor in place (Figure 8.1). Following sensor insertion, the rib cage was removed to evaluate sensor positioning (Figure 8.2).
Figure 8.1. Photographs depicting development of a percutaneous implantation technique. (a-c) A skin incision was made through which the Jamshidi needle was introduced. The needle was placed perpendicular to the thoracic wall, introduced into the thoracic cavity and advanced into lung tissue. (d-g) The stylet was removed, and the sensor introduced down the bore of the needle. The obturator advances the sensor to position it within the lung tissue. (h-j) Removal of the obturator and implantation needle leaves the sensor in situ. (k&l) The lead wire was sutured in place.
8.3.2 Post-mortem cases allowed mapping of accessible regions of the thoracic cavity for sensor implantations

Using post-mortem cases, we performed simulated surgeries on 8 sheep cadavers with multiple implantations in each carcass. These surgeries allowed the development of the implantation procedure and investigation of the potential accessible regions of the thoracic cavity and lung lobes which could be safely implanted into during experimental cases.

The ovine thorax is composed of 13 ribs and 12 intercostal spaces; access to the cranial rib spaces (1-4) was almost entirely prevented by the appendicular skeleton and musculature of the forelimbs, making access to the cranial thoracic cavity impracticable through a lateral approach. Caudally the ovine thoracic cavity does not extend over the whole thorax, and access gained through intercostal spaces caudal to the 8th space resulted in implantation into the costodiaphragmatic recess or penetration through the diaphragm into the abdominal cavity. The 4th-8th intercostal spaces on both sides of the thorax were all used successfully to implant sensors into lung tissue; implants were placed most reliably into the caudal lobes and right middle lung lobe using the 5th and 6th intercostal spaces (Figure 8.3). During implantation the Jamshidi needle caused significant elastic deformation of lung tissue prior to visceral pleural penetration, after which the needle could be advanced through the parenchyma with relative ease, allowing sensor implantation to be performed.

Figure 8.2. Photographs depicting sensor placement through the thoracic wall into lung tissue. The rib cage has been removed to assess sensor position within (a) lung tissue and (b) within the intercostal space.
Figure 8.3. Photographs depicting lung lobes which can be accessed through a lateral percutaneous approach for sensor implantations. (a) Right hemithorax. (b) Left hemithorax. Yellow circles outline sensor implantation sites.

8.3.3 Development of a CT-guided trans-thoracic percutaneous technique for sensor implantation into OPA tumours

To refine the initial procedure used in post-mortem cases we used 3 sheep diagnosed with OPA (Table 8.1). Following induction of anaesthesia as described in section 3.4.2, the sheep were placed in lateral recumbency with the OPA affected lung uppermost. The thorax was clipped in preparation for surgery; this area extended cranially from just beyond the last rib to the caudal border of the scapula with the dorso-ventral margins extending from the dorsal spinous process of the thoracic vertebrae to the sternum. Following an initial thoracic CT scan, OPA lesion localisation was performed; lesions were localised cranio-caudally based on intercostal spaces and dorso-ventrally based on measurements from the dorsal spinous process of thoracic vertebrae to the OPA lesion. A mark was drawn on the skin to identify the position of thoracic wall penetration for sensor implantation.

Table 8.1. OPA cases used for initial refinement of the CT-guided implantation technique.

<table>
<thead>
<tr>
<th>Case</th>
<th>Signalment</th>
<th>Weight (kg)</th>
<th>CT lesion localisation</th>
<th>Total anaesthesia time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Blackface Female Adult</td>
<td>51</td>
<td><strong>Left cranial lobe</strong>: entire lobe affected</td>
<td>124</td>
</tr>
<tr>
<td>B</td>
<td>Blackface Female Adult</td>
<td>56</td>
<td><strong>Right caudal lobe</strong>: 2 focal lesions (1 dorsal, 1 ventral), approximately 4-5 cm diameter</td>
<td>142</td>
</tr>
<tr>
<td>C</td>
<td>Blackface Female Adult</td>
<td>76</td>
<td><strong>Right cranial lobe</strong>: entire lobe affected</td>
<td>200</td>
</tr>
</tbody>
</table>
Case A underwent an initial CT scan for lesion localisation, with subsequent sensor implantation performed using the same technique as was developed in the post-mortem cases. The sensor was implanted without CT guidance with one single needle advancement. Although penetration of the parietal and visceral pleura was easily appreciated, this blind technique made it difficult to judge how deep the needle had penetrated into OPA tissue. Post-implantation CT scans identified a severe pneumothorax, and although the sensor was positioned within OPA tissue, it was at the deep margins of the lung lobe (Figure 8.4a). The iatrogenic severe pneumothorax was likely due to the needle passing through a large volume of lung tissue or from air tracking into the thoracic cavity through the subcutaneous tunnel.

To improve accuracy of sensor implantations cases B and C were performed under CT guidance. Following lesion localisation, as performed in case A, repeat CT scans were performed following the initial placement of the needle through the chest wall and following each needle advancement, until the needle was positioned at the desired point within OPA tissue. Post-implantation CT scans of case B identified a small pneumothorax in the region of the implant site, with the sensor positioned in the pneumothorax and not within OPA tissue (Figure 8.4b). Post-implantation CT scans of case C identified the sensor positioned in subcutaneous tissue outside the thoracic cavity (Figure 8.4c). In both cases sensor ‘back out’ was likely due to the sensor not been fully pushed past the tip of the needle into OPA tissue, or the sensor or lead wire catching within the bore of the needle (Table 8.2).
Figure 8.4. Axial CT images documenting surgical complications in the initial 3 OPA cases. CT scans were taken immediately post-sensor implantation. (a) Case A. Severe pneumothorax with extensive retraction of the lung lobes away from the chest wall. The sensor is positioned deep within OPA tissue. A small amount of air can be seen in the subcutaneous tissues just proximal to the rib. (b) Case B. Mild pneumothorax localised to the implantation site. The sensor and lead wire have ‘backed out’ during implantation and are positioned within the pneumothorax. (c) Case C. The sensor and lead wire have ‘backed out’ during implantation and are positioned within subcutaneous tissues.

Table 8.2. Results from OPA cases used for initial refinement of the implantation technique. Number of needle advancements, implantation time and complications are provided.

<table>
<thead>
<tr>
<th>Case</th>
<th>No. of CT scans/needle advancements</th>
<th>Time from initial CT scan to sensor implantation (min)</th>
<th>Sensor placed within OPA tissue (yes/no)</th>
<th>Complications post-implantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1</td>
<td>50</td>
<td>Yes</td>
<td>Immediate: Severe pneumothorax</td>
</tr>
<tr>
<td>B</td>
<td>2</td>
<td>32</td>
<td>No</td>
<td>Immediate: Mild pneumothorax with sensor positioned within pneumothorax</td>
</tr>
<tr>
<td>C</td>
<td>4</td>
<td>29</td>
<td>No</td>
<td>Immediate: Sensor positioned within thoracic wall musculature</td>
</tr>
</tbody>
</table>
8.3.4 Refined procedure for OPA lesion localisation and CT-guided trans-thoracic percutaneous sensor implantation

Following the initial 3 cases, further refinement of OPA lesion localisation and CT-guided sensor implantation was performed (Table 8.3). Sheep were anaesthetised as described in section 3.4.2, clipped, prepared and positioned for CT scanning and surgery as described in section 8.3.3.

Table 8.3. OPA cases used following refinement of the CT-guided implantation technique. Signalment, CT localisation and total anaesthesia time (time from induction of anaesthesia to euthanasia) are provided.

<table>
<thead>
<tr>
<th>Case</th>
<th>Signalment</th>
<th>Weight (kg)</th>
<th>CT lesion localisation</th>
<th>Total anaesthesia time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Highlander</td>
<td>65</td>
<td><strong>Left caudal lobe</strong>: 1 focal lesion at cranial aspect, approximately 4-5 cm diameter</td>
<td>174</td>
</tr>
<tr>
<td>2</td>
<td>Blackface</td>
<td>51</td>
<td><strong>Right caudal lobe</strong>: diffuse area affecting caudal aspect, approximately 4-5 cm diameter</td>
<td>234</td>
</tr>
<tr>
<td>3</td>
<td>Blackface</td>
<td>39</td>
<td><strong>Left caudal lobe</strong>: entire lobe affected</td>
<td>161</td>
</tr>
<tr>
<td>4</td>
<td>Blackface</td>
<td>52</td>
<td><strong>Left cranial lobe</strong>: entire lobe affected</td>
<td>158</td>
</tr>
<tr>
<td>5</td>
<td>Blackface</td>
<td>57</td>
<td><strong>Right cranial lobe</strong>: almost entire lobe affected &lt;br&gt;<strong>Left caudal lobe</strong>: 1 focal lesion at caudal aspect, approximately 10-15 cm diameter</td>
<td>234</td>
</tr>
<tr>
<td>6</td>
<td>Blackface</td>
<td>39</td>
<td><strong>Left cranial lobe</strong>: entire lobe affected</td>
<td>247</td>
</tr>
<tr>
<td>7</td>
<td>Blackface</td>
<td>55</td>
<td><strong>Right cranial lobe</strong>: entire lobe affected &lt;br&gt;<strong>Left cranial lobe</strong>: entire lobe affected, extending into the cranial aspect of the left caudal lobe</td>
<td>343</td>
</tr>
<tr>
<td>8</td>
<td>Blackface</td>
<td>58</td>
<td><strong>Right middle lobe</strong>: entire lobe affected &lt;br&gt;<strong>Left cranial lobe</strong>: entire lobe affected, extending into the cranial aspect of the left caudal lobe</td>
<td>270</td>
</tr>
<tr>
<td>9</td>
<td>Mule</td>
<td>64</td>
<td><strong>Right cranial lobe</strong>: almost entire lobe affected</td>
<td>195</td>
</tr>
</tbody>
</table>

To improve the accuracy of OPA lesion localisation and the site for percutaneous sensor implantation a self-adhesive sheet of non-metallic, radiopaque grid lines (GuideLines, Oncology Imaging Systems, UK) was placed on the thoracic wall skin surface in the centre of the clipped area. An initial thoracic CT scan was obtained to assess intra-thoracic pathology and identify OPA lesion(s) (Figure 8.5). OPA lesions for implantation were selected so the needle path would avoid bullae,
fissures, blood vessels and large bronchioles. Peripheral tumours of at least 4 cm in diameter were also preferred to limit the volume of normal aerated lung the needle would pass through and improve sensor implantation into the centre of a lesion. The distance between the skin and pleura was measured at the anticipated penetration site. OPA lesions were localised dorso-ventrally based on the grid lines and cranio-caudally based on intercostal spaces. A mark was drawn on the skin surface to identify the position of thoracic wall penetration for sensor implantation (Figure 8.6). The grid lines were removed, and the skin was aseptically prepared for surgery using chlorohexidine solution before the area was four quarter draped for surgery.

Figure 8.5. Initial CT scan performed to assess intra-thoracic pathology and localise OPA lesions. (a) Axial. (b) Coronal. (c) Sagittal planes. Large areas of increased radiopacity can be seen affecting the ventral regions of the left cranial and caudal lung lobes and the ventral regions of the right caudal lung lobe (outlined in black). Air bronchograms are visible within this consolidated region (white arrows). A patchy and hazy increased opacity (ground glass appearance) within the dorsal regions of the lung, with preservation of bronchial and vascular margins, suggest the presence of interstitial pneumonia or small foci of neoplastic tissue (outlined in white). The radiopaque circles on the skin surface seen on the axial plane are the grid lines used for OPA lesion localisation.
Figure 8.6. OPA lesion localisation. (a) The hemithorax has been clipped for surgery and the radiopaque grid lines placed on the skin surface prior to the initial CT scan. (b-d) Following the CT scan the skin was marked both dorso-ventrally and cranio-caudally at the desired point of thoracic wall penetration for sensor implantation.

All sensors were implanted using a trans-thoracic percutaneous technique under CT guidance based on the developed protocol described in section 8.3.1. A skin incision was made 1-2 intercostal spaces caudal to the desired thoracic wall entry point. The Jamshidi biopsy needle, with its stylet in place, was introduced through the skin incision and tunnelled cranially to the desired intercostal space. The tunnel was made long enough to minimise the risk of air entering the thoracic cavity from the external environment following sensor implantation. Once at the desired intercostal space the needle was positioned at 90 degrees to the thoracic wall in the centre of the intercostal space. The needle was then advanced the distance measured from the initial CT scan (approximately 1 cm) through the chest wall so that the needle was just within the thoracic cavity, penetrating the parietal pleura, but not entering lung/OPA tissue. A second CT scan was performed to ensure accurate placement of the needle at the desired position. If the needle position was suboptimal it could be re-positioned with minimal risk of lung damage. Once correctly positioned, the needle was advanced through the visceral pleura into OPA tissue;
repeat CT scans were taken following each needle advancement to ensure correct needle trajectory and accurate localisation of the needle tip. Measurements were taken from each CT scan from the needle tip to the point of desired sensor implantation to make needle advancements more accurate. Once the needle tip was positioned centrally within OPA tissue the stylet was removed, and the sensor and lead wire were introduced down the bore of the needle. The obturator was then introduced to advance the sensor past the tip of the needle into OPA tissue. Once in place, the obturator and implantation needle were withdrawn, leaving the sensor and lead wire in situ. Care was taken to ensure the lead wire did not catch on the needle, risking sensor displacement. The lead wire had been previously marked at 1 cm intervals to verify that it was not ‘backing out’ during needle removal. The lead wire was then sutured in place as described in section 8.3.1 (Figure 8.7 & Figure 8.8).

Following implantation, CT scans were performed to evaluate sensor positioning and assess the presence of any immediate or delayed post-operative complications such as pneumothorax or haemorrhage; these CT scans were performed immediately after implantation and suturing and also following euthanasia (Figure 8.8 & Figure 8.9). If a pneumothorax developed the decision to drain it was made on severity and whether ventilation was compromised. Intermittent percutaneous thoracocentesis was performed if required.
Figure 8.7. Intra-operative photographs depicting trans-thoracic percutaneous sensor implantation. (a&b) A skin incision was made through which the Jamshidi needle was introduced. (c-e) Following successive CT scans the needle was progressively advanced into OPA tissue. (f-h) Once the needle was in position the stylet was removed and the sensor introduced down the bore of the needle. (i) The obturator was used to push the sensor past the tip of the needle into OPA tissue. (j-l) The Jamshidi needle was removed, leaving the sensor and lead wire in place. (m-o) The skin was closed, and the lead wire secured in place with a purse string and Chinese finger trap suture.
Figure 8.8. Serial CT images taken during sensor implantation. Coronal, axial and sagittal planes are viewed following initial needle placement and after successive needle advancements. The needle was advanced until the tip was at the desired position within the OPA lesion. CT images taken immediately post-implantation demonstrates sensor placement within OPA tissue in all 3 planes (red arrows).
Figure 8.9. CT images taken immediately post-sensor implantation. Images are from 3 separate cases. The sensor and lead wire (red arrows) can be seen within the area of increased radiopacity, consistent with a large consolidated OPA tumour. Repeat CT scans were taken following completion of sensor measurements and euthanasia; these showed no evidence of complications and confirmed the sensor had remained within OPA tissue throughout sensor recordings.

8.3.5 Refined procedure for CT-guided implantation of multiple sensors

Following procedure refinement for single sensor implantations the technique was modified to allow 2 sensors to be implanted into a single lesion. The initial CT
scan verified that the lesion was large enough to accommodate 2 sensors and allowed for sensor implantation planning. Sensors were placed through the same intercostal space 2-3 cm apart. The first needle was placed as previously described, penetrating the parietal pleura. Following CT confirmation of correct needle positioning the needle was advanced into OPA tissue and a second needle was placed, again only penetrating the parietal pleura. A CT scan confirmed placement of the first needle into OPA tissue and the second at the correct position. Both needles were then advanced simultaneously based on sequential CT scans and the sensors implanted as previously described (Figure 8.10).

![CT images](image)

**Figure 8.10. CT images taken immediately post-sensor implantation.** The sensors and lead wires (red arrows) can be seen within the area of increased radiopacity, consistent with a large consolidated OPA tumour. Sensor 1 is placed centrally within the tumour whereas sensor 2 has been placed further towards the deep margin of the lung lobe. Repeat CT scans were taken following completion of continuous sensor measurements and euthanasia; these documented no evidence of complications and confirmed the sensors had remained within OPA tissue throughout sensor recordings.

### 8.3.6 CT-guided trans-thoracic percutaneous sensor implantation resulted in a high success rate of delivery of sensors into OPA lesions

A total of 7 OPA sheep underwent CT-guided single sensor implantations (Table 8.4). Time taken from the initial CT scan to sensor placement was 45 ± 5 min
The number of sequential CT scans and needle advancements required from initial needle placement to obtaining the desired position within the OPA lesion ranged from 3–5; however, 4 advancements were required in 5 of the 7 cases. All implantation procedures resulted in sensor placement within OPA tissue. No immediate or delayed complications were identified in 4 of the cases.

Two sheep underwent CT-guided 2 sensor implantations (cases 8 & 9). Time taken from the initial CT scan to sensor placement was 73 and 50 min for each case. The number of sequential CT scans and needle advancements required from the initial placement to correct positioning within OPA tissue was 4 for each needle. In both cases all implantation procedures resulted in sensor placement within OPA tissue. No immediate or delayed complications were identified in 1 of the cases.

Table 8.4. Results from the OPA cases used in CT-guided implantation procedures. Number of needle advancements, implantation time and complications are provided (cases 1-7 are single sensor implantations, cases 8 and 9 are double sensor implantations).

<table>
<thead>
<tr>
<th>Case</th>
<th>No. of CT scans/needle advancements</th>
<th>Time from initial CT scan to sensor implantation (min)</th>
<th>Sensor placed within OPA tissue</th>
<th>Complications post-sensor placement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4</td>
<td>31</td>
<td>Yes</td>
<td>Immediate: Mild pneumothorax – not treated</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>58</td>
<td>Yes</td>
<td>Immediate: Mild pneumothorax – treated successfully with a single thoracocentesis</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>46</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>56</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>4</td>
<td>26</td>
<td>Yes</td>
<td>None</td>
</tr>
</tbody>
</table>
| 6    | 4                                 | 60                                                   | Yes                             | Immediate: Mild pneumothorax – not treated  
Delayed: Progression of pneumothorax with severe lung lobe collapse and development of subcutaneous emphysema. Final sensor position was within the pneumothorax |
| 7    | 5                                 | 43                                                   | Yes                             | None                                 |
| 8    | 4                                 | 73                                                   | Yes                             | None                                 |
| 9    | 4                                 | 50                                                   | Yes                             | Immediate: Mild pneumothorax – treated successfully with a single thoracocentesis |
8.3.7 Iatrogenic pneumothorax is a potential complication following percutaneous sensor implantation

Sensor implantation in 4 cases was associated with iatrogenic pneumothorax. One case (case 1) developed a mild pneumothorax immediately post-sensor implantation; this did not require thoracocentesis and did not progress over the course of the experiment. Two cases (case 2 and 9) also developed a mild pneumothorax immediately post-sensor implantation; each case received a single percutaneous thoracocentesis immediately following pneumothorax detection. CT scans post-thoracocentesis confirmed lung lobe re-expansion with removal of most of the air from within the thoracic cavity. Continuous sensor recordings were performed for approximately 2 h before each sheep was euthanised and a post-mortem CT scan performed. These scans identified no pneumothorax recurrence and confirmed that the sensor had remained within OPA tissue throughout sensor recordings (Figure 8.11).

A final case (case 6) also developed a mild pneumothorax immediately post-sensor implantation, with evidence of a small amount of air surrounding the lead wire in the thoracic wall musculature and subcutaneous tunnel. Thoracocentesis was not performed as only a small volume of air was initially present within the thoracic cavity. Continuous sensor recordings were performed for approximately 4.5 h before the sheep was euthanised and a post-mortem CT scan performed. This CT scan identified pneumothorax progression with further retraction of the lung margins away from the chest wall in the region of the implantation site. Lung lobe retraction was associated with sensor displacement causing both the sensor and lead wire to be situated within the pneumothorax. Significant progression of subcutaneous emphysema had also occurred (Figure 8.12).
Figure 8.11. CT images documenting iatrogenic pneumothorax. CT images are from case 2. The OPA target lesion is seen as a patchy area of increased radiopacity affecting the ventral region of the right caudal lung lobe. CT scans were taken immediately post-sensor implantation and following euthanasia (2 h post-sensor implantation). A mild pneumothorax was evident immediately post-sensor implantation, predominately localised to the region of the implantation site. The sensor can be seen within OPA tissue (red arrows). Thoracocentesis was performed immediately post-sensor placement, which resulted in lung lobe re-expansion and removal of most of the air from within the thoracic cavity. Following euthanasia, CT scans confirmed successful management of the pneumothorax with reinflation of the collapsed caudal lung lobe and confirmed the sensor had remained within OPA tissue throughout sensor recordings.
Figure 8.12. CT images documenting iatrogenic pneumothorax. CT images are from case 6. CT scans were taken immediately post-sensor implantation and following euthanasia (4.5 h post-sensor implantation). A mild pneumothorax was evident immediately post-sensor implantation. A small amount of air can be seen in subcutaneous tissues where the lead wire is exiting the thoracic cavity. The sensor can be seen positioned within OPA tissue (red arrows). Thoracocentesis was not performed. Following euthanasia CT scans identified significant progression of the subcutaneous emphysema and pneumothorax. In the axial and coronal planes, the sensor can now be seen positioned on the lung surface within the pneumothorax.

8.3.8 Appropriate anaesthetic protocols enable OPA sheep to remain physiologically stable throughout anaesthesia

To assess physiological stability of OPA sheep throughout anaesthesia, blood-gas, biochemical and haematological data was combined with variables such as HR, RR, CT, and MAP. Results from sheep maintained at FiO\textsubscript{2} of 1.0 showed that physiological and arterial blood variables remained stable with no statistically significant changes occurring over time. Elevated blood lactate levels were identified throughout anaesthesia but showed a tendency to reduce at later time points. Although PaO\textsubscript{2} levels showed marked individual variation and were lower than expected given the FiO\textsubscript{2} of 1.0 (suggesting compromised alveoli O\textsubscript{2} uptake), it was possible to maintain SaO\textsubscript{2} levels above 95%. Peak inspiratory pressure increased throughout anaesthesia, with values at 180 min almost 1.5 times greater than that recorded at 30 min (Figure 8.13).
Physiological parameters remained stable throughout anaesthesia. Physiological data obtained from OPA cases maintained at FiO\textsubscript{2} of 1.0 throughout anaesthesia (data expressed as mean ± SEM, n=3-5 per time point; times indicate min post-induction of anaesthesia) (Hb, haemoglobin; ABE, arterial base excess; HCO\textsubscript{3}\textsuperscript{-}, bicarbonate; SaO\textsubscript{2}, haemoglobin O\textsubscript{2} saturation; PaO\textsubscript{2}, arterial O\textsubscript{2} partial pressure; PaCO\textsubscript{2}, arterial CO\textsubscript{2} partial pressure; CT, core temperature; PIP, peak inspiratory pressure; RR, respiratory rate; HR, heart rate).

8.3.9 Current generated by the sensor responded to alterations in inspired oxygen concentrations

To assess the ability of the sensors to detect changes in intra-tumoural ptO\textsubscript{2} through changes in blood oxygenation we performed sequential alterations in FiO\textsubscript{2}, ranging from 0.21-1.0 (Figure 8.14a). Each FiO\textsubscript{2} alteration was performed at 20 min intervals delivered through a flowmeter via the isoflurane vaporiser. The cycle of FiO\textsubscript{2} alterations was: 1.0 for 20 min (baseline), 0.5 for 20 min (inducing mild hypoxaemia), 0.21 for 20 min (inducing moderate hypoxaemia) before finally returning to 1.0 for 20 min. Arterial blood samples were taken at the end of each FiO\textsubscript{2} challenge.

Baseline current recordings were first obtained using FiO\textsubscript{2} of 1.0. The mean sensor current recorded during this baseline period was -1.67 ± 0.80 nA. Following FiO\textsubscript{2} reductions to 0.5 and then to 0.21 sensor recordings decreased to -1.27 ± 0.59 nA and -0.78 ± 0.30 nA respectively. Upon increasing FiO\textsubscript{2} back to 1.0 sensor recordings rose to -1.24 ± 0.69 nA (Figure 8.14b & Table 8.5). Alterations in sensor currents occurred over a period of 10-15 min following each change in FiO\textsubscript{2} and
although trends were identified, these current changes were not statistically significant when compared with baseline recordings. At the end of each FiO\textsubscript{2} challenge arterial blood-gas analysis confirmed the expected physiological changes induced by each challenge. SaO\textsubscript{2} and PaO\textsubscript{2} both decreased at 0.5 and 0.21 and increased back to baseline levels at 1.0. Hb concentration remained the same throughout each challenge, as expected (Figure 8.14c & Figure 8.14d).

Figure 8.14. Sensor currents change in accordance with alterations in FiO\textsubscript{2}. (a) Representative graph showing current generated at the working electrode of the sensor during continuous sensor recordings over a period of 100 min. Each FiO\textsubscript{2} challenge was performed in 20 min blocks. (b) Combined analysis comparing current generated at the working electrode of the sensor during each FiO\textsubscript{2} challenge; results show mean current readings from throughout each 20 min period (one-way ANOVA with Holm-Šídák multiple comparisons test; data expressed as mean ± SEM, n=4). (c&d) Arterial O\textsubscript{2} partial pressure, total haemoglobin and haemoglobin O\textsubscript{2} saturation measured at the end of each FiO\textsubscript{2} challenge.

Table 8.5. Current recordings generated during each FiO\textsubscript{2} challenge. (n=4; mean ± SEM).

<table>
<thead>
<tr>
<th>FiO\textsubscript{2}</th>
<th>100% (1)</th>
<th>50%</th>
<th>21%</th>
<th>100% (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current (nA)</td>
<td>-1.67 ± 0.80</td>
<td>-1.27 ± 0.59</td>
<td>-0.78 ± 0.30</td>
<td>-1.24 ± 0.69</td>
</tr>
</tbody>
</table>
8.3.10 All implantation sites were identified during post-mortem examination

Following completion of sensor recordings, euthanasia and final CT scans all sheep underwent post-mortem examination. Gross pathology allowed the assessment of lung pathology, identification of the implant site and provided the opportunity to obtain biopsy specimens for histopathological analysis.

Upon entering the thoracic cavity OPA affected regions failed to collapse. Gross pathology identified lesions that were in accordance with those identified on the CT scans in terms of number of lesions, location and size. The majority of tumours were extensive, often involving the majority or entire lung lobe (Figure 8.15a & Figure 8.15b); however occasional multifocal discrete lesions affecting different lung lobes were seen (Figure 8.15c). OPA tumours typically caused distortion of the normal architecture of the affected lung lobe and had a grey colouration, with clear boundaries between tumour tissue and adjacent pink aerated lung. Although the smooth contour of the overlying pleura typically remained intact, several cases had the presence of fibrinous adhesions between the visceral pleura and chest wall. No evidence of intra-thoracic metastasis was identified, with all tracheobronchial and mediastinal lymph nodes appearing grossly normal in all cases. All sensor implantation sites were successfully identified with an entry site seen in the visceral pleura overlying OPA tissue. In 1 case an area of petechial haemorrhage was evident to the lung surface in the region of the implantation site; however, the remaining cases had no gross evidence of parenchymal haemorrhage or haemothorax.
Figure 8.15. Photographs depicting gross pathology seen in typical OPA cases. These photographs are from the implantation cases presented in Figure 8.9. Each implantation site is highlighted with a black arrow. (a) Large grey consolidated mass affecting the majority of the left caudal lung lobe. An area of petechial haemorrhage can be seen on the surface of the lung surrounding the needle entry point. (b) Large grey consolidated mass affecting the majority of the left cranial lung lobe. Fibrous tissue can be seen adherent to the lung surface just cranial and ventral to the needle entry point. (c) One large dark coloured mass affecting the right cranial lung lobe containing the implant site with a further focal lesion within the left caudal lung lobe.

8.3.11 Histopathology of OPA tissue and implant site identified variable amounts of intra-pulmonary haemorrhage

Following gross pathology, the implant site was dissected from OPA tissue. The biopsy specimen was used for both OPA diagnosis and to assess the effects of the implantation procedure on OPA/lung tissue. Histological examination confirmed OPA diagnosis in all cases used for implantations, identifying non-encapsulated neoplastic foci forming acinar and papillary proliferations. In advanced cases separate foci had coalesced into a single large tumour (Figure 8.16a). The extent of inflammation varied considerably between cases and between different tumour areas
in the same case. In all cases large numbers of alveolar macrophages were identified within alveolar spaces (Figure 8.16b). Mononuclear cells including plasma cells and lymphocytes were also common, with some showing prominent lymphofollicular aggregates (Figure 8.16c). Neutrophilic infiltration was also seen, but not to the same extent as lymphocyte numbers. In all tumours, fibrovascular connective tissue was identified surrounding tumour cells (Figure 8.16d).

Figure 8.16. Histological appearance of OPA tumours. (a-c) H&E stained sections. (a) Columnar tumour cells can be seen lining the alveolar septa (black arrows). Two groups of neutrophils (red arrows) can be seen between the tumour cells. (b) Alveolar macrophages are present at the top right-hand side of the image. (c) Mononuclear cells, lymphocytes and plasma cells can be observed at the top left-hand side of the image. (d) Masson’s trichrome stained section. Collagen is stained blue (yellow arrow heads) and can be identified surrounding the tumour cells.

Histopathology identified tumour cells immediately adjacent to the implant site in all cases; however, the percentage area composed of tumour cells varied ranging from 50% in 2 cases up to 80-95% in the remaining 7 cases. Evidence of haemorrhage within the needle tract and implantation site was identified in all cases; however, there was marked variation in the extent of haemorrhage seen between cases. Cases in which the needle passed through areas predominantly composed of tumour cells had evidence of bleeding restricted to within the needle tract itself, whereas cases in which the needle passed through areas of more normal lung showed evidence of intra-alveolar haemorrhage (Figure 8.17 & Figure 8.18).
Figure 8.17. Histological appearance of OPA tissue and implantation site. H&E stained sections. The top image shows the needle tract penetrating through the visceral pleura and into OPA tissue. Large numbers of erythrocytes can be seen within the needle tract. Higher magnification images document smaller numbers of erythrocytes extending up to 250 µm from the implant site, predominately located within stromal tissue.
Figure 8.18. Histological appearance of OPA tissue and implant site with minimal and moderate intra-parenchymal haemorrhage. H&E stained sections. (a) The implant site is contained within an area consisting predominantly of tumour cells. The needle tract contains large numbers of erythrocytes; however, only small numbers are identified within OPA tissue adjacent to the implant site. (b) The implant site is contained within an area consisting of both tumour cells and more normal aerated lung tissue. The needle tract contains large numbers of erythrocytes; however, large numbers of erythrocytes are also identified within alveolar spaces and stromal tissue adjacent to the implant site.

8.4 Discussion

Similarities between OPA and human lung adenocarcinomas, in terms of disease presentation, progression and histological classification, has led to OPA becoming regarded as an excellent model for studying various aspects of human lung cancer biology. *In vitro* and *in vivo* OPA experimental models are well documented and have been used to elicit molecular pathways involved in lung cancer pathogenesis. However, if the disease is to be used as a pre-clinical research tool for human lung cancer, then techniques used in human medicine must be incorporated into the OPA model to demonstrate its translational ability. In order to achieve this,
our novel OPA model, used for validation of the IMPACT O₂ sensors, was developed from protocols currently used in human thoracic medicine\textsuperscript{700}.

Human lung cancer diagnosis and staging is typically performed from aspirates or biopsy specimens taken using a flexible bronchoscope\textsuperscript{701} or via a trans-thoracic approach\textsuperscript{702-704}. As both techniques provide an accurate way to obtain a diagnosis\textsuperscript{705,706} the choice of which technique to use is largely dependent on lesion location. Central lesions that involve bronchi are readily assessible with a bronchoscope. Peripheral lesions, not visible on endobronchial examination\textsuperscript{705}, or are less than 3 cm in diameter that do not show a bronchus entering the lesion on CT images, are diagnosed more accurately by minimally invasive trans-thoracic needle biopsy (TTNB)\textsuperscript{702,703,707}. Modified techniques of both endoscopic and percutaneous biopsy approaches could have been used in our OPA model for sensor implantations; however, the trans-thoracic percutaneous approach was chosen for several reasons. Initial OPA lesions from naturally occurring cases typically begin at the peripheral regions of the lung lobes. Only as neoplastic foci enlarge and coalesce do the central regions of the lobes become affected. Although bronchioles will frequently be surrounded by tumour tissue the larger bronchi may remain largely unaffected. Although endoscopy can be performed in sheep\textsuperscript{275}, successful endoscopic sensor implantation would only be possible in tumours which involved bronchi of sufficient diameter that can accommodate the endoscope. This selection criteria would significantly limit the number of cases that could be used and realistically would only be able to be assessed once sheep are anaesthetised and CT images have been obtained. Significant volumes of lung fluid produced by OPA tumours, present in the large and small airways, would also hamper endoscopic airway visualisation and make sensor implantation challenging. The presence of the endoscope within the airway could also hinder the delivery of fresh airflow and hamper attempts to suction away lung fluid. The IMPACT O₂ sensor is also currently wired, and endoscopic delivery would mean that the lead wire would be required to run up through the large airways and out through the larynx; the presence of the endotracheal tube would make this almost impossible. These limitations directed us to develop the trans-thoracic percutaneous approach for sensor implantations\textsuperscript{700}. 
For the development of our OPA model we undertook a staged series of experiments. Each development stage increased the complexity of the model; initially beginning with post-mortem cadavers and finally resulting in a refined protocol used in experimental sheep. Although the cadavers did not have lung pathology, these experiments allowed the initial development and refinement of the surgical procedure and provided information on accessible lung regions through each intercostal space. Using cadavers, we were able to successfully implant sensors into lung tissue using the 4th-8th intercostal spaces on both sides of the thorax. An important consideration is that in live, anaesthetised sheep the positions of accessible regions of the lungs are likely to be slightly different from the results gathered using post-mortem cases. In ruminants the costodiaphragmatic recess can enlarge following death due to atelectasis (causing the caudal border of the lung to move cranially) and from cranial displacement of the diaphragm due to ruminal bloat. These factors are likely to have reduced the implantation window seen using these post-mortem cases. Sensor implantation in these experiments was performed blind, without any image guidance; consequently, assessment of sensor implantation into lung parenchyma was difficult as there was little perceptible tactile feedback from penetration of the visceral pleura. Significant elastic deformation of the lung occurred prior to Jamshidi penetration; this degree of lung deformation could increase the risk of undesirable lung contusions surrounding the implantation site. However, as OPA tumours are likely to be consolidated with areas of fibrosis and adhesions to the parietal pleura, elastic deformation of the visceral pleura as seen using these cadavers was likely to be less of an issue. Following completion of post-mortem experiments, the next stage in model development was identifying an appropriate image guidance technique to aid sensor implantation.

In human medicine TTNB requires the use of image guidance. Fluoroscopy was once the preferred imaging modality of choice as it enabled needle advancements to be visualised in real-time\textsuperscript{708}; however, access to deep lesions and avoidance of vascular structures and bullae proved difficult with this method\textsuperscript{709}. Ultrasound has the advantage that needle movements can be monitored precisely and extremely quickly during the procedure and can improve the accuracy of obtaining samples from necrotic lesions\textsuperscript{710,711} whilst avoiding radiation exposure; however, its
use is restricted to peripheral lesions that produce an acoustic window. CT is now the most commonly used image guidance technique for TTNB. Samples obtained using this procedure have excellent diagnostic accuracy rates ranging from 66–96%\textsuperscript{706,712,713}. CT has the advantage over fluoroscopy in that it allows accurate planning of needle path trajectories that avoid aerated lung, bullae, fissures or blood vessels. The procedure can also be used to sample central lesions and those less than 1 cm in diameter\textsuperscript{714}. As with ultrasound, CT images can distinguish between necrotic and solid regions of a lesion, allowing for better diagnostic samples to be obtained.

CT can be combined with fluoroscopy (CTF) to allow needle adjustments to be made in almost real-time. The technique is primarily used for very small lesions located in difficult to access thoracic regions such as in the costodiaphragmatic recess, or those close to the mediastinum or critical at-risk structures. The procedure can also be performed quickly, which is advantageous in high risk or un-cooperative patients\textsuperscript{715}.

Although any of these image techniques could have been used in our OPA model, CT was chosen for several reasons. CTF was not considered necessary for our cases and would have required the use of lead aprons and radiation shields for safety purposes. Although ultrasound guidance could have been used for sensor implantations into OPA lesions affecting pleural surfaces, it cannot provide an assessment of pathological lesions occurring throughout the entire thorax. These factors directed us to use CT guidance for sensor implantations\textsuperscript{700}.

During implantation procedures each CT scan was carefully reviewed. The initial scan allowed for lesion selection for sensor implantation with sequential scans being used to accurately assess needle trajectory and position. Lesion selection and needle path planning was based on risk factors associated with the development of TTNB complications such as pneumothorax and haemorrhage. Risk factors that contribute to TTNB complications include lesion characteristics and underlying disease pathology such as small lesions and the presence of emphysema\textsuperscript{716} or chronic obstructive pulmonary disease\textsuperscript{717}. Technical factors when performing TTNB including increased amounts of normal aerated lung crossed by the needle\textsuperscript{718,719}, a small oblique needle angle with the thoracic pleura\textsuperscript{720}, multiple needle repositionings\textsuperscript{721}, a greater number of sampling procedures\textsuperscript{722}, the absence of previous ipsilateral surgery\textsuperscript{723}, using a trans-fissure approach\textsuperscript{719} and damage to
Thoracic vasculature can also increase complication rates. In accordance with these known risk factors, lesions were chosen so that the needle path avoided passing through bullae, large vessels, bronchi and interlobar fissures. If possible, a short straight path from the skin to the lesion, that crossed the pleura into the lung at 90 degrees was planned. If more than 1 lesion was present, a peripheral lesion was chosen to decrease the amount of lung tissue that would be traversed.

The length of time required to perform CT-guided TTNB in human patients is 1 potential limitation of the procedure, even though procedural length or needle dwell time within the lung has not been associated with increased risk of pneumothorax. In our model single sensor implantations were performed in a time of 45 ± 5 min (mean ± SEM), which is similar to studies in human patients that have documented CT-guided TTNB procedure times of up to 66 min. The radiation risk associated with CT-guided TTNB is a potential concern as the patient effective dose is often greater than standard thoracic CT scans. In our study we did not consider radiation exposure as experiments were performed as non-recovery procedures. However, future studies to investigate if the radiation dose received by these sheep is comparable with that used in human TTNB procedures could be performed.

TTNB in humans is commonly performed under local anaesthesia; however, general anaesthesia was mandatory in our OPA model to ensure sheep and personnel safety. General anaesthesia of OPA sheep can be challenging due to respiratory compromise originating from OPA lesions, lung lobe consolidation, increased respiratory tract secretions, secondary infections and anaesthesia-induced atelectasis. These factors have the potential to lower PaO₂ levels by decreasing the effective movement of inspired O₂ into the blood. In our cases adequate haemoglobin oxygen saturation was achieved by increasing FiO₂ in combination with mechanical ventilation. Although OPA cases may require additional anaesthetic monitoring with respiratory and cardiovascular support, all our cases were successfully managed throughout sensor validation experiments, providing evidence that OPA cases can be used in procedures that require general anaesthesia.

The surgical procedure itself underwent several refinements until the final protocol was defined. From our initial 3 cases the major refinements included the use of radiopaque grid lines for improved accuracy of lesion localisation and performing
serial CT scans to aid needle positioning and sensor implantation. Careful handling of the implantation needle was essential to reduce the risk of iatrogenic lung damage during the surgical procedure, both during its initial insertion and subsequent advancements. One hand placed at the needle tip, near the skin surface, was used to stabilise the needle and prevent excessive needle advancement, while the other hand held the needle hub and provided downward pressure to advance the needle. The needle trajectory was maintained with each advancement as small deviations at the needle hub would produce large deviations at the needle tip. One issue that was encountered was the hub weight of the Jamshidi needle, which had the potential to cause the needle to list/move to one side until it was advanced sufficiently into OPA tissue to support its weight. To reduce the risk of needle movement causing lung damage it was only advanced to the level of the parietal pleura during its initial placement. Only when the needle position was confirmed on CT images was it advanced through the pleura, to the pre-measured depth, seating the needle sufficiently within lung/OPA tissue to prevent listing. Between each subsequent needle advancement, the needle was allowed to move with respiratory motions to prevent damage to lung tissue. Only following CT confirmation of the desired position of the needle tip in the OPA lesion was sensor implantation performed.

Following sensor implantation an immediate CT was performed to evaluate sensor positioning and assess for complications. Known TTNB associated complications are pneumothorax, bleeding (haemoptysis, haemothorax), infection, air embolism, lung lobe torsion and needle tract metastasis. Estimated TTNB mortality rates are very low (approximately 0.02%) and are mainly caused by air embolism or massive haemoptysis\textsuperscript{726}. By far the most common complications associated with TTNB are pneumothorax and haemorrhage\textsuperscript{700}.

Pneumothorax is the most common complication seen following TTNB. Although rates as high as 54\% have been documented\textsuperscript{727,728}, accepted occurrence rates are more likely to be in the region 17–26\%, of which only 14\% will require treatment through percutaneous aspiration or chest tube insertion\textsuperscript{720,723,729,730}. Although most cases will be evident within 60 min following the procedure, serial x-rays up to 3 h post-procedure are usually performed to ensure that a delayed pneumothorax has not occurred\textsuperscript{731,732}. In our series of experiments 4 out of 9 cases
developed an immediate pneumothorax. Three of these cases were classified as mild, with 2 requiring percutaneous needle thoracocentesis. The 2 cases that received thoracocentesis fully resolved and did not show any pneumothorax recurrence; this was likely due to removal of all the excess pleural air from around the implant site, allowing apposition of visceral and parietal pleural surfaces. The remaining case also developed a mild immediate pneumothorax which was not severe enough to warrant drainage. However, following 4.5 h of sensor recordings the post-mortem CT scan identified progression of the pneumothorax with significant subcutaneous emphysema. This case demonstrated the need for repeat CT scans to detect delayed complications. Measures that were taken to reduce the risk of pneumothorax included the use of a coaxial technique to allow the sensor to be placed with a single pleural puncture, and as described above, careful needle path planning. Other techniques which may help reduce pneumothorax occurrence is the technique of obliterating, or ‘patching’ the needle track by injecting 2–3 ml of blood during withdrawal of the needle. Although this would have been possible to perform it may have interfered with the lead wire and caused the sensor to move whilst the needle was being removed. Following sensor placement, the sheep could also have been repositioned with the puncture site down; however, this would have made connections from the lead wire to recording instrumentation difficult.

Haemorrhage is the second most common TTNB complication occurring in approximately 4-10% of cases. Bleeding may be evident as fresh blood passing up through the bore of the needle, or as a ground-glass appearance in CT images in the area of the biopsy or along the needle tract. Fortunately, haemothorax is exceedingly rare, with an incidence of less than 1%. Measures that were taken to reduce the risk of haemorrhage included the avoidance of large pulmonary vessels by the needle path and directing the needle away from the aorta and the heart. Placing the needle through the centre of the intercostal space also reduced the risk of damage to intercostal neurovascular bundles. In our series of experiments no cases were identified as having post-implantation haemorrhage based on CT image evaluation; however, following post-mortem examination and implant site histopathology erythrocytes were identified within the needle tract in all cases. Variable amounts of erythrocytes were also identified in OPA tissue away from the needle tract itself,
possibly to a greater extent in cases where the needle passed through more normal areas of lung tissue. This observation is likely due to OPA affected regions having reduced compliance compared with normal lung tissue, with OPA tissue potentially acting as a tamponade preventing the escape of erythrocytes into the tumour tissue, whereas alveolar spaces would act as reservoir for the erythrocytes. The under reporting of alveolar haemorrhage based on the CT scans is likely due to the appearance of the OPA lesions themselves. All cases had large OPA lesions involving the visceral pleura that were characterised as having increased radiopacity, frequently with the presence of air bronchograms. This OPA CT appearance would have likely obscured any haemorrhage that occurred within the needle path.

One factor that could have contributed to the complication rate seen in our model is the choice of needle that was used for sensor implantations. Needle selection was dictated by the dimensions of the IMPACT sensors; a needle with an internal bore diameter of sufficient size was therefore needed to accommodate the sensor and lead wire. As a result of this an 8G Jamshidi needle was required. This size of needle is considerably larger than the 18-22G needles that would be routinely used in human TTNB procedures. Further development and miniaturisation of the IMPACT O2 sensor will ultimately allow smaller diameter needles to be used, which will reduce complication rates, especially as bleeding complications are thought to be minimised by using needles smaller than 18G.

Following successful development of the implantation procedure we wished to investigate the functionality of the IMPACT O2 sensor within the OPA TME. In order to achieve this, we determined if alterations in blood oxygenation levels, through changes in FiO2, would cause changes in intra-tumoural ptO2 that could be detected by the sensor. Arterial blood-gas analysis was used to confirm the expected physiological responses to FiO2 alterations. Hypoxia caused reductions in both PaO2 and SaO2, whereas hyperoxia caused their levels to increase. Changes in sensor currents occurring with FiO2 challenges matched the same pattern of results obtained using arterial blood-gas analysis, with lower and higher currents generated in hypoxaemic and hyperoxaemic conditions respectively. Although, these current changes were not statistically significant when compared to baseline currents generated at FiO2 of 1.0, they demonstrated that the IMPACT O2 sensor could detect
changes in intra-tumoural $\text{ptO}_2$. The large variation seen in the results between sheep is likely due to the underlying dynamic nature and heterogeneity of the TME, highlighting the need to spatially map $\text{O}_2$ levels within a tumour. These results document, to the best of our knowledge, the first time that a sensor capable of monitoring intra-tumoural $\text{ptO}_2$ in real-time has been implanted into a solid tumour.

8.5 Conclusion

This chapter has described the use of naturally occurring OPA cases in the development of a novel $\textit{in vivo}$ ovine model for the CT-guided trans-thoracic percutaneous implantation of IMPACT $\text{O}_2$ sensors into lung tumours. This model was further developed to produce acute and reversible changes in intra-tumoural $\text{ptO}_2$ through alterations in $\text{FiO}_2$. These dynamic changes were detectable by the IMPACT $\text{O}_2$ sensors implanted into OPA tumours. Through the integration of techniques such as ultrasound, general anaesthesia, CT and surgery into the OPA model, we have shown the models translational potential and effectiveness as a pre-clinical research tool for human lung cancer. These results have provided evidence for further development of the IMPACT $\text{O}_2$ sensor towards clinical applications in cancer therapy. Our results also demonstrate that the model could be developed further for other pre-clinical uses, such as the procurement of biopsy specimens, the development of medical devices for the local delivery of chemotherapeutic agents, monitoring the TME and to assess the effectiveness of RT or systemic chemotherapeutic agents.
9 Future work

The development and characterisation of our novel human and canine breast and ovine lung cancer radioresistant cell lines in combination with the preliminary data obtained from the secretomic experiments has created numerous opportunities for future research. We envisage these 2 areas of research running both as standalone projects and in combination with each other.

Although genotypic, phenotypic and functional characterisation of the novel human ER\(^{-}\) and ER\(^{+}\) radioresistant breast cancer cell lines was undertaken, time restrictions prevented analysis of the animal cell lines. Using transcriptomic data from the REM-134 and JS7 parental and RR cell lines, characterisation could be performed using similar analysis criteria as was applied to the human cell line datasets. This could provide important data, as this study is the first to describe the development of radioresistant canine mammary and ovine lung cancer cell lines. This may prove useful in the case of the REM-134 cell line, as canine mammary tumours are seen as excellent models for human mammary tumours and so could represent an excellent comparative model of human disease\(^{734}\). In particular, canine mammary tumours show homology to human mammary tumours in the activation of numerous pathways such as PI3K/AKT, KRAS, PTEN, WNT-\(\beta\)-catenin and MAPK\(^{735}\), some of which were found to be differentially activated in our human parental and RR breast cancer cell lines. Characterisation of the JS7 RR cell line would also investigate the effects that chronic radiation exposure has on \textit{in vitro} JSRV production. Evidence that suggests JS7 RR produces JSRV either in 2D or 3D cultures would provide an exciting and novel model to study virus production and radioresistance.

As stocks of the RR cell lines have been created and stored in liquid nitrogen this will allow future studies to be performed aimed at targeting the differentially activated pathways that we have identified in the RR cell lines. These studies would ultimately focus on radioresistance reversal. Although out-with the scope of this PhD study, these types of experiments are the logical next phase in the use of our radioresistance model. These types of models will likely be instrumental in the development of new therapeutic strategies for patients that either fail to respond to treatment or develop recurrent disease.
One area of research could involve the use of inhibitors against EGFR or its downstream targets. Several phase I and II trials have investigated the use of gefitinib with RT as a means of improving patient outcomes\textsuperscript{736}. Although conflicting reports regarding the clinical benefit of using EGFR inhibitors have prevented the routine clinical use of these drugs, some studies have shown they can improve survival rates and quality of life\textsuperscript{737,738}. As our results have reported that RR cell lines derived from ER\textsuperscript{+} cells showed a shift from ER to EGFR signalling, with a corresponding increase in sensitivity to EGFR inhibition, it would seem logical to investigate inhibition of this pathway, including its downstream targets such as MAPK and PI3K as a means of overcoming radioresistance.

Another area of research would be to investigate WNT signalling, as this pathway was also found to be upregulated in RR cell lines derived from ER\textsuperscript{+} cells. WNT and its downstream effectors regulate various processes that are important for tumourigenesis, progression, differentiation and metastasis\textsuperscript{739} and further dissection of the pathway may identify targets that can be inhibited to reverse radioresistance. The global approach taken using multiple techniques for characterisation of our radioresistance model identified numerous pathways that were differentially expressed or activated between paired parental and RR cell lines. Although only 2 potential areas of future work have been highlighted here, multiple other pathways could be investigated in order to further characterise the mechanisms of acquired radioresistance and identify possible ways of targeting its development.

The secretomic pilot study has generated a vast amount of data that has yet to be fully analysed. Future work involving the secretomic-based biomarker experiments could be broken down into 4 primary areas: continued biomarker in-lab validation, biomarker detection in blood, mechanisms of biomarker secretion and the development of a potential biomarker signature predictive of RT response. The use of the developed RR cell lines could also continue for the identification of differentially secreted biomarkers as a means of determining radiosensitivity.

Secretome characterisation of untreated and radiation-treated MCF-7 cells identified 9 candidate biomarkers of which we have only started to validate 4. Future in-lab validation would investigate the remaining 5 biomarkers by assessing their secretion levels in CM from parental and RR cell lines 24 h after radiation treatment.
Further secretomic experiments could also be performed using MTS, as we have shown that MCF-7 RR, ZR-751 RR, MDA-MB-231 RR and REM-134 RR all form MTS. Although MTS are a more complex model compared with 2D cultured cells, they still suffer from the same limitations as 2D cultured cells in that they fail to account for the TME and the influence that stromal cells can have on cancer cells and their secretion profiles. Currently, our results are restricted to biomarkers released from cancer cells up to 24 h post-radiation. In order to assess biomarker secretion profiles in response to multiple fractions of radiation, experiments would need to include longer post-radiation time points. In order to overcome some of the aforementioned limitations of 2D and 3D MTS models, further experiments could include not only cancer cell line models, but also tumour explants. Precision cut lung slices of OPA tumours is a well-documented in vitro OPA model system. This technique could be used in a variety of tissue types such as canine and human breast tumours. These experiments would begin to validate the biomarkers in a more complex model system. Currently, we have no evidence regarding biomarker secretion profiles from cells that have received multiple radiation fractions or how these profiles change beyond 24 h post-radiation. Further experiments continuing this work could begin to answer these questions and help move towards biomarker validation in real cancer tissue. Time course experiments would also allow for fixation of tumour samples after each radiation fraction in order to assess gene expression and intra-cellular protein levels.

Detection of biomarkers in CM of cancer cells or explants could provide robust evidence of their secretion in response to radiation. However, these biomarkers will need to be shown to be detectable in blood before they can be used clinically. Detection protocols and methods would need to be developed for use with either plasma or serum, using techniques such as immunoprecipitation or ELISA. If in-lab detection of biomarkers in blood samples can be achieved, then this could increase the scope of experiments further to include obtaining blood samples from human and veterinary cancer patients undergoing RT. Further in vivo validation experiments could be performed using our novel paired sensitive and RR cell lines grown in a xenograft tumour model. Although the generation of xenograft tumours using our RR cell lines has not been attempted before, this would provide an excellent model to
identify differentially secreted biomarkers from known sensitive and RR tumours. Tumours could be radiated and 24 h post-treatment blood samples could be obtained for biomarker analysis.

In order to investigate mechanisms of biomarker secretion, further work could also assess extra-cellular vesicle secretion pathways, as literature searches identified that all 33 candidate biomarkers are known to be secreted in exosomes or microvesicles. Experimental work could include microvesicle and exosome isolation and biomarker detection from the CM following radiation of cells, MTS and explants. The UPR also warrants further investigation, as we showed that the 3 pathways (PERK, IRE1α and ATF6) are differentially activated in ER⁺ parental and RR cell lines and that several of our candidate biomarkers are involved with translation or protein trafficking. Using parental and RR cell lines, inhibition of each of the 3 pathways and through inducing ER stress and the UPR would indicate if these pathways play roles in radioresistance development or if they are involved in the secretion of our candidate biomarkers.

As we have shown that there is differential gene and intra-cellular protein expression between parental and RR cell lines, a further area of research would be to investigate whether these biomarkers could be used to produce a predictive signature of RT response. Validation of a panel of biomarkers with a gene signature that can differentiate between our parental and RR cell lines could initially be performed using publicly available datasets of breast cancer cell lines with a range of inherent radiosensitivities and by using clinical samples where follow up data on tumour recurrence and survival is known.

Running in parallel to the *in vitro* experiments, the animal work conducted in this PhD project was aimed at producing pre-clinical data on the safety and functionality of the IMPACT O₂ sensor.

The successful validation of the ability of the IMPACT O₂ sensor to accurately detect dynamic changes in intestinal ptO₂ through ischaemic insults and alterations in FiO₂ in our murine model has provided justification for progressing the experiments into more complex translational large animal anastomotic leak models. Pigs are regarded as excellent gastrointestinal translational models, as they are similar to humans in size, anatomy and physiology. A porcine anastomotic leak model using a
low rectal resection and anastomosis, performed with a double-stapled anastomosis without protective ileostoma, has previously been described in the literature. This model shows anastomotic leak rates of up to 30% within 9 days following surgery, which is similar to that reported in the human literature. Development of this model could be used in future experiments using the IMPACT O\textsubscript{2} sensors. Initial experiments using a porcine model could involve a staged series of experiments like those used in the development of our ovine model. Experiments would progress from post-mortem cases to develop the surgical technique and assess the feasibility of placing sensors around a low rectal anastomotic site, through to non-recovery and recovery procedures. Porcine non-recovery models could be performed in which sensors are placed on normal bowel, bowel rendered ischaemic by vascular ligation and in proximity to a rectal resection and anastomosis. The resection and anastomosis could also be made to leak through the creation of a full thickness incision through the intestinal wall across the anastomotic site. These experiments would provide data on the ability of the sensors to detect ptO\textsubscript{2} in normal, ischaemic and peri-anastomotic intestine, as well as assessing their suitability for surgical implantation. Clinical, haematological and biochemical data with regards to anastomotic leakage and septic peritonitis could also be obtained. If these initial experiments provide encouraging results, then studies could progress into recovery models providing further evidence of the in vivo safety and performance of the IMPACT O\textsubscript{2} sensors.

One question that needs to be answered if the IMPACT O\textsubscript{2} sensor is to be used for resection and anastomotic applications in patients is how these sensors might be placed at the anastomotic site during surgery so that they remain at the site to measure post-operative intestinal ptO\textsubscript{2}. Solutions to this issue would include their use akin to a surgical drain or through their incorporation into surgical staples.

Drains are used commonly in anastomotic surgery; although their effectiveness at reducing the occurrence of an anastomotic leak remains open to debate\textsuperscript{741-743} they are not associated with any significant complications. Drains are placed in the region of the anastomotic site and exit the body through a skin incision to be connected to external drainage bags. These drains can be easily removed when no longer required, typically several days post-surgery. Drains have been used to obtain post-operative

283
peritoneal samples from anastomotic sites for measuring bacterial colonisation, cytokines and metabolites that might serve as indicators of early anastomotic leakage. We envisage that designing the IMPACT O₂ sensor in a similar configuration to a surgical drain would allow easy clinical use. The sensors, along with an electrical lead (similar in design to the current IMPACT O₂ sensor and lead wire), could be positioned on the intestine next to the anastomosis site at the time of surgery. The electrical lead would then pass out through the skin in a similar manner to a surgical drain allowing the sensor to be connected to the end-of-bed monitor in the surgical high-dependency unit, providing the surgical team with post-operative, real-time data on peri-anastomotic intestinal pO₂ levels. The sensors could then be removed in a similar manner to the surgical drains. The advantage of this application would be that the IMPACT O₂ sensor would not require significant further development. Incorporation of IMPACT O₂ sensors into staples would have the advantage that peri-anastomotic pO₂ could be measured around the entire circumference of the intestine, thus providing detailed spatial information. However, further technological development of the sensor through miniaturisation and the development of wireless technology would be required in order to achieve sensor integration into surgical staples.

The development of our novel OPA model was aimed at validating functionality of the IMPACT O₂ sensor within a solid tumour. However, as the model successfully incorporated techniques commonly used in the management of human lung cancer patients, we have demonstrated the model’s translational potential and effectiveness as a pre-clinical model for human lung cancer. The use of the model for sensor implantation was associated with a complication rate similar to that seen in human medicine for TTNB, with pneumothorax being the most commonly encountered complication. We suspect that the size of the sensor and needle required for implantations were major contributing factors related to the complication rate seen. The potential for iatrogenic damage to alveolar spaces and small airways will be increased by using larger diameter implantation devices, which may then promote larger volumes of air to escape from airways within the lung into the pleural space. As the current IMPACT O₂ sensor is also wired, this meant that the lead wire had to run from the sensor (implanted within the tumour) through the chest wall to be
connected to external instrumentation. Although a subcutaneous tunnel was created to reduce the chances of air entering the thoracic cavity from the external environment, we did identify in a couple of cases air within subcutaneous tissues, suggesting that air was able to track within the needle tract created for sensor implantation. Further engineering development of the sensor, rather than modifying the model itself, will be needed to overcome these issues.

Further miniaturisation of the sensor will allow smaller gauge implantation needles to be used, which should reduce the volume of tissue damaged during implantation. Wireless technology would also eliminate the need for the lead wire and subcutaneous tunnel. If these technological advances could be achieved, then they could be utilised in experiments that require sheep to be recovered from anaesthesia following sensor implantation. Although we did investigate the use of wired sensors in recovery procedures by means of connecting the lead wire to a battery pack which was then secured to the sheep using a ram harness, this proved difficult to maintain for long periods of time and was not taken forward. The use of wireless sensors would overcome the need for external devices and make recovery procedures feasible. This would not only advance the OPA model but also provide a means by which new areas of research could be investigated, such as intra-tumoural biocompatibility and modelling of RT treatment programmes.

Our work to date did not investigate the effects of RT on in vivo sensor function; this will need to be addressed in the future as the primary aim of the IMPACT O₂ sensor is to monitor intra-tumoural pO₂ throughout a patient’s RT treatment programme. From initial CT scan images, before sensor implantation, RT treatment planning could be carried out in our model as is done in human medicine. Following routine sensor implantation, sheep could be allowed to recover from anaesthesia, and over a period of 2-3 weeks, undergo repeated anaesthetics and external beam RT. Clinically relevant fractionated dose regimes could be delivered to the OPA tumour which would validate the IMPACT O₂ sensor under clinically relevant conditions. Although this type of experiment would not be designed to assess the clinical response of the OPA tumour to RT, if they could be performed on multiple occasions over a period of several weeks then this would provide further evidence for the use of the IMPACT O₂ sensor towards clinical applications in cancer therapy.
Incorporating RT into the OPA model could also enable validation of the biomarkers released from OPA cancer cells in response to radiation. Blood samples taken before and 24 h after a radiation dose could be used to investigate the biomarkers identified through our *in vitro* secretomic experiments.

One of the limitations of the murine biofouling experiments was that the model was unable to be extended for periods that would include the entire chronic inflammatory phase of the FBR. Using OPA recovery procedures would overcome this limitation and would have the advantage of using functional sensors composed of all the biomaterials that were tested individually in the murine model. This would assess for any interactions between the individual biomaterials that could affect the FBR whilst using solid tumours in immunocompetent animals and provide further confidence in the intra-tumoural biocompatibility of the functional sensor and its constituent biomaterials.

The OPA model holds potential to be used for other pre-clinical applications beyond functional validation of the IMPACT O$_2$ sensor, especially as the disease itself is similar to human lung adenocarcinomas. The model could be adapted for the assessment of either systemically or locally delivered (image-guided injection or implantable drug release device) chemotherapeutic agents, with clinical effectiveness evaluated through a combination of imaging, on-treatment biopsies and post-mortem examination with sample collection.

The *in vivo* work described in this PhD study, ranging from small animal murine models to large animal ovine models, aimed to produce initial pre-clinical data to establish the safety and functionality of an implantable sensor that could be used to monitor *in vivo* environments in human medicine. While not specifically considered in this study, these implantable devices would be equally applicable for use in veterinary patients. Although significant progress has been made towards sensor validation for multiple clinical applications, further engineering development of the sensor with continued large animal validation is required. The ultimate goal of the project would be to apply to the Medicines and Healthcare products Regulatory Agency for approval for use in humans which would allow sensor validation to progress into human clinical trials.
10 References


Koong AC, Chen EY, Mivechi NF, Denko NC, Stambrook P, Giaccia AJ. Hypoxic activation of nuclear factor-κB is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Research 1994;54(20):5273-5279.


Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001;107(7):881-891.


119. Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J. Gene expression classifier predicts for hypoxic modification of radiotherapy with


150. Park J, Pak YK, Pak JJ. A microfabricated reservoir-type oxygen sensor for measuring the real-time cellular oxygen consumption rate at various conditions. Sensors and Actuators B: Chemical 2010;147(1):263-269.


186. McNally AK, Anderson JM. Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Differential lymphokine regulation of


Hoffman RM. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. The lancet oncology 2002;3(9):546-556.


309


310


376. Turnbull AK, Kitchen RR, Larionov AA, Renshaw L, Dixon JM, Sims AH. Direct integration of intensity-level data from Affymetrix and Illumina


317


Cooper S. Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points. The FASEB journal 2003;17(3):333-340.


Hershey JW. The role of eIF3 and its individual subunits in cancer. Biochim Biophys Acta 2015;1849(7):792-800.


Miller E, Antonny B, Hamamoto S, Schekman R. Cargo selection into COPII vesicles is driven by the Sec24p subunit. EMBO Journal 2002;21(22):6105-6113.


Tauro BJ, Greening DW, Mathias RA, Mathivanan S, Ji H, Simpson RJ. Two distinct populations of exosomes are released from LIM1863 colon


325.


623. Christenson EM, Anderson JM, Hiltner A. Oxidative mechanisms of poly (carbonate urethane) and poly (ether urethane) biodegradation: in vivo and in


## 11 Appendix

### 11.1 Gene lists used in chapter 4 for characterisation of the parental and radioresistant cell lines

Table 11.1. **Epithelial and mesenchymal gene lists.** Epithelial and mesenchymal genes are taken from a pan-cancer EMT-associated gene expression signature\textsuperscript{345}.

<table>
<thead>
<tr>
<th>Epithelial</th>
<th>Mesenchymal</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFTPH</td>
<td>ACOT9</td>
</tr>
<tr>
<td>AIM1L</td>
<td>LGALS1</td>
</tr>
<tr>
<td>ANKRD5</td>
<td>ANXA5</td>
</tr>
<tr>
<td>ANXA9</td>
<td>LOC100505634</td>
</tr>
<tr>
<td>API1M2</td>
<td>API5S2</td>
</tr>
<tr>
<td>ARHGEF16</td>
<td>MRC2</td>
</tr>
<tr>
<td>ARHGEF5</td>
<td>ASAP1</td>
</tr>
<tr>
<td>ATP2C2</td>
<td>MSN</td>
</tr>
<tr>
<td>ATXN7L3B</td>
<td>C14orf149</td>
</tr>
<tr>
<td>BLCAP</td>
<td>C17orf51</td>
</tr>
<tr>
<td>BSPRY</td>
<td>NMT2</td>
</tr>
<tr>
<td>C17orf28</td>
<td>C6orf225</td>
</tr>
<tr>
<td>C1orf172</td>
<td>C9orf21</td>
</tr>
<tr>
<td>C1orf210</td>
<td>P4HA3</td>
</tr>
<tr>
<td>C2orf15</td>
<td>CCDC98A</td>
</tr>
<tr>
<td>C6orf132</td>
<td>PDLM4</td>
</tr>
<tr>
<td>CASMAP3</td>
<td>CCDC99</td>
</tr>
<tr>
<td>CBLC</td>
<td>PGBD1</td>
</tr>
<tr>
<td>CCDC64B</td>
<td>EMP3</td>
</tr>
<tr>
<td>CDDC1</td>
<td>SACS</td>
</tr>
<tr>
<td>CDDH1</td>
<td>ETS1</td>
</tr>
<tr>
<td>CDDH3</td>
<td>SCARF2</td>
</tr>
<tr>
<td>CDS1</td>
<td>FAM101B</td>
</tr>
<tr>
<td>CDM7</td>
<td>SGCB</td>
</tr>
<tr>
<td>CMTM4</td>
<td>FAM127A</td>
</tr>
<tr>
<td>CNKSR1</td>
<td>SH2B3</td>
</tr>
<tr>
<td>CRB3</td>
<td>FERMT2</td>
</tr>
<tr>
<td>CTHS</td>
<td>ST3GAL2</td>
</tr>
<tr>
<td>CYB561</td>
<td>FEZ2</td>
</tr>
<tr>
<td>DDR1</td>
<td>STX2</td>
</tr>
<tr>
<td>DENND2D</td>
<td>FGRF1</td>
</tr>
<tr>
<td>DSP</td>
<td>SYDE1</td>
</tr>
<tr>
<td>DTX4</td>
<td>GFRF1</td>
</tr>
<tr>
<td>DFNA1</td>
<td>ZEB1</td>
</tr>
<tr>
<td>ELF1</td>
<td>GNAI2</td>
</tr>
<tr>
<td>ELF3</td>
<td>TTC7B</td>
</tr>
<tr>
<td>ENG</td>
<td>HABP4</td>
</tr>
<tr>
<td>FFAR2</td>
<td>IKBIP</td>
</tr>
<tr>
<td>GMTL2</td>
<td>UROD</td>
</tr>
<tr>
<td>HNRNPA</td>
<td>KATNAL1</td>
</tr>
<tr>
<td>ITPKC</td>
<td>VIM</td>
</tr>
<tr>
<td>JUP</td>
<td>KIAA1949</td>
</tr>
<tr>
<td>LNX1</td>
<td>WTIP</td>
</tr>
<tr>
<td>LNX2</td>
<td>LAT52</td>
</tr>
<tr>
<td>LOC440335</td>
<td>WWC2</td>
</tr>
<tr>
<td>LOC15A2</td>
<td>LEPRE1</td>
</tr>
<tr>
<td>MAP72A</td>
<td>ZEB1</td>
</tr>
</tbody>
</table>

\textsuperscript{345}Data from Reference 345.
Table 11.2. WNT signalling and WNT target gene lists. WNT signalling pathway members and their down-stream targets were taken from the KEGG database\textsuperscript{342}.

<table>
<thead>
<tr>
<th>WNT Signalling</th>
<th>WNT Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVL2</td>
<td>LEF1</td>
</tr>
<tr>
<td>DKK3</td>
<td>PRICKLE1</td>
</tr>
<tr>
<td>RHOA</td>
<td>WNT9A</td>
</tr>
<tr>
<td>LRP6</td>
<td>SKP2</td>
</tr>
<tr>
<td>FBXW11</td>
<td>TCF7L1</td>
</tr>
<tr>
<td>GSK3B</td>
<td>FZD7</td>
</tr>
<tr>
<td>NLK</td>
<td>FZD1</td>
</tr>
<tr>
<td>EP300</td>
<td>CTBP1</td>
</tr>
<tr>
<td>DAAM1</td>
<td>LRP5</td>
</tr>
<tr>
<td>PORCN</td>
<td>FZD5</td>
</tr>
<tr>
<td>AXIN1</td>
<td>FZD6</td>
</tr>
<tr>
<td>FZD3</td>
<td>FRAT1</td>
</tr>
<tr>
<td>DVL1</td>
<td>BTRC</td>
</tr>
<tr>
<td>MAPK8</td>
<td>CTNNB1</td>
</tr>
<tr>
<td>DKK1</td>
<td>AXIN2</td>
</tr>
<tr>
<td>CCND1</td>
<td>FZD4</td>
</tr>
<tr>
<td>WNT5B</td>
<td>FOSL1</td>
</tr>
<tr>
<td>PPARD</td>
<td>RUVBL1</td>
</tr>
<tr>
<td>CSNK1A1</td>
<td>FZD8</td>
</tr>
<tr>
<td>WNT5A</td>
<td>JUN</td>
</tr>
<tr>
<td>NFATC1</td>
<td>CTNNBP1</td>
</tr>
<tr>
<td>APC</td>
<td>FZD2</td>
</tr>
<tr>
<td>MYC</td>
<td>WNT7B</td>
</tr>
</tbody>
</table>
11.2 Protein lists generated in chapter 5 for characterisation of MCF-7 secretome

Table 11.3. The total 927 secreted proteins identified in the conditioned media of untreated MCF-7 cells up to 24 h post-serum starvation.

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CON P02769</td>
<td>HSPA4</td>
<td>HIST1H4A</td>
<td>CNDP2</td>
<td>NPEPL1</td>
</tr>
<tr>
<td>PPIA</td>
<td>TXNDC17</td>
<td>YWAHAQ</td>
<td>G6PD</td>
<td>PTMA</td>
</tr>
<tr>
<td>ENO1</td>
<td>GDH</td>
<td>MTPN</td>
<td>AKR1A1</td>
<td>TMA7</td>
</tr>
<tr>
<td>ALDOA</td>
<td>RPL11</td>
<td>FANCD2</td>
<td>CON P02668</td>
<td>HMGN1</td>
</tr>
<tr>
<td>HSPA8</td>
<td>GLO1</td>
<td>CON P00978</td>
<td>PPP1CA</td>
<td>FAHD1</td>
</tr>
<tr>
<td>TP1</td>
<td>YWAHA</td>
<td>UBE2I</td>
<td>CKAP4</td>
<td>RRM2</td>
</tr>
<tr>
<td>CFL1</td>
<td>EIF5A</td>
<td>CS</td>
<td>HSPH1</td>
<td>NUDT2</td>
</tr>
<tr>
<td>GAPDH</td>
<td>CON Q3SZR3</td>
<td>YWAHA</td>
<td>CON P02663</td>
<td>DDT</td>
</tr>
<tr>
<td>HSPA1B</td>
<td>ADH5</td>
<td>ALDH9A1</td>
<td>ADK</td>
<td>GMFB</td>
</tr>
<tr>
<td>KRT8</td>
<td>DPP3</td>
<td>NUTF2</td>
<td>TTN</td>
<td>HSPB11</td>
</tr>
<tr>
<td>FGK1</td>
<td>PGLS</td>
<td>RNPEP</td>
<td>LRRCC1</td>
<td>GLUD1</td>
</tr>
<tr>
<td>ACTB</td>
<td>KRT1</td>
<td>PGP</td>
<td>KARS</td>
<td>CON 24466</td>
</tr>
<tr>
<td>FBP1</td>
<td>ATIC</td>
<td>FABP5</td>
<td>NEDD8 MDP1</td>
<td>UBE2L3</td>
</tr>
<tr>
<td>PEBP1</td>
<td>PDIA3</td>
<td>Clorf123</td>
<td>HPRT1</td>
<td>ACO2</td>
</tr>
<tr>
<td>CALM1</td>
<td>APEX1</td>
<td>PGD</td>
<td>SHMT1</td>
<td>TFF1</td>
</tr>
<tr>
<td>MIF</td>
<td>PA2G4</td>
<td>PEPD</td>
<td>DLD</td>
<td>LSM2</td>
</tr>
<tr>
<td>MDH2</td>
<td>NPEPPS</td>
<td>LXN</td>
<td>PCNA</td>
<td>CON P06868</td>
</tr>
<tr>
<td>GDI</td>
<td>HMGN2</td>
<td>DNPEP</td>
<td>NLN</td>
<td>GNPD1</td>
</tr>
<tr>
<td>TMSB4X</td>
<td>HSPA6</td>
<td>ERH</td>
<td>CON REFSEQ</td>
<td>OTUB1</td>
</tr>
<tr>
<td>PGAM1</td>
<td>SORD</td>
<td>CON P02662</td>
<td>DDAH2</td>
<td>CBS</td>
</tr>
<tr>
<td>YWAHAZ</td>
<td>TALDO1</td>
<td>SH3BGR1</td>
<td>GCLC</td>
<td>TRPV1</td>
</tr>
<tr>
<td>LDHA</td>
<td>COTL1</td>
<td>ES</td>
<td>DCTPP1</td>
<td>TRFC</td>
</tr>
<tr>
<td>MDH1</td>
<td>PNP</td>
<td>CON Q95121</td>
<td>CKMT1A</td>
<td>TATDN1</td>
</tr>
<tr>
<td>CON P00761</td>
<td>SUMO2</td>
<td>HIST1H2AJ</td>
<td>LSM3</td>
<td>PPP1CC</td>
</tr>
<tr>
<td>SOD1</td>
<td>CON Q2KJF1</td>
<td>KRT19</td>
<td>GSTM3</td>
<td>BOLA2</td>
</tr>
<tr>
<td>CON Q3SZ57</td>
<td>GGCT</td>
<td>PRDX6</td>
<td>PGM2</td>
<td>SHMT2</td>
</tr>
<tr>
<td>YWAHA</td>
<td>DDB1</td>
<td>WDR1</td>
<td>HIST2H3A</td>
<td>MAT2B</td>
</tr>
<tr>
<td>TKT</td>
<td>GLOD4</td>
<td>GOT2</td>
<td>PHPT1</td>
<td>DLG1</td>
</tr>
<tr>
<td>CON Q01K2</td>
<td>CON P02754</td>
<td>RBBP4</td>
<td>TARS</td>
<td>MYH9</td>
</tr>
<tr>
<td>PFN1</td>
<td>CBR1</td>
<td>PKM</td>
<td>ENO2</td>
<td>PCBD1</td>
</tr>
<tr>
<td>UBA52</td>
<td>TXNRD1</td>
<td>THOP1</td>
<td>MAT2A</td>
<td>GYG1</td>
</tr>
<tr>
<td>NAPA</td>
<td>TPT1</td>
<td>ASS1</td>
<td>RAB11A</td>
<td>CON 18229</td>
</tr>
<tr>
<td>CLIC1</td>
<td>CON P12763</td>
<td>NME2</td>
<td>IDH1</td>
<td>EIF4H</td>
</tr>
<tr>
<td>KRT18</td>
<td>LAP3</td>
<td>AIMP1</td>
<td>GCSH</td>
<td>NUDT1</td>
</tr>
<tr>
<td>GNB2L1</td>
<td>KRT10</td>
<td>APEH</td>
<td>S100A11</td>
<td>TXN</td>
</tr>
<tr>
<td>PPIB</td>
<td>FBP2</td>
<td>CON Q55D62</td>
<td>MYDGF</td>
<td>TBCA</td>
</tr>
<tr>
<td>DUT</td>
<td>GSR</td>
<td>RCC2</td>
<td>GNPAT1</td>
<td>DDH1</td>
</tr>
<tr>
<td>GD2</td>
<td>KRT9</td>
<td>CSTB</td>
<td>CON P41361</td>
<td>TSN</td>
</tr>
<tr>
<td>RAN</td>
<td>DSTN</td>
<td>LTAH4</td>
<td>CON P28800</td>
<td>ACTG1</td>
</tr>
<tr>
<td>TMSB10</td>
<td>HIST1H2BM</td>
<td>DBI</td>
<td>EIF6</td>
<td>PP1F</td>
</tr>
<tr>
<td>CON Q3MHN5</td>
<td>CON Q3SZV7</td>
<td>SEN</td>
<td>ACLY</td>
<td>DYNC1L2</td>
</tr>
<tr>
<td>CON P34955</td>
<td>GSS</td>
<td>Streptavidin</td>
<td>PPIL3</td>
<td>ME1</td>
</tr>
<tr>
<td>ALDOC</td>
<td>YWAHA</td>
<td>FH</td>
<td>CMPK1</td>
<td>TXNL1</td>
</tr>
<tr>
<td>PARK7</td>
<td>SELENBP1</td>
<td>SCR1</td>
<td>MT2A</td>
<td>HMCN1</td>
</tr>
<tr>
<td>TSTA3</td>
<td>DNAE2</td>
<td>PDAP1</td>
<td>EE1A1P5</td>
<td>SPTAN1</td>
</tr>
<tr>
<td>CON P21752</td>
<td>PSMA7</td>
<td>RAC1</td>
<td>FLNB</td>
<td>PPP2R1A</td>
</tr>
<tr>
<td>HN1</td>
<td>DPYSL2</td>
<td>GORASP2</td>
<td>ALB</td>
<td>UGF2</td>
</tr>
<tr>
<td>WDR5</td>
<td>NT5DC1</td>
<td>FLS3</td>
<td>F11</td>
<td>FKB2</td>
</tr>
</tbody>
</table>

343
<table>
<thead>
<tr>
<th>Gene 1</th>
<th>Gene 2</th>
<th>Gene 3</th>
<th>Gene 4</th>
<th>Gene 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRIM28</td>
<td>GSTO1</td>
<td>REXO2</td>
<td>PRDX1</td>
<td>ABCE1</td>
</tr>
<tr>
<td>MSN</td>
<td>ADSS</td>
<td>ANXA5</td>
<td>ACTN1</td>
<td>RANBP1</td>
</tr>
<tr>
<td>ECI1</td>
<td>COX17</td>
<td>PTRHD1</td>
<td>VCP</td>
<td>GABARAPL2</td>
</tr>
<tr>
<td>OLA1</td>
<td>ANXA3</td>
<td>CSDE1</td>
<td>CANX</td>
<td>UFM1</td>
</tr>
<tr>
<td>PFAS</td>
<td>NANS</td>
<td>TCEB2</td>
<td>CLTC</td>
<td>AARS</td>
</tr>
<tr>
<td>CON P50448</td>
<td>HN1L</td>
<td>LMAN2</td>
<td>RCN1</td>
<td>VAPA</td>
</tr>
<tr>
<td>CPPED1</td>
<td>YTHDF2</td>
<td>ABAT</td>
<td>HSPE1</td>
<td>RAB21</td>
</tr>
<tr>
<td>FLNA</td>
<td>FKBP4</td>
<td>HSPB1</td>
<td>SGTA</td>
<td>CRYZ</td>
</tr>
<tr>
<td>OAT</td>
<td>MAPRE1</td>
<td>RPSA</td>
<td>RAB7A</td>
<td>NQO1</td>
</tr>
<tr>
<td>ARHGDI1</td>
<td>PPIH</td>
<td>CON P17690</td>
<td>RABIF</td>
<td>ARMT1</td>
</tr>
<tr>
<td>HSPA4L</td>
<td>ISOC1</td>
<td>CON Q3Y5Z3</td>
<td>TUBA1B</td>
<td>TAGLN2</td>
</tr>
<tr>
<td>EIF2A</td>
<td>ENOPH1</td>
<td>COX4I1</td>
<td>AHCY</td>
<td>FSCN1</td>
</tr>
<tr>
<td>FDP5</td>
<td>HI1A</td>
<td>ACTN4</td>
<td>CYCS</td>
<td>PPAI</td>
</tr>
<tr>
<td>NIF3L1</td>
<td>SERF2</td>
<td>SH3BGRL</td>
<td>HSPA9</td>
<td>CDH1</td>
</tr>
<tr>
<td>PPP1CB</td>
<td>DTP2</td>
<td>MAGOHB</td>
<td>EEF2</td>
<td>SLC9A3R1</td>
</tr>
<tr>
<td>APRT</td>
<td>MVD</td>
<td>HNRNPA1</td>
<td>HNRNPA2B1</td>
<td>ACA2</td>
</tr>
<tr>
<td>CON P02672</td>
<td>IDI1</td>
<td>CON Q3KUS7</td>
<td>NME1</td>
<td>UBA1</td>
</tr>
<tr>
<td>OVCA2</td>
<td>CON Q1RMN8</td>
<td>LGALS3BP</td>
<td>P4HB</td>
<td>S100A16</td>
</tr>
<tr>
<td>PROSC</td>
<td>POLR2H2</td>
<td>NIT2</td>
<td>TPM4</td>
<td>PYCARD</td>
</tr>
<tr>
<td>FAH</td>
<td>PIR</td>
<td>RAB6B</td>
<td>HNRNPAB</td>
<td>PLOD3</td>
</tr>
<tr>
<td>CON 38329</td>
<td>VCL</td>
<td>CTSB</td>
<td>QSOX1</td>
<td>PSMB2</td>
</tr>
<tr>
<td>BLMH</td>
<td>WDR12</td>
<td>KRT2</td>
<td>ECH1</td>
<td>PSPH</td>
</tr>
<tr>
<td>CBR3</td>
<td>CALU</td>
<td>PSMB1</td>
<td>EIF5</td>
<td>ACTA1</td>
</tr>
<tr>
<td>VAPB</td>
<td>EIF2S2</td>
<td>CON Q9TRI1</td>
<td>ARPC4</td>
<td>PSMA1</td>
</tr>
<tr>
<td>MAP4</td>
<td>GRPEL1</td>
<td>HSPA5</td>
<td>OXCT1</td>
<td>PIN4</td>
</tr>
<tr>
<td>BASP1</td>
<td>BPN1</td>
<td>DTD1</td>
<td>ERP29</td>
<td>CNBP</td>
</tr>
<tr>
<td>S100A13</td>
<td>GLRX</td>
<td>CTSD</td>
<td>CON 15497</td>
<td>A0A0U1RRE5</td>
</tr>
<tr>
<td>PPP2R4</td>
<td>ZNF300</td>
<td>PCMT1</td>
<td>HPDL</td>
<td>VPS26A</td>
</tr>
<tr>
<td>UFC1</td>
<td>HEBP2</td>
<td>PLEC</td>
<td>BANF1</td>
<td>COR1B</td>
</tr>
<tr>
<td>PFN2</td>
<td>VPS29</td>
<td>UBE2V1</td>
<td>AIFM1</td>
<td>PSMA2</td>
</tr>
<tr>
<td>LAMB1</td>
<td>ANXA2</td>
<td>TP53I3</td>
<td>C21orf33</td>
<td>SPARC</td>
</tr>
<tr>
<td>EPPK1</td>
<td>AAMP</td>
<td>UBE2V2</td>
<td>MAPK1IP1L</td>
<td>ARPC2</td>
</tr>
<tr>
<td>CON Q2UVX4</td>
<td>HSPD1</td>
<td>PSAT1</td>
<td>PSAP</td>
<td>ACTR3</td>
</tr>
<tr>
<td>ACYP1</td>
<td>NAGK</td>
<td>CMBL</td>
<td>MANF</td>
<td>IGHA2</td>
</tr>
<tr>
<td>MIPOL1</td>
<td>NRBP1</td>
<td>PROCR</td>
<td>PSMA6</td>
<td>RAD23B</td>
</tr>
<tr>
<td>RBBP9</td>
<td>ADI1</td>
<td>CON Q9QWL7</td>
<td>WARS</td>
<td>KRT5</td>
</tr>
<tr>
<td>IMPA1</td>
<td>DENER</td>
<td>RAP1B</td>
<td>PARS2</td>
<td>APOA1BP</td>
</tr>
<tr>
<td>FKBP1A</td>
<td>PPI1</td>
<td>CTTN</td>
<td>HDGF</td>
<td>CTSL</td>
</tr>
<tr>
<td>FASN</td>
<td>HRSPI2</td>
<td>LMNB1</td>
<td>PRDX2</td>
<td>RAB1A</td>
</tr>
<tr>
<td>VIM</td>
<td>EML2</td>
<td>TD52L2</td>
<td>STARD10</td>
<td>TXND12</td>
</tr>
<tr>
<td>NR2C2AP</td>
<td>GART</td>
<td>SPINT2</td>
<td>DSG2</td>
<td>PSMA4</td>
</tr>
<tr>
<td>CLIC4</td>
<td>NUP37</td>
<td>PRRC2C</td>
<td>PDXK</td>
<td>RNH1</td>
</tr>
<tr>
<td>BLVRB</td>
<td>SUMO1</td>
<td>EIF4A1</td>
<td>PAFAH1B3</td>
<td>ACP1</td>
</tr>
<tr>
<td>RPL19</td>
<td>CNPY2</td>
<td>B2M</td>
<td>TUBB</td>
<td>RSU1</td>
</tr>
<tr>
<td>EE1FG</td>
<td>CON Q9TT36</td>
<td>CST3</td>
<td>LDLR</td>
<td>IGHG1</td>
</tr>
<tr>
<td>PRKCSH</td>
<td>CSTF1</td>
<td>AP1G1</td>
<td>EEF1A2</td>
<td>FKBP3</td>
</tr>
<tr>
<td>PSMB5</td>
<td>DYNLL2</td>
<td>C1orf54</td>
<td>GGH</td>
<td>KRT16</td>
</tr>
<tr>
<td>FAICS</td>
<td>ZNF706</td>
<td>NBEA</td>
<td>UCHL1</td>
<td>EIF4EBP1</td>
</tr>
<tr>
<td>KPNA2</td>
<td>BAG3</td>
<td>NUDT14</td>
<td>COPB2</td>
<td>GCLM</td>
</tr>
<tr>
<td>ATP5B</td>
<td>TAX1BP3</td>
<td>MCM4</td>
<td>MB</td>
<td>GLA</td>
</tr>
<tr>
<td>PSMA5</td>
<td>EZR</td>
<td>RBMX</td>
<td>CCT3</td>
<td>LRRCC59</td>
</tr>
<tr>
<td>SLC7A5</td>
<td>CON Q2KIT0</td>
<td>ALAD</td>
<td>NUDT3</td>
<td>PCNP</td>
</tr>
<tr>
<td>MTDH</td>
<td>PAFAH1B1</td>
<td>C1QBP</td>
<td>NASP</td>
<td>TWF1</td>
</tr>
<tr>
<td>LAMC1</td>
<td>DCPS</td>
<td>PDCD5</td>
<td>TCP1</td>
<td>CD44</td>
</tr>
<tr>
<td>CKS1B</td>
<td>CLEC3B</td>
<td>ASNS</td>
<td>RNASET2</td>
<td>VBP1</td>
</tr>
<tr>
<td>Gene</td>
<td>Gene</td>
<td>Gene</td>
<td>Gene</td>
<td>Gene</td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>RBM8A</td>
<td>PVRL4</td>
<td>ETF1</td>
<td>PMM2</td>
<td>GFRA1</td>
</tr>
<tr>
<td>PPP1R14B</td>
<td>UBE2A</td>
<td>TPM3</td>
<td>CON 2777</td>
<td>CIRBP</td>
</tr>
<tr>
<td>SCIN</td>
<td>CON 735</td>
<td>PRTFDC1</td>
<td>HEXB</td>
<td>RPS3</td>
</tr>
<tr>
<td>PKIB</td>
<td>CON P19001</td>
<td>HMGN3</td>
<td>MCM4</td>
<td>ABHD14B</td>
</tr>
<tr>
<td>PGM1</td>
<td>DHX38</td>
<td>PLIN3</td>
<td>XRC6</td>
<td>UBE2N</td>
</tr>
<tr>
<td>SERPINB1</td>
<td>CAPN1</td>
<td>CFL2</td>
<td>RUVBL2</td>
<td>NLE1</td>
</tr>
<tr>
<td>ARPC5</td>
<td>CCT8</td>
<td>TMSB15B</td>
<td>SUPT5H</td>
<td>UBAP2L</td>
</tr>
<tr>
<td>UCHL3</td>
<td>MYL6</td>
<td>PTPRK</td>
<td>IQGAP1</td>
<td>GOLM1</td>
</tr>
<tr>
<td>GRB2</td>
<td>Sep-02</td>
<td>ARFIP1</td>
<td>HIST1H1B</td>
<td>KRT7</td>
</tr>
<tr>
<td>P2P2CA</td>
<td>PVRL1</td>
<td>KRT6A</td>
<td>HPX</td>
<td>MAVS</td>
</tr>
<tr>
<td>CUTA</td>
<td>WDR92</td>
<td>NUP107</td>
<td>GARS</td>
<td>TLN1</td>
</tr>
<tr>
<td>RARS</td>
<td>EEF1B1</td>
<td>HNRNPM</td>
<td>EPRS</td>
<td>EFNA1</td>
</tr>
<tr>
<td>KIAA1279</td>
<td>CAPZ1A</td>
<td>EIF3G</td>
<td>CON 81644</td>
<td>EIF3A</td>
</tr>
<tr>
<td>LANCL1</td>
<td>CDV3</td>
<td>EPCAM</td>
<td>GSN</td>
<td>TMPO</td>
</tr>
<tr>
<td>ARCN1</td>
<td>RPIA</td>
<td>CARHSP1</td>
<td>CTC5</td>
<td>RPL27A</td>
</tr>
<tr>
<td>CON 3SZH5</td>
<td>RAB14</td>
<td>BTD</td>
<td>CORO1C</td>
<td>PABPC1</td>
</tr>
<tr>
<td>DAG1</td>
<td>PSME1</td>
<td>LACTB2</td>
<td>GNS</td>
<td>LDHB</td>
</tr>
<tr>
<td>EIF1AX</td>
<td>SUMO3</td>
<td>PPP5C</td>
<td>SKP1</td>
<td>DSP</td>
</tr>
<tr>
<td>HIST1H1C</td>
<td>KATNAL2</td>
<td>HAGH</td>
<td>STMN1</td>
<td>PITHD1</td>
</tr>
<tr>
<td>BCAT2</td>
<td>ESYT1</td>
<td>SHROOM2</td>
<td>HSP90AA1</td>
<td>MARCKSL1</td>
</tr>
<tr>
<td>GMPS</td>
<td>EIF4B</td>
<td>CAPRIN1</td>
<td>FREM2</td>
<td>ACACA</td>
</tr>
<tr>
<td>EDF1</td>
<td>AK2</td>
<td>PIN1</td>
<td>RPL10A</td>
<td>PC</td>
</tr>
<tr>
<td>ISG15</td>
<td>AK1</td>
<td>CTSC</td>
<td>GLRX3</td>
<td>CCT6A</td>
</tr>
<tr>
<td>CALR</td>
<td>SFPQ</td>
<td>LMNA</td>
<td>SLC3A2</td>
<td>PCCB</td>
</tr>
<tr>
<td>ITTPA</td>
<td>COPG1</td>
<td>PUF60</td>
<td>EIF4G2</td>
<td>KRT6B</td>
</tr>
<tr>
<td>CRK</td>
<td>SRP9</td>
<td>LCPI</td>
<td>MAP7</td>
<td>PCCA</td>
</tr>
<tr>
<td>DDX39B</td>
<td>CRABP2</td>
<td>SEC23B</td>
<td>SART3</td>
<td>KRT14</td>
</tr>
<tr>
<td>PSMA3</td>
<td>RPS2B</td>
<td>TOP1</td>
<td>SRRM2</td>
<td>SDC1</td>
</tr>
<tr>
<td>TXN2</td>
<td>PAWR</td>
<td>PBP1</td>
<td>EIF2B1</td>
<td>CON 8VED5</td>
</tr>
<tr>
<td>CLSTN1</td>
<td>GOT1</td>
<td>PSMB7</td>
<td>HTATSF1</td>
<td>TWSG1</td>
</tr>
<tr>
<td>PCK2</td>
<td>CON 7350</td>
<td>YBX1</td>
<td>DDR1</td>
<td>S100A6</td>
</tr>
<tr>
<td>PREPL</td>
<td>CBX3</td>
<td>CAP1</td>
<td>LSM6</td>
<td>FUCA2</td>
</tr>
<tr>
<td>RPE</td>
<td>CON V8M9</td>
<td>MYOD1</td>
<td>GALNS</td>
<td>ZBTB8OS</td>
</tr>
<tr>
<td>PSMB6</td>
<td>ADPRHL2</td>
<td>ALCAM</td>
<td>DLS7</td>
<td>GNB4</td>
</tr>
<tr>
<td>XPNPEP1</td>
<td>HARS</td>
<td>CON Q2KJ62</td>
<td>HIST1H1D</td>
<td>KRT74</td>
</tr>
<tr>
<td>TXNDC5</td>
<td>STIP1</td>
<td>FKBP15</td>
<td>CRKL</td>
<td>CON 1252647</td>
</tr>
<tr>
<td>LGALS1</td>
<td>CON 7665</td>
<td>MSRA</td>
<td>COL5A1</td>
<td>KRT6C</td>
</tr>
<tr>
<td>MYH15</td>
<td>UBE2K</td>
<td>CAST</td>
<td>ENSA</td>
<td>CON Q95M1</td>
</tr>
<tr>
<td>HMGN4</td>
<td>USP8</td>
<td>RPL5</td>
<td>MARCKS</td>
<td>CSNK1A1</td>
</tr>
<tr>
<td>MT1E</td>
<td>STMN2</td>
<td>PTK7</td>
<td>DBN1</td>
<td>RABEP1</td>
</tr>
<tr>
<td>TPP2</td>
<td>SEC24C</td>
<td>PCBP2</td>
<td>NPW</td>
<td>S100A8</td>
</tr>
<tr>
<td>AMY1A</td>
<td>MYO1C</td>
<td>XRC5</td>
<td>PPP2R5E</td>
<td>TOR1AIP1</td>
</tr>
<tr>
<td>DYNC1H1</td>
<td>CON Q32PI4</td>
<td>SCAMP3</td>
<td>SNRPD3</td>
<td>SUCLGI</td>
</tr>
<tr>
<td>CON P01966</td>
<td>HNRNPU</td>
<td>SLC25A5</td>
<td>AP2B1</td>
<td>SF3B4</td>
</tr>
<tr>
<td>COX7C</td>
<td>KIF5A</td>
<td>CAPZB</td>
<td>CCT7</td>
<td>SNRPC</td>
</tr>
<tr>
<td>THBS1</td>
<td>F11R</td>
<td>CON Q3SX09</td>
<td>EIF4G1</td>
<td>PSMD6</td>
</tr>
<tr>
<td>RBBP7</td>
<td>BID</td>
<td>SF3B3</td>
<td>DARS</td>
<td>SNRPA</td>
</tr>
<tr>
<td>CON P03730-1</td>
<td>IGFBP4</td>
<td>PRPF19</td>
<td>PITPNB</td>
<td>LASP1</td>
</tr>
<tr>
<td>HNRNPD</td>
<td>CAD</td>
<td>PTBP1</td>
<td>AP1B1</td>
<td>RPS10</td>
</tr>
<tr>
<td>PSMB3</td>
<td>CLEC3A</td>
<td>ILF3</td>
<td>SEC13</td>
<td>CCD124</td>
</tr>
<tr>
<td>SORT1</td>
<td>THUMPDP1</td>
<td>LGMN</td>
<td>AREG</td>
<td>NR1P1</td>
</tr>
<tr>
<td>SERBP1</td>
<td>KHDRBS1</td>
<td>TNF1SF12A</td>
<td>IAR5</td>
<td>DDX17</td>
</tr>
<tr>
<td>NAGLU</td>
<td>SERPINB9</td>
<td>DDX21</td>
<td>CON 3ZBS7</td>
<td>EFHD1</td>
</tr>
<tr>
<td>ALYREF</td>
<td>HSP90AB1</td>
<td>HK1</td>
<td>SEC23A</td>
<td>BROX</td>
</tr>
<tr>
<td>TSNAX</td>
<td>NUCB1</td>
<td>PSMC2</td>
<td>PCSK1N</td>
<td>PHGDH</td>
</tr>
</tbody>
</table>
Table 11.4. The 239 secreted proteins common to all time points in the conditioned media of untreated MCF-7 cells up to 24 h post-serum starvation.

<table>
<thead>
<tr>
<th>Protein</th>
<th>CON 2769</th>
<th>LDHA</th>
<th>ALDOC</th>
<th>SORD</th>
<th>HIST1H2BM</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPIA</td>
<td>MDH1</td>
<td>PARK7</td>
<td>TALD01</td>
<td>GSS</td>
<td>CON Q3SZV7</td>
</tr>
<tr>
<td>ENO1</td>
<td>CON P00761</td>
<td>HSPA4</td>
<td>COTL1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDOA</td>
<td>SOD1</td>
<td>TXNDC17</td>
<td>PNP</td>
<td></td>
<td>YWHAQ</td>
</tr>
<tr>
<td>HSPA8</td>
<td>CON Q3SZ57</td>
<td>GID1</td>
<td>SUMO2</td>
<td></td>
<td>SELENBP1</td>
</tr>
<tr>
<td>TPI1</td>
<td>YWHAE</td>
<td>RPL11</td>
<td>CON Q2KJF1</td>
<td>HIST1H4A</td>
<td></td>
</tr>
<tr>
<td>CFL1</td>
<td>TKT</td>
<td>GLL1</td>
<td>GGCT</td>
<td>YWHAQ</td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>CON Q0IJK2</td>
<td>YWHAH</td>
<td>DDB1</td>
<td></td>
<td>MTPN</td>
</tr>
<tr>
<td>HSPA1B</td>
<td>PFN1</td>
<td>EIF5A</td>
<td>GLOD4</td>
<td>FANCD2</td>
<td></td>
</tr>
<tr>
<td>KRT8</td>
<td>UBA52</td>
<td>CON Q3SZR3</td>
<td>CON P02754</td>
<td>CON P00978</td>
<td></td>
</tr>
<tr>
<td>PGK1</td>
<td>NAPA</td>
<td>ADI5</td>
<td>CBR1</td>
<td>UBE2I</td>
<td></td>
</tr>
<tr>
<td>ACTB</td>
<td>CLI1</td>
<td>DPP3</td>
<td>TXNRD1</td>
<td>CS</td>
<td></td>
</tr>
<tr>
<td>FBP1</td>
<td>KRT18</td>
<td>PGLS</td>
<td>TPT1</td>
<td>YWHAH</td>
<td></td>
</tr>
<tr>
<td>PEBP1</td>
<td>GNB2L1</td>
<td>KRT1</td>
<td>CON P12763</td>
<td>ALDH9A1</td>
<td></td>
</tr>
<tr>
<td>CALM1</td>
<td>PPIB</td>
<td>ATIC</td>
<td>LAP3</td>
<td>NUTF2</td>
<td></td>
</tr>
<tr>
<td>MIF</td>
<td>DUT</td>
<td>PDIA3</td>
<td>KRT10</td>
<td>RNPEP</td>
<td></td>
</tr>
<tr>
<td>MDH2</td>
<td>GD2</td>
<td>APEX1</td>
<td>FBP2</td>
<td>PGP</td>
<td></td>
</tr>
<tr>
<td>GAPI</td>
<td>RAN</td>
<td>PA2G4</td>
<td>GSR</td>
<td>FABP5</td>
<td></td>
</tr>
<tr>
<td>TMSB4X</td>
<td>TMSB10</td>
<td>NPEPS</td>
<td>CON 24146</td>
<td>Clorf123</td>
<td></td>
</tr>
<tr>
<td>PGAM1</td>
<td>CON Q3MHN5</td>
<td>HMGN2</td>
<td>KRT9</td>
<td>PGD</td>
<td></td>
</tr>
<tr>
<td>YWHAZ</td>
<td>CON P34955</td>
<td>HSPA6</td>
<td>DSTN</td>
<td>PEPD</td>
<td></td>
</tr>
<tr>
<td>LNX</td>
<td>G6PD</td>
<td>CON 28800</td>
<td>EIF4H</td>
<td>ADSS</td>
<td></td>
</tr>
<tr>
<td>DNPEP</td>
<td>AKR1A1</td>
<td>EIF6</td>
<td>TXN</td>
<td>COX17</td>
<td></td>
</tr>
<tr>
<td>ERH</td>
<td>CON P02668</td>
<td>ACLY</td>
<td>DDAH1</td>
<td>YTHDF2</td>
<td></td>
</tr>
<tr>
<td>CON 02662</td>
<td>PPP1CA</td>
<td>PPI3</td>
<td>TSN</td>
<td>FKBP4</td>
<td></td>
</tr>
<tr>
<td>SH3BGRL3</td>
<td>CKA4P4</td>
<td>CMPK1</td>
<td>PPIF</td>
<td>SERF2</td>
<td></td>
</tr>
<tr>
<td>CON 95121</td>
<td>HSPN1</td>
<td>MT2A</td>
<td>ME1</td>
<td>ID1</td>
<td></td>
</tr>
<tr>
<td>HIST1H2AJ</td>
<td>CON P02663</td>
<td>NPEPL1</td>
<td>TSTA3</td>
<td>CON IRMN8</td>
<td></td>
</tr>
<tr>
<td>KRT19</td>
<td>TTN</td>
<td>PTMA</td>
<td>CON P21752</td>
<td>POLR2H</td>
<td></td>
</tr>
<tr>
<td>PRDX6</td>
<td>LRRCC1</td>
<td>TMA7</td>
<td>HN1</td>
<td>HEBP2</td>
<td></td>
</tr>
<tr>
<td>GOT2</td>
<td>KARS</td>
<td>HMGN1</td>
<td>WDR5</td>
<td>ADI1</td>
<td></td>
</tr>
<tr>
<td>RBBP4</td>
<td>NEDD8-MDP1</td>
<td>FAHD1</td>
<td>OLA1</td>
<td>PPI1</td>
<td></td>
</tr>
<tr>
<td>PKM</td>
<td>HPRT1</td>
<td>NUDT2</td>
<td>CON P50448</td>
<td>SUMO1</td>
<td></td>
</tr>
<tr>
<td>THOP1</td>
<td>DLD</td>
<td>DDT</td>
<td>ARHGDA</td>
<td>REXO2</td>
<td></td>
</tr>
<tr>
<td>ASS1</td>
<td>NLN</td>
<td>GLUD1</td>
<td>FDP5</td>
<td>HSPB1</td>
<td></td>
</tr>
<tr>
<td>NME2</td>
<td>CON 585019</td>
<td>CON 24466</td>
<td>NIF3L1</td>
<td>COX4I1</td>
<td></td>
</tr>
<tr>
<td>AIMP1</td>
<td>DDAH2</td>
<td>UBE2L3</td>
<td>CON P02672</td>
<td>ACTN4</td>
<td></td>
</tr>
<tr>
<td>APEH</td>
<td>GCLC</td>
<td>TFF1</td>
<td>PROSC</td>
<td>MAGOHB</td>
<td></td>
</tr>
<tr>
<td>CON 58D62</td>
<td>DCTPP1</td>
<td>CON P06868</td>
<td>FAH</td>
<td>HNRNPA1</td>
<td></td>
</tr>
<tr>
<td>RCC2</td>
<td>CKMT1A</td>
<td>GNPDA1</td>
<td>BLMH</td>
<td>LGALS3BP</td>
<td></td>
</tr>
<tr>
<td>CSTB</td>
<td>PG2</td>
<td>OTUB1</td>
<td>CBR3</td>
<td>CTSB</td>
<td></td>
</tr>
<tr>
<td>LTA4H</td>
<td>PHPT1</td>
<td>CBS</td>
<td>VAPB</td>
<td>KRT2</td>
<td></td>
</tr>
<tr>
<td>DBI</td>
<td>ENO2</td>
<td>TFRC</td>
<td>BASP1</td>
<td>HSPA5</td>
<td></td>
</tr>
<tr>
<td>SFN</td>
<td>RAB11A</td>
<td>TATDN1</td>
<td>EPPK1</td>
<td>CTSD</td>
<td></td>
</tr>
<tr>
<td>Streptavidin</td>
<td>IDH1</td>
<td>BOLA2</td>
<td>CON Q2UVX4</td>
<td>UBE2V1</td>
<td></td>
</tr>
<tr>
<td>FH</td>
<td>GCSH</td>
<td>MYH9</td>
<td>FKBP1A</td>
<td>B2M</td>
<td></td>
</tr>
<tr>
<td>SCRN1</td>
<td>S100A11</td>
<td>PCBD1</td>
<td>DNASE2</td>
<td>EEF1A1P5</td>
<td></td>
</tr>
<tr>
<td>CNDP2</td>
<td>CON 41361</td>
<td>CON 18229</td>
<td>PSMA7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 11.5. The 147 secreted proteins which had greater than 2-fold increase in secretion levels in radiation treated MCF-7 cells compared to untreated controls at 24 h post-treatment.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Protein</th>
<th>Protein</th>
<th>Protein</th>
<th>Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSRP1</td>
<td>C11orf54</td>
<td>SUMO3</td>
<td>FSCN1</td>
<td>DDAH2</td>
</tr>
<tr>
<td>EIF3G</td>
<td>ASNS</td>
<td>BLVRB</td>
<td>GNB2L1</td>
<td>ISG15</td>
</tr>
<tr>
<td>RAC1;RAC3;RAC2</td>
<td>SUPT5H</td>
<td>NIT2</td>
<td>KARS</td>
<td>CBR3</td>
</tr>
<tr>
<td>GNPNAT1</td>
<td>NUDT3</td>
<td>GAPDH</td>
<td>HNRNPA1</td>
<td>ADH5</td>
</tr>
<tr>
<td>CAP1</td>
<td>SEC24C</td>
<td>EIF2A</td>
<td>MGMT</td>
<td>TALDO1</td>
</tr>
<tr>
<td>MIPOL1</td>
<td>FAM49B</td>
<td>PGD</td>
<td>GSTM3</td>
<td>CCDC124</td>
</tr>
<tr>
<td>TP53I3</td>
<td>RAP1B;RAP1A</td>
<td>EIF6</td>
<td>PGK1</td>
<td>CBR1</td>
</tr>
<tr>
<td>Ovca2</td>
<td>NAP1L4</td>
<td>WDR1</td>
<td>CRIP2</td>
<td>TEMPO</td>
</tr>
<tr>
<td>PIN4</td>
<td>YBX3</td>
<td>PAG24</td>
<td>PKB1</td>
<td>PDCD5</td>
</tr>
<tr>
<td>TK1</td>
<td>ATXN7L3B</td>
<td>CLIC1</td>
<td>RPIA</td>
<td>SORD</td>
</tr>
<tr>
<td>RPE;RPEL1</td>
<td>DKK1</td>
<td>ESD</td>
<td>TMA7</td>
<td>EIF4G1</td>
</tr>
<tr>
<td>EIF4EBP2</td>
<td>DCTN2</td>
<td>RAN</td>
<td>ARMT1</td>
<td>HNRNPAB</td>
</tr>
<tr>
<td>TRPV1;SHPK</td>
<td>MAP7</td>
<td>AHCY</td>
<td>CFL1</td>
<td>RBMX;RBMXL1</td>
</tr>
<tr>
<td>FKB2</td>
<td>CON 2777</td>
<td>ASS1</td>
<td>PPIA</td>
<td>RNPEP</td>
</tr>
<tr>
<td>LANCL1</td>
<td>FUBP1</td>
<td>NUTF2</td>
<td>ACP1</td>
<td>PHPT1</td>
</tr>
<tr>
<td>TMSB15B</td>
<td>TIGAR</td>
<td>AKR1A1</td>
<td>ALDH9A1</td>
<td>GART</td>
</tr>
<tr>
<td>VPS29</td>
<td>IDH1</td>
<td>YWHAH</td>
<td>PKM</td>
<td>ATIC</td>
</tr>
<tr>
<td>CORO1B</td>
<td>OLA1</td>
<td>S100A11</td>
<td>MAPRE1</td>
<td>SUMO2</td>
</tr>
<tr>
<td>GSTO1</td>
<td>RAD23B</td>
<td>HMGN3</td>
<td>HMGN1</td>
<td>VAPA</td>
</tr>
<tr>
<td>PIN1</td>
<td>FABP5</td>
<td>EDF1</td>
<td>ENO1</td>
<td>CAT</td>
</tr>
<tr>
<td>VAPB</td>
<td>ALDOC</td>
<td>ID1</td>
<td>GSR</td>
<td>AIM5P1</td>
</tr>
<tr>
<td>ANXA2;ANXA2P2</td>
<td>ERH</td>
<td>DTD1</td>
<td>NUDT1</td>
<td>HRSP12</td>
</tr>
<tr>
<td>NAGK</td>
<td>COTL1</td>
<td>RBBP9</td>
<td>POLR2H</td>
<td>MTDH</td>
</tr>
<tr>
<td>CDV3</td>
<td>PARK7</td>
<td>BASP1</td>
<td>LTA4H</td>
<td>TPI1</td>
</tr>
<tr>
<td>DSTN</td>
<td>DDT;DDTL</td>
<td>OTUB1</td>
<td>ESYT1</td>
<td>CDH1</td>
</tr>
<tr>
<td>FAM107B</td>
<td>CLIC4</td>
<td>PGP</td>
<td>SUMO1</td>
<td>EFHD1</td>
</tr>
<tr>
<td>EPPK1</td>
<td>SH3BGR1L</td>
<td>HMGN2</td>
<td>TCEB2</td>
<td>ABHD14B</td>
</tr>
<tr>
<td>ENSA</td>
<td>MAP4</td>
<td>ITPA</td>
<td>EIF4H</td>
<td></td>
</tr>
<tr>
<td>HNRNPM</td>
<td>NT5DC1</td>
<td>CTTN</td>
<td>TSTA3</td>
<td></td>
</tr>
<tr>
<td>ALDOA</td>
<td>CMBL</td>
<td>SERBP1</td>
<td>PPP2R4</td>
<td></td>
</tr>
</tbody>
</table>

Table 11.6. The 33 secreted proteins which had up to 12-fold increase in secretion levels in radiation treated MCF-7 cells compared to untreated controls at 24 h post-treatment.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Protein</th>
<th>Protein</th>
<th>Protein</th>
<th>Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSRP1</td>
<td>PIN4</td>
<td>TK1</td>
<td>IDH1</td>
<td>NUDT3</td>
</tr>
<tr>
<td>EIF3G</td>
<td>RPE</td>
<td>EIF4EBP2</td>
<td>SUPT5H</td>
<td>YBX3</td>
</tr>
<tr>
<td>GNPNAT1</td>
<td>TRPV1</td>
<td>ASNS</td>
<td>RAP1B</td>
<td>MAP7</td>
</tr>
<tr>
<td>MIPOL1</td>
<td>LANCL1</td>
<td>DKK1</td>
<td>VPS29</td>
<td>TIGAR</td>
</tr>
<tr>
<td>TP53I3</td>
<td>C11orf54</td>
<td>DCTN2</td>
<td>ATXN7L3B</td>
<td>SUMO3</td>
</tr>
<tr>
<td>Ovca2</td>
<td>RAC1</td>
<td>TMSB15B</td>
<td>SEC24C</td>
<td></td>
</tr>
<tr>
<td>FKB2</td>
<td>CAP1</td>
<td>FAM49B</td>
<td>NAP1L4</td>
<td></td>
</tr>
</tbody>
</table>
11.3 Journal articles

11.3.1 Published articles


11.3.2 Submitted articles
